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Abstract 
 
Parkinson’s Disease (PD) is a progressive, neurodegenerative condition characterised by 
deterioration of the dopaminergic (DA) neurons of the substantia nigra pars compacta (SNpc).  
The exact mechanism by which SNpc cell death in PD occurs is poorly understood but several 
lines of evidence implicate both environmental and genetic factors.  Trichloroethylene (TCE) is 
an industrial solvent used as a degreasing agent and in dry cleaning.  TCE is a major 
environmental contaminant in the air, the water system and soil and is therefore exposed at 
low levels to various groups in the population.  There have been links between chronic 
exposure to TCE and Parkinson-like symptoms reported and in vivo experiments support this 
link.  It has also been discovered that TCE can be converted, via chloral, to a potentially DA 
neurotoxin TaClo in man.  This project investigated this link between TCE and PD and to 
elucidate any causative mechanisms. 
 
Cellular exposure paradigms were used to show neurotoxicity of TCE, chloral and TaClo in DA 
neurons.  The mechanism of this cell death in TaClo was found to be necroptotic - and not 
apoptotic - in nature and involve induction of autophagy, DNA damage and an increase in 
reactive oxygen species (ROS) in exposed cells.  A possible source of this ROS was suggested 
with the findings that TaClo significantly inhibits Complex I of the mitochondrial oxidative 
phosphorylation chain - an effect known to produce superoxide - and an increase in 
mitochondrial ROS seen in cells following TaClo treatment.  The cell death induced by chloral 
was found to follow a different path, with neither apoptotic or necroptotic characteristics 
observed in exposed cells, and Complex I only inhibited at high doses.  However, chloral was 
found to block the reduction of cytochrome c at lower doses, a property that may be involved 
in the neurotoxicity seen with chloral. 
 
Animal models of TCE, chloral and TaClo exposure found no significant motor or cognitive 
abnormalities in behavioural testing of either wild-type mice or rats or human A30P mutated 
α-synuclein overexpressing mice.  However, TCE and TaClo exposed wild-type and A30P mice 
did show a significant decrease in DA neuronal number and density in the SNpc, suggesting 
both compounds are neurotoxic to DA neurons in vivo.  An LC-MS/MS assay was developed to 
assess neurotransmitter levels in the brains of toxin exposed animals, however the method 
was not found to be consistently accurate and showed extreme variability in results. 
 
In conclusion, the main results of this thesis suggest that TCE does lead to DA 
neurodegeneration in the SNpc of exposed individuals, probably through metabolism to the 
ii 
 
neurotoxic compound TaClo.  The neurotoxic properties of TaClo are DA specific and relatively 
potent.  The mechanism of neurotoxicity is hypothesised to be through inhibition of 
mitochondrial Complex I, inducing increased ROS production and damage of intracellular 
organelles, DNA and proteins, which in turn leads to the activation of autophagy and PARP 
activation.  This intracellular stress instigates RIP1 mediated necroptosis and death of the cells. 
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Parkinson’s Disease (PD) is a progressive, neurodegenerative condition characterised by 
deterioration of the dopaminergic (DA) neurons of the substantia nigra pars compacta (SNpc) 
(Bernheimer, Birkmayer et al. 1973; Dickson, Braak et al. 2009; Lees, Hardy et al. 2009).  The 
exact mechanism by which SNpc cell death in PD occurs is poorly understood but several lines 
of evidence implicate both environmental and genetic factors. 
 
Trichloroethylene (TCE) is an industrial solvent used as a degreasing agent and in dry cleaning.  
TCE is a major environmental contaminant in the air, the water system and soil and is 
therefore exposed at low levels to various groups in the population. 
 
There have been links between chronic exposure to TCE and Parkinson-like symptoms 
reported (Guehl, Bezard et al. 1999; Reif, Burch et al. 2003; Gash, Rutland et al. 2008) and in 
vivo experiments support this link (Liu, Choi et al. 2010).  It has also been discovered that TCE 
can be converted, via chloral, to a potentially DA neurotoxin 1-Trichloromethyl-1,2,3,4-
tetrahydro-β-carboline (TaClo) in man (Bringmann, God et al. 1999). 
 
This project intends to investigate this link between TCE and PD and to elucidate any causative 
mechanisms. 
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1.1 Parkinson’s Disease 
PD is a progressive, neurodegenerative condition characterised by deterioration of the DA 
neurons of the SNpc (Bernheimer, Birkmayer et al. 1973; Dickson, Braak et al. 2009; Lees, 
Hardy et al. 2009) (Fig 1.1) leading to disruption of the nigrostriatal pathway and control of 
movement. 
 
Fig. 1.1 Degeneration of SNpc DA neurons in PD PD is characterised by the loss of DA neurons 
in the area of the midbrain known as the SNpc.  These neurons are a dark brown colour due to 
a high content of neuromelanin and their deterioration can be seen in the loss of pigmentation 
in  horizontal sections of the midbrains of a PD patient (P) compared to a healthy control (C) 
(adapted from (Mackenzie 2001)). 
 
The condition was first characterised in 1817 in James Parkinson’s ‘Essay on the Shaking Palsy’, 
and involvement of the DA system was confirmed in 1967 with the discovery that oral 
administration of L-DOPA (L-3,4-dihydroxyphenylalanine), a DA precursor molecule, was 
successful at inducing remission of PD symptoms (Cotzias, Van Woert et al. 1967). Forms of the 
disease can be either familial or idiopathic, with idiopathic cases making up approximately 
two-thirds of those diagnosed.  PD is the second most common neurodegenerative condition 
after Alzheimer’s disease and affects approximately 0.25% of people in industrial countries.  
The disease is age-related with the majority of patients aged over 50 (Schrag, Ben-Shlomo et 
al. 2000) and prevalence rising exponentially to 1% of the population over 60 and 4% by 80 
years and over.  PD appears to have a higher incidence in men than women with a reported 
prevalence ratio of 155 males per 100 females in the USA (Wright Willis, Evanoff et al. 2010). 
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1.1.1 Pathogenesis & Clinical Development of Parkinson’s Disease 
1.1.1.1 Diagnosis & Clinical Signs 
Idiopathic PD is most commonly diagnosed according to the UK Parkinson’s Disease Society 
Brain Bank clinical diagnostic criteria, which state that the patient must suffer from 
bradykinesia, as well as at least one of muscular rigidity, 4-6 Hz resting tremor or postural 
instability not caused by primary visual, vestibular, cerebellar or proprioceptive dysfunction.  If 
these primary symptoms are present, the patient must, in addition, not show evidence of any 
of the following exclusion criteria: 
 
 history of repeated strokes with stepwise progression of Parkinsonian features 
 history of repeated head injury 
 history of definite encephalitis 
 oculogyric crises 
 neuroleptic treatment at onset of symptoms 
 more than one affected relative 
 sustained remission 
 strictly unilateral features after three years 
 supranuclear gaze palsy 
 cerebellar signs 
 early severe autonomic involvement 
 early severe dementia with disturbances of memory, language and praxis 
 Babinski sign 
 presence of a cerebral tumour or communicating hydrocephalus on CT scan. 
 negative response to large doses of levodopa (if malabsorption excluded) 
 MPTP exposure 
 
Finally three or more of the following supportive prospective positive criteria are required for 
diagnosis of definite PD: 
 unilateral onset 
 rest tremor present 
 progressive disorder 
 persistent asymmetry affecting the side of onset most 
 excellent response (70-100%) to levodopa 
 severe levodopa-induced chorea 
 levodopa response for 5 years or more 
 clinical course of 10 years or more 
(criteria taken from (Gibb and Lees 1988)). 
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Clinically, PD manifests as the triad of classic symptoms mentioned above: bradykinesia, 
rigidity and resting tremor which become apparent when 50-70% of the DA neurons of the 
SNpc have been lost (Hirsch, Graybiel et al. 1988; Fearnley and Lees 1991).  This motor 
disruption is due to the lack of DA projection to the striatum brought about by the 
degeneration of DA neurons in the SNpc leading to a loss of input to the nucleus of the basal 
ganglia which consists of a complex network that integrates cortical areas, basal ganglia nuclei 
and thalamus and controls movement (Alexander, Delong et al. 1986).  A model has been 
proposed to explain how DA depletion in the striatum leads to motor dysfunction (Albin, 
Young et al. 1989; DeLong 1990) through a lack of DA input from the striatum to the GABAergic 
medium spiny neurons of both the direct (induces movement) and indirect (supresses 
movement) pathways of motor behaviour control in the basal ganglia.  This deletion affects the 
balance of these pathways and results in motor alterations (deficits in movement initiation and 
execution) deriving from the lack of DA neurotransmission in the striatum.  Figure 1.2 
summarises the pathways of the basal-ganglia in health and PD. 
 
In addition to these core indications, patients may display disturbances in balance and posture 
as well as non-motor signs including neuropsychiatric symptoms, sleep disorders, autonomic 
symptoms, gastrointestinal symptoms, sensory dysfunctions and more (PD non-motor 
symptoms are detailed in Table 1.1) (Chaudhuri, Healy et al. 2006) and are due to disruption of 
noradrenergic, serotonergic and cholinergic systems; PD is therefore now considered a multi-
system disorder. 
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Neuropsychiatric symptoms 
Depression, apathy, anxiety 
Anhedonia 
Attention deficit 
Hallucinations, illusion, delusions 
Dementia 
Obsessional behaviour (usually drug induced), repetitive behaviour 
Confusion 
Delirium (could be drug induced) 
Panic attacks 
Sleep disorders 
Restless legs and periodic limb movements 
Rapid eye movement (REM) sleep behaviour disorder and REM loss of atonia 
Non-REM-sleep related movement disorders 
Excessive daytime somnolence 
Vivid dreaming 
Insomnia 
Sleep disordered breathing 
Autonomic symptoms 
Bladder disturbances 
Sweating 
Orthostatic hypotension 
Sexual dysfunction 
Dry eyes (xerostomia) 
Gastrointestinal symptoms (overlaps with autonomic symptoms) 
Dribbling of saliva 
Ageusia 
Dysphagia and choking 
Reflux, vomiting 
Nausea 
Constipation 
Unsatisfactory voiding of bowel 
Faecal incontinence 
Sensory symptoms 
Pain 
Paraesthesia 
Olfactory disturbance 
Other symptoms 
Fatigue 
Diplopia 
Blurred vision 
Seborrhoea 
Weight loss 
Weight gain (possibly drug induced) 
 
 
Table 1.1 Summary non-motor symptoms of PD (adapted from (Chaudhuri, Healy et al. 2006)) 
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Fig. 1.2 Proposed major pathophysiological changes in the basal ganglia in PD Schematic 
diagram of basal ganglia in a healthy and in PD individual. The relative size of the arrows 
indicates the increases or decreases in neuronal activity in the various pathways, and the 
green (increase) and red (decrease) boxes represents the increase or decrease in neuronal 
activity within each of the nuclei. Abbreviations: D1/D2 = dopamine receptors; e/iGP = 
external/internal segment of globus pallidus; STN = subthalamic nucleus; SNpc = substantia 
nigra pars compacta; SNr = substantia nigra pars reticulata; . Green and red lines indicate 
excitatory and inhibitory connections, respectively. 
 
 
Dementia is a very common non-motor symptom of PD, with reports suggesting 40-50% of PD 
patients also suffer from dementia (Cummings 1988; Hely, Morris et al. 2005).  Indications of 
dementia in PD may be seen with the presence of Lewy bodies (pathological hall marks of PD, 
described in more detail in section 1.1.1.2 below) in cortical brain regions with the number of 
Lewy bodies in several cortical areas significantly correlating with cognitive impairment 
(Mattila, Rinne et al. 2000).  The basis for dementia in PD has been suggested to be due to the 
presence of co-morbid Alzheimer’s disease, with a number of studies reporting Alzheimer’s 
pathology in the cerebral cortex of most PD patients with dementia (Boller, Mizutani et al. 
1980; Mann and Jones 1990; Jellinger 1997; Jellinger, Seppi et al. 2002).  Dementia in PD has 
Chapter 1                                                                  Introduction 
7 
 
been correlated with atrophy of nucleus basalis Meynert, resulting in a cholinergic deficit, a 
feature that is shared with Alzheimer’s patients, giving a pathological basis for the condition 
(Candy, Perry et al. 1983; Whitehouse, Hedreen et al. 1983).  For a more detailed review of 
dementia in PD see (Emre 2003). 
 
Olfactory and gastrointestinal disturbances have been reported to be amongst the earliest 
clinical symptoms of PD (Abbott, Petrovitch et al. 2001; Ponsen, Stoffers et al. 2004; Ross, 
Petrovitch et al. 2008) and suggested as possible preclinical markers to aid earlier diagnosis of 
the disease.  The early manifestation of olfactory impairment in PD concurs with the 
developmental staging of the disease proposed by Braak et al. (discussed in detail in section 
1.1.1.3 below) which suggests early degeneration of extranigral neurons in the olfactory bulb 
and anterior olfactory nucleus in the presymptomatic early stages of the disease (Braak, 
Ghebremedhin et al. 2004).  The early presentation of gastrointestinal dysfunction can also be 
related to early Braak staging with the degeneration of the dorsal nucleus of the vagus nerve 
seen in Braak stage 1.  However, loss of DA neurons in the enteric nervous system is also seen 
in PD (Singaram, Gaumnitz et al. 1995), but gastrointestinal symptoms do not respond to DA 
treatment suggesting a possible non-DA pathogenic mechanism is involved (Byrne, Pfeiffer et 
al. 1994). 
1.1.1.2 Pathological Features 
The primary pathological characteristic of PD is the death of DA neurons in the SNpc.  The 
severity of the DA neuronal degeneration is not homogeneous in PD, with the cell loss 
preferentially occurring in the ventrolateral region of the SNpc (Fig 1.3), followed by the 
mediolateral and then dorsal tiers respectively, directly opposite to the cell loss pattern seen 
across the SNpc of aging controls (Fearnley and Lees 1991).  The ventrolateral region of the 
SNpc contains the majority of the projections to the striatum (i.e. the nigrostraital DA 
neurons), leading directly to the depletion in striatal dopamine seen in the PD. 
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Fig. 1.3 DA neuron distribution & number in PD SNpc The severity of the DA neuronal loss in 
PD is not homogeneous and is more pronounced in the ventral and lateral regions of the SNpc.  
Left images show templates of the distribution of pigmented neurons and right show examples 
of SNpc DA neuron density (x40 magnification, haematoxylin & eosin stained sections) in (A) 
healthy controls and in patients with (B) mild, (C) moderate, or (D) severe PD.  3n=exiting 3rd 
nerve fibres. cp=cerebral peduncle. R=red nucleus. (Taken from (Dickson, Braak et al. 2009)) 
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The second major pathological hallmark of PD is the presence of proteinaceous intraneuronal 
inclusions termed Lewy bodies (LBs) along with the presence of Lewy neurites within neuronal 
dendrites and axons of surviving cells of the SNpc as well as other brain regions (Spillantini, 
Crowther et al. 1998; Wakabayashi, Tanji et al. 2007) (Fig. 1.4).  LBs are typically found in 
brainstem nuclei and in limbic and neocortical regions in PD, and additionally can be identified 
in autonomic ganglia in the periphery (McKeith, Galasko et al. 1996). There are two 
morphological types of LBs: brainstem (classic) and cortical Lewy bodies. Classic Lewy bodies 
are intracytoplasmic eosinophylic inclusions that consist of a dense core surrounded by a pale 
halo (Spillantini, Crowther et al. 1998). They are spherical in shape; however a recent report of 
Kanazawa et al. also showed convoluted LBs and their continuity with Lewy neurites, which 
may suggest LBs evolve from Lewy neurites (Kanazawa, Uchihara et al. 2008). Typically, classic 
LBs are seen in dopaminergic neurons of the substantia nigra and noradrenergic neurons of 
the locus coeruleus, although they were originally described in neurons of the basal forebrain 
(Burkhardt, Filley et al. 1988). Cortical LBs are less well-defined structures compared to classic 
LBs, lacking the halo and located predominantly in limbic areas of the brain, such as the 
amygdala, entorhinal, insular and cingulate cortices (McKeith, Galasko et al. 1996).  
Ultrastructurally, both classic and cortical LBs are composed of filamentous material that is 
insoluble in SDS and resembles neurofilament (Galloway, Mulvihill et al. 1992). 
 
Fig. 1.4 Lewy bodies & neurites Immunohistological staining of Lewy bodies & neurites in the 
SNpc of a PD patient brain. (a) Lewy body stained for α-synuclein, (b) Lewy body stained for 
ubiquitin, (c) Lewy neurite stained for α-synuclein.  (Adapted from (Licker, Kövari et al. 2009)) 
 
Electron-microscope examination of Lewy bodies demonstrates that the core contains dense 
granular material, whereas the outer halo is composed of radiating filaments of 7-20 nm in 
diameter (Spillantini, Crowther et al. 1998).  Immunohistochemical staining and proteomic 
analyses have deciphered the complexities of the molecular composition of Lewy bodies and 
Lewy neurites. α-synuclein (Spillantini, Schmidt et al. 1997; Spillantini, Crowther et al. 1998), 
ubiquitin (Kuzuhara, Mori et al. 1988) and neurofilaments (Schmidt, Murray et al. 1991) appear 
to be the major components (Fig. 1.4 a & b), with α-synuclein representing the most 
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prominent and consistent marker of LBs. More recently triple immunolabeling for these 
epitopes has revealed a three-layered internal structure of LBs and neurites (Kanazawa, 
Uchihara et al. 2008). These primary molecular constituents are stratified into concentric 
layers with ubiquitin staining in the centre, surrounded by α-synuclein and neurofilament on 
the periphery, which is consistent with previous observations (McNaught, Shashidharan et al. 
2002).  This accumulation of abnormal aggregated α-synuclein in the brains of PD patients 
classifies the disease as a synuclienopathy. 
 
Dysfunction of protein metabolism appears to be an important factor in LB formation and the 
neurodegeneration associated with their presence (for review see(Ciechanover and Brundin 
2003)), but the significance of these aggregates is still a subject of debate. It is unclear if LBs 
are pathogenic and mechanistically cause neuronal death (Trojanowski, Goedert et al. 1998) or 
rather the actual function of LBs is neuroprotective by sequestering unwanted, potentially 
toxic proteins such as mutated α-synuclein  (Lashuel, Hartley et al. 2002; Lashuel, Petre et al. 
2002; Olanow, Perl et al. 2004).  The latter hypothesis is supported clinically by evidence, 
particularly from autosomal recessive juvenile Parkinson’s disease due to Parkin mutation, 
demonstrating that neurodegeneration can occur without the presence of LBs in both 
apparently sporadic and familial forms of PD (Mori, Kondo et al. 1998; Wakabayashi, 
Toyoshima et al. 1999). LBs are also reported in cognitively intact individuals over 65 years 
(Braak, Del Tredici et al. 2003) although this may indicate an early phase of PD  prior to cell loss 
and clinical presentation.  
 
1.1.1.3 Development 
The progression of PD has been assessed post mortem leading to the development of a 
neuropathological staging scheme based on the distribution of α-synuclein/Lewy bodies 
throughout the brain by Braak et al. (Braak, Ghebremedhin et al. 2004).  The stages are 
characterised by sequential involvement of brain regions, defined by the presence of LBs, 
starting with the dorsal nucleus of the vagus nerve and anterior olfactory nucleus and 
spreading through the rest of the brainstem, mid and forebrain and finally throughout the 
cortex with symptoms increasing in severity and scope as more brain regions develop 
pathology (See Fig. 1.5 for further details).  Patients are typically described as presymptomatic 
in stages 1-3 until a threshold is passed with sufficient pathology and DA cell death in the SNpc 
accumulating at stage 3 or 4 to manifest as motor dysfunction through loss of dopamine 
neurotransmission in the striatum.  Further neurodegeneration proceeds to first order sensory  
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and premotor and high-order sensory association areas, prefrontal neocortex, and finally into 
primary sensory and motor areas. This degeneration induces several late stage PD symptoms 
including hallucinatory episodes, dementia and states of confusion. 
 
Fig. 1.5 Progression of PD-related intraneuronal pathology (A)The pathological process 
targets specific subcortical and cortical induction sites. Lesions initially occur in the dorsal IX/X 
motor nucleus and frequently in the anterior olfactory nucleus as well. Thereafter, less 
susceptible brain structures gradually become involved (see white arrows). The pathology in 
the anterior olfactory nucleus expands less readily into related areas than that evolving in the 
brain stem. The brain stem pathology takes an upward course (see white arrows). Cortical 
involvement follows, commencing with the anteromedial temporal mesocortex. From there, 
the neocortex succumbs, beginning with high order sensory association and prefrontal areas. 
First order sensory association/premotor areas and, thereafter, primary sensory and motor 
fields follow suit. The gradual decrease in shading intensity is intended to represent the 
topographical expansion of the lesions during the course of the disease. 
(B) Simplified diagram showing the topographic expansion of the lesions (from bottom to top: 
dorsal motor X nucleus to neocortex, primary, secondary) and, simultaneously, the growing 
severity on the part of the overall pathology (from left to right: stages 1–6). With the addition 
of further predilection sites, the pathology in the previously involved regions increases. 
(Adapted from (Braak, Del Tredici et al. 2003; Braak, Ghebremedhin et al. 2004)) 
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1.1.1.4 Management 
Although there are currently no cures for PD available, there are a number of ways that the 
disease can be managed.  Pharmacologically, PD can be treated by modulating DA levels at the 
synapse of remaining DA neurons, using a variety of strategies; DA production can be 
increased, breakdown of DA inhibited, or the actions of DA mimicked (Fig 1.6). 
 
The major and most successful treatment strategy is to increase DA levels by administering the 
DA precursor molecule L-DOPA, known by the trade name Levodopa.  In vivo, DA is formed 
from L-DOPA by the enzyme dopa decarboxylase; therefore increasing levels of L-DOPA in the 
brain will lead to an increase in DA levels in the striatum and a reduction in the motor 
dysfunction seen in PD.   DA cannot be used directly to treat PD as it does not cross the blood 
brain barrier; however Levodopa can be actively transported into the brain by the L-type 
amino acid transporter (Oldendorf and Szabo 1976).  The major problems with Levodopa are 
that chronic treatment can lead to dyskinesia, tolerance and diminished effects, and rapid 
fluctuations in clinical state where hypokinesia and rigidity suddenly worsen for a period of 
time, known as an ‘on-off effect’.  Despite this, Levodopa is currently the most commonly used 
and effective PD treatment. 
 
Mimicking the effect of DA by the use of DA receptor agonists is another strategy used in the 
management of PD.  Current therapeutic agents in use include the D2, D3 and D4 specific 
agonists Pramipexole (Shannon, Bennett Jr et al. 1997) and Ropinirole (Adler, Sethi et al. 1997), 
and the non-specific DA agonist Apomorphine (Merims, Galili-Mosberg et al. 2000). Although 
these DA agonists do show some effect in reducing motor dysfunction and do not show the 
tolerance and dyskinesia seen with Levodopa, they have been shown to be less effective than 
Levodopa (Holloway, Shoulson et al. 2000) and can cause hallucinations, oedema, excessive 
diurnal somnolence, and impulse control disorder (Gottwald, Bainbridge et al. 1997).  Further 
compounds are in development with varying DA receptor specificity and solubility to try and 
improve efficacy and reduce adverse effects. 
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Fig. 1.6 Pharmacological strategies for PD management Schematic representation of a DA 
neuronal synapse showing the molecular targets of various pharmacological agents used to 
manage the disease.  Key: COMT – Catechol-O-Methyl Transferase, DR- DA receptor 1/2, MAO-
B – monoamine-oxidase-B. 
 
To increase striatal DA, compounds that inhibit the enzymes that breakdown DA can be used.  
Monoamine-oxidase-B (MAO-B), an enzyme located in the outer mitochondrial membrane, 
and Catechol-O-methyl-transferase (COMT), an enzyme located in the synaptic cleft, 
sequentially catalyse the breakdown of DA to its major metabolite homovanillic acid (HVA) in 
neurons and glia.  Inhibition of MAO-B by Selegiline and Rasagiline has been shown to increase 
free levels of DA and so reduce motor dysfunction in the striatum of PD patients particularly 
when used in combination with Levodopa (Przuntek, Conrad et al. 1999; Rabey, Sagi et al. 
2000).  COMT is also responsible for the breakdown of L-DOPA, so the COMT inhibitors 
Entacapone and Tolcapone are often given in combination with Levodopa to improve efficacy 
and have been shown to reduce the ‘on-off effect’ seen with Levadopa treatment alone 
(Dupont, Burgunder et al. 1997; Smith, Jackson et al. 2005). 
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Preventing DA reuptake using the DAT (dopamine active transporter) inhibitor Amantadine is 
used to treat motor dysfunction and Levodopa induced dyskinesia in PD patients by increasing 
the amount of DA in the synaptic cleft.  However, reviews on Amantadine use have found 
inadequate evidence to support its use for either the motor disruption or Levodopa induced 
dyskinesia in PD (Crosby, Deane et al. 2003; Crosby, Deane et al. 2003). 
 
As well as the pharmacological management of PD mentioned above, surgical and 
rehabilitation techniques can be used to alleviate symptoms.  There are two main surgical 
approaches used to manage PD - generally in cases where drug therapy is no longer effective - 
deep brain stimulation and lesioning of overactive cortical regions.  Deep brain stimulation 
involves the bilateral implantation of a device in the brain which sends electrical impulses to 
the subthalamic nucleus or globus pallidus of the brain to activate them.   Although it has been 
shown to be more effective than pharmacological therapy, it is far more invasive and 
associated with an increased risk of serious adverse events so not widely used (Weaver, Follett 
et al. 2009).  Although destruction of specific brain regions has been shown to alleviate PD 
symptoms, leisioning is most widely and successfully used to treat the dyskinesia suffered 
following long term Levodopa treatment by destroying cells in the globus palladius by 
pallidotomy (Laitinen, Bergenheim et al. 1992; Lozano, Lang et al. 1995).  Surgery is not a 
routine occurrence and generally reserved for patients in the advanced stages of the disease.   
In addition to the more invasive management strategies described, it has been shown that 
regular exercise regimes can have a positive effect on motor function in PD patients (Goodwin, 
Richards et al. 2008), an effect that is more pronounced when combined with a supervised 
physiotherapy programme (Dereli and Yaliman 2010).  
 
In summary, while the motor symptoms of PD can be reduced, the treatment methods 
currently available are inadequate, transient and associated with significant adverse effects 
meaning the prognosis for - and quality of life of - patients is unsatisfactory.  Consequently, the 
disease is still a great unmet medical need with greater knowledge of the pathogenesis and 
elucidation of the mechanisms underlying PD needed to improve the current situation. 
 
 
 
 
 
 
Chapter 1                                                                  Introduction 
15 
 
1.1.2 Molecular Mechanisms of Parkinson’s Disease 
The exact mechanism by which SNpc cell death in PD occurs is poorly understood but several 
lines of evidence implicate mitochondrial dysfunction, oxidative stress, ubiquitin system 
impairment and excitotoxicity, all of which may be interlinked (Bedford, Hay et al. 2008; 
Meredith, Totterdell et al. 2009; Navarro, Boveris et al. 2009). 
1.1.2.1 Mitochondrial Dysfunction 
Mitochondrial dysfunction with Complex I deficiency and impaired electron transfer in the 
substantia nigra in PD have been reported (Schapira, Cooper et al. 1990; Keeney, Xie et al. 
2006). Moreover, mutations in several mitochondrial proteins have been associated with 
familial forms of PD (Kitada, Asakawa et al. 1998; Bonifati, Rizzu et al. 2003; Valente, Abou-
Sleiman et al. 2004), as well as the presence of deletions in mitochondrial DNA identified in 
aging controls and PD substantia nigra (Bender, Krishnan et al. 2006).  For a detailed review of 
the involvement of mitochondrial dysfunction in PD see (Keane, Kurzawa et al. 2011). 
 
Mitochondria are found in virtually all eukaryotic cells and function to generate cellular energy 
in the form of adenosine triphosphate (ATP) by oxidative phosphorylation and are also 
involved in regulation of cell death via apoptosis, calcium homeostasis, haem biosynthesis, the 
formation and export of iron-sulphur (Fe-S) clusters (reviewed in detail elsewhere (Jiang and 
Wang 2004; Lill, Dutkiewicz et al. 2006; Szabadkai and Duchen 2008)), and function in the 
control of cell division and growth.  The mitochondrial electron transport chain is composed of 
four complexes and an ATP-synthase located in the inner mitochondrial membrane.  The 
function of the chain is to generate cellular energy in the form of ATP.  This is accomplished by 
the transport of electrons between Complexes causing proton (H+ ions) movement from the 
matrix to the inter-membrane space generating a proton concentration gradient used by ATP-
synthase to produce ATP (for details of individual complex functions see Fig. 1.7 & Table 1.2). 
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Fig. 1.7 Mitochondrial electron transport chain  Schematic representation of the 
mitochondrial electron transport chain involved in oxidative phosphorylation.  CI & II 
(Complexes I & II) transport electrons (e-s) generated by the conversion of NADH to NAD+ (CI) 
or FADH2 to FAD (CII) through Q (ubiquinone), CIII,  Cyt c (cytochrome c) and finally CIV, which 
uses an e- to convert O2 to H2O.  During electron transfer, CI, II & IV pump protons (H
+s) from 
the mitochondrial matrix into the intermembrane space generating an H+ concentration 
gradient that drives the formation of ATP from ADP by ATP-synthase (Complex V). 
 
Whilst electron transport is a highly efficient process in mitochondria (Chan 2006), during the 
process of oxidative phosphorylation, electrons can leak from the chain, specifically from CI 
(Takeshige and Minakami 1979) and CIII (Beyer 1992), and react with oxygen to form 
superoxide (∙O2
-).  Under normal physiological conditions this ∙O2
- production occurs at 
relatively low levels, with approximately 1% of the mitochondrial electron flow forming ∙O2
-  
(Lass, Agarwal et al. 1997), and is removed by mitochondrial antioxidants such as manganese 
superoxide dismutase (MnSOD) which converts ∙O2
- to H2O2 which is then converted to H2O by 
glutathione (GSH).  Given the high activity of the respiratory chain under even normal 
circumstances, the small leakage of electrons in mitochondria is still a major source of ∙O2
- 
within many eukaryotic cells (Cadenas and Davies 2000). It is thought that dysfunction in this 
process leading to an increase in ∙O2
- production could be one of the main drivers of cell death 
in the SNpc in PD (Sian, Dexter et al. 1994; Jha, Jurma et al. 2000). 
 
Chapter 1                                                                  Introduction 
17 
 
As neurons have a considerable energy need and are also highly equipped with mitochondria 
they are extremely sensitive to mitochondrial dysfunction. Several neurological disorders are 
associated with mitochondrial dysfunction and demonstrate enhanced production of free 
radical species (Finsterer 2006; Lin and Beal 2006). The first line of evidence for a link between 
mitochondrial dysfunction and PD came from the description of Complex I (CI) deficiency in the 
post-mortem SNpc of PD patients and has been suggested to be one of the fundamental 
causes of the disease (Mizuno, Ohta et al. 1989; Schapira, Cooper et al. 1990).  This CI 
deficiency was also seen in the frontal cortex in PD (Parker Jr., Parks et al. 2008), and in 
peripheral tissues such as platelets (Haas, Nasirian et al. 1995) and skeletal muscle (Bindoff, 
Birch-Machin et al. 1991) suggesting that there is a global reduction in mitochondrial CI activity 
in PD. This defect may be due to oxidative damage to CI and its mis-assembly since this is a 
feature of isolated PD brain mitochondria (Keeney, Xie et al. 2006).  Incidental Lewy body 
disease (ILBD) which is considered by some to be a preclinical indicator of PD, has been shown 
to have an intermediate level of CI activity in the SNpc between healthy and PD patients 
(Schapira, Mann et al. 1990) which further supports the theory of mitochondrial dysfunction.  
This inhibition of CI can lead to the degeneration of affected neurons by a number of 
mechanisms such as increased oxidative stress and excitotoxicity (Sherer, Betarbet et al. 2002) 
which will be described below. 
 
A decrease in the function of Complex III (CIII) has also been reported in the lymphocytes and 
platelets of PD patients (Haas, Nasirian et al. 1995; Shinde and Pasupathy 2006).  A link 
between impairment of mitochondrial CIII assembly, an increase in free radical production and 
PD has also been identified (Rana, De Coo et al. 2000).  This increase in free radical release may 
be due to the increased leakage of electrons from CIII (as explained below).  Alternatively the 
inhibition of CIII assembly, causes a severe reduction in the levels of functional CI in 
mitochondria (Acín-Pérez, Bayona-Bafaluy et al. 2004) which could lead to an increase in free 
radical production through CI deficiency. In addition, the CI and II electron acceptor 
ubiquinone has also shown to be reduced in the mitochondria of PD patients (Shults, Haas et 
al. 1997) and loss of DA neurons in aged mice treated with the Parkinsonian neurotoxin 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was attenuated by ubiquinone (Beal, 
Matthews et al. 1998), providing more evidence for the involvement of mitochondrial 
dysfunction in PD. 
 
There is less evidence for the involvement of Complexes II, IV and ATP-synthase in PD. This 
being said, a link between Complex IV (CIV) inhibition and PD pathogenesis has been proposed; 
it has been shown that knockdown of Pink-1, mutations of which have been linked with PD, 
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leads to inhibition of CIV (Gegg, Cooper et al. 2009) suggesting possible CIV inhibition in the 
disease.  No significant evidence of Complex II (CII) dysfunction has been reported, as any 
possible inhibition of CII by known PD-linked toxins is small enough to be insignificant in 
relevance when compared to the extent of CI inhibition mediated by these compounds 
(Krueger, Tan et al. 1993).  Finally, while there has been a report of reduced ATP-synthase 
levels in the SN of PD patients (Ferrer, Perez et al. 2007), there is no evidence as to whether 
this is a pathological effect or a consequence of the mitochondrial dysfunction and damage 
seen in the disease. 
 
Complex Name Evidence of involvement in PD 
I NADH 
dehydrogenase 
 Reduced function widely reported in tissue of PD 
patients. 
 Range of PD-linked toxins shown to inhibit CI. 
 Inhibition shown to increase ROS and induce DA 
neuronal death. 
 
II Succinate 
dehydrogenase 
 Possible inhibition by toxins but at significantly 
lower levels to the CI inhibition observed. 
 
III Cytochrome c 
reductase 
 Reduced function in tissue of PD patients. 
 
 
IV Cytochrome c 
oxidase 
 Inhibited when Pink-1 knocked out. 
 
 
- ATP-synthase  Levels reduced in PD patient SN. 
 
Table 1.2 OXPHOS pathway Complexes and involvement in PD Summary of the names of the 
various OXPHOS Complex enzymes and evidence of their involvement in PD. 
 
Mitochondria have also been shown to be linked to LBs, with large numbers of mitochondria 
observed in early-stage LBs (Gai, Yuan et al. 2000; Bedford, Hay et al. 2008). Mitochondrial 
accumulation has also been found in nigral Lewy and pale bodies (possibly precursors of LBs 
(Dale, Probst et al. 1992)), and cortical LBs, but not in classical LBs in PD patients or a mouse 
26S proteasomal knockout model (Bedford, Hay et al. 2008). This may suggest direct 
involvement of mitochondria in early stages of LB formation. According to the aggresome-
related model of LB formation, mitochondria may be sequestered to the inclusion bodies in 
order to facilitate the removal of unwanted proteins (see (Olanow, Perl et al. 2004) for 
extensive review). 
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1.1.2.2 Oxidative Stress 
Inhibition of Complex I or III of the mitochondrial electron transport chain described above 
causes an increase in the release of electrons from the transport chain into the mitochondrial 
matrix which then react with oxygen to form reactive oxygen species (ROS) such as ∙O2
-, 
hydroxyl radicals (∙OH) and nitric oxide (NO∙).  This increase in the normal electron leakage 
occurs by blockage of electron movement along the chain to the next acceptor molecule.  An 
example of this is the finding that blockade of the electron accepting capability of the 
ubiquinone binding site of Complex I leads to an increased production of electron radicals in 
rat skeletal muscle mitochondria (Lambert and Brand 2004).  The ROS formed, can act as 
signalling molecules by causing lipid peroxidation or can promote excitotoxicity, both of which 
lead to modification of proteins and eventual cell death.  The main areas in which ROS cause 
damage in the cell include oxidative DNA damage, lipid peroxidation, and protein oxidation 
and nitration.  The ∙OH radical has been shown to react with the double bond of DNA bases 
leading to damaging DNA lesions (Cooke, Evans et al. 2003), and an impairment of normal 
cellular function.  There is evidence linking this mechanism of cell death to PD in the finding of 
increased levels of 8-hydroxyguanosine, produced by oxidative damage to DNA, in the SNpc of 
PD patients (Alam, Jenner et al. 1997; Zhang, Perry et al. 1999).  Peroxynitrite (formation 
discussed below) also increases DNA single strand breaks (Szabo, Zingarelli et al. 1996) which 
causes activation of poly(ADP-ribose) polymerase (PARP) which, in turn, disrupts the 
mitochondrial respiratory chain and ATP production via depletion of intracellular NAD+ stores, 
so exacerbating the original mitochondrial dysfunction (Przedborski and Vila 2001). 
 
Amongst the most common mechanisms of protein damage caused by ROS are oxidation to 
form carbonyl groups on proteins and nitration by peroxynitrite.  Reactive ROS can readily 
oxidise amino acids on various cellular proteins to form carbonyl groups which can disrupt the 
physiological function of the affected protein and lead to cytotoxic protein aggregates, 
activation of cell death pathways and impairment of neuroprotective pathways (Esrefoglu 
2009).  An increase in these carbonyl groups has been reported in the SNpc and in the basal 
ganglia and prefrontal cortex of PD patients (Floor and Wetzel 1998) suggesting a role in the 
disease which is widespread throughout the brain.  Peroxynitrite is formed by the reaction of 
ROS with nitric oxide and can nitrate tyrosine residues on proteins (Reiter, Teng et al. 2000), 
damaging them and leading to cell death.  These nitrotyrosine residues are present in LBs in PD 
neurons signifying the possibility that protein nitration may contribute to the pathology of PD 
(Good, Hsu et al. 1998).  Peroxynitrite (Radi, Beckman et al. 1991) and other ROS (Armstrong 
and Buchanan 1978) can also oxidise sulphydryl groups on glutathione, leading to depletion of 
anti-oxidant defences, and other thiol containing co-factors, disrupting various cellular 
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processes and structures.  The final link between PD and mitochondrially generated ROS 
through protein damage comes with the discovery of nitrated and oxidatively damaged 
misfolded proteins that have strong genetic links with the disease such as α-synuclein, DJ-1, 
Parkin and PINK-1 (Polymeropoulos, Lavedan et al. 1997; Kitada, Asakawa et al. 1998; Kruger, 
Kuhn et al. 1998; Bonifati, Rizzu et al. 2003; Valente, Abou-Sleiman et al. 2004; Zarranz, Alegre 
et al. 2004) suggesting that these disease associated proteins are major targets of free radical 
damage in sporadic forms of PD. 
 
Lipid peroxidation is another of the main types of cellular damage caused by ROS occurring 
when ROS react with hydrogen in the lipid leading to the formation of a lipid radical.  This 
radical can then form a further lipid radical via an intermediary by reacting with a hydrogen 
atom leading to a chain reaction and breakdown of the lipid.  In the cell membrane 
phospholipids are particularly susceptible to this damage due to their polyunsaturated nature, 
leading to damage of both cell and organelle membranes and severe cellular dysfunction.  
There have been strong links between increased lipid peroxidation and PD with increased 
levels shown to be present and cause cell death in the nigral cells of PD patients (Dexter, 
Carter et al. 1986; Dexter, Carter et al. 1989) suggesting a role for it in the mechanisms of 
neuronal death. 
 
All of these mechanisms of oxidative stress can feed back to the mitochondria via a series of 
signalling pathways and cause further exacerbation and mitochondrial dysfunction by 
damaging mitochondrial DNA (mtDNA).  In this way ROS driven mitochondrial dysfunction acts 
to propagate itself via a feedback loop leading to accelerated cellular damage and death and 
contributing to PD. 
 
This oxidative damage could be exacerbated in PD by the discovery of reduced antioxidant 
defences in patients with the disease.  The main line of evidence relates to reduced GSH, which 
has been found to be selectively decreased in the SNpc of patients with PD (Jenner, Dexter et 
al. 1992), leading to a decline in cellular capability to inactivate H2O2 and peroxynitrite.  This is 
thought to be an early event in PD pathology since lower levels of reduced GSH in incidental LB 
disease are of the same magnitude as those found in PD (Jenner 1993).  There have not been 
consistent reports of changes in the levels of most of the other major antioxidant systems; 
however cases of an increase in mitochondrially located MnSOD in PD patients have been 
described (Saggu, Cooksey et al. 1989; Yoritaka, Hattori et al. 1997).  This supports a link 
between mitochondrial dysfunction generated superoxide and PD since MnSOD is the main 
∙O2
- scavenging system in mitochondria. 
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Since there are elevated markers of oxidative damage in the brains of PD patients, including 
lipid peroxidation (Dexter, Carter et al. 1989) protein damage (Floor and Wetzel 1998; Good, 
Hsu et al. 1998) and oxidative DNA damage (Alam, Jenner et al. 1997; Zhang, Perry et al. 1999) 
oxidative stress is an established event in PD.  This evidence combined with the PD-like effects 
of known Complex I inhibitors and ROS inducers such as MPTP (Przedborski, Tieu et al. 2004) 
and rotenone (Betarbet, Sherer et al. 2000) and an increase in the activity of neutralising 
Superoxide Dismutase (SOD), particularly the mitochondrially localised MnSOD, being found in 
neurodegenerative disease patients (Yoshida, Mokuno et al. 1994) points to a strong link 
between ROS and PD. 
 
Iron has also been suggested to be involved in the production and propagation of oxidative 
stress in DA neurons in PD. Iron is intrinsically linked with mitochondrial function and 
particularly the brain, since iron is an integral component of all respiratory chain complexes 
and the uptake of iron by the brain is linked with mitochondrial energy demands (Mash, Pablo 
et al. 1990). Increased iron levels in the brain have long been associated with PD (Lhermitte J 
1924; Sofic, Riederer et al. 1988; Gerlach, Ben-Shachar et al. 1994; Gerlach, Double et al. 1997) 
although this increase may be an effect of the normal  pathological clearance of iron during 
cell death that occurs in PD. More recently a specific increase in intracellular iron has been 
observed in SNpc neurones in PD patients (Oakley, Collingwood et al. 2007) suggesting an 
increase in the cellular accumulation of iron in the disease.  Cellular iron normally enters into 
neurones via the transferrin receptor system and evidence suggests that there is a reduction of 
this system in PD (Morris, Candy et al. 1994; Mastroberardino, Hoffman et al. 2009), although 
this may relate more to the loss of SNpc neurones in PD (Faucheux, Hauw et al. 1997). This iron 
may also be taken up into the mitochondria in the SNpc via the transferrin receptor 2 and 
increased levels of ferritin have been reported in the mitochondria of SNpc DA neurons of PD 
patients and rats treated with rotenone (Mastroberardino, Hoffman et al. 2009).  ROS with a 
low oxidative potential, like ∙O2
- generated via dysfunction of oxidative phosphorylation, can 
increase the release of reactive ferrous iron from this ferritin so leading to the creation of 
more ROS via the Fenton reaction (Double, Maywald et al. 1998) and increasing oxidative 
stress and cell damage. The evidence that abnormal iron homeostasis is present in PD is clear; 
however the role of iron in PD as either an initiator or a consequence of pathology remains to 
be elucidated. 
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1.1.2.3 Impaired Protein Degradation 
The build-up of abnormal protein aggregates is one of the pathological hallmarks of PD, and as 
such, impairments in the systems involved in protein degradation have been implicated in the 
disease. 
 
The ubiquitin–proteasome system (UPS) is one of the major mechanisms of protein 
degradation in the cell whereby proteins for degradation are tagged by multiple ubiquitin 
molecules and recognised and degraded by the 26/20S proteasome.  Impairment of the UPS 
has been shown to lead to DA neuron degeneration and the formation of LB-like α-synuclein 
inclusions in surviving neurons (McNaught, Mytilineou et al. 2002).  The UPS has also been 
shown to be involved in the degradation of wild-type α-synuclein in healthy cells (Webb, 
Ravikumar et al. 2003), suggesting dysfunction in the system may contribute to α-synuclein 
pathology and DA degeneration in PD.  This is supported by the finding that LBs contain 
components of the ubiquitin-proteasome system, although unlike functional aggresomes in 
healthy cells, they fail to degrade abnormal proteins, but are thought to sequester them to 
delay their ability to damage, and lead to the death of, DA neurons (McNaught, Shashidharan 
et al. 2002).  This build-up of ubiquitinated protein aggregates may be explained by reports 
that 26/20S proteasome structure and function is disrupted in the SNpc of PD patients 
(McNaught and Jenner 2001; McNaught, Belizaire et al. 2002; McNaught, Belizaire et al. 2003), 
meaning that while toxic protein aggregates are tagged, they are not able to be degraded.  
However, care is needed in the interpretation of this, as it is not clear whether the inhibition of 
the proteasome actually results in a reduced capacity of the UPS to degrade protein in vivo 
and, if so, whether the reduction is large enough to inflict sufficient damage to the cells to lead 
to the neurodegeneration seen in PD. 
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Fig. 1.8 UPS, autophagy, protein quality control, and neurodegeneration in PD Normal 
proteins are routinely turned over by different protein degradation systems, including the 
ubiquitin-proteasome system (UPS), chaperone-mediated autophagy (CMA), and 
macroautophagy (referred to herein as “autophagy”). In autophagy-deficient neurons, there is 
an accumulation of ubiquitinated protein aggregates which is associated with 
neurodegeneration. Proteins altered by mutations, posttranslational modifications, or stress 
(such as oxidative stress, UV irradiation, toxins) undergo a conformational change, are 
recognized by molecular chaperones, and are either refolded and repaired or delivered to 
protein degradation systems (usually UPS or CMA). If these protein degradation systems are 
impaired or if the altered proteins form oligomeric complexes that cannot be recognized by 
the UPS or CMA, autophagy may be the primary route for the removal of these abnormal and 
potentially toxic proteins. Impaired autophagy is associated with the formation of protein 
aggregates and increased neurodegeneration. (Taken from (Levine and Kroemer 2008)) 
 
The second major group of pathways by which proteins are degraded are the autophagic 
pathways whereby cellular contents are engulfed in autophagasomes and fuse with lysosomes 
for degradation (discussed in more detail in section 1.3.3).  Autophagy has been linked with PD 
as an increase in autophagic vacuoles and autophagasomes has been reported in PD patients 
(Anglade 1997) and exposure of mice to the PD-linked neurotoxin MPTP is reported to increase 
autophagy in DA-neurons (Öztaş and Topal 2003).   Autophagy has been reported to be 
integrally involved in the degradation of wild-type α-synuclein in healthy cells (Webb, 
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Ravikumar et al. 2003) and the presence of pathogenic A30P & A53T mutated α-synuclein has 
been shown to impair autophagy, preventing degradation of not only toxic mutant α-synuclein 
but also other autophagy substrates (Cuervo, Stafanis et al. 2004) providing a hypothesis that 
impaired autophagic clearance of α-synuclein and other proteins may be an important 
mechanism in DA neuronal degeneration in PD.  Further support for the involvement of 
autophagy in PD comes when combining the age-related nature of the disease with reports 
that autophagic activity has been shown to be reduced with age (Terman 1995; Cuervo and 
Dice 2000).  However, these findings suggest that autophagic dysfunction is commonly a 
secondary contributor to the pathology of PD, driven by the build-up of damaged or mutated 
proteins.  Mutations in proteins involved in protein clearance mechanisms which may be a 
more primary cause of PD, are discussed in section 1.1.3. 
 
The final major cellular content clearance mechanism linked with PD is mitophagy, the process 
whereby damaged mitochondria are removed from the cell.  As damage to mitochondria and 
the electron transport chain have been heavily linked to PD, and malfunctioning mitochondria 
can exacerbate this damage, mitophagy may be extremely important in PD.  The involvement 
of mitophagy in PD will be discussed in relation to mutations in PINK1 and Parkin in section 
1.1.3.2 below.  
 
1.1.2.4 Ca2+/ Excitotoxicity 
Excitotoxicity is the mechanism by which nerve cells are damaged by over activity and 
excessive depolarisation due to overstimulation of N-methyl-D-aspartate (NMDA) and AMPA 
receptors by neurotransmitter substances such as glutamate.  Although, in itself, excitotoxicity 
is not thought to be a driving mechanism behind PD, glutamate mediated changes to the SNpc 
may contribute to the induction of the disease and excitotoxicity may well play a secondary 
role in the DA cell death seen in PD.  Several mechanisms for excitotoxicity in 
neurodegenerative conditions have been proposed (Albin and Greenamyre 1992; Greene and 
Greenamyre 1996).  Excitotoxicity occurs when depolarisation of the neuronal cell membrane 
from -90mV to between -60 and -30mV leads to a decrease in the magnesium blockade of 
NMDA receptors.  This, in turn, leads to NMDA receptor activation by latent levels of 
glutamate and causes an intracellular Ca2+ accumulation.  This increase in Ca2+ is then thought 
to cause neurotoxicity by two main mechanisms.  Firstly, Ca2+ causes an increase in 
intracellular NO via activation of nitric oxide synthase (NOS).  The excess of NO in the cell can 
react with ∙O2
- to form peroxynitrite (Dawson and Dawson 1996), which can cause cell death by 
mechanisms similar to those caused by ROS and mentioned above.  As well as the 
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peroxynitrite, NO itself can lead to cell damage via nitrosylation of various proteins.  A second 
mechanism driven by intracellular Ca2+ increase causes toxicity in DA neurons by acting on 
mitochondria; the Ca2+ influx seen in excitotoxicity is extensively accumulated in the 
mitochondria and leads to effects on mitochondrial membrane potential and ATP synthesis as 
well as generation of ROS (Nicholls and Budd 1998).  This contributes to the oxidative damage 
discussed above and feeds back causing further malfunction of the cell’s Ca2+ homeostasis and 
additional cellular damage. 
 
Mitochondrial dysfunction can lead to excitotoxicity and cause a reduction in cellular ATP 
levels, an increase in cellular Ca2+ or a combination of both (Sherer, Betarbet et al. 2002).  
Inhibition of Complex I, and consequently ATP generation, lowers intracellular ATP, leading to 
partial neuronal depolarisation, due to a reduction in the activity of Na+/K+-ATPase.  The 
Na+/K+-ATPase acts to maintain the resting membrane potential of the cell.  A reduction in ATP 
levels will compromise this function leading to depolarisation and therefore excitotoxicity via 
over activation of NMDA receptors.  Intracellular Ca2+ can be increased by two methods: either 
directly by mitochondrial impairment or by over activity of NMDA receptors.  Mitochondria 
can take up Ca2+ from the cytosol via an uniporter transporter or a transient “rapid mode”, 
both of which rely on the mitochondrial membrane potential, reviewed by Gunter et al. 
(Gunter, Buntinas et al. 2000).  The ROS generated by mitochondrial respiratory chain 
dysfunction can damage the mitochondrial membranes and disrupt this mechanism of Ca2+ 
uptake and storage thereby raising intracellular Ca2+ levels and exacerbating the excitotoxicity.  
Sherer et al showed that this could be a viable mechanism for cell death in PD by inhibiting 
Complex I in SH-SY5Y cells and showing a disruption in the mitochondrial membrane potential 
leading to an increased susceptibility to calcium overload (Sherer, Trimmer et al. 2001).  It has 
also been shown that there is an increase in glutamate activity linked to excitotoxicity in the 
SNpc of mice treated with the Parkinsonian toxin MPTP, which may be linked to apoptosis and 
autophagy (Meredith, Totterdell et al. 2009). 
 
Ca2+ has been implicated in other mechanisms of cell death in PD that may involve a 
compromise in the role of mitochondria as one of the major intracellular Ca2+ stores.  It has 
been reported that mitochondria from PD patients showed lower sequestration of calcium 
than age matched controls implicating Ca2+ homeostasis dysfunction in PD (Sheehan, Swerdlow 
et al. 1997).  This would lead to higher intracellular Ca2+ levels, which has been shown to 
amplify free radical production (Dykens 1994) and therefore increase ROS.  An increase in 
cytosolic Ca2+ due to mitochondrial dysfunction has also been suggested to activate calpains 
and so raise levels of toxic α-synuclein proposing another link with PD (Esteves, Arduíno et al. 
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2010), a discovery supported by the protective effect of calpain inhibition in an MPTP model of 
PD (Crocker, Smith et al. 2003). 
 
A particular role for Ca2+ and mitochondria has been suggested in a mechanism of increased 
susceptibility to cell death specific to SNpc DA neurons and therefore relevant for PD.  SNpc DA 
neurons are atypical in the brain in that they have self-generated pacemaker activity (Grace 
and Bunney 1983) mediated by Cav1.3, a rare L-type Ca2+ channel (Striessnig, Koschak et al. 
2006).  This activity means that that the Cav1.3 channels are open for a higher proportion of 
time than Ca2+ channels in other neurons leading to an increased ATP usage in the cells to 
pump Ca2+ across the membrane up steep concentration gradients (Surmeier, Guzman et al. 
2010).  This elevated need for ATP would lead to an increase in the activity of the electron 
transport chain, therefore increasing ROS production, exacerbating any mitochondrial 
dysfunction and making SNpc DA neurons more prone to cell death. 
 
1.1.2.5 Dopamine Metabolism 
Oxidative stress generated during DA metabolism has long been implicated in PD (Olanow 
1993).  Dopamine is normally metabolised to DOPAC (3,4-Dihydroxyphenylacetic acid)  by 
MAO, but can also be oxidised to form a reactive quinone, either by autoxidation, a process 
that is accelerated in the presence of ROS, metal ions or other catecholamines (Donaldson, 
McGregor et al. 1982; Nappi, Vass et al. 1995), or by the enzymes tyrosinase (Korner and 
Pawelek 1982) and prostaglandin H synthase (Hastings 1995) (Fig 1.9). 
 
The major mechanisms by which DA metabolism is thought to contribute to PD pathology are 
through the formation of ROS (for details on ROS mediated damage in PD see section 1.1.2.2 
above) and DA-quinones (Zahid, Saeed et al. 2011) (Fig. 1.9).  DA-quinones have been shown to 
stabilise toxic α-synuclein aggregates in the cell, (Conway, Rochet et al. 2001), to form 
potentially damaging DNA adducts (Zahid, Saeed et al. 2011), to inactivate oxidative defence 
molecules (Belluzzi, Bisaglia et al. 2012) and inactivation and to cause conversion of  tyrosine 
hydroxylase into a ROS producing redox quinoprotein (Kuhn, Arthur Jr et al. 1999), suggesting 
further mechanisms for the involvement of DA metabolism in PD pathology. 
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Fig. 1.9 Metabolic pathways of DA Several different pathways of DA metabolism exist in DA 
neurons. DA can be catabolized by the actions of MAO to DOPAC and DA & DOPAC can both be 
oxidized through various mechanisms to reactive quinones.  ROS are generated during these 
reactions and it is they and the quinones which lead to cellular damage and death. 
 
It has also been suggested that ROS or DA-quinones, may have an inhibitory effect on the 
proteins of the mitochondrial respiration chain (Cohen, Farooqui et al. 1997; Berman and 
Hastings 1999; Gluck and Zeevalk 2004).  Hossain-Khan et al. showed that DA inhibits 
Complexes I and IV, most probably through the actions of the DA-quinones rather than 
through ROS (Hossain Khan, Sen et al. 2005).  MAO-A is bound to the outer mitochondrial 
membrane and can oxidise dopamine to form the metabolite DOPAC, which can itself, or 
through oxidation to quinones, locally inhibit Complexes I and IV (Gluck and Zeevalk 2004; 
Hossain Khan, Sen et al. 2005), although a contradictory report suggests DA but not DOPAC 
inhibits the electron transport chain (Jana, Maiti et al. 2007).  A recent study has shown that 
DA itself, rather than any oxidation products can directly inhibit Complex I (Brenner-Lavie, 
Klein et al. 2009); however, more work would need to be carried out to confirm this as there is 
no corroborating evidence.   These links between mitochondrial dysfunction and dopamine are 
supported by reports that the PD neurotoxins and Complex I inhibitors MPTP and rotenone 
increase DA oxidation and turnover (Lotharius and O'Malley 2000; Thiffault, Langston et al. 
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2000), although whether this is indirectly due to the ROS generating effects of the toxins is not 
clear. 
 
These hypotheses based around DA metabolism could offer explanations as to why DA 
neurons are more susceptible than others to toxin or mutation mediated mitochondrial 
dysfunction PD, as they are already under a higher level of oxidative stress due to dopamine 
metabolism. 
 
1.1.2.6 Neuroinflammation 
Neuroinflammation has been proposed as a mechanism involved in PD pathogenesis with 
reports that increased numbers of glia and astrocytes were found in post mortem brains 
(Damier, Hirsch et al. 1993; Braak, Sastre et al. 2007) and levels of the pro-inflammatory 
cytokines  tumour necrosis factor-α (TNF-α), interleukins and transforming growth factors 
(TGFs) are increased in the cerebrospinal fluid and brains of PD patients (Mogi, Harada et al. 
1994; Mogi, Harada et al. 1994; Mogi, Harada et al. 1996).  One possible mechanism of 
neuroinflammation in PD could be due to the formation of DA-quinones (see section 1.1.2.5), 
with reports showing that DA-quinones can lead to activation of microglia and hence cause 
neurotoxicity (Kuhn, Francescutti-Verbeem et al. 2006).  It has also been proposed that 
neuroinflammatory activation in PD may be due to an effect of aggregates of the PD-linked 
protein α-synuclein (see section 1.1.3.1 below for more details), as these aggregates have been 
shown to activate glial cells and initiate production of ROS in the glia by activating NADPH 
oxidase (Zhang, Wang et al. 2005).  The proposed mechanisms of immunological activation 
contributing to DA neurodegeneration are summarised in Fig. 1.10.  
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Fig. 1.10 Inflammation in PD Aggregates of α-synuclein form intermediate-state oligomers 
that when released from neurons activate microglia through Toll-like receptor (TLR)-
independent mechanisms. This leads to activation of NF-κB and production of ROS and pro-
inflammatory mediators. These factors act directly on DA neurons of the SNpc. These factors 
also activate microglia, which amplify the inflammatory response in a positive feedback loop, 
leading to further activation of microglia. Products derived from microglia and astrocytes act in 
a combinatorial manner to promote neurotoxicity. Bacterial lipopolysaccharide (LPS), acting 
primarily through TLR4 expressed by microglia, is sufficient to induce an inflammatory 
response in the SNpc that results in loss of DA neurons. The transcription factor NURR1 acts to 
suppress inflammatory responses in microglia and astrocytes by inhibiting NF-κB target genes. 
(Taken from (Glass, Saijo et al. 2010)) 
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1.1.2.7 Interaction of the Molecular Mechanisms of Parkinson’s Disease 
Although the primary pathology underlying the disease has yet to be elucidated, there is 
strong evidence for the involvement of all of the mechanisms described in the progression of 
DA neurodegeneration in PD.  In addition, many of the mechanisms are involved in a positive 
feedback loop that exacerbates cellular damage and enhances the neurodegeneration of DA 
neurons, aiding disease progression (Fig. 1.11) 
 
 
Fig. 1.11 Interaction of molecular mechanisms of PD The major pathological mechanisms 
linked with PD have been shown to initiate and exacerbate each other during progression of 
the disease.  Oxidative stress appears integral to this feedback loop, with ROS being generated 
during and contributing to all of the other major mechanisms involved in DA cell death in the 
SNpc during PD.  Mitochondrial dysfunction can lead to altered Ca2+ handling and 
excitotoxicity, as it is a major intracellular Ca2+ store, and impaired protein degradation as 
reduced ATP production will limit the ability of energy dependent processes such as autophagy 
and UPS.  Build-up of toxic protein aggregates due to impaired degradation can trigger 
neuroinflammation by activating glia and aggravate mitochondrial dysfunction by impaired 
mitophagy.  In conclusion, once triggered, the harmful processes involved in DA neuronal 
death can feedback to each other, enhancing their damaging effects on the cells and 
accelerating pathology. 
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1.1.3 Genetic Mutations linked with Parkinson’s disease 
Various inherited forms of PD have been discovered with the disease linked to mutations in a 
number of genes.  Genome-wide linkage analysis implicated 16 genetic loci, termed "PARK" 
loci, linked with monogenetic forms of PD.  These loci and the mutations they correspond to 
are summarised in Table 1.3, and discussed, along with other mutations linked to PD, in more 
detail below. 
1.1.3.1 α-Synuclein 
The α-synuclein gene encodes a small protein of the synuclein family which is known to be 
localised to nerve terminals; however the exact physiological functions of α-synuclein remain 
unclear.  The first link between α-synuclein and PD came with the discovery of mutations in 
the α-synuclein gene in PD patients (Polymeropoulos, Lavedan et al. 1997; Kruger, Kuhn et al. 
1998; Zarranz, Alegre et al. 2004).  This evidence was supported by the discovery that 
aggregates of α-synuclein are the major components of LBs (Spillantini, Crowther et al. 1998).  
The structure of α-synuclein, along with main functional regions and the location of common 
mutations, is shown in Fig. 1.12. 
 
 
Fig. 1.12 α-synuclein structure The α-synuclein protein is divided into three overlapping 
regions, namely an N-terminal repeat region (aa. 1–95), a central hydrophobic NAC region (aa. 
60–95) and an acidic C-terminus (aa. 96–140). The repeat region contains six conserved repeat 
motifs (grey boxes) and is believed to be involved in α-synucleins interactions with lipids; the 
NAC domain is essential for the aggregation of α-synuclein, whereas the C-terminus is critical 
for binding of various ions and proteins.  The locations of 3 major mutations (A30P, E46K & 
A53T) are shown; all are present in the N-terminal repeat region, without the NAC domain 
essential for aggregation. (Taken from (Lundvig, Lindersson et al. 2005)). 
 
There are many theories on the mechanism by which α-synuclein is linked to neuronal cell 
death in PD, including toxic aggregate build-up, neuroinflammation, disrupted ion 
homeostasis, impaired DA neurotransmission and mitochondrial dysfunction.  Mutant α-
synuclein has been shown to form fibrils and oligomers in cells (Conway, Harper et al. 1998; 
Conway, Lee et al. 2000), reportedly through exposure to ROS (Hashimoto, Hsu et al. 1999), 
and these protein aggregates have been shown to be toxic to the cell (El-Agnaf, Jakes et al. 
1998).  The mechanism of this toxicity and involvement in PD pathology has not been 
completely elucidated but may include a combination of various properties of the aggregates.  
Primarily, α-synuclein has been widely reported to disrupt the UPS, with fibrils and oligomers 
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shown to inhibit the activity of the 20 & 26S proteasome (Snyder, Mensah et al. 2003; 
Lindersson, Beedholm et al. 2004).  Overexpression of mutant human α-synuclein in mice has 
been shown to lead to a decrease in proteasome function proportional to levels of SNpc DA 
neurodegeneration (Chen, Thiruchelvam et al. 2006).  α-synuclein aggregates have also been 
shown to bind to and inhibit the transcriptional regulator HMGB-1 suggesting an effect on 
gene expression (Lindersson, Højrup et al. 2004), and oligomers have been shown to form 
pores in vesicle membranes altering Ca2+ permeability and therefore exerting an effect on ionic 
homeostasis in the cell (Volles, Lee et al. 2001; Volles and Lansbury Jr 2002).  Finally, 
extracellular α-synuclein aggregates released from damaged nigral neurons have been 
reported to activate microglia, suggesting a role in the neuroinflammation associated with PD 
(Zhang, Wang et al. 2005). 
 
In addition to the effects of aggregated α-synuclein described, wild-type α-synuclein  has been 
shown to be involved in DA neurotransmission, with α-synuclein null mice shown to have 
altered DA release (Abeliovich, Schmitz et al. 2000), possibly due to impaired vesicle 
mobilisation at nerve terminals (Cabin, Shimazu et al. 2002) or an effect on DA biosynthesis 
(Perez, Waymire et al. 2002). It is reasonable to surmise, therefore, that mutations which 
affect the function of α-synuclein could cause problems in DA neurotransmission in PD.  Wild-
type α-synuclein may also have a protective effect in neurons that is lost in PD, as wild-type, 
but not A53T α-synuclein, has been shown to protect against apoptosis inducing agents in a 
neuronal cell line (Da Costa, Ancolio et al. 2000). 
 
It has also recently been reported that there is an association between α-synuclein and 
mitochondrial dysfunction (Devi, Raghavendran et al. 2008; Nakamura, Nemani et al. 2008).  
Overexpression of α-synuclein has been reported to alter mitochondria resulting in increased 
oxidative stress in a neuronal cell line (Hsu, Sagara et al. 2000), and mutant α-synuclein has 
been shown to be targeted to, and accumulate in, the inner mitochondrial membrane and 
cause Complex I impairment and an increase in ROS, possibly leading to cell death (Devi, 
Raghavendran et al. 2008).  Finally, wild-type α-synuclein has been shown to be protective 
against excitotoxic injury in neurons (Leng and Chuang 2006), and may have an antioxidant 
effect that is lost in mutant forms of the protein (Orth, Tabrizi et al. 2004; Zhu, Qin et al. 2006).  
A lack of these protective abilities in PD due to mutant or aggregated α-synuclein may 
contribute towards disease pathology by increasing the risk of excitotoxcity and oxidative 
damage. 
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The relative involvement of these findings in the progression and pathology of PD have not 
been fully explored; however - with evidence of the involvement of α-synuclein in a wide range 
of the pathogenic molecular mechanisms of the disease - it is strongly suggestive that a 
combination of the toxic effects of mutated and aggregated α-synuclein and a loss of 
protective characteristics of wild-type α-synuclein play a major role in the mechanism of DA 
degeneration in the SNpc of PD patients. 
 
1.1.3.2 Parkin/PINK1/DJ-1 
The Parkin gene encodes an E3 ubiquitin ligase involved in the ubiquitin-proteasomal system 
(Shimura, Hattori et al. 2000), marking proteins for degradation by the proteasome.  Mutations 
in Parkin have been linked to a form of  autosomal recessive juvenile parkinsonism (Kitada, 
Asakawa et al. 1998).  This mutation leads to a form of PD without Lewy bodies, probably 
related to the loss of the ability of Parkin to ubiquinate synphilin-1, a protein that interacts 
with α-synuclein in the formation of LBs (Chung, Zhang et al. 2001).  Parkin has been shown to 
be localised to LBs (Schlossmacher, Frosch et al. 2002) and has been shown to interact with 
and promote degradation of α-synuclein, possibly through sequestration into LBs (Shimura, 
Schlossmacher et al. 2001; Kim, Sung et al. 2003); therefore a loss of function Parkin mutation 
could contribute to the build-up of toxic α-synuclein and subsequently cause the cell death 
present in PD.  Pael-R, a substrate of Parkin, has also recently been shown to be a component 
of LBs (Murakami, Shoji et al. 2004), providing more links between Parkin and LB pathology in 
PD.  It has been suggested that Parkin may also be involved in mitochondrial function and 
protection from mitochondrially generated ROS.   Recent work in Parkin null mice has shown a 
reduction in subunits of Complex I & IV and reduced function in the mitochondrial respiratory 
chain along with increased oxidative stress in brain tissue (Palacino, Sagi et al. 2004).  This is 
supported by reduced mitochondrial Complex I activity in Parkinsonian patients with Parkin 
mutations (Muftuoglu, Elibol et al. 2004) and the increased age-dependent or rotenone (a 
Complex  I inhibitory toxin) induced DA neuronal degeneration and mitochondrial 
abnormalities in Parkin mutant drosophila (Wang, Lu et al. 2007).  Moreover, a recently 
generated zebrafish model of Parkin deficiency showed increased sensitivity of Parkin mutants 
to proteotoxic stress with no manifestation of dopaminergic neuron loss or affected 
mitochondrial morphology or function (Fett, Pilsl et al. 2010).    
 
PTEN induced putative kinase 1 (PINK1) is a serine/threonine kinase located in the inner 
mitochondrial membrane (Silvestri, Caputo et al. 2005) which functions to protect neurons 
against various types of cell stress.  Mutations in PINK-1 are found to be associated with a 
autosomal recessive form of PD (Valente, Abou-Sleiman et al. 2004). This pathogenesis may be 
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associated with the loss of kinase activity as PINK-1 is known to protect against cell death only 
if the kinase function is intact (Petit, Kawarai et al. 2005).  Several independent groups 
reported a role for PINK1 in mitochondrial integrity by regulating the mitochondrial fission 
machinery (Hoppins, Lackner et al. 2007), which might have an impact on dopaminergic 
synapses and contribute to DA neuron degeneration (Yang, Ouyang et al. 2008; Dagda, Cherra 
et al. 2009; Gispert, Ricciardi et al. 2009).  Knockdown of PINK1 has been shown to induce 
mitochondrial oxidative stress, mitochondrial fragmentation, autophagy, dysregulated calcium 
homeostasis, α-synuclein aggregation and disrupt the UPS in cell models (Dagda, Cherra et al. 
2009; Gandhi, Wood-Kaczmar et al. 2009; Liu, Vives-Bauza et al. 2009), suggesting links 
between PINK1 and a wide range of PD-linked pathologies. 
 
Moreover, there is evidence of interplay between PINK1 and Parkin since Parkin can reduce 
mitochondrial dysfunction caused by down-regulation of PINK1 (Exner, Treske et al. 2007).  
Furthermore, it has been shown recently that both PINK1 and Parkin are involved in removal of 
damaged mitochondria. The proposed model suggests that in response to mitochondrial 
depolarization PINK1 accumulates on the mitochondrial membrane and recruits Parkin to 
promote mitophagy (Geisler, Holmstrom et al. 2010; Narendra, Jin et al. 2010). Therefore, the 
pathology of mutant PINK1 and/or Parkin in parkinsonism may arise from the inability to 
remove dysfunctional mitochondria (Chu 2010). 
 
The DJ-1 gene encodes a widely expressed protein found in neurons and glia in all central 
nervous system (CNS) regions (Bader, Zhu et al. 2005).  Bonifati et al. first identified an 
association between DJ-1 and autosomal recessive early-onset PD (Bonifati, Rizzu et al. 2003), 
with numerous further familial mutations in DJ-1 being identified (Van Duijn, Dekker et al. 
2001).  One of these mutations is a large scale deletion in the gene, which effectively knocks 
out the protein, while the other is a L166P point mutation which has been shown to lead to 
increased degradation of DJ-1 (Miller, Ahmad et al. 2003).  Proteomic analysis of mitochondrial 
protein composition of the substantia nigra of mice treated with MPTP compared to controls 
showed significant changes in expression of numerous proteins. Of these proteins, DJ-1 
protein levels were significantly increased in the toxin-treated mice and also colocalised with 
α-synuclein in LB-like inclusions in the remaining nigral neurons. Moreover, DJ-1 was present in 
the halo of classical LBs in nigral tissue of PD patients (Jin, Meredith et al. 2005). 
 
Reports have shown that DJ-1 is present in mitochondria and protects against oxidative 
neuronal death (Canet-Aviles, Wilson et al. 2004), DJ-1 deficient mice are more susceptible to 
MPTP (Kim, Smith et al. 2005) and DJ-1 knockdown in a neuroblastoma cell line renders the 
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cells vulnerable to oxidative stress (Taira, Saito et al. 2004).  Finally, a critical role for DJ-1 in 
mitochondrial function is shown by a rescue effect of DJ-1 on neuronal cell death caused by 
PINK-1 but not Parkin deletion (Hao, Giasson et al. 2010), suggesting a possible interplay with 
PINK1 in maintaining mitochondrial populations and function.  Moreover, loss of DJ-1 leads to 
mitochondrial fragmentation, impaired dynamics, induced oxidative stress and autophagy 
(Irrcher, Aleyasin et al. 2010; Krebiehl, Ruckerbauer et al. 2010).  In conclusion, DJ-1 protein 
has been observed to have pleiotropic functions (see (Cookson 2010) for further review), with 
an anti-oxidative role being the most consistent finding.  This may provide a link to PD whereby 
a loss of function mutation of DJ-1 causes an increase in mitochondrial dysfunction and 
oxidative damage leading to nigral neuron cell death. 
 
Despite all the evidence implicating Parkin, PINK1 and DJ-1 loss of function mutations in PD, 
studies have shown that knocking out these proteins individually or in combination does not 
lead to PD pathology in mice (Kitada, Tong et al. 2009), suggesting that other contributing 
factors are needed in combination with loss of Parkin, PINK1 and DJ-1 for development of the 
disease or that it is the presence of the mutated forms of the proteins that is more important 
in their toxic mechanisms. 
 
1.1.3.3 LRRK2 
Leucine-rich repeat kinase 2 (LRRK2) is a large (280kDa) protein with kinase activities.  
Mutations in LRRK2 were first linked with autosomal dominant PD by Zimprich et al. in 2004 
(Zimprich, Biskup et al. 2004) and represent the most significant cause of autosomal dominant 
PD.  The precise mechanisms by which LRRK2 functions are as yet unclear, however, the kinase 
activity of the protein has been shown to be integral to the toxic properties of mutant forms of 
LRRK2 (Greggio, Jain et al. 2006; Smith, Pei et al. 2006; Lee, Shin et al. 2010).  LRRK2 has been 
shown to be involved in the autophagic clearance of damaged proteins in the cell with LRRK2 
knockout cells and mice shown to have impaired clearance of autophagic structure suggesting 
an impaired process (Alegre-Abarrategui, Christian et al. 2009; Tong, Giaime et al. 2012), 
although these findings were only in the kidney and similar results were not seen in these 
studies in the brain.  However, overexpression of mutant LRRK2 in mice resulted in loss of DA 
neurons and autophagic abnormalities (Ramonet, Daher et al. 2011) and a similar study in SH-
SY5Y, a DA model cell line, found abnormal accumulation of autophagic vacuoles in the brain 
(Plowey, Cherra Iii et al. 2008).  A study has also reported a high level of LRRK2 in dopamine 
innervated areas of the brain (Gaiter, Westerlund et al. 2006), supporting the involvement of 
LRRK2 mutation and autophagic disruption in PD. 
Chapter 1                                                                  Introduction 
36 
 
 
LRRK2 has been shown to be localised to the outer mitochondrial membrane (West, Moore et 
al. 2005; Biskup, Moore et al. 2006)  and Drosophila with LRRK2 mutations showed increased 
DA neurodegeneration and increased susceptibility to the Complex I inhibitor rotenone, effects 
that could be reversed by expression of  mitochondrially protective protein Parkin in 
Drosophila (Ng, Mok et al. 2009) providing associations between mutations in this protein in 
PD and mitochondrial dysfunction in PD. 
 
1.1.3.4 UCH-L1 
Ubiquitin C-terminal hydrolase-L1 (UCH-L1) is a neuron-specific enzyme involved in various 
ubiquitin modulating activities (Wilkinson, Lee et al. 1989; Liu, Fallon et al. 2002; Osaka, Wang 
et al. 2003), that was first linked to PD by an autosomal dominant point mutation (I93M) that 
was identified in two siblings with a strong family history of PD (Leroy, Boyer et al. 1998).  
Furthermore, UCH-L1 levels have also been shown to be down regulated and oxidatively 
damaged in idiopathic PD brains (Choi, Levey et al. 2004), suggesting an integral role for this 
protein in the pathogenesis of the disease.  As previously mentioned in section 1.1.2.3, 
disruption in the UPS has been strongly implicated in PD, and, due to the role of UCH-L1 in 
ubiquitin homeostasis, this is the most likely mechanism by which it contributes to the disease.  
Indeed, mutant forms of UCH-L1 linked with the disease have been shown to increase α-
synuclein levels in a cellular model (Liu, Fallon et al. 2002).  Interestingly, however, a 
polymorphism of UCH-L1 (S18Y) in a Japanese population has been shown to have a weakly 
protective effect against PD (Zhang, Hattori et al. 2000), possibly due to an increased hydrolase 
and  decreased ligase activity in comparison to the harmful 193M mutation (Liu, Fallon et al. 
2002; Nishikawa, Li et al. 2003).  These findings suggest a complex involvement of this protein 
and a sensitive balance of the UPS which may be disrupted in PD. 
 
1.1.3.5 Other nuclear mutations 
Omi/Htra2 is a mitochondrially located stress protective serine protease which has been linked 
to neurodegeneration (Jones, Datta et al. 2003; Martins, Morrison et al. 2004) with loss of 
function mutations being seen in some PD patients (Strauss, Martins et al. 2005).  Although 
certain studies report no clear genetic association between the Omi/HtrA2 gene sequence 
variations and PD (Kruger, Sharma et al. 2009), there is evidence of mitochondrial pathology 
caused by loss of the Omi/HtrA2 protein function (Jones, Datta et al. 2003). Omi/Htra2 has also 
been shown to have links with PINK1 in protecting against oxidative stress (Plun-Favreau, 
Klupsch et al. 2007) and interacting in a pro-survival pathway (Whitworth, Lee et al. 2008; Tain, 
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Chowdhury et al. 2009).  Omi/Htra2 has also been shown to co-localise with LBs in the brain of 
PD patients (Kawamoto, Kobayashi et al. 2008), suggesting a role in LB pathology or UPS 
protein trafficking.  Therefore, mutations in this mitochondrially targeted gene may predispose 
cells to damage via oxidative stress generated from mitochondrial dysfunction. 
 
A loss of function mutation in the brain and stomach located lysosomal type 5 P-type ATPase, 
ATP13A2, has been shown to have links with a hereditary form of autosomal recessive early 
onset PD with dementia (Ramirez, Heimbach et al. 2006) and missense mutations of the gene 
have been linked with juvenile/early onset PD (Di Fonzo, Chien et al. 2007).  It has been 
reported that functional ATP13A2 can protect against α-synuclein over expression induced 
toxicity and that knockdown of ATP13A2 enhances α-synuclein misfolding in neuronal models 
of PD (Gitler, Chesi et al. 2009), probably due to the role ATP13A2 plays in the degradation of 
abnormal proteins with ATP13A2 mutant patient derived cell lines showing disrupted UPS 
activity and increased endoplasmic reticulum stress (Park, Mehta et al. 2011).  In addition to its 
effects on protein handling, ATP13A2 mutations have also been linked with abnormal iron and 
manganese handling and their resultant accumulation in the brain (Schneider, Paisan-Ruiz et 
al. 2010; Tan, Zhang et al. 2011), which have been shown to contribute to excess ROS 
production and oxidative damage. 
 
PLA2G6 is a calcium independent Phospholipase A2 linked to infantile neuroaxonal dystrophy 
(Khateeb, Flusser et al. 2006) and neurodegeneration with brain iron accumulation (Morgan, 
Westaway et al. 2006) that has recently been implicated in PD (Tan, Ho et al. 2010; Yoshino, 
Tomiyama et al. 2010).  PLA2G6 has been shown to locate to (Seleznev, Zhao et al. 2006), and 
have a protective role against oxidative stress in (Zhao, Zhang et al. 2010), pancreatic β-cell 
mitochondria providing a possible link between loss of function mutations in this protein and 
mitochondrial dysfunction in PD. How, for example, PLA2G6 regulates iron, a major 
mitochondrial cofactor is not clear. 
 
F-box only protein 7 (FBXO7) is a substrate recognition component of a set of E3 ubiquitin 
ligases and so involved in protein degradation by the UPS.  Mutations in the gene encoding 
FBXO7 have been linked with a recessive, early onset, progressive form of PD (Fonzo, Dekker et 
al. 2009).  FBXO7 function is relatively poorly characterised but has been reported to be 
involved in control of proteasome activity, the cell cycle and apoptosis (Laman, Funes et al. 
2005; Chang, Cheng et al. 2006; Kirk, Laman et al. 2008; Bader, Benjamin et al. 2011); a loss of 
any or a combination of these functions could be involved in PD pathology seen in patients 
with mutations in FBXO7. 
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There have been reports that mutations in Grb10-Interacting GYF Protein-2 (GIGYF2) had been 
proposed as having a genetic association with familial PD (Lautier, Goldwurm et al. 2008; Guo, 
Jankovic et al. 2009).  However, since these reports, a number of further studies have been 
unable to find consistent evidence of the link between GIGFY2 mutations and PD and suggest 
that a mutation in another un-investigated gene in the patients in the primary investigations 
could be the cause of the disease in this group (Bras, Simán-Sánchez et al. 2009; Di Fonzo, 
Fabrizio et al. 2009; Nichols, Kissell et al. 2009; Vilariño-Güell, Ross et al. 2009; Zimprich, 
Schulte et al. 2009).  This lack of effect of a GIGYF2 mutation is supported in a study in mice 
which found no differences between cells expressing wild-type or PD-linked mutant GIGYF2, 
and low levels of GIGYF2 in the SN and striatum relative to other brain regions and organ 
systems (Higashi, Iseki et al. 2010).  A further study found that a GIGYF2 deficient zebrafish 
model did not show any DA neuronal degeneration (Guella, Pistocchi et al. 2011).  Taken 
together, this evidence suggests that the primary reports of PD due to GIGFY2 mutation are 
more likely due to a separate, undetected, mutation. 
 
MnSOD is an enzyme found in the mitochondria (Weisiger and Fridovich 1973) that protects 
against superoxide induced oxidative damage by catalysing the dismutation of superoxide into 
oxygen and hydrogen peroxide (McCord, Keele Jr et al. 1971).  There have been suggestions 
that a polymorphism in the mitochondrial targeting sequence of the MnSOD gene may have a 
link with PD in Japanese patients with an allelic frequency of 19.3% in PD patients compared to 
12.2% in controls (Shimoda-Matsubayashi, Matsumine et al. 1996).  However, a further study 
on a German population did not support a link between this mutation, or a separate mutation 
affecting the stability of MnSOD, and PD (Grasbon-Frodl, Kösel et al. 1999).  As MnSOD is 
involved in defence against oxidative stress at the mitochondria, and this has been widely 
implicated in PD pathology, it makes an interesting candidate for a PD-linked mutation; 
however, the evidence to date is inconclusive. 
 
1.1.3.6 mtDNA mutations 
As well as nuclear DNA mutations there have been links between mtDNA mutations and PD, 
with a number of studies reporting high levels of mtDNA deletions in neurons in the SNpc of 
PD patients (Bender, Krishnan et al. 2006; Kraytsberg, Kudryavtseva et al. 2006).  It has been 
hypothesised that these pathologic DNA rearrangements are not primary drivers of the disease 
but may be caused by oxidative stress generated during mitochondrial dysfunction and this 
may further exacerbate cellular damage (Kirches 2009). The mitochondrial transcriptional 
factor A (TFAM) regulates transcription of mtDNA and was linked to PD by the finding that 
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TFAM knockout mice (MitoPark mice) had reduced mtDNA expression and a respiratory chain 
deficiency in SNpc DA neurons, which lead to a parkinsonian phenotype (Ekstrand, Terzioglu et 
al. 2007).  Although some studies showed that TFAM mutations do not significantly increase 
the risk of PD (Belin, Björk et al. 2007; Alvarez, Corao et al. 2008), an investigation into the 
influence of TFAM variants on PD depending on mtDNA haplogroup found certain variants 
increased the chances of developing PD (Gaweda-Walerych, Safranow et al. 2010) suggesting a 
possible role for mtDNA, in some instances, and respiratory chain dysfunction in PD. 
Mitochondrial DNA polymerase γ 1 (POLG1) is an enzyme involved in the synthesis and 
regulation of mtDNA and has been shown to have links with PD, including reduced activity of 
mitochondrial respiratory chain complexes (Luoma, Melberg et al. 2004; Davidzon, Greene et 
al. 2006).  The involvement of mutations of this protein in PD suggests a role for dysregulation 
of mtDNA in mitochondrial dysfunction in the disease.  However, whether or not there is a 
common hereditary role for POLG1 in PD needs further study, since a large scale study does 
not support this hypothesis (Tiangyou, Hudson et al. 2006). 
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PARK locus 
(Chromosomal position) 
Gene Inheritance Proposed Pathological Involvement in PD 
Mitochondrial 
dysfunction 
Oxidative 
stress 
Impaired 
protein 
degradation 
Ca2+/ 
excitotoxicity 
Dopamine 
metabolism 
Neuro-
inflammation 
PARK1 (4q21-q23) α-synuclein* Dominant       
PARK2 (6q25.2-q27) Parkin Recessive       
PARK3 (2p13) Unknown Dominant       
PARK4 (4p14-16.3) α-synuclein* Dominant       
PARK5 (4p14) UCH-L1 Dominant       
PARK6 (1p35-p36) PINK1 Recessive       
PARK7 (1p36.33 - p36.12) DJ-1 Recessive       
PARK8 (12p11.23-q13.11) LRRK2 Dominant       
PARK9 (1p36) ATP13A2 Recessive       
PARK10 (1p32) Unknown Dominant       
PARK11 (2q36-q37) GIGYF2** Dominant       
PARK12 (Xq21-q25) Unknown X-linked       
PARK13 (2p12) Omi/Htra2 Dominant       
PARK14 (18q11) PLA2G6 Recessive       
PARK15 (22q12-q13) FBXO7 Recessive       
PARK16 (1q32) Unknown Risk Gene       
* PARK1 and PARK4 were initially assigned to different regions on chromosome 4, but were later ascribed to the same underlying locus. 
** Link to PD not confirmed 
 
Table 1.3 Summary of PD mutations Summary of the major PARK PD-linked mutations and their proposed involvement in disease pathology 
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1.1.4 Environmental toxins linked with Parkinson’s Disease 
There is extensive evidence that PD can be caused by neurotoxins, specifically MPTP (Davis, 
Williams et al. 1979), rotenone (Greenamyre, MacKenzie et al. 1999), paraquat (Liou, Tsai et al. 
1997), diquat (Sechi, Agnetti et al. 1992) and TaClo (Bringmann, God et al. 1995; Bringmann, 
God et al. 1995). 
 
 
Fig. 1.13 Parkinson’s Disease linked toxins Structures of the PD linked neurotoxins 
MPTP/MPP+, Rotenone, Paraquat, Diquat and TaClo and similarity to DA 
 
1.1.4.1 MPTP  
MPTP (Fig 1.13) is produced as a by-product of the synthesis of a meperidine analogue with 
heroin-like properties (Ziering, Berger et al. 1947).  Langston et al described in 1983 that users 
of meperidine reported striking Parkinsonian symptoms and related this to the presence of 
MPTP (Langston, Ballard et al. 1983).  It has since been shown to closely reproduce the DA 
degeneration and symptoms of PD in various animal experimental models (Burns, Chiueh et al. 
1983; Seniuk, Tatton et al. 1990; Hantraye, Varastet et al. 1993) and has been the most widely 
used toxin in animal models of PD (Beal 2001).  MPTP readily crosses the blood brain barrier 
and is converted to the toxic 1-methyl-4-phenyl-2,3-dihydropyridium ion (MPP+) (Fig. 1.13) by 
MAO-B in astrocytes (Nicklas, Vyas et al. 1985) following uptake by various transporters 
(Brooks, Jarvis et al. 1989; Marini, Lipsky et al. 1992).  MPP+ is taken up into DA neurons by 
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DAT, seen as a reduction in MPTP toxicity in DAT deficient mice (Bezard, Gross et al. 1999), and 
then taken up into mitochondria via passive transport due to the large mitochondrial 
transmembrane gradient (Hoppel, Greenblatt et al. 1987).  MPP+ inhibits mitochondrial 
Complex I (Nicklas, Vyas et al. 1985; Nicklas, Youngster et al. 1987) leading to cell death via 
energy deficits (Przedborski, Jackson-Lewis et al. 2000), free radical and ROS generation 
(Cleeter, Cooper et al. 1992) and possibly excitotoxicity (Bezard, Gerlach et al. 2006) (Fig. 1.16).  
Although there is extensive evidence for this theory of MPTP toxicity, there has been a 
contradictory report that MPTP exposure in marmosets that displayed PD behavioural 
symptoms, reduced DA levels and DA neurodegeneration in the SNpc, showed no 
mitochondrial dysfunction or increased oxidative damage markers when assessed ex vivo a 
week following end of MPTP administration (Gerlach, Gotz et al. 1996).  In an MPTP mouse 
model of PD, α-synuclein is nitrated disrupting its normal properties (Przedborski, Chen et al. 
2001) providing another link between MPTP and PD. Despite all of the evidence of links 
between MPTP and PD in humans and animal models, there are differences between MPTP 
derived PD and idiopathic forms of the disease with MPTP PD showing an acute onset, 
variations in progression, and a lack of typical LB formation (Forno, DeLanney et al. 1993). 
 
1.1.4.2 6-OHDA 
6-hydroxydopamine (6-OHDA) is DA analogue (Fig. 1.14) and experimental tool that has been 
shown to be specifically neurotoxic to central monoamine neurons (Ungerstedt 1968).  As it is 
not able to cross the blood brain barrier, and is not thought to be produced in vivo, the effects 
of 6-OHDA have been studied via direct injection into the SNpc. 
 
                       (A)  (B)   
Fig. 1.14 DA and 6-OHDA Structural similarity of DA (A) and the analogue 6-OHDA (B)  
 
Unilateral injection of 6-OHDA into the SNpc has been shown to cause a drastic reduction in 
the number of DA neurons of the SNpc and lead to motor dysfunction in rodent models (Javoy, 
Sotelo et al. 1976; Iancu, Mohapel et al. 2005) (Fig. 1.15).  Due to this potent degeneration, the 
reproducibility of this and the ease of assessment of motor function with unilateral 
degeneration, this animal model of PD has been widely used to investigate the disease (Beal 
2001). 
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The mechanism by which 6-OHDA causes neurodegeneration is thought to be via inhibition of 
mitochondrial Complex I and generation of ROS leading to oxidative stress and cell death 
(Betarbet, Sherer et al. 2002) (Fig. 1.16).  In addition to this, an up regulation in genes that 
would lead to a strong inflammatory response has recently been reported suggesting a role for 
inflammation in the neurotoxicity of 6-OHDA (Na, DiLella et al. 2010). 
 
 
Fig.1.15 6-OHDA lesion Representative microphotographs of a mouse (A) striatum and (B) 
SNpc stained for TH (representing DA neurons) following unilateral treatment with 6-OHDA 
(right hemisphere as seen).  Approximately 97% degeneration of TH positive DA neurons seen.  
(Taken from (Iancu, Mohapel et al. 2005)) 
 
Whilst being a good model for PD, 6-OHDA does lack some of the main pathological and 
clinical traits of the disease.  6-OHDA does cause motor dysfunction; however it does not 
regularly produce tremor in animal models, a primary trait of PD.  It also does not produce LB 
or LB-like inclusions in the brains of affected animals.  So, while 6-OHDA is a reasonable model 
of the degeneration of DA neurons, it is not a completely reliable model of the pathology and 
symptoms of PD. 
 
1.1.4.3 Rotenone 
Rotenone (Fig. 1.13) is a widely used pesticide and naturally occurring neurotoxin that has 
been found to have links to PD (Greenamyre, MacKenzie et al. 1999).  Rotenone is highly 
lipophilic and able to easily cross the blood brain barrier and enter neuronal cells and 
intracellular organelles, such as mitochondria, without the aid of transporters.  Rotenone 
specifically blocks the ubiquinone binding site of Complex I, preventing the transport of 
electrons from Complex I to ubiquinone leading to the release of free radicals into the 
mitochondrial matrix and ROS formation (Lambert and Brand 2004) (Fig. 1.16).  This evidence 
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that rotenone is a specific inhibitor of Complex I which in turn leads to ROS production and 
oxidative stress can also cause PD-like behavioural symptoms such as akinesia and rigidity in 
rats (Bashkatova, Alam et al. 2004).  Rotenone administration has been shown to oxidatively 
modify DJ-1 and cause α-synuclein aggregation, effects linked to PD and localised to the DA 
neurons of the SNpc (Betarbet, Canet-Aviles et al. 2006) and  LB-like ubiquitin and α-synuclein 
containing cytoplasmic inclusions have been reported in the brains of rotenone treated rats 
(Betarbet, Sherer et al. 2000).  In vitro, chronic low dose exposure of SH-SY5Y neuroblastoma 
to rotenone (5nM for 4 weeks) has been shown to induce accumulation and aggregation of α-
synuclein and ubiquitin, oxidative damage, and cell death (Sherer, Betarbet et al. 2002).  This 
evidence, taken together, presents a strong link between rotenone exposure and PD via 
mitochondrial dysfunction.  However there is also evidence to suggest rotenone causes 
damage to neurons in the striatum but not the SNpc (Ferrante, Schulz et al. 1997) suggesting 
that it may not be DA specific and therefore not an entirely accurate model of PD. 
 
1.1.4.4 Paraquat/diquat 
Paraquat and diquat are widely used herbicides shown to have links with PD (Sechi, Agnetti et 
al. 1992; Liou, Tsai et al. 1997).  They are hydrophilic compounds and therefore do not readily 
cross the blood brain barrier and the mechanism by which they enter the brain is unclear, 
although uptake by a neutral amino acid (McCormack and Di Monte 2003) or polyamine (Karl 
and Friedman 1983) transporter has been suggested.  Paraquat can then be taken up into DA 
or other neurons via DAT or the organic cation transporter-3 respectively (Rappold, Cui et al. 
2011).  As paraquat and diquat have very similar structures to MPTP and MPP+ (Fig. 1.13), it 
was thought that they would act via a similar toxic mechanism.  However, unlike rotenone and 
MPP+, paraquat does not inhibit Complex I and is not taken up by DAT, suggesting an 
alternative mechanism of cell death (Richardson, Quan et al. 2005).  A likely toxic mechanism is 
described where paraquat is reduced to the paraquat radical.  There are a number of proposed 
mechanisms for the formation of this radical: firstly reduction of paraquat by Complex I leading 
to accelerated lipid peroxidation (Fukushima, Tawara et al. 1995; Cochemé and Murphy 2008); 
and secondly whereby paraquat is reduced to the paraquat radical by Complex II has also been 
reported (Castello, Drechsel et al. 2007).  A final hypothesis for the formation of the paraquat 
radical is that paraquat is reduced by NADPH-cytochrome p450 reductase (Clejan and 
Cederbaum 1989) or NADPH-cytochrome c reductase (Fernandez, Subirade et al. 1995) in the 
cell.  Whichever complex or enzyme is involved, the paraquat radical can react with oxygen to 
form ∙O2
- leading to oxidative stress and generation of further ROS by mitochondrial 
dysfunction (Cochemé and Murphy 2008) (Fig. 1.16).  This mechanism of cell death may target 
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the DA neurons specifically because of their constant state of oxidative stress leaving them 
more vulnerable than other cells.  A large scale mouse study into the pharmacokinetics and 
SNpc and striatal toxicity of paraquat found that systemically administered paraquat can reach 
the brain, did reduce DA neurons in the SNpc of exposed animals in some studies but not in 
others when assessed by stereology, but did not affect DA levels or find evidence of cell death 
markers (Breckenridge, Sturgess et al. 2013).  This study does not show conclusive evidence of 
paraquat toxicity in mouse brain but shows some contradictory evidence that it may, and 
suggests that more work needs to be carried out to confirm or deny the hypothesis.  It has also 
been shown that paraquat can lead to an increase in both α-synuclein levels and aggregation 
(Manning-Bog, McCormack et al. 2002).  Although the exact mechanism has yet to be 
elucidated, mitochondrially derived paraquat radical, combined with its effects on α-synuclein, 
indicate paraquat toxicity as a possible causative agent in PD, although this needs confirming.  
The structurally similar compound diquat also generates oxygen radicals in rat brain 
microsomes (Yumino, Kawakami et al. 2002), a discovery that, when coupled with its similarity 
in structure and properties with paraquat, suggests a possible similar role for diquat in radical 
generation and PD. 
 
The TCE derived β-carboline TaClo has also been implicated in PD; this will be discussed in 
more detail in Section 1.2.2.3. 
 
However, this evidence of mitochondrial Complex I inhibition leading to neuronal cell death in 
PD following toxin exposure requires further investigation following the findings of Choi et al. 
that midbrain neurons in mice without Complex I activity were still susceptible to cell death 
following rotenone, MPTP or paraquat treatment and were, in the case of rotenone, more 
susceptible (Choi, Kruse et al. 2008).  This suggests that mitochondrial dysfunction could either 
be occurring parallel to another non-mitochondrial cell death mechanism or as a secondary 
effect driven by some other cellular stress or damage such as toxic protein accumulation due 
to ubiquitin-proteasome system impairment (McNaught, Olanow et al. 2003), inflammation 
(Bartels and Leenders 2007) or DNA damage (Kao 2009).  However, these results have not 
been confirmed and do not seem to be compatible with the literature, and in particular, a 
study carried out by Marella et al..  They found that expression of NDI1 - a yeast NADH-
quinone oxidoreductase that can act as an alternative to Complex I - in a rat model significantly 
protected against rotenone toxicity (Marella, Seo et al. 2008) suggesting the results seen by 
Choi et al. are unlikely to be relevant, possibly due to incomplete knockdown of Complex I. 
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Fig. 1.16 Mechanisms of DA cell death mediated by common PD neurotoxins Paraquat 
crosses the blood brain barrier (BBB) by an as yet unclear mechanism, possibly via an amino 
acid transporter (AAT) /polyamine transporter (PAT), where it enters the cell and is 
spontaneously reduced to the paraquat radical (PQ∙) and can then form ROS.  6-OHDA can be 
injected directly into the brain and rotenone can cross from the periphery, from where they 
enter neurons and can cause CI inhibition which leads to the production of ROS.  MPTP enters 
the brain where it is taken up and converted to MPP+ in glial cells by MAO-B.  This MPP+ is 
then transported out of the glia and taken up into neurons by the DAT.  Once in the cell MPP+ 
also causes CI inhibition and generation of ROS.  ROS formed by these environmental toxins 
can then lead to lipid peroxidation, protein damage, DNA damage and, ultimately, cell death 
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1.1.5 Animal Models of Parkinson’s Disease 
1.1.5.1 Toxin induced Models of PD 
A number of PD models have been generated using exposure to compounds shown to 
replicate elements of the disease.  The major toxin induced models of PD that have been 
studied are 6-OHDA, MPTP, rotenone and paraquat and have all been mentioned in detail in 
section 1.1.4 above.  6-OHDA was the first major animal model of the disease but has since 
been replaced by MPTP due to easier delivery methods and a more accurate replication of the 
disease pathology.  Rotenone and paraquat are more recently developed models that are not 
as fully characterised but do seem to relatively accurately reproduce the symptoms of the 
disease. 
 
One less commonly used toxin that may induce PD like symptoms and pathology in animal 
models is methamphetamine.  Extremely high methamphetamine exposure in rats has been 
shown to produce selective reduction in tyrosine hydroxylase, a common marker of DA 
neurons, in the nigro-striatum (Trulson, Cannon et al. 1985), possibly inducing cell death 
through increased DA release and turnover leading to higher levels of oxidative stress. While it 
may show promise, this model is not very reliable nor is it as accurate in replicating PD as the 
other models mentioned.  Another PD model not widely used is systemic Reserpine 
administration.  This leads to a depletion of DA in the striatum and mimics the motor 
dysfunction seen in the disease (Fernandes, Santos et al. 2012); however, the Reserpine model 
does not recreate the underlying pathology of PD so is of limited use.  Recently, an animal 
model has been developed to test the effects of oxidative stress on PD pathology by 
administration of 3-nitrotyrosine, a compound formed by the reaction of peroxynitrite with 
protein molecules possibly involved in protein aggregation.  Injection of free 3-nitrotyrosine 
induced a correlated reduction in motor function and striatal DA neurons (Mihm, Schanbacher 
et al. 2001), suggesting this may be a useful model in the study of PD.  However, 3-
nitrotyrosine does not seem to mimic the progressive nature of PD and needs to be 
characterised more fully to elucidate its use in studying the disease. 
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1.1.5.2 Genetic Models of PD 
In addition to the toxin induced models of PD, a number of transgenic animal lines have been 
generated that have attempted to replicate the pathology of the disease. 
 
A number of models have been developed using α-synuclein, with mutated (mainly A30P & 
A53T mutations) or wild-type forms of the protein expressed under the control of various 
promoters.  Early α-synuclein transgenic mice used a tyrosine hydroxylase promoter to try and 
target the mutations to DA neurons, however, these models expressing wild-type or mutant α-
synuclein only produced minor motor dysfunction and little to no PD pathology (Masliah, 
Rockenstein et al. 2000; Matsuoka, Vila et al. 2001).  A strain of mouse expressing human A30P 
mutant α-synuclein under the pan-neuronal Thy1 promoter develops a condition that mimics 
the development of PD with abnormal age dependent α-synuclein accumulation in the 
brainstem and an overexpression of tau phosphorylation (Kahle, Neumann et al. 2000; Frasier, 
Walzer et al. 2005) as well as decreased motor function occurring with age (Freichel, Neumann 
et al. 2007).  However, as with other models, there are no reports of decreased DA levels or 
decreased DA neuron number in this model.  As PD pathology has been suggested to occur at 
an early stage in the olfactory bulb, a model expressing A30P mutant α-synuclein under a 
promoter specific for olfactory neuron reported a significant decrease in DA in this region and 
a decrease in DA neuron number, that was not quite significant (P=0.08) (Nuber, Petrasch-
Parwez et al. 2011), showing promise as a good model of the disease.  A recent study 
expressed wild-type, A30P and A53T mutant forms of α-synuclein in mice under the mouse 
prion protein promoter and found LB-like α-synuclein inclusions, mitochondrial defects and 
cell death in neocortical, brainstem and motor neurons in A53T mutants, with similar but less 
severe pathology in A30P mutants and little to no pathology in wild-type mutant animals 
(Martin, Pan et al. 2006). 
 
LRRK2 is another mutation that has been used to try and recreated the features of PD in a 
mouse model.  G2019S mutant LRRK2 has been expressed in mice under a bacterial artificial 
chromosome promoter, and showed altered DA transmission in the striatum but no DA cell 
loss or motor dysfunction by 12 months (Li, Patel et al. 2010);this may be a good model of 
early pathology in PD, but does not fully replicate the disease progression.  A more recent 
model expressing wild-type and two mutant forms of LRRK2 under a CMV enhanced human 
platelet derived growth factor β promoter showed more promise in replicating PD pathology.  
G2019S mutant LRRK2 overexpressing animals showed an age-dependent reduction in DA 
neurons and dysfunctional autophagic and mitochondrial activities in the nigrostriatal 
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pathway, but no motor dysfunction, and R1441C mutant mice showed reduced motor 
function, but no striatal pathology, due to a lack of expression (Ramonet, Daher et al. 2011). 
 
Due to the probable involvement of the UPS and the presence of misfolded proteins in PD 
pathology, a model has been developed whereby the 26S proteasome is inactivated in the SN 
and forebrain of a strain of mice.  These mice have been shown to develop intraneuronal 
inclusions similar to LBs and extensive neurodegeneration in the nigrostriatal pathway and 
forebrain (Bedford, Hay et al. 2008).  In addition to this model, mice expressing a mutated 
version of the ubiquitin modulating enzyme UCH-L1, were reported to show a loss of DA 
neurons of the SN and decrease in striatal DA content (Setsuie, Wang et al. 2007). 
 
DA D2 receptors are found in the SN on DA nerve terminals where they act to inhibit the 
neuron following DA release. A D2-knockout mouse has been generated which shows PD-like 
motor impairments, evidence of increased oxidative stress and LB inclusions in neurons of the 
SN, but although there is evidence of DA neuron axonal degeneration, no progressive cell loss 
is seen in the SNpc (Baik, Picetti et al. 1995; Tinsley, Bye et al. 2009). 
 
The ‘MitoPark’ mouse is a model of mitochondrial dysfunction generated by conditionally 
knocking out TFAM in DA neurons.  TFAM is essential for mitochondrial gene expression and 
maintenance so knocking it out leads to mitochondrial dysfunction in the DA neurons.  These 
mice have been shown to replicate the slow progressive motor deficit seen in PD, which can be 
reversed by L-DOPA treatment, and is preceded by the formation of intraneural inclusions, 
reduced DA levels in the striatum and DA cell loss in the SNpc (Ekstrand, Terzioglu et al. 2007; 
Galter, Pernold et al. 2010; Good, Hoffman et al. 2011).  MitoPark mice seem to be a promising 
model of PD pathology and clinical features; however, in contrast to the disease, the inclusions 
seen in the model have not been shown to contain α-synuclein. 
  
Current transgenic models have been shown to replicate some features of the disease and are 
useful in investigating the mechanisms that lead to the SNpc DA cell loss seen but none, so far, 
are accurate replications of the complex pathology and clinical signs of PD. 
 
1.1.5.3 Non-mammalian Animal Models of PD 
Although mammal models of PD are the most useful in replicating disease pathology and 
progression, non-mammal models can often be used to mimic facets of the disease to better 
understand the mechanisms underlying the condition. 
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Human gene C. elegans ortholog Drosophila ortholog Zebrafish ortholog 
α-synuclein UNK UNK UNK 
PINK1 pdr-1 Parkin Parkin 
Parkin pink-1 Pink-1 Pink-1 
DJ-1 djr1.1, djr1.2 DJ-1α, DJ-1β Dj-1 
LRRK2 lrk-1 Lrrk Lrrk2 
Table 1.4 Summary of human PD genes and non-mammalian orthologs 
 
 
Caenorhabditis elegans (C. elegans) is nematode worm that is well characterised and a 
commonly used experimental organism.  The neurobiology of C. elegans has been widely 
studied and been shown to be highly conserved with that of mammals (Bargmann 1998), and 
all the major PD-linked genes, apart from α-synuclein, have been shown to have analogues in 
C. elegans (Table 1.4), which when combined with its ease of care and maintenance in a 
laboratory have led to its widespread use in investigating PD.  C. elegans have been generated 
with GFP tagged DA neurons, making them easy to visualise, and these worms have been 
shown to have selective DA neurodegeneration when exposed to 6-OHDA (Nass, Hall et al. 
2002).  Although C. elegans has not been shown to express α-synuclein, worms transgenically 
manipulated to overexpress wild-type or mutated human α-synuclein have been shown to 
suffer DA degeneration, abnormal motor function and the formation of LB-like inclusions 
(Lakso, Vartiainen et al. 2003; Kuwahara, Koyama et al. 2006; Van Ham, Thijssen et al. 2008).  
In addition, C. elegans expressing α-synuclein, or undergoing deletion of pdr-1 (parkin 
ortholog) or djr1.1 & djr1.2 (DJ-1 orthologs) showed increased vulnerability to rotenone (Ved, 
Saha et al. 2005). 
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Fig. 1.17 Selectivity of the 
neuronal degeneration 
induced by rotenone in 
drosophila                             (A) 
Co-immunolabeling of adult 
brains with anti-tyrosine 
hydroxylase (TH) (A1, A2) and 
anti-Elav (A3, A4) antibodies 
after 7 d of exposure to 125 
μm rotenone. The pesticide 
induced obvious dopaminergic 
neuron loss, whereas the 
general pattern of the pan-
neuronal Elav marker was not 
modified. 
(B) Total number of 
serotoninergic (5-HT) and 
dopaminergic (DA) neurons in 
fly brains exposed for 7 d to 
125 μm rotenone (white bars) 
compared with control brains 
(black bars), expressed as a 
percentage of the mean value 
of the control. n indicates the 
number of brain hemispheres 
examined in each condition. 
***P<0.001 (Taken from 
(Coulom and Birman 2004)) 
 
 
 
 
Drosophila melanogaster (drosophila) is a fruit fly that is widely used in biological research due 
to its well characterised genome and cost and ease of culturing.  Its nervous system is more 
complex than C. elegans but still far more simple than its mammalian counterpart, and 
drosophila has been shown to have orthologs of the major PD-linked genes apart from α-
synuclein (Table 1.4).  Drosophila has been shown to be a good model for sporadic PD with 
chronic rotenone exposure leading to a loss of DA neurons (Fig 1.17) and motor dysfunction 
assessed by climbing activity that can be reversed by L-DOPA administration (Coulom and 
Birman 2004).  Drosophila expressing human wild-type or mutant α-synuclein were found to 
have DA neurodegeneration, loss of climbing ability and developed intraneuronal a-synuclein-
positive inclusions that resemble LBs (Feany and Bender 2000).  Finally, flies which have been 
modified to knockout parkin, pink1, dj-1α and lrrk2 have all shown DA neuronal cell loss and 
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behavioural abnormalities relating to PD (Yang, Gehrke et al. 2005; Park, Lee et al. 2006; Wang, 
Lu et al. 2007; Liu, Wang et al. 2008), providing a variety of drosophila models of the disease. 
 
The zebrafish, Danio rerio, is widely used as a biological model system due to its relative 
closeness to humans in comparison to invertebrate models and the fact that it is more easily 
visualised and manipulated than other common vertebrate model species.  The zebrafish 
genome has been sequenced and is well characterised and it has orthologs of the major 
human genes linked with PD (Table 1.4); however, although orthologs of various synuclein 
proteins have been found in the zebrafish, an α-synuclein ortholog has not, as yet, been 
established (Sun and Gitler 2008).  In zebrafish DA neuron clusters in the ventral diencephalon 
(vDC) have been shown to be analogous to the ascending midbrain DA of the nigrostriatal 
pathway in mammals (Rink and Wullimann 2002).  Zebrafish exposed to 6-OHDA and MPTP 
have been reported to show behavioural deficits and reduced DA levels (Anichtchik, Kaslin et 
al. 2004), and further studies have shown a decrease in DA neurons in specific areas of the vDC 
of zebrafish exposed to MPTP (Wen, Wei et al. 2008).  Knockout of zebrafish Parkin, PINK1 and 
DJ-1 othologs have not been reported to show any DA degeneration; however, in all three 
cases, knockout of these genes has increased susceptibility of DA neurons to environmental 
stress and subsequent cell death (Bretaud, Allen et al. 2007; Fett, Pilsl et al. 2010; Sallinen, 
Kolehmainen et al. 2010), similar to mouse models. 
 
1.1.5.4 Problems with Animal Models of PD 
Animal models have been key in reaching the levels of understanding of PD we are at today; 
however, there are problems with, and limitations to, these models.  Primarily, the difference 
in physiological make-up between model species and humans leads to difficulties in accurately 
replicating the disease; this can be seen in the varying results seen between species with 
different species showing markedly differing sensitivities to certain genetic manipulations and 
toxin exposures.  Although some models have come close to replicating the features of the 
disease, none have as yet managed to produce a model that accurately reproduces PD 
meaning results seen cannot be entirely extrapolated to fully represent the disease.  In 
addition to this, slight differences in the techniques used to generate and measure PD 
pathology and clinical signs in different laboratories seem to give widely varying results in 
similar experiments, with this especially apparent in mammalian behavioural studies, casting 
doubt on some findings.  While animal models are extremely useful in PD research, more 
representative and robust models are needed to advance understanding more fully. 
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1.1.6 Other Parkinsonian Syndromes 
There are a number of other syndromes that share the clinical hallmarks of PD but have been 
shown to have differing pathologies, including multiple system atrophy, progressive 
supranuclear palsy and corticobasal degeneration.  A summary of clinical and pathological 
differences can be seen in Table 1.5. 
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 PD MSA PSP CBD 
Clinical discriminators of parkinsonian syndromes 
Tremor Asymmetrical; post 4–8 
Hz, rest 3–5 Hz; arms and 
legs, jaw, eyelids; latency 
to onset 
Asymmetrical; post 4–8 
Hz, rest 3–5 Hz; arms or 
legs; latency 
Uncommon Asymmetrical; postural, 
with stimulus sensitive 
myoclonus 
Rigidity Asymmetrical; limb Asymmetrical; limb Symmetrical; axial >limb Asymmetrical; limb 
Finger Movements Progressive slowing with 
decreasing amplitude 
Progressive slowing with 
decreasing amplitude 
Spared early Early apraxia—hand can 
become useless 
Facies Early loss of expression 
and blinking. Late 
blepharoclonus 
Early loss of expression; 
facial dyskinesias 
Lid retraction; staring; 
eye opening apraxia 
Early loss of expression; 
orobuccal apraxia 
Dysautonomia Early impotence, late OH, 
bladder, constipation 
Early OH, bladder, impotence, 
constipation 
Early impotence, bladder, OH 
rare 
Early impotence, bladder, 
OH rare 
Ulbar Late dysarthria; hypophonia Early dysarthria, dysphagia; 
night stridor 
Early dysarthria, dysphagia Early dysarthria, dysphagia 
Gait and posture Late falls; retropulsion; 
festination, flexed posture 
Early falls, flexed posture; 
antecollis ++ 
Early falls, retrocollis Early falls 
Eye movements Hypometric Nystagmus, hypometric Eye deviation to OKN, SGP Occasional SGP 
Ataxia None Frequent Rare Rare 
Apraxia None None End stage limb; eye 
opening 
Limb, alien phenomena 
Pathological discriminators of parkinsonian syndromes 
Neurodegeneration SNpc Olivopontocerebellar & 
striatonigral 
Brain stem, basal ganglia and 
occular motor nucleii 
Cerebral cortex and 
subcortical nuclei 
Pathological hallmarks LB (α-synuclein) GCI (α-synuclein) Neurofibrillary tangles (tau) Astrocytic plaques& 
neurofibrillary tangles (tau) 
Table 1.5 Summary of clinical and pathological differences in parkisonian syndromes  Abbreviations:  OH, orthostatic hypotension; OKN, opticokinetic nystagmus; 
SGP, supranuclear gaze palsy (adapted from (Brooks 2002)).
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1.1.6.1 Multiple System Atrophy 
Multiple system atrophy (MSA) is a neurodegenerative condition which combines a variety of 
parkinsonian clinical signs with dysautonomia and cerebellar symptoms.  It has a prevalence of 
4-5 cases per 100,000 (Tison, Yekhlef et al. 2000) and develops more rapidly than PD with a life 
expectancy of less than 9 years following diagnosis (Schrag, Wenning et al. 2008) and no 
current treatments. MSA was first characterised by Papp et al. who found a common 
pathological feature of glial cytoplasmic inclusions in the brains of patients diagnosed with 
what was then thought to be three separate conditions: olivopontocerebellar atrophy, 
striatonigral degeneration and Shy-Drager syndrome (Papp, Kahn et al. 1989).  The presence of 
these glial cytoplasmic inclusions (GCI) is now a hallmark of the disease and, when combined 
with olivopontocerebellar and striatonigral neurodegeneration, used for neuropathological 
diagnosis of MSA.  A pathological link with PD was discovered when it was reported that GCIs, 
along with similar inclusions in neurons of the nigra, pontine and inferior olivary nuclei, and 
dentate fascia, in MSA patients were shown to contain α-synuclein (Wakabayashi, Yoshimoto 
et al. 1998).  Clinically, MSA is subcategorised into a parkinsonian (MSA-P) or a cerebellar 
(MSA-C) form dependent on the predominance of a parkinsonian or cerebellar symptoms, with 
dysautonomia present in both subtypes and  including urinary incontinence, respiratory 
failure, dysarthria, dysphagia and orthostatic hypotension (Gilman, Low et al. 1999; Gilman, 
Wenning et al. 2008), but clinical symptoms can substantially differ between patients.  In vitro 
findings that mutated α-synuclein can lead to activation of glia and increased inflammatory 
modulators suggest a possible role for neuroinflammation in the disease mechanism (Klegeris, 
Pelech et al. 2008; Su, Federoff et al. 2009). 
 
There have been reports of inherited familial forms of MSA in Germany and Japan (Soma, Yabe 
et al. 2006; Hara, Momose et al. 2007; Filosto, Tonin et al. 2009); however, due to the limited 
numbers of individuals affected, a causative gene has not yet been identified.  Due to the 
presence of α-synuclein in GCIs in MSA, mutations in this gene may be involved in the disease, 
with genetic variants of the α-synuclein gene shown to lead to an increased risk of MSA (Al-
Chalabi, Dürr et al. 2009; Scholz, Houlden et al. 2009; Ross, Vilariño-Güell et al. 2010).  Another 
candidate gene for mutation in MSA is microtubule associated protein tau, with the H1-
haplotype having been shown to be present in a number of MSA cases and shown to confer an 
increased risk of developing the disease (Vilariño-Güell, Soto-Ortolaza et al. 2011).  This is 
interesting as MSA is primarily thought of as a synucleinopathy and has not been thought to 
have tau pathology. 
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Attempts have been made at using toxin induced animal models to try and recreate the 
symptoms and pathology of MSA-P.  The simultaneous injection of PD-linked toxins MPTP or 6-
OHDA, with the neuroinflammation-linked excitotoxic compound quinolinic acid or the 
succinate dehydrogenase inhibitor 3-nitropropionic to create lesions in the striatum and nigra 
has produced the motor impairment seen in the disease; however these models have not been 
able to replicate the GCIs characteristic of the disease so are only of limited use (Scherfler, 
Puschban et al. 2000; Waldner, Puschban et al. 2001; Ghorayeb, Fernagut et al. 2002). 
 
1.1.6.2 Progressive Supranuclear Palsy 
Progressive Supranuclear Palsy (PSP) is the second most common parkinsonian syndrome that 
was first distinguished from PD by Steele et al. in 1964 (Steele, Richardson et al. 1964) and has 
a prevalence of 6.5 per 100,000 people in the UK (Nath, Ben-Shlomo et al. 2001).  The disease 
is characterised by early gait and balance impairment, with postural instability and recurrent 
falls being primary signs of the disease (Birdi, Rajput et al. 2002), followed by development of 
the ocular manifestations characteristic of the condition, namely supranuclear 
ophthalmoparesis (paralysis of down gaze) (Litvan, Campbell et al. 1997) and saccades (rapid 
eye movement between two stimuli) (Bhidayasiri, Riley et al. 2001) as well as general eye 
complaints such as blurred vision, diplopia, eye irritation or discomfort, eyelid abnormalities 
and photophobia (Friedman, Jankovic et al. 1992).  PSP patients may also present with 
dementia, dysarthria, dysphagia and dystonia (Kluin, Foster et al. 1993; Pillon, Deweer et al. 
1994; Barclay and Lang 1997; Nath, Ben-Shlomo et al. 2003).  Pathologically, PSP manifests as 
neurofibrillary tangles composed of intracellular aggregates of the microtubule-associated 
protein tau in neurons and glia (Pollock, Mirra et al. 1986) and degeneration of neurons and a 
proliferation of glia in the globus pallidus, subthalamic nucleus, red nucleus, substantia nigra, 
periaqueductal grey matter, pontine tegmentum and dentate nucleus (Armstrong, Lantos et al. 
2007). 
 
A report of an autosomal dominant inherited form of PSP with incomplete penetrance has 
been published (Rojo, Pernaute et al. 1999) and mutations in MAPT have been linked with the 
disease development (Conrad, Andreadis et al. 1997; Baker, Litvan et al. 1999) suggesting a 
possible familial form of the disease related to mutations in tau.  It has also been suggested 
that PSP may be due to mutations in mtDNA, leading to mitochondrial electron transport chain 
misassembley, Complex I dysfunction and increased oxidative stress (Swerdlow, Golbe et al. 
2000).  The involvement of environmental toxins in the pathology of PSP has been proposed 
but there have been no significant reports of this so far. 
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1.1.6.3 Corticobasal Degeneration 
Corticobasal Degeneration (CBD) is a neurodegenerative condition similar to PSP that was first 
described as a distinct condition by Gibb et al. in a review of 3 patients (Gibb, Luthert et al. 
1989).  It combines asymmetric parkinsonian symptoms with a phenomenon known as ‘Alien 
Hand Syndrome’, apraxia, aphasia and, occasionally,  dementia (Rinne, Lee et al. 1994).  CBD is 
characterised pathologically by the presence of astrocytic plaques and ‘ballooned’ neurons 
(Takahashi, Amano et al. 1996) as well as asymmetrical atrophy of the cerebral cortex and 
subcortical nuclei, especially the substantia nigra (Ikeda 1997). 
 
CBD is generally considered a sporadic disease; however there have been reports that the 
condition shares a common tau haplotype with PSP (Di Maria, Tabaton et al. 2000; Houlden, 
Baker et al. 2001), suggesting a possible genetic component in CBD development through 
MAPT.  Although environmental factors may be involved in the pathology of CBD, no wide 
scale studies into this have been carried out as yet. 
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1.2 Trichloroethylene 
TCE (Fig. 1.18) is a volatile industrial solvent that is used as a metal degreasing agent, paint 
stripper and as an ingredient in paints and varnishes (Wu and Schaum 2000), as well as being 
used in the past in industrial scale dry cleaning and as an inhalational anaesthetic (Lock and 
Reed 2006).  TCE is also found in the food chain and water system to due to environmental 
contamination (Wu and Schaum 2000; Lock and Reed 2006), which, combined with the 
occupational contact, leads to a proportion of the population exposed to chronic low levels of 
the chemical. 
 
Fig. 1.18 TCE Chemical structure of TCE 
 
1.2.1 Trichloroethylene Exposure 
TCE is released in to the environment during its manufacture, use and disposal.  Most TCE is 
released into the atmosphere, although it is also present, due to disposal, in water and landfill 
sites.  Due to its volatile nature most environmental TCE is present in the atmosphere but also 
at lower levels in the groundwater as a result of its moderate water solubility (Wu and Schaum 
2000).  Once in the air, TCE has a relatively short half-life of seven days, due to degradation by 
reacting with hydroxyl radicals, meaning that is not a persistent atmospheric contaminant.  
However, owing to the constant release of TCE, it is continually present in areas of production 
(Williams-Johnson, Eisenmann et al. 1997). 
 
Workers in industrial areas, especially the degreasing trade, have the highest exposure to TCE, 
mainly through inhalation, with levels ranging from 1-100 ppm (Williams-Johnson, Eisenmann 
et al. 1997).  The general public can also be exposed to lower levels of TCE through drinking 
water with the U.S. state surveys reporting between 9% and 34% of drinking water sources 
contaminated with TCE (Williams-Johnson, Eisenmann et al. 1997), and a separate study found 
that subjects from a community adjacent to a known TCE contaminated water supply were 
exposed to TCE at levels up to 19.1 ppb (Reif, Burch et al. 2003).  The U.S. Department for 
Health and Human Services document on the toxicological profile for TCE estimated average 
daily intakes of TCE of 11-33mg/day from air and 2-20mg/day from drinking water in America.  
This data shows that the populace can be exposed to chronic low levels of TCE both 
Chapter 1          Introduction 
59 
 
occupationally and through proximity to environmental contamination.  A study of an 
individual exposed to TCE occupationally for twenty years reported TCE present in exhaled air 
up to six years following final exposure, with 128ng/l present three years post exposure which 
had reduced to 3ng/l by six years (Kochen, Kohlmüller et al. 2003).  Re-exposure was 
absolutely excluded in this individual suggesting that TCE is persistent in the body for a 
relatively long period following exposure. 
 
1.2.2 General Trichloroethylene Toxicity 
In 1976, the U.S. Department of Health, Education and Welfare published a paper on the links 
between TCE and carcinogenicity in animals (U.S. Department of Health 1976).  Since then 
studies have shown links between TCE and its metabolites and renal, respiratory, reproductive 
and hepatic carcinogenicity in animal models although there is some dispute whether this will 
translate into risk in humans (Davidson and Beliles 1991; Committee on Human Health Risks of 
Trichloroethylene 2006).  Lock & Reed reviewed renal carcinogenicity data of adenoma and 
carcinoma formation in animal studies following TCE exposure, and propose a weak 
association between high level TCE and renal carcinoma.  They suggest a mechanism for this 
carcinogenicity that involves conjugation with GSH leading to formation of a reactive 
electrophile (Lock and Reed 2006). 
 
There have also been reported links between TCE and pulmonary carcinogenicity in mouse 
models (Davidson and Beliles 1991) but it has been suggested that this is due to the high 
activity of p450 in the mouse lung, approximately 600-fold that in humans, and therefore will 
not translate to humans (Green 2000).  Further to the possible pulmonary carcinogenicity, TCE 
has also been linked to toxicity in the lungs, specifically the Clara cells of the bronchiolar 
epithelium in mice after acute dosing (Forkert and Birch 1989).  Comparable to the lung cancer 
causing effects of TCE, hepatic tumours have been found, mainly in mouse models, and are 
thought to be associated with peroxisome proliferation and increased cell division.  These are 
also thought not to translate well to humans due to metabolic differences between the species 
(Green 1997). 
 
TCE has also been reported to cause severe damage to kidney, intestine, liver and brain, as 
well as altered carbohydrate metabolism in rats, with suppressed antioxidant defence system 
suggested as a possible mechanism for this (Khan, Priyamvada et al. 2009).  This suspected 
reduction in antioxidant defence was given further credence by previous reports that the 
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activity of molecules involved in endogenous antioxidant defence, superoxide dismutase and 
glutathione peroxidase were decreased in dogs (Aslan, Tütüncü et al. 2000). 
 
1.2.3 Trichloroethylene Neurotoxicity & Metabolism 
There have been widespread reports of neurotoxicological effects of TCE.  In humans, acute 
TCE exposure has been shown to lead to headache, fatigue, drowsiness, inability to 
concentrate, dizziness, loss of facial sensation and unconsciousness (Williams-Johnson, 
Eisenmann et al. 1997; Committee on Human Health Risks of Trichloroethylene 2006), and 
chronic low exposure, has been linked to general neurobehavioral deficits (Reif, Burch et al. 
2003).  TCE has also been shown to depress conductance in squid giant axons, at least partly 
due to a decrease in resting potassium permeability, leading to a potential for general 
anaesthetic properties in mammals (Bhushan Shrivastav, Narahashi et al. 1976).  In animal 
models, inhibition of long term potentiation and plasticity in mouse hippocampus has been 
reported in TCE exposed mice (Ohta, Saito et al. 2001; Altmann, Welge et al. 2002), suggesting 
a possible role of TCE in memory impairment.  In studies into early life exposure of TCE, altered 
social behaviours and increased aggression associated with markers of oxidative stress in the 
brain were seen.  The mechanism of these pre-natal effects of TCE on the brain which may 
involve modulation of the immune system by a redox-associated differentiation of T-cells in 
the thymus and an associated increase in pro-inflammatory cytokines from CD4+ T-cells 
affecting the developing brain (Blossom, Doss et al. 2008).  TCE exposure in juvenile MRL +/+ 
mice, has been shown to lead to an increased oxidative state and decreased expression of 
neurotrophic factors in the hippocampus (Blossom, Melnyk et al. 2012) , suggesting a possible 
cellular mechanism for the neurotoxic effects of TCE discussed. 
 
TCE exposure has been suggested to have links with idiopathic PD, with small scale case report 
studies showing high levels of occupational TCE exposure in PD patients and a higher than 
expected occurrence of motor deficits in similarly exposed co-workers (Guehl, Bezard et al. 
1999; Kochen, Kohlmüller et al. 2003; Gash, Rutland et al. 2008).  More recently, an 
investigation into ninety-nine pairs of twins discordant for PD found that occupational 
exposure to TCE increased the odds ratio of developing PD by over six times (Goldman, 
Quinlan et al. 2012), supporting the case reports in a population based study. 
Trichloroethylene has been identified in at least 861 of the 1,428 hazardous waste sites that 
have been proposed for inclusion on the EPA National Priorities List in the USA (Williams-
Johnson, Eisenmann et al. 1997) and a geographical comparison of these sites with PD 
prevalence among Medicare beneficiaries (Wright Willis, Evanoff et al. 2010) reinforced the 
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link between TCE and PD with areas showing high PD prevalence (orange and red areas in Fig. 
1.19 B), such as the northeast and south central regions of the country, generally correlating 
well with the areas shown to have >10 TCE waste sites (dark grey and large dotted areas in Fig. 
1.19 A).  These links between TCE exposure and PD have recently been supported by a report 
that rats orally dosed with TCE over six weeks showed a reduction in DA neurons in the SNpc, 
reduced levels of DA metabolism, motor deficits and reduced mitochondrial Complex I activity 
(Liu, Choi et al. 2010).  A study in rats reportS a reduction in mitochondrial function in the 
striatum of TCE exposed rats and reduced motor performance and SNpc TH positive neuron 
number in animals that suffered traumatic brain injury in addition to this TCE exposure 
(Sauerbeck, Hunter et al. 2012).  This study further indicates a link between TCE and PD but 
suggests concurrent insults may be needed for neuronal damage and functional development 
of the disease.  As well as potential links with PD, a number of patients with the severe 
Parkinsonian syndrome MSA have been found to have had high exposure levels to TCE (Blain, 
personal communication), providing more evidence of the link between the chemical and DA 
neurodegeneration. 
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Fig. 1.19 Comparison of TCE waste sites and PD prevalence in the USA (A) Frequency of EPA 
National Priorities List hazardous waste sites with TCE contamination.  Taken from (Williams-
Johnson, Eisenmann et al. 1997)(B) County level age- and race-standardized prevalence (per 
100,000) of Parkinson disease among Medicare beneficiaries in the United States (year = 
2003). Taken from (Wright Willis, Evanoff et al. 2010) 
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1.2.3.1 TCE Metabolism 
It has been hypothesised that some of these neurotoxicological effects of TCE may be 
mediated by products of TCE metabolism.  TCE is metabolised predominantly by two major 
routes, either by the cytochrome p450 oxidative pathway (Fig. 1.20) or the GSH conjugation 
pathway, with the oxidative pathway predominating and being the pathway that generates the 
major toxic metabolites of TCE (Maull and Lash 1998) and will be discussed in more detail. 
 
Fig. 1.20 TCE metabolic pathway Schematic of the oxidative pathway of TCE metabolism 
leading to formation of potentially toxic metabolites; chloral, TaClo and dichloroacetic acid 
(highlighted red) 
 
In the oxidative pathway (Fig. 1.20), TCE is metabolised to the aldehyde chloral by a 
cytochrome p450 enzyme, most likely CYP2E1 (Jiang, Mutch et al. 2007).  Chloral can 
spontaneously react with endogenous tryptamine by a Pictet-Spengler type condensation to 
form TaClo (Bringmann, Feineis et al. 2000).  Chloral can also be oxidised by aldehyde 
dehydrogenase to trichloroacetic acid or reduced by alcohol dehydrogenase to form 
trichloroethanol.  Trichloroethanol can be further metabolised by mixed function oxidases to 
form more trichloroacetic acid which can undergo final additional metabolism to become 
dichloroacetic acid (DCA) (Maull and Lash 1998).  The metabolites that have been most 
strongly linked with neurological effects are chloral, TaClo and DCA and are discussed in more 
detail below. 
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1.2.3.2 Chloral Neurotoxicity 
Chloral has been widely used as an anaesthetic agent in its hydrate form, particularly in 
infants.  The main neurotoxic effects of chloral are thought to be mediated by its metabolites 
such as TaClo and DCA (described later in more detail), but there have been some reports of 
neurotoxicity caused by the compound itself.  Primarily, a study found that chloral induced 
neuroapoptosis (cell death in the brain) in the infant mouse brain, particularly the cerebral 
cortex and caudate-putamen, at doses as low as 100mg/kg i.p. (Cattano D., Straiko M.M.W. et 
al. 2008).  Chloral has also been shown to antagonise the neurotoxic effects of the recreational 
drug 3,4-methylenedioxymethamphetamine (MDMA), an effect thought to be due to a 
blockade of DA release (Schmidt, Black et al. 1990).  While this has not been confirmed, if it is 
true, interference with DA transmission could have relevance in the suspected PD effects seen 
with TCE exposure.  While these are single studies that have not been supported, there is at 
least an indication that chloral itself may possibly be neurotoxic at some level. 
 
1.2.3.3 TaClo Neurotoxicity 
As β-carbolines such as TaClo (Fig. 1.13 & 1.20) have structures similar to that of MPTP, they 
could be neurotoxic for DA neurons in the SNpc and lead to a PD-like syndrome supported by 
the finding that the β-carboline norharmon leads to reduced motor function and cell death in 
the DA neuron model cell line PC12 (Östergren, Fredriksson et al. 2006).  TaClo can cross the 
blood brain barrier following intraperitoneal injection in the rat (Riederer, Foley et al. 2002), 
suggesting peripherally exposed TCE or TaClo can enter brain neuron, although these results 
should be viewed with caution as they use doses higher than those required to elicit 
behavioural changes. 
 
Reports have shown that micromolar concentrations of TaClo caused up to 50% cell death in 
primary C57/B16 mouse mesencephalon cultures of DA neurons and astrocytes (Rausch, Abdel-
Mohsen et al. 1995), and in the human neuroblastoma cell line SK-N-SH, possibly by an 
apoptotic mechanism (Akundi, Hüll et al. 2003; Akundi, Macho et al. 2004).  This was 
supported by in vivo studies showing intranigral TaClo exposure led to a reduction in DA 
metabolism (Grote, Clement et al. 1995), with further studies showing a progressive reduction 
in locomotion and increase in apomorphine induced rotations in behavioural tests (Sontag, 
Heim et al. 1995; Heim and Sontag 1997; Sontag, Lange et al. 2009) and the discovery of a 
strong inhibition of mitochondrial Complex I in vitro (Janetzky, God et al. 1995).  This Complex I 
inhibition is supported by work that shows a real time increase in superoxide released from 
isolated mitochondria exposed to TaClo which is similar in magnitude and response time to 
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known Complex I inhibitor rotenone (Boulton, Keane et al. 2012).  A possible explanation for 
the DA specificity of TaClo may come with the finding that β-carbolines have high binding 
affinity to neuromelanin, a pigment found particularly in DA neurons, and to have high 
retention times (>30days) in neuromelanin containing tissues (Östergren, Annas et al. 2004).  
Taken together these data presented a strong case for the neurotoxic properties of TaClo 
against DA neurons.  Interestingly, further work showed that N-methyl-TaClo is a more potent 
inhibitor of mitochondrial Complex I and more neurotoxic than TaClo itself (Janetzky, Gille et 
al. 1999).  This is thought to be due to the fact that N-methylation would enhance the 
lipophilicity of the compound, enhancing its ability to cross membranes.  When combined with 
the fact that tetrahydro-β-carbolines have been shown to undergo N-methylation in the brain 
(Matsubara, Collins et al. 1993), this gives further evidence of TCE generated TaClo 
neurotoxicity. 
 
A study of the effects of TaClo on motor behaviour in rats found that motor deficits do not 
occur immediately following treatment, with no effects on motor function seen four to nine 
days after a chronic dosing period, but decreased motor function observed twelve weeks later 
(Sontag, Heim et al. 1995).  This indicates that TaClo may be acting as a persistent neurotoxin - 
possibly due to retention in the neuromelanin previously mentioned - in this model producing 
slowly progressive lesions of the SN rather than immediate effects seen with other PD-linked 
toxins such as MPTP, and possibly providing a model system that better represents the 
condition in humans. 
 
It has also been reported that TaClo can cause single strand DNA breaks in cell-free plasmids, 
possibly caused due to the formation of a reactive species by a Cu(II)/Cu(I) mediated redox 
cycle (Bringmann, Münchbach et al. 2001).  However, further work is required before 
accepting this finding as a factor in TaClo mediated cell death. 
 
A significant increase in extracellular serotonin (5-HT) and a non-significant increase in DA 
release immediately after dosing rats with TaClo, followed by an increase in the production of 
hydroxyl radicals, has been shown (Gerlach, Xiao et al. 1998) and in work carried out in 5-
HTergic JAR cells, TaClo has been shown to be cytotoxic and to cause a release of 5-HT 
(Bringmann, Bruckner et al. 2000).  This finding led to suggestions that TaClo may be more 
specific to 5-HT than DA neurons (Bringmann, Bruckner et al. 2000) and not selectively toxic to 
DA as previously proposed.  This lack of specificity of TaClo is supported by the reports that 
show, in vitro, TaClo shows no selective toxicity for DA neurons or cells expressing DAT (Storch, 
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Hwang et al. 2006).  These recent findings on the neurotoxicity of TaClo to 5-HT neurons in 
vitro need more investigation but provide an interesting novel scheme of TaClo neurotoxicity. 
 
While more work needs to be carried out to elucidate the effects by which TaClo leads to cell 
death in the neurotransmitter pathways in the central nervous system, and whether or not it is 
involved in the neurotoxicity of TCE, there is compelling evidence that this compound is 
neurotoxic at some level. 
 
1.2.3.4 DCA Neurotoxicity 
DCA (Fig. 1.20) is another metabolite that it is thought to contribute to the neurotoxicity of 
TCE.  Toxicology studies on dogs and rats have shown DCA to cause myelin vacuolation and 
gliosis in the white matter of the forebrain, cerebrum, cerebellum, brainstem and spinal cord, 
accompanied at high doses by partial hind leg paralysis (Yount, Felten et al. 1981; Bhat, Kanz et 
al. 1991; Cicmanec, Condie et al. 1991).  A therapeutic trial in 1995 found a polyneuropathy 
with areflexia with reduced nerve conduction in the peroneal nerve in children treated with 
DCA for Complex I deficiency (Kurlemann, Paetzke et al. 1995), with a further trial of DCA being 
discontinued due to peripheral neuropathies in seventeen of nineteen patients (Kaufmann, 
Engelstad et al. 2006).  This evidence led to a study into the neurobehavioural effects of DCA in 
the rat which found that DCA produced a reversible peripheral neurotoxicity that consisted of 
limb weakness, deficits in gait and righting reflex and mild tremors (Moser, Phillips et al. 1999).  
There were distinct age and strain differences in this effect, which should be taken in to 
account in any further research.  Exposure of cultured dorsal root ganglia neurons and 
Schwann cells to DCA over twelve days shows a reversible decrease in myelination and a 
moderate decrease in cell viability (Felitsyn, Stacpoole et al. 2007) that could explain the 
effects described in the rat study above.  This evidence suggests a possible peripheral effect of 
DCA in the neurotoxicity of TCE, although there have been no studies into any direct link 
between TCE and peripheral neuropathies. 
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1.3 Cell Death Pathways 
Programmed cell death is a regulated process of death that can occur in cells for a number of 
reasons, including during development or when cells are no longer needed.  The death of cells 
in this manner is generally an advantageous process; however, programmed cell death 
pathways can be activated when cells undergo stress and damage and may lead to the death 
of cells that are otherwise needed, for example DA neurons in PD.  There are three major 
methods of cell death, apoptosis, programmed necrosis and autophagy mediated death, which 
are described in more detail below. 
 
1.3.1 Apoptosis 
Apoptosis was the first major programme of cell death described in 1972 (Kerr, Wyllie et al. 
1972) and has since been extensively studied and characterised.  Apoptosis is a mode of 
programmed cell death linked with cell shrinkage, membrane blebbing, nuclear fragmentation 
and chromatin condensation.  There are two main families of proteins involved in apoptosis, a 
group of proteases known as caspases (for in depth review see (Fuentes-Prior and Salvesen 
2004)) and the Bcl-2 family of proteins (for in depth review see (Youle and Strasser 2008)).  The 
Bcl-2 proteins are involved in modulating mitochondrial integrity during apoptosis, and can be 
pro- or anti-apoptotic in nature.  The caspases are proteases that mediate cleavage of specific 
cellular substrates causing cell death; they can be split into initiator caspases (2, 8, 9 & 10), 
which activate other proteins involved in the apoptotic cascade, and executor caspases (3, 6 & 
7), which carry out the breakdown of cellular components and lead to cell death. 
 
Apoptosis can be initiated by two main methods, extrinsic - mediated by stimulation of death 
receptors - or intrinsic, mediated by cellular stress.  During the intrinsic pathway of apoptosis 
intracellular stress induces or activates the BH3-only class of proteins (Puthalakath, O'Reilly et 
al. 2007; Steckley, Karajgikar et al. 2007).  These BH3-only proteins then inhibit the Bcl-2 family 
of proteins, leading to disinhibition of the pro-apoptotic factors Bax and Bak (Willis, Fletcher et 
al. 2007).  Bax and Bak dimerise and form pores in the mitochondrial membrane leading to 
release of pro-apoptotic proteins (Korsmeyer, Wei et al. 2000).  One of these proteins is 
cytochrome-c which associates with Apaf-1 forming the apoptosome and activating the 
initiator caspase-9, which, in turn, activates the downstream executioner caspases which carry 
out the breakdown and destruction of the cell (Li, Nijhawan et al. 1997).  Also released from 
the mitochondria by Bax/Bak are pro-apoptotic molecules such as Smac/Diablo, which are 
thought to contribute to the apoptosis pathway via inhibition of pro-survival molecules, such 
Chapter 1          Introduction 
68 
 
as cIAP1 & 2 (described in more detail below), so facilitating activation of the caspase cascade 
(Du, Fang et al. 2000). 
 
The extrinsic pathway is induced by activation of the TNFR family of death receptors such as 
TNF, Fas and TRAIL-R and bypasses the mitochondrial involvement of the intrinsic pathway by 
the formation of intracellular death inducing signalling complexes (DISCs) containing FADD 
which directly activates  the initiator caspases (8,10) (Micheau and Tschopp 2003; Duprez, 
Wirawan et al. 2009).  These initiator caspases then activate the executor caspases (3,6,7) 
(Stennicke, Jürgensmeier et al. 1998), which execute cell death by cleaving intracellular 
substrates, activating DNases and causing destruction of cellular contents (Cohen 1997; Enari, 
Sakahira et al. 1998).  Initiator caspase-8 can also cleave the BH3-only protein Bid which 
amplifies the death process by activating the intrinsic mitochondrial pathway of apoptosis by 
BCl-2 inhibition, and possibly direct activation of Bax/Bak (Li, Zhu et al. 1998; Luo, Budihardjo 
et al. 1998). 
 
Activation of TNFR does not always lead to apoptosis.  When activated, TNFR1 recruits 
receptor interacting protein 1 (RIP1), TRADD and TRAF2 and forms a pre-DISC complex I (Hsu, 
Xiong et al. 1995; Hsu, Huang et al. 1996; Shu, Takeuchi et al. 1996). If present, cIAP1 & 2 can 
interact with TRAF2 thereby associating with complex I and ubiquitinating RIP1.  This 
contributes to activation and relocation of NF-κB to the nucleus where it up regulates 
expression of anti-apoptotic genes, promoting cell survival (Mahoney, Cheung et al. 2008).  Fig 
1.21 shows a schematic representation of the various apoptotic pathways discussed. 
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Fig. 1.21 Intrinsic and 
extrinsic pathways of 
apoptosis Apoptosis can be 
induced by cell surface 
receptors (TNFR1/FAS) 
(extrinsic pathway, green), or 
by various environmental 
stresses (intrinsic pathway, 
blue). The intrinsic pathway 
starts with BH3-only protein 
induction or activation, which 
results in the inactivation of 
some BCL-2 family members. 
This relieves inhibition of BAX 
and BAK activation, which in 
turn promotes apoptosis. 
Some BH3-only proteins, such 
as Bid, may also be able to 
activate Bax/Bak via the 
extrinsic pathway (as shown 
by the dotted line). Once 
activated, Bax and Bak 
promote cytochrome c (cyt c) 
release, which leads to the 
assembly of APAF1 into an 
apoptosome and activates 
caspase-9 to initiate executor 
caspases (3/ 6/7).  Executor 
caspases in turn cleave a series of substrates, activate DNases and orchestrate the demolition of the cell (red).  The extrinsic pathway can bypass the mitochondrial 
step and activate caspase-8/10 by the formation of DISC, which leads to caspase-3 activation and cell death.
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1.3.2 Necroptosis (Programmed Necrosis) 
Necrosis had long been thought to be an unregulated form of cell death but more recently a 
programmed, caspase-independent form of cell death with a necrotic morphology has been 
described that has been termed ‘necroptosis’ (Degterev, Huang et al. 2005) and the name was 
formally defined and recommended for use in 2009 (Kroemer, Galluzzi et al. 2009).  It is 
thought that this death mechanism is induced by activation of the same death receptors that 
bring about apoptosis.  A small molecule that specifically inhibits necroptosis over apoptosis 
subsequent to death receptor activation has been discovered and named  ‘necrostatin-1’(Nec-
1)(Degterev, Huang et al. 2005).  Nec-1 has since been found to act via inhibition of the kinase 
domain of RIP1 and hence reduce its ability to associate with RIP3 (Degterev, Hitomi et al. 
2008), the serine/threonine kinase previously linked to caspase-independent death receptor 
initiated cell death (Holler, Zaru et al. 2000).  RIP3 has also been implicated in control and 
execution of necroptosis (Cho, Challa et al. 2009; He, Wang et al. 2009; Zhang, Shao et al. 
2009).  Studies suggest that RIP3 complexes with RIP1 via direct interaction of their RIP 
homotypic interaction motif domains and that the complex acts as a switch between apoptosis 
and necroptosis following death receptor activation (Declercq, Vanden Berghe et al. 2009; He, 
Wang et al. 2009).  The formation of this complex requires caspase 8 inhibition, suggesting that 
caspase 8 cleavage of RIP1 during propagation of apoptosis blocks the progress of necroptosis 
(He, Wang et al. 2009).  The RIP1/RIP3 complex has been named Complex IIb or the necrosome 
and involves other proteins such as FADD and caspase 8 (He, Wang et al. 2009; Christofferson 
and Yuan 2010), as well as the mixed lineage kinase domain-like protein (MLKL), a protein 
which has been found to associate with RIP3 and is essential for necroptosis (Sun, Wang et al. 
2012).  The mitochondrial phosphoglyceratemutase 5 (PGAM5) has also been reported to be 
associated with the RIP1/3 complex, through association with RIP3 (Wang, Jiang et al. 2012).  
The ubiquitination state of RIP1 may be involved in the interaction of Complex IIb and 
downstream effectors, as evidenced by the finding that the RIP1 acting deubiquitinase CYLD 
can protect against necroptosis (Hitomi, Christofferson et al. 2008). 
 
The downstream pathways of necroptosis have yet to be clearly characterised; however there 
is some evidence to indicate involvement of certain cell death mediators.  Increased ROS levels 
have been suggested as a major mediator of cell death in necroptosis.  ROS producing enzyme 
phospholipase A2 (PLA2) has been suggested as a possible necroptosis mediator; when death 
receptors are stimulated during apoptosis, PLA2 is activated but rapidly cleaved and 
deactivated by activate caspases; however, with caspases inactive during necroptosis, PLA2 
could increase ROS production and contribute to necroptotic cell damage and death (Tait and 
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Green 2008).  RIP3 is known to interact with several metabolic enzymes and increase energy 
metabolism-associated ROS (Zhang, Shao et al. 2009)  Another possible involvement of ROS in 
necroptosis is suggested with evidence that activation of the NADPH oxidase Nox1 via an 
interaction with RIP1 leads to an increase in ROS (Kim, Morgan et al. 2007).  However, this 
evidence of the involvement of ROS in executing necroptosis needs to be balanced by other 
studies suggesting that ROS is not a key mediator with antioxidants having been reported to 
not inhibit necroptosis in certain cell lines (Degterev, Huang et al. 2005).  This conflicting 
evidence proposes a possible role for ROS in necroptosis execution, but suggests this effect 
may be cell type specific and requires more investigation. 
 
Mitochondria are known to be involved in many types of cell death and have been implicated 
in necroptosis.  Cyclophillin D and adenine nucleotide translocase have been shown to interact 
with RIP1 to form the mitochondrial transmembrane pore (MTP) during necroptosis (Temkin, 
Huang et al. 2006).  The mitochondrially related  BH3-only protein Bmf has also been linked 
with necroptosis in a genetic screen (Hitomi, Christofferson et al. 2008) and further studies 
have shown that knockdown of Bmf can block necroptosis (Nagley, Higgins et al. 2010) 
implicating it in the execution of necroptotic death.  The mitochondrial apoptosis inducing 
factor (AIF) has been strongly implicated as a mediator of necroptosis (Boujrad, Gubkina et al. 
2007).  Release of AIF from mitochondria in a similar caspase independent form of cell death 
designated ‘partanthos’ has been shown to be induced by PARP1 (Wang, Dawson et al. 2009) 
which could indicate a possible mechanism for AIF release in necroptosis.  Mitochondrial 
fission has been a reported characteristic of necroptosis, a possible mechanism for this can be 
hypothesised by the finding that the regulator of mitochondrial fission dynamin-related 
protein 1 (Drp1) can be dephosphorylated by PGAM5, a component of Complex IIb (Wang, 
Jiang et al. 2012).  This combination of evidence suggests a strong probability that 
mitochondria are involved in the execution of necroptosis. 
 
Autophagy may also be involved in necroptosis execution; studies have shown that 3-
methyladenine and RNAi inhibition of autophagy can inhibit necroptotic cell death, in certain 
cell types (Tait and Green 2008; Christofferson and Yuan 2010) and an autophagy phenotype 
has been observed in necroptotic cells (Bonapace, Bornhauser et al. 2010).  A link between 
necroptosis and autophagy has also been demonstrated by showing the presence of the 
autophagy marker microtubule –associated protein 1 light chain 3 (LC3-B) in necroptotic 
systems, an effect that can be blocked by Nec-1 administration (Degterev, Huang et al. 2005).  
While there appear to be links between excess autophagy and necroptosis, this is a relatively 
unexplored field.  Another link between necroptosis and autophagy comes with the finding 
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that the anti-tumour agent granulysin has been shown to cause release of lysosmal contents 
into the cytoplasm leading to AIF release from the mitochondria and necroptotic cell death 
(Zhang, Zhong et al. 2009).  However, it is unclear whether excessive autophagy leads to cell 
death or is cytoprotective in necroptosis.  Fig 1.22 shows the proposed mechanisms of 
necroptotic cell death. 
 
Fig. 1.22 Potential pathways of necroptosis  Necroptosis is triggered by the formation of 
Complex IIb from RIP1 & 3, FADD, MLKL, PGAM5 and inactive caspase-8 following death 
receptor activation when caspase activation is inhibited.  This may leads to a necrotic cell 
death phenotype by unknown mechanisms thought to include increased ROS production, 
dysregulated autophagy and mitochondrial fission/AIF release.  In the presence of the RIP1 
deubiquitinating enzyme CYLD, Complex IIb formation is pro-survival as opposed to inducing 
necroptosis. 
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However, thinking of apoptosis and necrosis as 2 completely distinct pathways may not be the 
correct view as findings such as that of Pang and Geddes that the mitochondrial toxin 3-
nitropropionic acid has been shown to cause acute necrosis mediated by NMDA receptor 
driven excitotoxicity, followed by delayed apoptosis, suggesting both death mechanisms can 
occur in sequence (Pang and Geddes 1997). 
 
1.3.3 Autophagy 
Autophagy is a process by where the cell proteolyses damaged or unwanted cytosolic 
components by use of the lysosomal machinery and is thought to be activated in times of 
starvation to regenerate amino acids; however, over activation of autophagy can lead to cell 
death by excessive degradation of cellular contents.  Autophagy can be split into three 
subtypes: macro-autophagy, micro-autophagy and chaperone mediated autophagy - all of 
which involve sequestration of cell contents for breakdown by the lysosome.  Macro-
autophagy delivers cellular components for degradation in a structure known as the 
autophagosome which then fuses with a lysosome allowing lysis of its contents.  In micro-
autophagy and chaperone mediated autophagy however, the targets are taken up directly in 
to the lysosome, with chaperone mediated cargo forming a complex with a chaperone protein 
which is recognised by the lysosomal-associated membrane protein 2A and translocated across 
the lysosomal membrane (Saftig, Beertsen et al. 2008) 
 
Macroautophagy, referred to as ‘autophagy’ from now on, is the most studied and well 
characterised.  The first step in autophagy is the sequestration of the cargo proteins for 
degradation by elongation and encircling of the phagophore to form the autophagosome.  The 
autophagosome then fuses with the lysosome leading to degradation of the protein cargo by 
the lysosomal enzymes with the degradation products being exported out of the lysosome 
back into the cytosol for re-use (Fig. 1.23). 
 
So far, there are approximately thirty autophagy related genes (ATGs) identified in yeast, 
which are conserved in most phyla, including mammals (Nakatogawa, Suzuki et al. 2009), and 
are thought to be involved in the control of autophagy.  Autophagy is initiated via inhibition of 
the mammalian target of rapamycin (mTOR) which senses a reduction of nutrients and/or 
growth factors.  Under these conditions various ATGs and phosphatidylinositol 3-kinase 
catalytic subunit 3 interact to induce phosphatidylinositol 3-phosphate  formation, lipidation of 
LC3 and recruitment of more ATGs which facilitate elongation of the phagophore and 
engulfment of proteins for destruction in the autophagosome (for a review of the control and 
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mechanism of autophagosome formation see (Xie and Klionsky 2007)).  The autophagosome 
then binds to the lysosome to form the autolysosome by a mechanism that is yet to be 
characterised but thought to involve microtubules (Webb, Ravikumar et al. 2004) and 
lysosomal-associated membrane protein 1 & 2 (Tanaka, Guhde et al. 2000).  The aspects and 
mechanisms of autophagy are summarised in Fig. 1.23. 
 
Autophagy has been proposed as a direct mediator of cell death called autophagic cell death 
(ACD) characterised by the presence of vacuoles in the cytoplasm due to the presence of 
autophagosomes (Kroemer, Galluzzi et al. 2009).  However, current opinion is tending towards 
seeing the presence of autophagic vacuolisation in end stage dying cells as a “death with 
autophagy” as opposed to “death by autophagy”, with the autophagy seen as an attempt to 
protect against cell death or an effect of the death mechanism rather than the causative factor 
(Kroemer and Levine 2008). 
 
Whether or not it is a mediator of cell death in and of itself, autophagy may have a particularly 
relevant role in this project as PD is characterised by the accumulation of misfolded proteins; a 
dysfunction of autophagy may contribute to the build-up of these toxic protein aggregates, 
alternatively over activation of autophagy due to the presence of so many damaged proteins 
may contribute to cell death. 
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Fig. 1.23 The cellular, molecular, and physiological aspects of autophagy The cellular events 
during autophagy follow distinct stages: vesicle nucleation (formation of the isolation 
membrane/phagophore), vesicle elongation and completion (growth and closure), fusion of 
the double-membraned autophagosome with the lysosome to form an autolysosome, and lysis 
of the autophagosome inner membrane and breakdown of its contents inside the 
autolysosome. This process occurs at a basal level and is regulated by numerous different 
signaling pathways. Shown here are only the regulatory pathways that have been targeted 
pharmacologically for experimental or clinical purposes. Inhibitors and activators of autophagy 
are shown in red and green, respectively. At the molecular level, Atg proteins form different 
complexes that function in distinct stages of autophagy. Shown here are the complexes that 
have been identified in mammalian cells, with the exception of Atg13 and Atg17 that have only 
been identified in yeast (Taken from (Levine and Kroemer 2008)). 
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1.4 Study Aims & Outline 
1.4.1 Hypothesis 
Parkinson’s disease is a major neurodegenerative condition with a complex and unknown 
pathological mechanism.  Environmental exposure to chemical agents, possibly through 
disruption of mitochondrial function, is regarded as a possible cause of Parkinson’s disease.  
Trichloroethylene, an industrial solvent and environmental contaminant is one agent that has 
recently been discussed in relation to this.  In this thesis we will test the hypotheses that: 
A) Trichloroethylene and metabolites cause cell death in both human  neuroblastoma and 
stem cell derived midbrain neuronal cells through programmed cell death 
B) The method of cell death is driven by disruption of mitochondrial function 
C) Trichloroethylene and metabolites cause degeneration of dopaminergic neurons in the 
substantia nigra of treated C57BL/6 mice and Wistar rats 
D) Trichloroethylene and metabolites cause an acceleration in the development of 
symptoms and degeneration of dopaminergic neurons in the substantia nigra of 
human A30P α-synuclein over expressing C57BL/6 mice 
 
1.4.2 Aims 
The aim of this project is to elucidate the mechanism of TCE neurotoxicity and to investigate 
possible links with PD.  This will be achieved using a number of techniques.  In vitro models of 
TCE, chloral and TaClo exposure will be developed based on a previous exposure paradigm that 
has been developed. We will utilise both tumour - specifically SH-SY5Y neuroblastoma - and 
stem cell approaches to understand toxic mechanisms of TCE exposure. Cell viability assays in 
the presence of specific inhibitors or gene transfection studies along with 
immunocytochemistry, biochemical assays, FACS and Western blotting will be used to 
characterise the pathways leading to cell death. 
 
To establish if TCE exposure causes motor impairment in exposed animals, longitudinal 
assessment of motor function will be undertaken using a variety of measures. 
Determination of pathology in the SN of exposed animals will be used and will utilise 
stereological analysis of neurone and glial numbers in paraffin sections of brain as well as LC-
MS/MS to determine the levels of various neurotransmitters in specific brain regions. 
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2.1 Cell Culture 
2.1.1 General Cell Culture 
2.1.1.1 SH-SY5Y & MEF 
SH-SY5Y neuroblastoma cells (European Collection of Cell Cultures (Salisbury, UK)), mouse 
embryonic fibroblasts (MEF) (GlobalStem (Maryland, USA)) and RIP1 knockout MEFs (sourced 
from the lab of Liu, Z.G. (NIH National Cancer Institute, Bethesda, US)) were grown and 
maintained in 75ml vented tissue culture flasks  (Scientific Laboratory Services Ltd. 
(Nottingham, UK) in growth medium (10% GM) containing 90% Dulbecco’s Modified Eagle’s 
Media-High Glucose (D6546), 10% Heat-Inactivated Fetal Bovine Serum, 4mM L-Glutamine, 40 
units/ml Penicillin, 200μg/ml Streptomycin, 1% MEM Non-Essential Amino Acids (all Sigma 
Aldrich Chemical Co. (Poole, UK)) and 5μg/ml Fungizone (Amphetericin B) (Invitrogen Ltd. 
(Paisley, UK)) at 37oC in a humidified atmosphere of 95% air/5% CO2 and split 1:3 when they 
reached ~80% confluence. 
 
2.1.1.2 Embryonic stem cell derived midbrain neurons 
2.1.1.2.1 Differentiation 
M1997 embryonic stem cells (generated in house), were differentiated into a representative 
midbrain neuronal population by following the method described by Yan et. al. (Yan, Yang et 
al. 2005) and Yang et. al. (Yang, Zhang et al. 2008). 
 
Cells were initially grown in Dulbecco’s Modified Eagle’s Media/F12 containing 2mM L-
Glutamine, 20 units/ml Penicillin, 1% MEM Non-Essential Amino Acids (all Sigma Aldrich), 
5μg/ml Fungizone (Amphotericin B) (Invitrogen), 1:100 Insulin-Transferrin-Selenium x 100, 
1:100 N2 Supplement x100, 1:100 B27 Supplement x 100 (all Invitrogen), 400µM Ascorbic Acid, 
0.75mg/ml NaHCO3, 675ng/ml D-Glucose, 5µg/ml Heparin (all Sigma Aldrich), 25ng/ml 
Fibroblast Growth Factor 2, 20ng/ml Epidermal Growth Factor (both R & D Systems, Abingdon, 
UK) and 5ng/ml Leukaemia Inhibitory Factor (Sigma Aldrich) (MAGICK) at 37oC in a humidified 
atmosphere of 95% air/5% CO2 and split 1:3 when they reached ~80% confluence. 
 
Cells were plated into 48-well plates pre-coated with 1:100 GelTrex (Invitrogen) in Dulbecco’s 
Modified Eagle’s Media and differentiated into midbrain neurons along an 18 day pathway, 
summarised in Table 2.1; 
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Day Treatment 
0 MAGICK 
5 75% MAGICK + 25% N2 + 20ng/ml SHH + 100ng/ml FGF8 
7 50% MAGICK + 50% N2 + 20ng/ml SHH + 100ng/ml FGF8 
9 25% MAGICK + 75% N2 + 20ng/ml SHH + 100ng/ml FGF8 + 20ng/ml BDNF + 200µM AA 
11 N2 + 20ng/ml SHH + 100ng/ml FGF8 + 20ng/ml BDNF + 200µM AA 
12 N2 + 20ng/ml BDNF + 20ng/ml GDNF + 1ng/ml TGFβ3 + 200µM AA + 500µM cAMP 
14 N2 + 20ng/ml BDNF + 20ng/ml GDNF + 1ng/ml TGFβ3 + 200µM AA + 500µM cAMP 
16 N2 + 20ng/ml BDNF + 20ng/ml GDNF + 1ng/ml TGFβ3 + 200µM AA 500µM cAMP 
18 N2 + 20ng/ml BDNF + 20ng/ml GDNF + 1ng/ml TGFβ3 + 200µM AA + 500µM cAMP – 
Cells differentiated & ready for treatment. 
Key:  N2 – N2 supplemented media (Dulbecco’s Modified Eagle’s Media/F12, 2mM L-
Glutamine, 20 units/ml Penicillin, 1% MEM Non-Essential Amino Acids, 5μg/ml Fungizone 
(Amphotericin B)), SHH – sonic hedgehog homolog, FGF8 – fibroblast growth factor 8, TGFβ3 – 
transforming growth factor 3 (all R & D Systems), BDNF – brain derived neurotrophic factor, 
GDNF – glial cell line derived neurotrophic factor (both ProSpec Bio, Ness Ziona, Isreal),  AA – 
ascorbic acid, cAMP – dibutyryl cyclic adenosine monophosphate (both Sigma Aldrich). 
 
Table 2.1 Differentiation pathway for midbrain neurons from embryonic stem cells 
 
2.1.1.2.2 Maintenance 
Differentiated midbrain neurons were maintained in Geltrex coated 48-well plates in growth 
media (N2, 20ng/ml BDNF,  20ng/ml GDNF, 1ng/ml TGFβ3, 200µM AA, 500µM cAMP).  Media 
was exchanged for fresh every two days. 
 
2.1.2 Cell Viability Assay 
2.1.2.1 Alamar Blue 
SH-SY5Y were grown in 48-well plates (Scientific Laboratory Services Ltd.) at a density of ~1 x 
105 cells per well in 350μl 10% GM and incubated overnight to allow recovery for assay.  TaClo 
(Supplied by Exclusive Chemistry Ltd. (Obninsk, Russia)) and TCE (Sigma-Aldrich Chemical Co. 
(Poole, UK)) were dissolved in Dimethylsulfoxide (DMSO) (Sigma-Aldrich) while Chloral and 
DCA (Sigma-Aldrich) were dissolved directly into 10% GM for toxicity assays.  Cell death 
modulators were dissolved in DMSO unless specified and summarised in Table 2.2. 
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Toxins, modulators or a combination were added to cells (modulator wells pre-treated for 1 
hour prior to toxin dosing unless mentioned elsewhere) in 10% GM (final DMSO concentration 
0.2%), incubated overnight for 21 hours and cell viability assessed by Alamar Blue assay 
(Nakayama, Caton et al. 1997).  Alamar Blue solution was prepared by dissolving resazurin 
(Sigma Aldrich) in Phosphate Buffered Saline (Sigma Aldrich) at 100µg/ml and sterile filtered 
before adding to cell media to give a final concentration of 10µg/ml.  Alamar Blue reduction 
was measured at an excitation wavelength of 530nm and emission wavelength of 590nm 
following 4 hours incubation with cells. 
 
Name Supplier Concentrations Vehicle 
zVAD.fmk Enzo Life Sciences (Exeter, 
UK) 
10 & 20µM DMSO 
Necrostatin-1 Enzo Life Sciences 50 & 100µM DMSO 
1-methyl-L-tryptophan Enzo Life Sciences 200µM DMSO 
N-acetylcysteine Sigma-Aldrich 2.5 & 5mM DMSO 
L-Buthionine Sulfoxamine Sigma-Aldrich 2.5mM 10% GM 
PJ-34 Tocris Biosciences 
(Abingdon, UK) 
20µM DMSO 
Rapamycin Enzo Life Sciences 2.5 & 5µM DMSO 
Bafilomycin A1 Enzo Life Sciences 500nM & 1µM DMSO 
Table 2.2 Summary of cell death modulator compounds used 
 
2.1.2.2 Crystal Violet 
SH-SY5Y treated as for Alamar Blue assay (Section 2.1.2.1), but cell viability assessed as 
follows; 
Following 21 hour toxin incubation, media removed from well and cells fixed with 4% 
formaldehyde (Sigma Aldrich).  Cells then incubated in Crystal Violet stain (0.5% Crystal Violet 
(Sigma Aldrich), 20% ethanol in ddH2O) for 10 minutes at room temperature.  Crystal Violet 
stain removed and well washed with ddH2O to remove excess stain.  Dye extracted from live 
cells with Sorenson’s Buffer (0.1% sodium citrate (Sigma Aldrich), 50% ethanol in ddH2O, pH 
4.2) and measured at an absorbance of 540nm and the background fluorescence from the 
blank wells subtracted from all other readings for analysis. 
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2.1.3 Confocal Microscopy 
2.1.3.1 Immunocytochemistry 
Plate wells were treated for required time and fixed in 4% paraformaldehyde (Sigma Aldrich) 
for 10 minutes and stored at 4oC in 10% Glycerol (Sigma Aldrich) phosphate buffer saline (PBS) 
containing Sodium Azide (Sigma Aldrich). 
Supplier Antibody Dilution Secondary 
Antibody 
Primary Antibody 
Abcam (Cambridge, UK) Rabbit polyclonal 
Tyrosine Hydroxylase 
(Ab112) 
1:1000 Goat anti-rabbit 
Alexa Fluor® 488 
Secondary Antibody 
Invitrogen (Paisley, UK) Goat anti-rabbit Alexa 
Fluor® 488 
1:500  
Table 2.3 ICC primary and secondary antibody details and dilutions used. 
 
For staining, cells were permeabilised with 0.1% Triton-X-100 (Sigma Aldrich) PBS for 10 
minutes and then blocked in 1% BSA in PBS for 30 minutes.  Cells were incubated overnight 
with primary antibodies (see Table 2.3 for details) at 4oC and gently agitated, washed with PBS 
3 times and treated with Image-iTTM FX signal enhancer (Invitrogen) for 30 minutes at room 
temperature.  Cells were washed with PBS 3 times and incubated with secondary antibodies 
(see Table 2.3 for details) for 60 minutes protected from light.  Counterstaining of total cell 
nuclei was carried out using DAPI (Invitrogen).  Cells were treated with 500nM DAPI in PBS for 
5 minutes and then washed in PBS 3 times.  Cells were then stored at 4oC in PBS protected 
from light until viewing. 
2.1.3.2 Confocal Microscopy 
Images of stained cells were taken using a Nikon A1r point scanning confocal microscope 
running NIS Elements software (Nikon, v3.2).  The microscope was located in the Newcastle 
University Bio-Imaging Unit using.  Cells were observed 40x (air,0.6NA) objective with the 
following instrument configurations:  DAPI, DNA (405 nm laser and 450 nm emission filter); 
Alexa Fluor® 488, TH positive neurons (488nm laser and 525 nm emission filter).  Images were 
captured at 1024 x 1024 pixel resolution and taken as volume acquisitions with 9 stacks 
6.177µm apart.  Images were represented and analysed as maximum intensity projections 
(MIP) where the final images is formed from pixels with the greatest intensity over the z-stack 
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volume captured.   This allowed in each channel, a two dimensional view of the volume 
captured to be represented and analysed (see below). 
 
2.1.3.2 Image Analysis & Quantification 
MIP for each well were analysed for estimated total cell number and total TH-positive neurons 
using Volocity (version 6.1) image analysis software (PerkinElmer). 
 
Due to the high density of cells and the high level of background fluorescence observed, at the 
magnification used, in many fields of view it was not possible to distinguish individual nuclei.  
Therefore an alternative method of cell counting was adopted; this was based upon the 
average nuclei size.  Nuclei size was calculated using fields of view taken from areas of low cell 
density / background fluorescence.  Volocity was used to quantify nuclei intensity and shape; 
using these measurements, an average DAPI nucleus size was calculated to be 82 µm2.  This 
figure was used to estimate total cell number by measuring the total area of DAPI staining 
above a constant threshold and dividing by this the average nuclei size. 
 
Based upon fluorescence intensity (AF488 signal), the number of TH positive neurons was 
estimated by using Volocity. 
 
2.1.4 Fluorescence Microscopy 
SH-SY5Y cells were grown in 4-well chamber slides (BD Biosciences, Oxford, UK) in 1ml 10% GM 
at a density of 3 x 105 cells per chamber and incubated overnight to allow recovery for 
imaging.  Cells were treated with 0.2% DMSO, 100 & 150µM TaClo or 850µM H202 and at 0, 4, 
8, 12 & 24 hours in all experiments. 
2.1.4.1 Cellular and Mitochondrial Superoxide Imaging 
Cells were pre-loaded with the DCFDA2 (10µM) (Invitrogen) to detect superoxide in 1ml 10% 
GM for 1 hour before treatment when assessing cellular superoxide levels, or cells loaded with 
1ml 10% GM containing the mitochondrial superoxide detector MitoSOX Red (5µM) 
(Invitrogen) for 10 minutes immediately following treatment when assessing mitochondrial 
superoxide.  Following treatment all slides were then fixed with 3.7% formaldehyde (Sigma 
Aldrich) before mounting and viewed under a Ziess Imager 21 microscope and representative 
pictures captured. 
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2.1.4.2 Aggresome Imaging 
Following treatment all slides were stained for aggresomes using the ProteoStat® Aggresome 
Detection Kit (Enzo Life Sciences) as manufacturer’s instructions.  Briefly, cells were fixed with 
3.7% formaldehyde (Sigma Aldrich), permeabilised on ice with 0.5% Triton X-100, 3 mM EDTA, 
pH 8, and stained with ProteoStat® Aggresome Detection Reagent and Hoechst 33342 Nuclear 
Stain before mounting and viewed under a Ziess Imager 21 microscope and representative 
pictures captured. 
 
Aggresomes were quantified manually by counting Hoechst 33342 stained nuclei to ascertain 
total cell number and red ProteoStat® foci to estimate aggresome number with aggresome 
number normailised to total cells. 
 
2.1.5 Glutathione Assay 
Total glutathione levels were measured using an adaption of the method developed by Shaik 
and Mehvar (Shaik and Mehvar 2006), briefly described below. 
2.1.5.1 Sample Generation 
SH-SY5Y cells were grown in 25ml flasks at a density of 1.5x106 in 5ml 10% GM and incubated 
overnight to allow recovery before assay.  Flask were treated with 100µM TaClo and at 0, 4, 8, 
12 & 24 hours cells were harvested in quadruplicate by scraping in 100µl ice cold 5% 5-
Sulfosalicylic acid dihydrate (SSA) (Sigma Aldrich), before centrifuging at 8000g for 5 minutes.   
5µl supernatant was diluted 1:2 with 5% SSA, further diluted to 1:2 with 400mM sodium 
carbonate, then further diluted 1:8 with Phosphate-EDTA Dilution Buffer (100 mM Na3PO4 – 1 
mM EDTA, pH 7.4), total final dilution 1:32.  Samples were then stored at -20oC until all 
samples were taken for assay. 
2.1.5.2 GSH Assay 
GSH levels were determined by reduction of 5-5’-dithiobis(2-nitrobenzoic acid) (DTNB) to the 
coloured product 2-nitro-5-thiobenzoic acid (abs 415nm).  Samples, standards QC samples and 
blanks were loaded onto a 96-well plate in duplicate in reaction buffer (1.9 units/ml 
glutathione reductase, 0.4 mM NADPH in phosphate dilution buffer) and incubated with DTNB 
for 10 minutes at room temperature before reading at an absorbance of 415nm. 
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2.2 SH-SY5Y Genetic Manipulation 
2.2.1 MnSOD Over Expression 
2.2.1.1 Transfection and Selection 
SH-SY5Y cells were seeded in a 25ml vented tissue culture flask and left to grow to ~70% 
confluence.  Cells were primed for transfection with 10µg/ml polybrene and then treated with 
25µl of at least 1 x108 TU/ml MnSOD2 Precision LentiORF lentivrus vector (Thermo Fisher 
Scientific Open Biosystems (St. Leon-Rot, Germany)) (clones PLOHS_100003217 (2.80 x108 
TU/ml) & PLOHS_100063998(4.54 x108 TU/ml))  and incubated at 37oC in a humidified 
atmosphere of 95% air/5% CO2 for 48 hours. 
 
The viral vector co-expresses GFP and confers blasticidin resistance to allow selection.  Cells 
were transferred to a 75ml vented tissue culture flask and transfected cells were selected for 
by introducing 50µg/ml blasticidin (Invivogen (San Diego, USA)) to the media and growing to 
confluence.  Selection was confirmed by seeding 4-well chamber slides with 3 x 105 cells per 
chamber, growing overnight and then fixing and counterstaining with DAPI.  Slides were 
viewed for GFP and DAPI under a Ziess Imager 21 microscope to assess transfection and 
representative pictures captured. 
 
MnSOD over expressing cells were maintained in 75ml vented tissue culture flasks in 10% GM 
containing 50µg/ml blasticidin at 37oC in a humidified atmosphere of 95% air/5% CO2 and split 
1:3 when they reached ~80% confluence. 
 
2.2.1.2 Assessment of MnSOD Level 
MnSOD over expressing or control SH-SY5Y cells were assessed for MnSOD levels as method in 
section 2.3.1 using relevant primary and secondary antibodies detailed in Tables 2.5 and 2.6. 
 
2.2.1.3 Toxicity Assay 
MnSOD over expressing or control SH-SY5Y cells were assessed for relative susceptibility to 
TaClo toxicity by Alamar Blue viability assay as method in section 2.1.2.1 but in 48-well plates 
with 24 wells containing control and 24 wells containing MnSOD overexpressing cells. 
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 2.2.2 RIP1 Knockdown 
2.2.2.1 Transfection 
SH-SY5Y cells were seeded in a 25ml vented tissue culture flask and left to grow to ~70% 
confluence.  Cells were primed for transfection with 10µg/ml polybrene and then treated with 
25µl of at least 1x108 TU/ml relevant RIP1 or control GIPZ lentiviral shRNAmir (Thermo Fisher 
Scientific Open Biosystems) (see Table 2.4 for clone numbers and TU/ml) and incubated at 
37oC in a humidified atmosphere of 95% air/5% CO2 for 48 hours. 
 
shRNA Clone no. TU/ml 
Control V3LHS_365648 6.22 x 108 
RIP1 V2LHS_241668 5.13 x 108 
V3LHS_340513 3.02 x 108 
Table 2.4 Clone number and titre of GIPZ lentivral SHRNAmir 
 
The viral vector co-expresses GFP and confers purimycin resistance to allow selection.  Cells 
were transferred to a 75ml vented tissue culture flask and transfected cells were selected for 
by introducing 1µg/ml puromycin (Sigma Aldrich) to the media and growing to confluence.  
Selection was confirmed by seeding 4-well chamber slides with 3 x 105 cells per chamber, 
growing overnight and then fixing and counterstaining with DAPI.  Slides were viewed for GFP 
and DAPI under a Ziess Imager 21 microscope to assess transfection and representative 
pictures captured. 
 
Knockdown or control cells were maintained in 75ml vented tissue culture flasks in 10% GM 
containing 1µg/ml puromycin at 37oC in a humidified atmosphere of 95% air/5% CO2 and split 
1:3 when they reached ~80% confluence. 
 
2.2.2.2 Assessment of Knockdown Extent 
RIP1 or control SH-SY5Y cells were assessed for relevant protein levels as method in section 
2.3.1 using relevant primary and secondary antibodies detailed in Tables 2.5 and 2.6. 
 
2.2.2.3 Toxicity Assay 
Clone 668 treated RIP1 or control SH-SY5Y cells were assessed for relative susceptibility to 
TaClo toxicity by Alamar Blue viability assay as method in section 2.1.2.1 but in 48-well plates 
with 24 wells containing control and 24 wells containing relevant knock down cells. 
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2.3 Protein Expression 
2.3.1 Sample Generation & Quantification 
2.3.1.1 Sample Generation 
SH-SY5Y cells following toxin exposure were scraped from flasks into Tris-buffered Saline 
(Sigma-Aldrich) containing 1% TritonX-100 (Sigma-Aldrich) and EDTA-free protease inhibitor 
cocktail (Roche, Welwyn, UK) on ice and stored at -20oC. 
2.3.1.2 Protein Quantification 
Protein in samples was determined using Bradford Reagent (Sigma-Aldrich) against bovine 
serum albumin (BSA) as a standard.  
2.3.2 Western Blotting 
2.3.2.1 Blotting 
Protein samples concentrations were standardised in buffer and NUPAGE Reducing Agent and 
LDS Sample Buffer (Invitrogen) were added.  Samples were heated to 70oC in a hot block for 10 
minutes, loaded into wells of NUPAGE 4-12% Bis-Tris gels (Invitrogen) and electrophoresed in 
NUPAGE MOPS SDS Running Buffer (Invitrogen) containing antioxidant (Invitrogen) alongside 
SeeBlue Plus2 Pre-Stained Standard (Invitrogen) and Biotinylated Protein Ladder (New England 
Biolabs (Hitchin, UK)) markers for band size comparison.  Proteins were transferred to 0.2μm 
nitrocellulose membranes using an iBlot® Gel Transfer Device (Invitrogen), with transfer 
efficiency assessed by reversibly staining protein with Ponceau S solution (Invitrogen).  
Membranes were blocked with tris buffered saline with 0.2% Tween 20 (Sigma-Aldrich) (TBST) 
containing 5% non-fat skimmed milk powder for 30 minutes and then incubated with primary 
antibody or peroxidise conjugated GAPDH monoclonal rabbit antibody for one hour before 
being washed in TBST and then incubated with the appropriate secondary antibodies for 30 
minutes (for antibody details and dilutions see Table 1). The membranes were exposed to ECL 
western blotting substrate (Perbio Science Ltd, UK) for 1 minute and developed onto Super RX 
Medical X-ray Film (FujiFilm, Bedford, UK) in a dark room using Kodak Processing for 
Audioradiography Films Solution (P7042) and Kodak GBX Fixer and Replenisher (P7167) (both 
Sigma Aldrich) at various time points to optimise resolution. 
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2.3.2.2 Primary Antibodies 
Primary antibodies used are summarised in Table 2.5. 
 
Supplier Antibody Dilution Secondary 
Antibody 
New England Biolabs  PARP &  cPARP (#9542) 1:1000 Rabbit IgG 
New England Biolabs  RIP1 & c RIP1 (#3493) 1:1000 Rabbit IgG 
New England Biolabs  Cleaved Caspase-3 (#9664) 1:1000 Rabbit IgG 
New England Biolabs LC3- B (#3868) 1:1000 Rabbit IgG 
New England Biolabs Phospho-Histone H2A.X 
(Ser139) (#2577) 
1:1000 Rabbit IgG 
GeneTex Calpain-1 (GTX102240S) 1:1000 Rabbit IgG 
Santa Cruz Biotechnology 
(Heidelberg, Germany) 
DJ-1 1:1000 Mouse IgG 
Abcam MnSOD2 (ab16956) 1:4000 Mouse IgG 
Santa Cruz Biotechnology  GAPDH (FL-335) 1:1000 Rabbit IgG 
Table 2.5 Primary antibody details and dilutions used. 
  
2.3.2.3 Secondary Antibodies 
Secondary antibodies used are summarised in Table 2.6. 
 
Supplier Antibody Dilution 
New England Biolabs  HRP linked Rabbit IgG 1:4000 
New England Biolabs  HRP linked Mouse IgG 1:2000 
Table 2.6 Secondary antibody details and dilutions used. 
 
2.3.2.4 Quantification 
Films were scanned and quantified by measuring band intensity by area using ImageJ (1.44p) 
software.  GAPDH was used to normalise results and protein/GAPDH ratios and fold change 
from control was calculated for all samples. 
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2.4 Mitochondrial Function Assays 
2.4.1 Mitochondrial Isolation 
Mitochondria were isolated from SH-SY5Y cells by differential centrifugation as follows:  
SH-SY5Y grown to confluence in T150 flasks, were removed from media and re-suspended in 
1ml ice cold Medium A (250mM sucrose, 2mM HEPES, 0.1mM EGTA. pH 7.4) before cell 
membrane disrupted by 20 passes in a dounce homogenizer (Ryobi CCD-1201) with a tight-
fitting power-driven Teflon plunger.  Homogenate was centrifuged at 600g for 10 minutes at 
4oC and the mitochondria rich supernatant collected.  Cell debris pellet was re-suspended in 
800µl Medium A and centrifuged as before.  Supernatants were pooled and centrifuged at 
11,000g for 10 minutes at 4oC with four pellets combined, re-suspended in 400µl Medium A, 
aliquoted and stored at - 80oC until use. 
 
2.4.2 Mitochondrial Activity Assays 
All mitochondrial activity assays were carried out as described by Kirby et al.(Kirby, Thorburn 
et al. 2007) on a Cary WinUV spectrophotometer at 30oC in the presence of various 
concentrations of TaClo, chloral or vehicle (0.2% DMSO) to investigate the effect of the test 
compounds on mitochondrial OXPHOS function.  Test compounds were added to the buffer 
immediately prior to the assay.  Pig heart mitochondrial (PHM) fraction (supplied by the 
Mitochondrial Diagnostic Service Laboratory, Newcastle University) was used as an internal 
control before each experiment to check normal function of assay, according to acceptance 
criteria described by Kirby et al.(Kirby, Thorburn et al. 2007).  All samples were diluted 1:7 in 
relevant Complex buffer (specific buffer details below) and stored on ice prior to assay.  
Complex specific assay details are described below. 
 
2.4.3.1 Complex I 
Complex I activity was calculated as rotenone-sensitive NADH:ubiquinone oxioreductase 
activity as determined by following the decrease in absorbance due to the oxidation of 
Nicotinamide adenine dinucleotide (NADH) at 340nm with 425nm as the reference wavelength 
using the following method: 
 
Prior to assay, mitochondrial fraction was diluted 1:5 and flash freeze thawed three times in 
liquid nitrogen to maximise Complex I activity.  Assay performed in Complex I buffer (25mM 
potassium phosphate, 5mM magnesium chloride in distilled water, adjusted to pH 7.2 with 
potassium hydroxide (prepared in advance and stored at 4oC for up to 3 months), BSA 
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(2.5mg/ml) and potassium cyanide (KCN) (3mM) added prior to use).  NADH (0.13mM), 
Ubiquinone1 (65µM) and Antimycin A (2µg/ml) added to buffer and activity read as absorbance 
change at 340nm for 30 sec.  10µl mitochondrial fraction added and activity recorded for 5 
minutes.  Rotenone (2µg/ml) added and activity recorded for 3-4 minutes. 
 
Complex I activity calculated as nmols of NADH oxidised/min as follows: 
 
δ slope x     1000 x dilution factor x 1000   _ 
   6.22       mitochondrial sample volume (µl) 
 
where 6.22/cm/mM is the extinction coefficient for NADH at 340nm (to account for the 
contribution of Ubiquinone1 to absorbance at 340nm (Watmough, Birch-Machin et al. 1989)) 
and δ slope = slope following mitochondrial addition (absorbance/min) - slope following 
rotenone addition (absorbance/min). 
 
2.4.3.2 Complex II 
Complex II activity was measured as succinate:ubiquinone1 oxioreductase activity by following 
the reduction of the artificial electron acceptor 2,6-dichlorophenol-indo-phenol (DCPIP) at 
600nm using the following method: 
 
Prior to assay, mitochondrial fraction was diluted 1:5 and flash freeze thawed three times in 
liquid nitrogen to maximise Complex II activity.  Assay performed in Complex II buffer (25mM 
potassium phosphate, 5mM magnesium chloride in distilled water, adjusted to pH 7.2 with 
potassium hydroxide (prepared in advance and stored at 4oC for up to 3 months), 3mM KCN 
added prior to use).  10 µl mitochondrial fraction was incubated at 30oC in CII buffer containing 
Sodium Succinate (20mM) for 30 minutes prior to assay to allow activation of the Complex II 
enzyme.  DCPIP (50µM), Antimycin A (2µg/ml), and rotenone (2µg/ml) added to mitochondria 
containing buffer and baseline activity read as absorbance change at 600nm for 30 sec.  
Ubiquinone1 added and activity recorded for 5 minutes. 
 
Complex II activity calculated as nmols DCPIP reduced/min as follows: 
 
δ slope x      1000 x dilution factor x 1000   _ 
  19.1         mitochondrial sample volume (µl) 
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where 19.1/cm/mM is the extinction coefficient for DCPIP at 600nm and δ slope = slope 
following ubiquinone1 addition (absorbance/min). 
2.4.3.3 Complex III 
Complex III activity measured by following the oxidation of ubiquinol2 with cytochrome c as 
the electron acceptor and monitoring the increase in absorbance due to the reduction of 
cytochrome c (oxidised) at 550nm with a relative wavelength of 580nm, expressed as an 
apparent first order rate constant after reduction of the remaining cytochrome c with 
ascorbate.  Ubiquinol2 prepared and Complex III activity was measured using the following 
methods: 
2.4.3.3.1 Ubiquinol2 Preparation 
Ubiquinol2 prepared in acidified ethanol and quantified prior to the assay and stored at      -
80oC until use.  Ubiquinone2 dissolved in 100% ethanol (acidified to pH 2 with HCl) before 
being reduced to Ubiquinol2 by addition of a few grains of NaBH4 causing the sample to go 
colourless.  The solution was vortexed in 2:1 diethylether/cyclohexane, with the Ubiquinol2 
separating to the solvent phase and was removed and vortexed with 2M NaCl again separating 
into the solvent phase.  The solvent is removed and evaporated to dryness in nitrogen before 
being dissolved in acidified ethanol.  The Ubiquinol2 was quantified by measuring its 
absorbance at 285nm. Ubiquinol2 concentration (mM) calculated as follows: 
 
δ abs  x    _ ___1000_____  _ 
3.5        sample volume (µl) 
 
where δ abs is the difference in absorbance between the peak and baseline of the trace and 
3.5 is the extinction coefficient for Ubiquinol2 at 285nm. 
2.4.3.3.2 Complex III Activity Assay 
Assay performed in CIII buffer (25mM potassium phosphate, 5mM magnesium chloride in 
distilled water, adjusted to pH 7.2 with potassium hydroxide, prepared in advance and stored 
at 4oC for up to 3 months, 3mM KCN and 2.5mg/ml essentially fatty acid free, Fraction V, BSA 
added prior to use).  Rotenone (2µg/ml), Cytochrome c (oxidised) (15µM) and n-dodrecyl-β-D-
maltoside (DDM) (0.6mM) added to buffer and spectrophotometer ‘zeroed’ and baseline 
activity read as absorbance change at 550nm for 30 seconds.  Ubiquinol2 (35µM) added and 
activity measured for 1 minute.  10µl mitochondrial fraction added and activity measured for 5 
minutes before addition of a few grains of L-ascorbic acid to allow reduction of remaining 
cytochrome c. 
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Fig. 2.1 Mitochondrial Complex III activity assay trace Example trace showing end point 
absorbance (End point), non-enzymatic absorbance rate change (NE rate) and 6 continuous 
absorbance timepoints (AbsT0-5) of mitochondrial Complex III activity assay (taken from 
Newcastle NHS Foundation Trust Mitochondrial NCG Service SOP 7957). 
 
As the increase in absorbance rapidly becomes non-linear after the addition of the 
mitochondrial fraction, Complex III activity is expressed as an apparent first-order rate 
constant after reduction of the remaining cytochrome c with ascorbate.  Six continuous time 
points and corresponding absorbances were picked from the exponential phase of the trace 
(AbsT0-AbsT5) (see Fig. 2.1) and the difference in absorbance between AbsT1-AbsT5 and the end 
point calculated (X1-X5 respectively).  Complex III activity was then calculated as 10
-3K.sec-1 as 
follows: 
 
___logA/X1-logA/X5__    x  __2.303 x 1000 x dilution x 1000__ 
               time period-NE rate/60       mitochondrial sample volume (µl) 
 
 
Where A is the change in absorbance between AbsT0 and the end point (see Fig. 2.1), the time 
period is the time difference between AbsT1 and AbsT5 in seconds, NE rate is the slope 
between cytochrome c addition and ubiquinol2 addition (see Fig. 2.1)  and 2.303 is the 
conversion factor for log10 to natural log. 
2.4.3.3.3 Non-enzymatic reduction of Cytochrome c (Oxidised) 
To examine the effect of chloral on the non-enzymatic reduction of cytochrome c (oxidised) 
the Complex II assay protocol was followed in the presence of various concentrations of chloral 
up to immediately before the addition of the mitochondrial fraction.  At this point the 
recording was stopped and the non-enzymatic reduction of cytochrome c (oxidised) measured 
as the slope of the line following cytochrome c (oxidised). 
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2.4.3.4 Complex IV 
Complex IV activity was measured by following the oxidation of cytochrome c (II) at 550nm 
with 580nm as the reference wavelength, expressed as an apparent first-order rate constant 
after oxidation of the remaining cytochrome c by potassium ferricyanide. Cytochrome c (II) 
was prepared and Complex IV activities were measured using the following methods: 
2.4.3.4.1 Cytochrome c II Preparation 
Cytochrome c II was prepared by reducing cytochrome c (III) (oxidised) with ascorbic acid and 
purified by gel filtration on Sephadex G-25M Column (Pharmacia, Sandwich, UK) equilibrated 
with CIV buffer (see below).  The dark fraction is collected and quantified prior to the assay 
and stored at -20oC until use.  The Cytochrome c (II) was quantified by measuring its 
absorbance at 285nm. Cytochrome c II concentration (mM) calculated as follows: 
 
δ abs  x    _ ___1000_____  _ 
 29         sample volume (µl) 
 
where δ abs is the difference in absorbance between the peak and baseline of the trace at 
550nm and 29 is the extinction coefficient for cytochrome cII at 500nm. 
 
Cytochrome c (II) purity was determined by measuring its absorbance at 500nm and 565nm 
and calculating the ratio of the difference in absorbance between the peak and baseline at 
550nm to 565nm.  If the ratio was lower than 6 the cytochrome c (II) was considered too 
oxidised to use in the assay. 
2.4.3.4.2 Complex IV Activity Assay 
Assay performed in CIV buffer (20mM potassium phosphate in distilled water adjusted to pH 
7.2 with potassium hydroxide prepared in advance and stored at 4oC for up to 3 months).  
Cytochrome c (II) (15µM) and DDM (0.345mM) added to buffer and spectrophotometer 
‘zeroed’ and baseline activity read as absorbance change at 550nm for 30 sec.  10µl 
mitochondrial fraction added and activity measured for 2 minutes before addition of a few 
grains of Potassium Ferricyanide to oxidise of remaining cytochrome c (II). 
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Fig. 2.2  Mitochondrial Complex IV activity assay trace Example trace showing end point 
absorbance (End point) and 6 continuous absorbance timepoints (AbsT0-5) of mitochondrial 
Complex IV activity assay (taken from Newcastle NHS Foundation Trust Mitochondrial NCG 
Service SOP 8878). 
 
As the absorbance declines exponentially and becomes nonlinear after the addition of the 
mitochondrial fraction, Complex IV activity is expressed as an apparent first-order rate 
constant after oxidation of the remaining cytochrome c (II) with Potassium Ferricyanide.  Six 
continuous time points and corresponding absorbances were picked from the exponential 
phase of the trace (AbsT0-AbsT5) (see Fig. 2.2) and the difference in absorbance between 
AbsT1-AbsT5 and the end point calculated (X1-X5 respectively).  Complex IV activity was then 
calculated as 10-3K.sec-1 as follows: 
 
 
_logA/X1-logA/X5_   x  __2.303 x 1000 x dilution x 1000__ 
                                       time period               mitochondrial sample volume (µl) 
 
Where A is the change in absorbance between AbsT0 and the end point (see Fig. 2.1), the time 
period is the time difference between AbsT1 and AbsT5 in seconds and 2.303 is the conversion 
factor for log10 to natural log. 
 
 
 
 
 
 
 
Chapter 2  Materials & Methods 
94 
 
2.5 Flow Cytometry 
2.5.1 Sample Generation 
SH-SY5Y cells were seeded in 25ml vented tissue culture flasks in 5ml 10% GM at a density of 5 
x 106 per flask for flow cytometric analysis and incubated overnight following seeding to allow 
recovery before treatment.  Cells were treated with 0.2% DMSO, 100 or 150µM TaClo or 
500nM staurosporine (Sigma) as a positive control for apoptosis (cell death mechanism assay 
only) for 0, 4, 8, 12, 16 or 24 hours before being trypsinised and spun down in to pellets at 
200g for 10 minutes and then assessed for cell death phenotype, mitochondrial superoxide or 
lysosome number. 
 
Cells to be assessed for cell death phenotype were probed using the ‘Chromatin Condensation 
/ Dead Cell Apoptosis Kit with Hoechst 33342 and PI for Flow Cytometry’ kit (Invitrogen) as per 
manufacturer’s instructions.  Briefly, cell pellets were re-suspended in 1ml PBS + 0.5% BSA, 
washed in 1ml PBS + 0.5% BSA and then spun down before being re-suspended in 200µl PBS + 
0.5% BSA  containing Hoescht 33342 (5µg/ml) and Propidium Iodide (PI) (1µg/ml) for 20-30 
min for analysis. 
 
Cells were probed for lysosome levels using Lysotracker Red probe (Invitrogen) or 
mitochondrial superoxide using MitoSOX™ Red probe (Invitrogen) as per manufacturer’s 
instructions.  In short, cell pellets were re-suspended in 1ml PBS + 0.5% BSA containing 5µM 
MitoSOX™ Red for 10 minutes or 50nM Lysotracker (Invitrogen) for 30 minutes.  Cells were 
washed in 1ml PBS + 0.5% BSA and spun down twice and finally re-suspended in 200µl PBS + 
0.5% BSA for analysis. 
 
2.5.2 Flow Cytometry 
Samples were acquired on a FACSCanto II flow cytometer (BD Biosciences, Oxford, UK) using 
FACSDiva (v.6.0) software. At least 10,000 events were analysed and a signal threshold was 
applied for forward (FSC-A) to exclude debris from which a distinct cell population was gated 
(Fig. 2.3) and fluorescence measured in this population. 
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Fig. 2.3 Representative flow cytometry density plot showing selection of whole single cells 
based on SSC-A and FSC-A 
 
When assessing cell death phenotype, distinct cell population gated events were defined as 
‘Healthy’, ‘Apoptotic’, ‘Necrotic’ and ‘Late Cell Death’ populations based on relative 
fluorescence of PI and Hoechst33342 (measured by 488/595nm and 405/450nm lasers, 
respectively), with approximately 90-95% of events defined in the ‘Healthy’ population of 
untreated or control samples (Fig. 3.26).  Results were analysed using FACSDiva (v.6.0) 
software. 
 
When assessing lysosome levels, distinct cell population gated events were defined as low or 
high lysosome populations based on Lysotracker Green fluorescence (measured by 488/585nm 
laser), with approximately 95% of events defined in the low lysotracker population of 
untreated or control samples (Fig. 3.32).  Quantification of mitochondrial superoxide levels 
involved defining distinct cell population gated events as low, medium or high mitochondrial 
superoxide populations based on MitoSOX™ Red fluorescence (measured by 488/585nm 
laser), with approximately 95% of events defined in the low mitochondrial superoxide 
population, and medium and high populations defined in relation to the presence of two 
distinct peaks on histogram display (Fig. 4.14 B).  Lysosome and mitochondrial superoxide level 
assay results were analysed using Cyflogic (v. 1.2.1) software. 
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2.6 In Vivo Assays 
All experiments were carried out in accordance with the UK Animals (Scientific procedures) Act 
of 1986, with UK Home Office Guidance on the implementation of the Act and with all 
applicable Codes of Practice for the care and housing of laboratory animals, and the European 
Community Council Directive of 24 November 1986 (86/609/EEC). 
2.6.1 Subjects 
2.6.1.1 Sourcing  
Wild-type C57BL/6 mice and Wistar rats were sourced from Charles River UK (Margate, UK) 
and A30P mutant human α-synuclein overexpressing C57BL/6 mice were sourced from Prof. 
Philipp Kahle, University of Tubingen, Germany (Kahle, Neumann et al. 2000). The animals 
were examined on arrival and prior to the study; all animals were healthy and considered 
suitable for experimental use. 
2.6.1.2 Husbandry 
Animals were housed in clean holding rooms in the Comparative Biology Centre, Newcastle 
University, for the duration of all studies.  Mice were kept in groups of up to six in solid 
bottomed, saw dust filled, filter top individually ventilated cages within a barrier facility which 
underwent 20 air changes per hour. Rats were kept in groups of up to four in solid bottomed, 
saw dust filled, open topped cages in rooms that underwent 15 air changes per hour.  Animals 
were transferred to cages with fresh bedding twice weekly and all cages had environmental 
enrichment available throughout the study period.  The rooms were illuminated by fluorescent 
lights set to give a twelve- hour light-dark cycle (on 07.00, off 19.00) and the air temperature 
and relative humidity were controlled and measured.  All were within normal ranges for study 
duration.  Animals were fed a diet of expanded RM03 rodent diet pellets (Special Diet Services, 
Edinburgh, UK) ad libitum and had access to mains tap water ad libitum. 
2.6.1.3 Animals 
Pilot study mice were in the age range 14-15 weeks and weight range 26-30g and rats were 
in the age range 14-15 weeks and the weight range 454-557g while A30P study wild-type 
and A30P mutant mice were in the age and weight range summarised in Table 2.7.  All 
animals were considered healthy and suitable for experimental use upon study start.  Pilot 
study animals were identified by waterproof tail markings and A30P study animals were 
identified by ear punch and waterproof tail markings; tail markings were reapplied as 
necessary throughout study duration. 
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Wild-Type 
 Age (week) Weight Range (g) 
Male 14-15 28-35 
Female 14-15 22-26 
A30P Mutant 
 Age (week) Weight Range (g) 
Male 13-16 29-39 
Female 13-15 23-28 
Table 2.7 Summary of A30P study mouse age and weight upon study start 
 
2.6.3.1 A30P Genotyping 
A30P mutant human α-synuclein overexpressing C57BL/6 mice were bred in house from 2 F1 
trios and genotyped as follows: 
 
Tissue biopsies were taken from the mice via ear punches and DNA isolated by Qiagen DNeasy 
Blood and Tissue DNA extraction kit (Qiagen, Crawley, UK) according to manufacturer’s 
instructions. 
 
A30P mutation presence was confirmed by PCR.  The primers used for the A30P gene were 
forward 5’-TGTAGGCTCCAAAACCAAGG-3’ and reverse 5’-TGTCAGGATCCACAGGCATA-3’ 
(personal communication, Heinrich Schell, University of Tubingen, Germany) and were 
synthesised by Eurofins (Eurofins MWG Operon, Ebesberg, Germany) .  PCR was performed on 
DNA samples generated from each animal along with wild type C57BL/6 DNA as a negative 
control, using Hot StarTaq Master Mix Kit (Qiagen) on a Hybaid PCR Express cycler (Thermo 
Fisher Scientific).  The cycling conditions used were 5 minutes at 94°C, 32× (30 s at 94°C, 30 s at 
62°C and 30 s at 72°C) and 5 minutes at 72°C before being held at 12°C.  The PCR products 
obtained were then run on a 1% agarose gel (Agarose in Tris/Borate/EDTA Buffer (both Sigma) 
+ SYBR® Safe DNAGel Stain) for 1 hour at 80 V alongside 2-Log DNA Ladder (0.1–10.0 kb) (New 
England Biolabs) and visualized under ultraviolet using a Syngene GeneSnap Imaging software 
(v7.04) on a Synoptics G:Box transilluminator. 
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2.6.2 Dosing & Welfare Checks 
Mice in the pilot study were split into five groups of six by cage and rats into four groups of 
four by cage assigned to the dosing regimens in Tables 2.8 for the study. 
 
Group Animals Dose Vehicle 
1 1-6 10 ml/kg Olive oil 
2 7-12 500 mg/kg TCE Olive oil 
3 13-18 100mg/kg Chloral 0.9% NaCl 
4 19-24 1 mg/kg TaClo 0.1% DMSO in 0.9% NaCl 
5 25-30 10 mg/kg MPTP 0.9% NaCl 
 
Group Animals Dose Vehicle 
1* 1-4 N/A N/A 
2 9-12 500 mg/kg TCE Olive oil 
3 13-16 100mg/kg Chloral 0.9% NaCl 
4 17-20 1 mg/kg TaClo 0.1% DMSO in 0.9% NaCl 
*It was intended to dose Group 1 with olive oil but due to licensing issues this did not occur 
and Group 1 were an untreated control 
 
Table 2.8 Pilot study dosing regimen 
 
Mice were split into four groups of five male (group xMx) and four groups of five female (group 
xFx) for both wild-type (W) and A30P (A) and assigned to the dosing regimens in Table 2.9 for 
the study.  A30P mutant mice were staggered in groups born at the same time. 
 
Wild Type 
Group Animals Dose Vehicle 
WM1 W1M -W5M 10 ml/kg Olive oil 
WM2 W6M -W10M 1000 mg/kg TCE Olive oil 
WM3 W11M -W15M 2 mg/kg TaClo 0.1% DMSO in 0.9% NaCl 
WF1 W1F -W5F 10 ml/kg Olive oil 
WF2 W6F -W10F 1000 mg/kg TCE Olive oil 
WF3 W11F-W15F 2 mg/kg TaClo 0.1% DMSO in 0.9% NaCl 
A30P 
Group Animals Dose Vehicle 
AM1 A1, 5, 9, 13 & 17M 10 ml/kg Olive oil 
AM2 A2, 6, 10, 14 & 18M 1000 mg/kg TCE Olive oil 
AM3 A3, 7, 11, 15 & 19M 2 mg/kg TaClo 0.1% DMSO in 0.9% NaCl 
AF1 A1, 5, 9, 13 & 17F 10 ml/kg Olive oil 
AF2 A2, 6, 10, 14 & 18F 1000 mg/kg TCE Olive oil 
AF3 A3, 7, 11, 15 & 19F 2 mg/kg TaClo 0.1% DMSO in 0.9% NaCl 
Table 2.9 Wild type & mutant C57BL/6 mouse A30P study dosing regimen 
 
Mice were dosed i.p. with a Microlance 25G X 5/8” and rats with a Microlance 23G X 1” needle 
(Scientific Laboratory Services) twice weekly for 8 weeks, in alternating sides of the abdomen. 
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Animals were observed constantly for 1 hour following the first dosing in case of adverse 
events occurring and for following this were checked every morning and at 1 & 4 hours after 
every dose.  Animal weight was recorded on dosing days 
 
2.6.3 Behaviour 
Motor and cognitive function were assessed in all pilot and A30P animals according to the 
schedule set out in Figure 2.4, using the behavioural battery described below.  
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Fig. 2.4 In vivo study summary Schematic representation of procedures carried out on all animals on pilot and A30P study. 
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2.6.3.1 Rotarod (all animals) 
Motor function was assessed by an accelerating rotarod protocol (Jones and Roberts 1968) , 
using the IITC Life Sciences Rotarod treadmill for rats and mice (WPI, Hertfordshire, UK).  
Animals in the pilot study were trained on the rotarod for three consecutive trials of 1 minute 
with the rod rotating at a constant speed of 4 rpm prior to testing.  On test days, animals were 
tested in three trials with 15 minutes between trials.  For each trial animals were placed on the 
rod at a rotating speed of 4 rpm.  When all the animals were on the rod the rod steadily 
accelerated to 40 rpm over 300 seconds and the fall latency for each animal was recorded.  If 
they did not fall, a latency of 300 seconds was recorded.  Due to low latencies seen in the pilot 
study, the protocol for mice in the A30P study was slightly modified so that animals were 
trained at 3 rpm and the rotarod accelerated from 3-30 rpm on trial days. 
2.6.3.2 Grip Strength (all animals) 
Four-paw grip strength was tested using a modified method of that described by Cabe et al. 
(Cabe, Tilson et al. 1978) using the Bioseb Grip Strength Tester (Bioseb, Vitrolles, France).  
Animals were positioned so that they grabbed hold of the transducer mesh and then gently 
pulled backwards until they released their grip on the mesh.  The maximum force attained was 
recorded over three separate trials with at least one minute between. 
2.6.3.3 Pole Test (mice only) 
Fine motor function was assessed the pole test (Matsuura, Kabuto et al. 1997).  Animals were 
trained to grip, face up - on to the top of a 8mm diameter, 55cm high polypropylene threaded 
pole (Shop4fasteners.co.uk, Sheffield, UK) standing in the home cage - and turn and to climb 
down on three separate occasions prior to testing.  On test days, animals were timed in the 
activity for three trials separated by at least 15 minutes.  Time to turn, time to descend, total 
time and number of falls over three trials were recorded.  If the animal did not complete the 
task or fell, a time of 30 seconds was recorded. 
2.6.3.4 Label Test  (pilot study mice only) 
Fine motor function was assessed the label test (Fleming, Salcedo et al. 2004).  A small (10mm 
diameter) adhesive label was placed on the snout of the animal and time to remove label was 
recorded up to a maximum of 60 seconds in three trials separated by at least 15 minutes.  All 
testing was performed in the animal's home cage, and cage mates were temporarily removed 
during testing because they can interfere with stimulus removal. If the animal did not remove 
the stimulus within 60 seconds, the experimenter removed it, and the trial for the next mouse 
was initiated. 
Chapter 2 Materials & Methods 
102 
 
2.6.3.5 Gait Analysis (A30P mice only) 
Fine motor function was assessed by gait analysis by a modified version of the method 
described by Carter et al. (Carter, Lione et al. 1999) in A30P study animals from week 28 
onwards.  Animals were trained to run along a paper floored corridor to the home cage.  On 
test days, animals’ hind paws were covered with ‘Måla’ water soluble, non-toxic blue paint 
(IKEA, Newcastle-Upon-Tyne, UK) before being run along the paper floored corridor to the 
home cage.  The length of three strides was measured in mm and averaged. 
2.6.3.6 Barnes Maze (A30P mice only) 
Spatial learning and memory were assessed in the A30P study using the Barnes maze (Barnes 
1979; Patil, Sunyer et al. 2009) in weeks 40 and 41.  The paradigm consists of a 96 cm diameter 
grey plastic disk maze with twenty equally spaced (7.5 cm between holes) holes (5 cm 
diameter) 2cm from the maze edge (see Fig. 2.6).  One hole, the ‘target’, has access to a small 
dark escape chamber located under the maze for the mice to exit, with no visual discrimination 
between this and other holes.  A cardboard barrier surrounded the maze with distinct visual 
cues (A4 size filled square, circle, triangle and cross) attached at the cardinal points to give the 
animals spatial reference points while the rest of the room, including the experimenter, was 
kept in constant configuration throughout the duration of the experimental protocol.  All 
experimental procedures were recorded using Panasonic SDR-S26 video camera for scoring.  
The test was carried out according to the timeline summarised in Fig. 2.5 as described below. 
 
 
Fig. 2.5 Barnes maze timeline Animals adapted to Barnes maze on Day 1 and learning 
investigated in the acquisition phase on Days 1-4.  Long and short term retention investigated 
on Days 5 & 12 in the probe phase. 
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Fig. 2.6 Schematic of Barnes maze Maze is a 92cm grey plastic disc elevated above the floor 
with 20 identical 5cm diameter holes spread evenly around the circumference, 2 cm from the 
edge.  Holes are numbered -1 to -9 on the right hand side of the target and +1 to +9 on the left.  
The target hole has an escape chamber underneath attached by magnets.  Taken from (Sunyer, 
Patil et al. 2007) [http://www.nature.com/protocolexchange/protocols/349/uploads/705] 
 
 
2.6.3.6.1 Adaptation Phase 
On Day 1 mice were placed in the 10.5cm diameter chamber in the centre of the maze (start 
chamber) for 10 seconds before being released.  The mouse was then gently guided to the 
target hole an encouraged to enter the escape chamber.  Once in the escape chamber, the 
entrance was covered and the mouse was left there for 2 minutes then returned to the home 
cage. 
2.6.3.6.2 Spatial Acquisition (Training Days) 
Mice were placed in the start chamber for 10 seconds and then released into the maze where 
they were allowed to explore for 3 minutes.  During the exploration period, primary errors (the 
number of times incorrect holes were explored before finding the target), total number of 
errors (the number of times incorrect holes were explored before entering the target hole 
escape chamber), primary latency (the amount of time taken to find target hole) and total 
latency (the amount of time taken to enter target hole) were recorded. The trial ended when 
the mouse entered the escape chamber or 3 minutes had elapsed.  If the escape chamber was 
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not entered in the 3 minutes, a total latency of 180 seconds was recorded and the mouse was 
gently encouraged to enter the chamber.  Once in the escape chamber, the entrance was 
covered and the mouse was left there for 1 minute then before being returned to the home 
cage. 
 
The test was repeated four times per day on days 1-4 with a 15 min inter-trial interval.  
Between trials, the maze was cleaned with 50% ethanol and the maze was rotated 90o to try to 
remove any olfactory cues. 
 
2.6.3.6.3 Reference Memory (Probe Trial) 
On Day 5, 24 hours following last training day, and on Day 12, a probe trial was conducted to 
assess short and long term retention respectively.  Mice were placed in the start chamber for 
10 seconds and then released into the maze and allowed to explore for 90 seconds.  The 
number of pokes (errors) in each numbered hole, along with primary latency and total latency 
were all recorded.  Error scores were calculated by assigning each error a value according to 
the distance from the target (i.e. -2 and + 2 = 2, opposite = 10 etc.) and combined to give a 
final numerical value. 
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2.6.4 Post Mortem 
Animals were anaesthetised in 3% isofluorane (Isoflo® 100% w/w inhalation vapour, liquid 
isofluorane, Abbott Laboratories Ltd, Maidenhead, UK) in O2 and terminated by decapitation at 
8 weeks post dose for the pilot study and at 42 weeks post dose for A30P study.  General post 
mortem observation carried out on major organs.  Brains dissected from animals and 3x2mm 
(mouse) or 6x2mm (rat) sections taken from anterior and flash frozen before storage at -80oC 
until neurotransmitter level assay.  Posterior fixed in 10% formaldehyde (Sigma). 
 
2.6.4.1 Neurotransmitter Level Assay 
2.6.4.1.1 Brain Homogenate Preparation 
Caudate Putamen and Forebrain were dissected from both hemispheres of frozen brain slices 
as Figure 2.7, weighed and homogenised for 20 seconds in 100µl 0.5M formic / 0.1M 
perchloric acid using a Kontes Pellet Pestle® Motor homogeniser fitted with a blue 
polypropylene disposable pellet pestle (Sigma).  Samples were centrifuged at 13,000g for 15 
min at 4oC, supernatants removed and pellets and supernatants stored separately at -20 / 80oC 
until sample clean up. 
 
Fig. 2.7 Brain areas dissected for neurotransmitter level assay Areas dissected from frozen 
brain samples for caudate putamen (C1 & 2) and forebrain (F1 & 2) for neurotransmitter level 
assay. 
 
2.6.4.1.3 Solid Phase Extraction 
30µl of each sample (DA, DOPAC, HVA, 5-HT, 5-HIAA, GABA and glutamate at 20, 10, 5, 2, 1 & 
0.5 ng/ml in mobile phase) made up to 150µl with ddH2O, acidified with 350µl 2% phosphoric 
acid.  Varian Bond Elut Plexa PCX 30 mg 96-well plate conditioned with methanol and H2O 
before samples drawn through plate by vacuum pump.  Plate washed with 2% (v/v) formic acid 
(Sigma) before samples eluted.  Primary acid elution in 1:1 methanol/acetonitrile and 
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secondary basic elution in 1:1 methanol/acetonitrile + 5% (v/v) ammonia.  Both elutes 
evaporated to dryness at 40oC and 17psi under nitrogen in a TurboVap®LV evaporation system 
(Caliper Life Sciences, Cambridge, UK).  Acid containing elute reconstituted in 100µl 90:10 
H2O/methanol and basic in 100µl 90:10 H2O/methanol + 0.1% (v/v) formic acid.  Samples were 
treated with dansyl chloride to add dansyl groups to the neurotransmitters to improve 
chromatography.  Briefly, 100µl dansyl chloride and 100µl of sodium bicarbonate/sodium 
carbonate buffer (pH 11) and incubated for 30 minutes in a water bath at 35oC protected from 
light.  The reaction was stopped by addition of 5µl 15% formic acid, samples centrifuged an 
supernatants stored at -80oC until mass spectrometry. 
 
2.6.4.1.4 LC-MS/MS 
Chromatographic analyses were performed in a Shimadzu Prominence LC system (Shimadzu, 
Milton Keynes, UK), using an Accucore column (100mm × 2.1mm × 1.8µM) from Thermo.  Mass 
spectrometric detection was carried out using a QTRAP 550 tandem quadrupole mass 
spectrometer (AB Sciex, Warrington, UK). The instrument was operated using an electrospray 
ionization source (ESI) in positive mode. ESI parameters were ion spray voltage 5500 V, source 
temperature 600 ◦C, cone gas flow 40 L/h and desolvation flow 30 L/h (both gases were 
nitrogen).  Collision induced dissociation was performed using nitrogen as the collision gas at 
the medium pressure setting in the collision cell. The multiple reaction monitoring transitions 
as well as the collision energies are shown in Table 2.10. Data acquisition was performed using 
Analyst v1.52 software (AB Sciex). 
 
Analyte RTW 
(min) 
Transitions (Ce) 
Quantification Confirmation 
DA 12.0 853.1 > 170.1 (50) 853.1 > 619.2 (35) 
DOPAC 11.1 635.1 > 170.1 (35) 635.1 > 401.1 (30) 
HVA 9.8 416.1 > 170.1 (33) 416.1 > 156.1 (35) 
5-HT 11.1 643.2 > 170.1 (50) 643.2 > 235.1 (50) 
5-HIAA 9.8 425.1 > 170.1 (35) 425.1 > 381.2 (30) 
GABA 8.2 337.1 > 170.3 (30) 337.1 > 157.1 (40) 
Glutamate 7.5 381.0 > 170.1 (25) 381.0 > 251.9 (25) 
Table 2.10 Retention time and MS/MS parameters of neurotransmitters Abbreviations:  Ce; 
Collision energy, RTW; retention time window. 
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The analytes were separated with a mobile phase consisting of water and 0.1% formic acid 
(eluent A) and methanol and 0.1% formic acid (eluent B) at a flow rate of 0.3 mL/min.  A 
gradient profile was used, starting at 10 % of eluent B, it was then increased linearly to 95 % in 
10 min. This composition was held for a further 5 min, before being returned to the initial 
conditions in 10 min, followed by a re-equilibration time of 2 min, to give a total run time of 27 
min. 5µL was injected into the chromatographic system. 
 
2.6.4.2 Substantia Nigra Stereology 
2.6.4.2.1 Sample Processing & Immunohistochemistry 
Brain tissue was fixed above (Section 2.7.3.4) for six animals (three male & three female) from 
each treatment group - of both wild type and A30P mutant mice - was processed in a Leica 
TP1020  processor for 2 hours under vacuum in each of the following reagents in sequence: 
 
 70% ethanol  
 80% ethanol  
 95% ethanol  
 100% ethanol (x3) 
 Xylene (x2) 
 Parrafin wax @ 65oC (x2)  
Processed tissue was embedded in paraffin wax with anterior cut face presented. 
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Fig. 2.8 Limits of stereological analysis Representative diagrams of brain slices at the (A) start 
and (B) end of sampling.  Corresponding Bregma coordinates are noted below the diagrams.  
Adapted from (Lein, Hawrylycz et al. 2007); website: ©2012 Allen Institute for Brain Science. 
Allen Mouse Brain Atlas [Internet]. Available from: http://mouse.brain-map.org/ 
 
 
 
Coronal sections of tissue (30µm) were taken rostral to the SNpc at bregma -2.78mm 
throughout the SNpc until caudal to bregma -3.78mm (Fig. 2.8) and every fifth section was 
selected for stereological analysis, giving a total of nine sections.  They were stained for DA 
neurons with an anti-tyrosine hydroxylase enzyme using the Vectastain Elite ABC Rabbit IgG kit 
(Vector, Peterborough, UK) and general nuclei, by Nissl staining, using the following stepped 
protocol: 
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o DE-WAXING; 1 x 5 minute and 1 x10 minute wash in xylene (Fisher Scientific) 
o REHYDRATION; decreasing ethanol solutions (2 x 100%, 95%, 70% 50% & 0% ethanol in 
ddH2O). 
o ANTIGEN RETREVAL; boiled in 1.27mM EDTA (Tetrasodium Dihydrate, USB Products, High 
Wycombe, UK), pH 8 in a microwave at half power for 10 minutes before allowing to cool 
for 20 minutes and then immediately transferred to ddH2O. 
o QUENCHING; 0.9% H2O2 in TBS followed by 3 x 3 minutes TBS wash. 
o BLOCKING; goat serum in TBS for 30 minutes. 
o PRIMARY ANTIBODY; Rabbit polyclonal antibody to TH (Abcam) 1:500 in TBS containing 
blocking goat serum at 4oC overnight. 
o SECONDARY ANTIBODY; Vectastain biotinylated anti-rabbit anitody 1:200 in blocking 
serum in TBS for 30 minutes at room temperature followed by 3 x 3 minutes TBS wash. 
o DETECTION; Vectastain ABC reagent (Avidin/Biotinylated Enzyme Complex)) in TBS for 30 
minutes at room temperature followed by 3 x 3 minutes TBS wash.  0.25mg/ml 3,3'-
Diaminobenzidine in TBS + 0.02% H2O2 for exactly 10 min, washed in cold running tap 
water for 5 minutes. 
o NISSL COUNTERSTAIN; 100µg/ml Cresyl Fixed Violet in Acetone Buffer (112.5µM Acetic 
Acid & 11.75mg/ml sodium acetate in ddH2O, ph 4.5) for 20 minutes, allowed to air dry. 
o COVERSLIP; Dehydrated by 1 x 95% and 2 x 100% ethanol, 2 x xylene washes and coverslips 
mounted with DPX (Fisher Scientific). 
 
2.6.4.2.2 Stereological Analysis 
Tyrosine hydroxylase positive neurones in the SNpc were counted stereologically by a blinded 
operator using a Zeiss Imager.Z1 microscope attached to an AxiocamMR3c camera with 
StereologerTM Ver 2.1 CP-Version (Stereology Resource Centre, Chester, Maryland, US) 
software. The SNpc was manually outlined at low (x2.5) magnification using TH positive nuclei 
running alongside the cerebral peduncle as a guide (Fig 2.10 A).  Estimated SNpc volumes used 
for counting all groups are summarised in Fig. 2.9; there was no significant difference between 
groups (unpaired t-test).  Counting frames of 34.5µm2 were placed throughout the structure at 
a frame spacing distance of 100 µm2.  A frame height of 12 + a guard height of 2µm was used 
based on an average section thickness following shrinkage during processing of 16.56+0.31 µm 
and there was no significant difference between thickness in any treatment group (group 
thickness data summarised in Table 2.12).  Frame heights were measured for each frame by 
measuring the z-axis positions between the first object coming into focus and the last object 
leaving focus. 
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Total number and volume of TH positive neurons with normal morphology were counted at 
high (x40) magnification using unbiased multi-level (fraction-based) estimates for every fifth 
section throughout the SNpc.  TH- positive neurons were identified as by immunopositively 
stained neurones containing a clearly defined nucleus. Immunopositive neurons were counted 
if the nucleus fell inside the counting frame or crossed the inclusion line (green); nuclei that 
crossed the exclusion line (red) were not counted (Fig. 2.10 B). 
 
Volumes of all TH positive neurons contained in the sampling frame area were estimated using 
an isotropic uniform randomly (IUR) assigned nucleator probe.  This method is based upon the 
idea that four random one dimensional lines from a point within an object can be used to 
make an unbiased estimate of its volume (Gundersen, Bagger et al. 1988).  The nucleator 
method developed by Gundersen (Gunderson 1988) employs four randomly oriented rays 
originating from the nucleolus and measures where they cross the border of the neuronal 
soma (Fig. 2.10 C).  The following formula is then used to calculate the particle volume: 
 
 ̂̅  
  
 
   ̅
  
  
   
∑    
 
 
   
 
 
where:   = distance from sampling point (nucleolus to edge of object) 
 
The coefficient of error (CE) is a widely used measure of the precision of data acquired by 
stereological analysis.  CE for cell number (num) and volume (vol) estimates were calculated 
according to the Gundersen-Jensen method (Gundersen and Jensen 1987) (West, Slomianka et 
al. 1991) using the following formulae: 
 
CEnum=SDnum/meannum 
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where: I = neurons counted 
 Volume = reference area • (sampling frame density)2 • section depth 
 N = number of fields  
 
CE values < 0.10 were considered acceptable and all sampled counts and volumes in this study 
had acceptable CE values (see Table 2.11 for group CE values). 
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Fig. 2.9 SNpc volume in A30P α-synuclein overexpressing & wt C57BL/6 Mice Total SNpc 
sampling volume of TCE (1000mg/kg), TaClo (2mg/kg) & vehicle (olive oil) treated wt & A30P 
overexpressing C57BL/6 mice assessed by stereological analysis.   Data presented as mean + SD 
(n=5/6).  No significant difference between treatment groups or starins, unpaired t-test 
 
Group Section Thickness (µm) Cells counted DA number CE Cell Volume CE 
wt     
Vehicle 16.78+0.31 258+38 0.064 0.017 
TCE 16.42+0.24 139+33 0.087 0.018 
TaClo 16.62+0.29 144+29 0.086 0.021 
A30P     
Vehicle 16.50+0.44 188+43 0.076 0.019 
TCE 16.39+0.21 127+15 0.090 0.014 
TaClo 16.52+0.24 117+7 0.093 0.016 
Table 2.11 Grouped average stereological analysis parameters Section thickness and cells 
counted presented as mean+SD, CE values presented as mean (n=5/6). 
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Fig. 2.10 Stereological analysis parameters used to assess DA neuron number in SNpc of 
C57BL/6 mice brains Example measurement parameters used to measure SNpc DA neuron 
numbers in fixed C57BL/6 mouse brains(A) outline of SNpc (x2.5) (B) DA neuron (DA) count 
(x40) (C) DA neuron volume measurement (x40) 
SNpc 
DA  
DA  
DA  DA  
DA  
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2.7 General Statistics 
All statistical analysis and graphical representations were carried out using SPSS Statistics 17.0 
(2008), GraphPad Prism 4 for Windows (2005) or Microsoft Excel (2007).  All graphs represent 
data as mean + standard deviation (SD) or + standard error of the mean (SEM).  Statistical 
significance was considered when *P<0.05, **P<0.01 or ***P<0.001. 
2.7.1 General In Vitro Statistics 
2.7.1.1 Cell Viability Assays 
ANOVA (One-way) was used to analyse differences within groups and Dunnett’s t-test to 
analyse specific difference between groups when investigating the effect of toxins on SH-SY5Y 
cells and midbrain neurons.  ANOVA (Two-way) was used to analyse difference in interaction 
and bonferroni’s t-test was used to investigate specific differences when investigating to 
effects of cell death manipulators on the toxicity of toxins in SH-SY5Y cells. 
2.7.1.2 Western Blot Statistics 
ANOVA (One-way) was used to analyse differences within groups and Dunnett’s t-test to 
analyse specific difference between groups when investigating the effect of toxins on protein 
levels over time. 
2.8.1.3 FACS Statistics 
ANOVA (Two-way) was used to analyse the effects of TaClo treatment over time on dyes 
assessed by FACS and bonferroni’s t-test was used to investigate specific differences. 
2.7.1.4 Mitochondrial Activity Assay Statistics 
ANOVA (One-way) was used to analyse differences within groups and Dunnett’s Multiple 
Comparison to analyse specific difference between groups when investigating the effect of 
toxins on mitochondrial OXPHOS Complex activity.   
2.7.2 General In Vivo and Ex Vivo Statistics 
2.7.2.1 Weight & Behavioural Assessment Statistics 
Repeated measures ANOVA (Two-way) was used to analyse the effect of treatment over time 
on animal weight and performance in motor function tests and learning in the acquisition 
phase of the Barnes Maze, with bonferroni’s t-test used to investigate specific differences. 
Kruskal Wallis test was used to assess memory in the probe phase of the Barnes Maze. 
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2.8.2.2 SNpc DA Neuron Number Assessment Statistics 
ANOVA (One-way) was used to analyse differences within groups and Dunnett’s t-test to 
analyse specific difference between groups when investigating the effect of toxins on DA 
neuronal number in the SNpc of treated animals. 
2.8.2.3 Neurotransmitter Level Assessment Statistics 
ANOVA (One-way) was used to analyse differences within groups and Dunnett’s t-test to 
analyse specific difference between groups when investigating the effect of toxins on 
neurotransmitter levels in the brains of treated animals. 
 
For sample outputs of statistical analysis, see Appendix C. 
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3.1 Introduction 
TCE is a commonly used industrial solvent and environmental contaminant.  Groups of the 
population are exposed to this chemical at various levels and it has been shown to have links 
to motor dysfunction and PD (Guehl, Bezard et al. 1999; Reif, Burch et al. 2003; Gash, Rutland 
et al. 2008; Goldman, Quinlan et al. 2011).  TCE can be extensively metabolised by various 
pathways into a number of products.  As it is, as yet, unknown whether it is TCE itself or one of 
its metabolites that mediate its neurotoxic effects, this study will examine the neurotoxicity of 
a number of metabolites in addition to the parent compound.  Metabolites to be examined 
were chosen based on previous evidence of neurotoxicity.  The TCE metabolite TaClo, formed 
via the intermediate compound chloral, has been reported to be neurotoxic and has been 
linked with PD (Bringmann, God et al. 1995; Bringmann, God et al. 1995); therefore both TaClo 
and chloral were investigated.  An additional metabolite chosen was DCA, exposure to which 
has been linked with peripheral neuropathies in humans and animal models (Kurlemann, 
Paetzke et al. 1995; Moser, Phillips et al. 1999; Kaufmann, Engelstad et al. 2006). 
 
SH-SY5Y is a human neuroblastoma cell-line cloned from the SK-N-SH cell-line which was 
derived from malignant tumours of immature neurons. It is a neuronal-like catecholaminergic 
cell line that maintains stem-cell characteristics, grows in a monolayer, proliferates rapidly for 
long periods, possesses tyrosine hydroxylase and dopamine-β-hydroxylase activity (Ross, 
Spengler et al. 1983), expresses the dopamine transporter and receptors and forms storage 
vesicles, although dopamine storage in the vesicles is impaired (Colapinto, Mila et al. 2006), 
and as such is extensively used as a model of DA neurons in studying PD (Xie, Hu et al. 2010). 
SH-SY5Y is also routinely used in studies of neuronal cell death and a variety of chemicals can 
induce these cells to differentiate into different phenotypes increasing its usefulness in 
neurotoxicity studies (Presgraves, Ahmed et al. 2003). 
 
Methods to differentiate embryonic stem cells into representative populations of midbrain 
neurons have been developed (Yan, Yang et al. 2005; Yang, Zhang et al. 2008).  These models 
allow investigations into the neurotoxic effects of compounds in PD in a more stable model of 
DA neurons in a mixed cell population closer to that seen in vivo than that provided by SH-
SY5Y.  Due to the stable numbers of cells in the differentiated midbrain line, more chronic 
studies are also possible. 
 
The actual cell death pathway - apoptosis, necroptosis (programmed necrosis) or another form 
of death - which occurs in DA neurons during the development of PD, is so far unclear. The 
driving mechanism behind any cell death is also unknown, although several hypotheses have 
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been proposed suggesting the involvement of protein misfolding and autophagic/ubiquitin 
system impairment, mitochondrial dysfunction, oxidative stress, DA metabolism and 
excitotoxicity/Ca2+ dysregulation. 
 
3.1.1 Aims 
The aims of this study were to investigate the toxicity of TCE and its metabolites chloral, DCA 
and TaClo in the DA model cell line SH-SY5Y and midbrain neurons differentiated from 
embryonic stem cells.  The possible involvement of known cell death mechanisms such as 
apoptosis, necroptosis and autophagy in any toxicity found was also to be investigated.  
 
To achieve these goals, a previously developed exposure paradigm was used and combined 
with known cell death mediators and gene transfection studies to investigate cell death 
mechanisms.  These methods were supported by Western blotting - to examine any changes in 
implicated protein levels, flow cytometry - to try and determine death morphology, and bright 
field and fluorescence microscopy to - visualise toxic effects. 
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3.2 Methods 
For detailed descriptions of all methods see Material and Methods (Section 2), apart from 
those described below: 
3.2.1 TCE Toxicity in a Closed System. 
SH-SY5Y were grown in 6-well plates at a density of ~7 x 105 cells per well in 350μl 10% GM 
and incubated overnight to allow recovery for assay.  Plates were placed inside 5L airtight 
containers containing either three vials of 3ml ddH2O or three vials TCE and incubated 
overnight for 17 hours.  Plates were removed from airtight containers and viability assessed by 
Alamar Blue assay confirmed by visual inspection as described in section 2.1.2.1. The amount 
of TCE left in vials was measured to calculate exposure levels. 
3.2.2 Statistical Analysis 
For information on statistical methods see General Statistics (Sections 2.8, 2.8.1.1, 2.8.1.2 & 
2.8.1.3) 
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3.3 Results 
3.3.1 Toxicity of TCE & Metabolites in Model Dopaminergic Cell Lines 
3.3.1.1 TCE 
SH-SY5Y cells were treated with various concentrations of TCE (1-1000µM) and assessed for 
toxicity at 21 hours. Midbrain neurons were treated with 250-5000µM TCE with viability 
assessed at baseline and following 24 hours and 1 & 2 weeks exposure.  Viability was assessed 
by the Alamar Blue assay using the conversion of the non-fluorescent blue dye resazurin to the 
fluorescent pink dye resorufin by mitochondrial metabolism as an indication of cell survival in 
both cell lines (Nakayama, Caton et al. 1997).  Viability was confirmed by visual inspection.  No 
significant toxicity was observed in either cell line, with all cells appearing morphologically 
sound when examined under magnification and no decrease in Alamar Blue reduction 
observed in either SH-SY5Y cells (Fig. 3.1 A) or midbrain neurons at any time point (Fig. 3.1 C) 
 
Midbrain neurons were treated with various concentrations of TCE for 2 weeks and then fixed.  
Fixed cells were stained for tyrosine hydroxylase (TH) to identify DA neurons and 
counterstained with DAPI for total cell number.  Images were taken and total number of cells 
and number of DA neurons were estimated using image analysis software.  There was no 
significant difference in DA neurons as quantified by TH staining following 2 weeks treatment 
with 0.25-5mM TCE (Fig. 3.2). 
 
SH-SY5Y cells were exposed to TCE or ddH2O in the atmosphere of an enclosed 5L volume 
airtight container to try and achieve stable TCE levels not attained in previous open systems 
due to the volatility of TCE.  Significant cell death was observed with a dramatic decrease in 
Alamar Blue fluorescence (Fig. 3.1 B) and near total destruction of cellular integrity when 
viewed at magnification following 24 hour exposure to TCE in the system when compared to 
control, suggesting TCE is toxic to SH-SY5Y cells when local levels are maintained.  To estimate 
exposure levels of TCE, TCE volumes were measured pre and post incubation and on all 3 
experiments 3ml TCE was observed to have evaporated. 
 
Exposure was calculated based on the assumptions TCE Density = 1.463g/ml, 3ml exposure in 
5000ml volume.  Therefore:  
3x 1.463 x 100= 0.08778% 
        5000 
Exposure = 8,778 ppm or 6.7mM 
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Fig. 3.1 Effect of TCE on cell viability  (A)SH-SY5Y cells were treated with various 
concentrations of TCE for 21 hours and viability measured by reduction of Alamar Blue 
(resazurin).  Data presented as mean % control + SD from quadruplicate assays (n=3).  No 
significant difference, One-way ANOVA. (B) SH-SY5Y cells were treated with TCE (6,000ppm) or 
ddH2O for 24hours and viability measured by reduction of Alamar Blue (resazurin).  Data 
presented as mean % control + SD from sextuplicate assays (n=3).  **P>0.01, paired t-test.  (C) 
Midbrain neurons were treated with various concentrations of chloral and viability measured 
by reduction of Alamar Blue (resazurin) at baseline, 24 hours, 1 & 2 weeks.  Data presented as 
mean % control + SD from triplicate assays (n=1).  No significant effect of TCE treatment over 
time (P<0.001), Two-way ANOVA. 
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Fig. 3.2 Effect of TCE on DA neurons in a differentiated mixed midbrain cultureMidbrain neurons were treated with various concentrations of TCE for 2 weeks 
and then stained with DAPI for total cell number (blue) and anti-TH for DA neurons (green). (A) Images show cells treated with 0 .2% DMSO, 0.25, 0.5, 1, 2.5 or 
5mM Chloral. (B) Graph shows % total cells TH positive.  Data presented as mean % control + SD from triplicate assays (n=1). No significant difference, One-way 
ANOVA 
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3.3.1.2 Chloral 
Chloral is an metabolic intermediate generated in vivo following TCE treatment (Jiang, Mutch 
et al. 2007).   SH-SY5Y cells were treated with various concentrations of chloral (5-5000µM) 
and assessed for toxicity at 21 hours and midbrain neurons with 25-1000µM chloral with 
viability assessed at baseline and following 24 hours and 1, 2, 3 & 4 weeks.  Viability was 
assessed by the Alamar Blue assay and confirmed by visual inspection.  Toxicity was observed 
in both cell lines, with a significant decrease in Alamar Blue reduction observed in SH-SY5Y 
cells at chloral concentrations  > 200µM and 5mM causing near total cell death (Fig. 3.3 A).  
This finding was supported by visual inspection of the cells under magnification showing a 
similar percentage of cell losing standard morphology as shown by the Alamar Blue test at the 
same concentrations. 
 
In the midbrain culture, chloral had a significant toxic effect on viability over time as assessed 
by Alamar Blue reduction (P<0.001, Two-way ANOVA, Fig. 3.6).  100µM chloral treated cultures 
showed significant cell death following 2 weeks exposure, with 50% cell death seen at week 2 
and 75% death by week 3 & 4, 250 & 500 µM reduced viability to less than 50% following 1 
week exposures with almost total death occurring by 2 weeks and cells exposed to 1000µM 
showed almost total death from 1 week (P<0.001, Bonferroni post-test, Fig. 3.3 B).  All Alamar 
Blue test results were confirmed by visual inspection of cell number and structural integrity 
under magnification.  These results may show midbrain neurons to be less susceptible to 
chloral than SH-SY5Y cells, but this phenomenon could be explained by the presence of far 
higher cell number per well for the midbrain neurons.  Although the midbrain cells are 
differentiated, they were stem cells when plated and, as such, will have been growing for a 
proportion of the >18 days prior to treatment as opposed to the 24 hours growth seen with 
the SH-SY5Y cells. 
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Fig. 3.3 Effect of Chloral on cell viability  (A) SH-SY5Y cells were treated with various 
concentrations of chloral for 21 hours and viability measured by reduction of Alamar Blue 
(resazurin).  Data presented as mean % control + SD from quadruplicate assays (n=3).  *** 
P<0.001, **P<0.01when compared to 10% GM, One-way ANOVA & Dunnett’s post-test.  (B) 
Midbrain neurons were treated with various concentrations of chloral and viability measured 
by reduction of Alamar Blue (resazurin) at baseline, 24 hours, 1, 2, 3 & 4 weeks.  Data 
presented as mean % control + SD from triplicate assays (n=3).  Significant effect of chloral 
treatment over time (P<0.001), Two-way ANOVA.  ***P<0.001 when 1000µM, +++P<0.001 
when 500µM, ^^^P<0.001 when 250µM & ###P<0.001 when 100µM chloral compared to 0.2% 
DMSO, Bonferroni post-test 
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Midbrain neurons were treated with various concentrations of Chloral for either 2 or 4 weeks 
and then fixed.  Fixed cells were stained for tyrosine hydroxylase to identify DA neurons and 
counterstained with DAPI for total cell number.  Images were taken and total number of cells 
and number of DA neurons were estimated using image analysis software.  A significant 
reduction in % TH positive cells was seen following 4 week chloral exposure (P<0.01, One-way 
ANOVA); however, there was no significant change in % TH positive cells following 25 & 50µM 
Chloral treatment and at doses >100µM Chloral there were no TH positive cells present (Fig. 
3.4 A & B).  Both of these findings agree with the effects observed in the general population of 
cells when viability was assessed by Alamar Blue (Fig. 3.6) suggesting that chloral is toxic at 
similar levels to all DA neurons in comparison to the general cell population in a differentiated 
mixed midbrain culture. 
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Fig. 3.4 Effect of Chloral on DA neurons in a differentiated mixed midbrain culture Midbrain neurons were treated with various concentrations of Chloral for 4 
weeks and then stained with DAPI for total cell number (blue) and anti-TH for DA neurons (green). (A) Images show cells treated with 0 .2% DMSO, 25, 50 & 
100µM Chloral. (B) Graph shows % total cells TH positive.  Data presented as mean % control + SD from triplicate assays (n=1). *** P<0.001, when compared to 
0.2% DMSO, One-way ANOVA & Dunnett’s post-test
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3.3.1.3 DCA 
The TCE metabolite DCA has been to shown to cause both central (Bhat, Kanz et al. 1991; 
Cicmanec, Condie et al. 1991) and peripheral (Moser, Phillips et al. 1999; Kaufmann, Engelstad 
et al. 2006) neuronal damage .  DA model SH-SY5Y cells were treated with DCA (1-2000µM) for 
17 hours and viability assessed by Alamar Blue reduction.  No significant toxicity was observed 
in Alamar Blue reduction (Fig. 3.5) and all cells showed regular morphology when viewed at 
magnification. 
 
 
 
Fig. 3.5 Effect of DCA on SH-SY5Y viability SH-SY5Y cells were treated with various 
concentrations of DCA for 21 hours and viability measured by reduction of Alamar Blue 
(resazurin).  Data presented as mean % control + SD from quadruplicate assays (n=3).  No 
significant difference, One-way ANOVA. 
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3.3.1.4 TaClo 
TaClo is a metabolite of TCE formed by the spontaneous reaction of the intermediate 
compound chloral with endogenous tryptamine (Bringmann, Feineis et al. 2000).  SH-SY5Y cells 
were treated with various concentrations of TaClo (1-1000µM) and assessed for toxicity at 21 
hours and midbrain neurons with 5-150µM TaClo with viability assessed at baseline and 
following 24 hours and 1, 2, 3 & 4 weeks.  Viability was assessed by Alamar Blue and confirmed 
by visual inspection.  Toxicity was observed in both cell lines, with a significant decrease in 
Alamar Blue reduction observed in SH-SY5Y cells at TaClo concentrations > 50µM and 200µM 
causing near total cell death (Fig. 3.6 A).  This finding was supported by visual inspection of the 
cells under magnification showing a similar percentage of cell losing standard morphology as 
shown by the Alamar Blue test at the same concentrations (Fig. 3.7). 
 
In the midbrain culture, TaClo had a significant toxic effect on viability over time as assessed by 
Alamar Blue reduction (P<0.001, Two-way ANOVA, Fig. 3.13).  100µM TaClo treated cultures 
showed significant cell death following 2 weeks exposure, with 50% cell death seen at week 2 
and almost total death by week 3.  150 µM TaClo reduced viability to less than 25% following 1 
week exposure with almost total death occurring by 2 weeks (P<0.001, Bonferroni post-test, 
Fig. 3.6 C).  All Alamar Blue test results were confirmed by visual inspection of cell number and 
structural integrity under magnification.  This appears to show a reduction in sensitivity of 
midbrain cultures to TaClo toxicity; investigations into the selectivity of the toxicity may 
explain this. 
 
To confirm the accuracy of the Alamar Blue assay, as it measures metabolic activity as an 
indicator as opposed to actual cell death itself, the toxicity assay was repeated with TaClo 
concentrations of 5-1000µM and viability assayed by the crystal violet assay.  The crystal violet 
assay works by the stain entering and binding to DNA fixed viable cells; excess dye is removed 
and the cells are then permeabilised allowing release of the dye trapped in the cells.  This dye 
can then be measured by a spectrophotometer with absorbance corresponding to the number 
of live cells in the plate.  In agreement with Alamar Blue assessed viability, crystal violet assay 
showed significant TaClo toxicity at doses > 50µM, with 200µM leading to the death of nearly 
all cells (Fig. 3.6 B).  This supports the Alamar Blue assay as a reliable method of measuring cell 
viability in TaClo toxicity assays. 
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Fig. 3.6 Effect of TaClo on SH-SY5Y viability SH-SY5Y cells were treated with various 
concentrations of TaClo for 21 hours and viability measured by (A) reduction of Alamar Blue 
(resazurin) or (B) retention of crystal violet.  Data presented as mean % control + SD from 
quadruplicate assays (n=3).  *** P<0.001, **P<0.01, *P<0.05 when compared to 0.2% DMSO, 
One-way ANOVA & Dunnett’s post-test.  (C) Midbrain neurons were treated with various 
concentrations of TaClo and viability measured by reduction of Alamar Blue (resazurin) at 
baseline, 24 hours, 1, 2, 3 & 4 weeks.  Data presented as mean % control + SD from triplicate 
assays (n=3).  Significant effect of TaClo treatment over time (P<0.001), Two-way ANOVA.  
***P<0.001 when 150µM & +++P<0.001 when 100µM TaClo compared to 0.2% DMSO, 
Bonferroni post-test 
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Fig. 3.7 Effect of TaClo on SH-SY5Y morphology SH-SY5Y cells were treated with various concentrations of TaClo for 21 hours.  Representative photographs of  (A) 
0.2% DMSO, (B) 1, (C) 5, (D) 10, (E) 20, (F) 50, (G) 100, (H) 200, (I) 500, (J) 1000µM TaClo at x 40 magnification. 
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To investigate the time course of TaClo toxicity, SH-SY5Y cells were exposed to 100 or 150µM 
TaClo for various time points up to 24 hours and viability assessed by Alamar Blue reduction.  
100µM TaClo treated cells showed a small but significant level of toxicity at 4 and 8 hours, and 
a relatively sharp increase in toxicity between 8 and 24 hours with ~50% cell death occurring 
(Fig. 3.8 A). When treated with 150µM TaClo, significant death was seen >8 hours and viability 
continued to decrease in a linear fashion until 24 hours when nearly all cells were dead (Fig. 
3.8 B). 
 
 
Fig. 3.8 Effect of TaClo on SH-SY5Y viability over time SH-SY5Y cells were treated with (A) 100 
& (B) 150µM TaClo and viability assessed by reduction of Alamar Blue (resazurin) at various 
timepoints.  Data presented as mean % control + SD from quadruplicate assays (n=3).  *** 
P<0.001, **P<0.01, *P<0.05 when compared to 0h treatment, One-way ANOVA & Dunnett’s 
post-test. 
 
 
Midbrain cultures were fixed following the 4 weeks of TaClo exposure and stained for tyrosine 
hydroxylase (TH) to identify DA neurons and counterstained with DAPI for total cell number.  
Images were taken and total number of cells and number of DA neurons were estimated using 
image analysis software.  A significant reduction in per cent TH positive neurons was observed 
following 4 weeks TaClo treatment (P<0.01, One-way ANOVA).  Cultures that were treated 
with 25 & 50µM TaClo showed a significant reduction in DA neurons (P<0.05, P<0.01 
respectively, Dunnett’s t-test) with almost total ablation of TH positive cells occurring following 
50µM TaClo exposure (Fig. 3.9), despite a lack of significant toxicity apparent in the total 
population as assessed by Alamar Blue (Fig. 3.13 F).  At doses >100µM TaClo there were no TH 
positive cells present (Fig. 3.14 A & B) as there was almost total reduction in the viability of the 
general population of cells(Fig. 3.13 F).  The toxicity of TaClo to DA neurons is slightly higher 
than that seen in SH-SY5Y; however, this is following far longer exposure time.  These findings 
suggest a specificity of TaClo toxicity to DA neurons when compared to a differentiated mixed 
midbrain culture and a slightly increased sensitivity to TaClo when compared to SH-SY5Y 
neuroblastoma. 
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Fig. 3.9 Effect of TaClo on DA neurons in a differentiated mixed midbrain culture Midbrain neurons were treated with various concentrations of TaClo for 4 
weeks and then stained with DAPI for total cell number (blue) and anti-TH for DA neurons (green). (A) Images show cells treated with 0.2% DMSO, 25, 50, 100,& 
150µM TaClo. (B) Graph shows % total cells TH positive.  Data presented as mean % control + SD from triplicate assays (n=2).  Significant reduction in %TH-positive 
cells (P<0.01, One-way ANOVA) *** P<0.001, **P<0.01, *P<0.05 when compared to 0.2% DMSO, Dunnett’s post-test. 
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LD50 values were estimated for TCE and each of its metabolites studied in SH-SY5Y and 
midbrain neurons (from exposures previously described) as well as neural stem cells (from 
data not shown) and summarised in Table 3.1.  As observed in the assays, TCE and DCA did not 
show significant toxicity in SH-SY5Y or midbrain neurons (TCE only).  Chloral was most toxic to 
midbrain neurons (LD50 250µM) followed by SH-SY5Y (LD50 500-1000µM) but showed relatively 
low toxicity in neural stem cells (LD50 2-5mM).  TaClo showed similar levels of toxicity in 
midbrain neurons and SH-SY5Y (LD50 100µM & 100-150 µM respectively) but was 
comparatively less toxic in neural stem cells and MEFs (LD50 200-500µM & 200 µM 
respectively). 
 
Compound Cell line LD50 
TCE SH-SY5Y Not toxic <1mM 
Midbrain Neurons Not toxic <5mM 
Chloral SH-SY5Y 500-1000µM 
Midbrain Neurons 250µM 
Neural Stem Cells 2-5mM 
DCA SH-SY5Y Not toxic <2mM 
TaClo SH-SY5Y 100µM 
Midbrain Neurons 100-150µM 
Neural Stem Cells 200-500µM 
MEF 200µM 
Table 3.1 TCE & metabolite LD50 Estimated LD50 of TCE and metabolites in various cell lines 
following 24 hour treatment in SH-SY5Y and neural stem cells and 1 week in midbrain neurons 
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3.3.2 Involvement of Apoptosis in TaClo Toxicity 
Apoptosis is the main form of programmed cell death in eukaryotes and also the most well 
characterised and studied.  A detailed discussion on the mechanism of apoptosis can be found 
in section 1.3.1 above. 
 
Caspases are a group of cysteine-aspartic acid protease enzymes (Alnemri, Livingston et al. 
1996) known to be integrally involved in the execution of chemically mediated apoptosis (Sun, 
MacFarlane et al. 1999); therefore inhibition of caspases should protect against apoptotic cell 
death.  The involvement of caspases, and so apoptosis, in the mechanism of TCE mediated cell 
death through TaClo was investigated by co-treating SH-SY5Y cells with toxic doses of chloral 
or TaClo and the pan-caspase inhibitor zVAD.fmk (Slee, Zhu et al. 1996).  No significant 
protection from chloral or TaClo induced cell death was conferred on SH-SY5Y cells by caspase 
blockade (Two-way ANOVA) (Fig.3.10) suggesting the cell death method triggered in SH-SY5Y 
by either TCE metabolite may not be apoptosis. 
 
Caspase-3 is the primary ‘executioner caspase’ that plays a key role in the mechanism of 
apoptosis by cleaving various substrates in what is known as the caspase cascade (Slee, Adrain 
et al. 2001).    Protein was isolated from SH-SY5Y cells treated with TaClo and Western blots 
were carried out for cleaved caspase 3, with induced Jurkat cell extract used as a positive 
control and untreated Jurkat cell extract as a negative control.  Induced Jurkat cell extract is 
taken from human macrophage cells induced to undergo apoptosis by the chemotherapeutic 
agent etoposide (Kaufmann, Desnoyers et al. 1993).  No bands were observed for cleaved 
caspase up to 8 hours after treatment with 100µM TaClo and non-induced Jurkat cell extract 
but bands were present following 24 hours 100µM TaClo and induced Jurkat cell extract (Fig. 
3.11).  This suggests that caspase cleavage/activation may occur as a terminal stage event in 
TaClo mediated toxicity. 
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Fig. 3.10 Effect of zVAD.fmk on chloral & TaClo toxicity in SH-SY5Y SH-SY5Y cells were pre-
treated with zVAD.fmk (10 & 20μM) for 1 hour and then co-treated with either (A) chloral (500 
or 1000μM) or (B) TaClo (50 or 100μM) for 21 hours and viability measured by reduction of 
Alamar Blue (resazurin).  Data presented as mean % control + SD from quadruplicate assays 
(n=3).  (A & B) No significant effect of zVAD.fmk on chloral or TaClo treatment, Two-way 
ANOVA. 
 
 
 
 
 
 
 Fig. 3.11 Expression of cleaved Caspase-3 (cCaspase 3) in 0.2% DMSO & 100µM TaClo 
treated SY-SY5Y SH-SY5Y cells were treated with 0.2% DMSO or 100µM TaClo for 0, 4, 8 & 24 
hours and protein harvested.  Samples were probed for cCaspase-3 alongside Jurkat cell 
extract either non-induced (ni) or induced to undergo apoptosis by etoposide treatment (i) as 
controls.  Image is representative blot of cCaspase-3 and GAPDH control. 
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3.3.3 Involvement of Necroptosis in TaClo Toxicity 
It has been shown that when cells are under stress and apoptosis does not occur, the cell can 
be forced down an alternative necrotic death pathway(Lemaire, Andr au et al. 1998), known 
as “necroptosis”.  Necroptosis is a previously uncharacterised,  programmed form of cell death 
that shares morphological features with necrosis but is regulated by the formation of a 
complex containing RIP1, RIP3 and caspase-8 (He, Wang et al. 2009).  The formation of this 
complex is blocked during apoptosis by cleavage of the component proteins by effector 
caspases, so it may function as an alternative death mechanism if caspase activation and 
apoptosis are inhibited (Vercammen, Beyaert et al. 1998).  More detail on necroptosis can be 
found in section 1.3.2 above. 
 
The necroptotic pathway has been shown to be inhibited by the small molecule inhibitor 
Necrostatin-1(Nec-1) (Degterev, Huang et al. 2005).  SH-SY5Y cells were treated with toxic 
doses of TaClo and Nec-1 to investigate whether this pathway was involved in TaClo mediated 
SH-SY5Y toxicity.  Statistically, there was a significant effect of Nec-1 on both chloral and TaClo 
induced toxicity (P<0.05, Two-way ANOVA).  The only significant increase in viability in chloral 
treated cells was conferred by 100µM Nec-1 on 0.2% DMSO treated cells (P<0.001, One-way 
ANOVA) but not following either dose of chloral treatment (Fig. 3.12 A), suggesting that the 
effect of Nec-1 observed preferentially occurs in unexposed cells and, therefore, that Nec-1 
does not protect against chloral mediated SH-SY5Y death.  However, in TaClo treated SH-SY5Y, 
Nec-1 significantly protected against both 100 & 150µM TaClo mediated toxicity (P<0.01, 
P<0.001 respectively, Dunnett’s t test) in a dose-dependent manner (Fig. 3.12 B), suggesting 
that the significant increase in viability mediated by Nec-1 is proportionally higher in TaClo 
exposed cells when compared to its effect on 0.2% DMSO treated cells - therefore protects 
against TaClo mediated SH-SY5Y toxicity. 
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Fig. 3.12 Effect of Necrostatin-1 on chloral & TaClo toxicity in SH-SY5Y SH-SY5Y cells were pre-
treated with Nec-1 (50 & 100μM) for 1 hour and then co-treated with either (A) chloral (500 or 
1000μM) or (B) TaClo (100 & 150μM) for 21 hours and viability measured by reduction of 
Alamar Blue (resazurin).  Data presented as mean % control + SD from quadruplicate assays 
(n=3).  (A & B) Significant effect of Nec-1 on chloral & TaClo treatment (P<0.05), Two-way 
ANOVA. ***P<0.001, **P<0.01 when compared to 0.2% DMSO, Bonferroni post-test 
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A recent report discovered that Nec-1 has an identical structure as methyl-thiohydantoin-
tryptophan, an inhibitor of indoleamine 2,3-dioxygenase (IDO), a rate limiting enzyme of the 
kynurenine pathway that metabolises tryptophan to NAD+ (Vandenabeele, Grootjans et al. 
2013).  This lack of specificity of Nec-1, questions whether the protective effects of the 
compound seen against TaClo toxicity are due to Nec-1 and necroptosis inhibition or IDO 
inhibition.  To further investigate this, SH-SY5Y cells - exposed to toxic doses of TaClo - were 
co-treated with  1-methyl-L-tryptophan, an IDO inhibitor that does not affect RIP1 (Cady and 
Sono 1991; Schmidt, Siepmann et al. 2012). 
 
No significant protection from TaClo induced cell death was conferred on SH-SY5Y cells by 
specific IDO blockade (Two-way ANOVA) (Fig.3.13) suggesting that IDO inhibition is not 
involved in Nec-1 induced protection against TaClo toxicity.  However, Nec-1s also had no 
significant effect on TaClo toxicity in this assay (Two-way ANOVA) (Fig.3.13), suggesting the 
possibility that RIP1 inhibition may not be involved in protection against TaClo induced death. 
 
 
 
Fig. 3.13 Effect of 1-metyl-L-tryptophan on TaClo toxicity in SH-SY5Y SH-SY5Y cells were pre-
treated with 1-methyl-L-tryptophan (200μM) for 1 hour and then co-treated with TaClo (100 & 
150μM) for 21 hours and viability measured by reduction of Alamar Blue (resazurin).  Data 
presented as mean % control + SD from quadruplicate assays (n=3).  No significant effect of 1-
methyl-L-tryptophan on TaClo toxicity, Two-way ANOVA 
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Nec-1 acts by inhibiting the kinase activity of the receptor interacting protein 1 (RIP1) 
(Degterev, Huang et al. 2005), which has been shown to be a critical effector in the switch to 
necroptosis (Holler, Zaru et al. 2000).  Protein isolated from SH-SY5Ys treated with TaClo over 
various time points was probed for RIP1 levels by Western blot.  TaClo treatment significantly 
reduced the proportion of RIP1 that was present in the cleaved, non-kinase domain-containing 
form (Fig. 3.14), possibly suggesting a blockage of the caspase-8 or caspase-6 mediated RIP1 
cleavage present during apoptosis (Lin, Devin et al. 1999; Van Raam, Ehrnhoefer et al. 2013) 
and more of a push of the cell towards necroptosis.  Full length RIP1 levels were not found to 
be significantly changed (Fig. 3.14).   
 
 
Fig. 3.14 Expression of full length (RIP1) and cleaved (cRIP1) RIP1 in 100µM TaClo treated SY-
SY5Y cells SH-SY5Y cells were treated with 100µM TaClo for 0, 4, 8 or 24 hours and protein 
harvested.  Samples were probed for RIP1.  (A) Image is representative blot of RIP1, cRIP1 and 
GAPDH control (B) RIP1 intensity relative to GAPDH.  Data presented as fold-untreated + SD 
from quadruplicate assays (n=3).  No significant difference when compared to 0h, One-way 
ANOVA.  (C) cRIP1 intensity relative to GAPDH.  Data presented as fold-untreated + SD from 
quadruplicate assays (n=3).  *** P<0.001, when compared to 0h, One-way ANOVA & Dunnett’s 
post-test 
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SH-SY5Y cells were treated with a shRNA containing lentiviral vector to knockdown RIP1 levels 
in order to confirm the finding that RIP1 is integrally involved in TaClo mediated SH-SY5Y cell 
death.  Viral take up was good, as seen by the viral conferred GFP expression relative to 
inherent DAPI staining (Fig. 3.15 A), and probing for RIP1 levels by Western blot showed RIP1 
levels knocked down to 60% or 40% of control by viral clones 513 & 668 respectively (Fig. 3.15 
B & C).  Due to the greater extent of RIP1 knockdown, clone 668 treated cells were used in 
further studies. 
 
RIP1 knockdown and control lentiviral transfected SH-SY5Y cells were then treated with TaClo 
(20-150µM) and viability assayed by Alamar Blue fluorescence confirmed by visual inspection.  
RIP1 knockdown showed a small but significant protection against TaClo toxicity when 
compared to control cells (P<0.001, Two-way ANOVA) (Fig. 3.16 A) with RIP1 knockdown 
significantly protecting SH-SY5Y at doses of 20, 50, 100 & 150µM TaClo (P<0.05, P<0.001, 
P<0.001, P<0.05, respectively, Dunnett’s t-test) supporting the evidence that TaClo treatment 
leads to SH-SY5Y cell death via necroptosis.  To investigate whether the protection mediated 
by Nec-1 in SH-SY5Y cells seen above was due to inhibition of RIP1 kinase activity, RIP1 
knockdown SH-SY5Y cells were treated with toxic doses of TaClo and Nec-1.  Nec-1 still had a 
significant effect on viability in RIP1 knockdown SH-STY5Ys (P<0.01, Two-way ANOVA); 
however, the increase in viability was significantly lower in TaClo treated cells than control 
(Fig. 3.16 B), suggesting that the protection conferred on SH-SY5Y by Nec-1 seen in wild-type 
cells may be mediated by RIP1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 The Toxicity of TCE & Metabolites 
140 
 
 
Fig. 3.15 Transfection efficiency and knockdown levels of lentiviral RIP1 knockdown in SH-
SY5Y SH-SY5Y cells were untreated or treated with control (CTL) or RIP1 clone 513 or 668 
knockdown lentivirus expressing GFP.  (A) Images show DAPI stained cell nuclei, GFP 
expression & DAPI & GFP overlaid (x 40 magnification). (B & C) Protein samples isolated from 
cells were probed for RIP1.  (B) Image is representative blot from CTL and 513 & 668 clone 
knockdown (kd) cells.  (C)  Protein intensity in untreated and knockdown cells relative to 
GAPDH.  Data presented as fold-untreated + SD from duplicate assays (n=3).  *** P<0.001, 
when compared to untreated, independent samples t-test 
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Fig. 3.16 Effect of RIP1 knockdown on TaClo toxicity and Nec-1 efficiency in SH-SY5Y (A) SH-
SY5Y cells were transfected with either control (CTL) or RIP1 knockdown lentiviruses and then 
treated with TaClo (20-150μM) for 21 hours and viability measured by reduction of Alamar 
Blue (resazurin).  Data presented as mean % control + SD from triplicate assays (n=3).   
Significant effect of RIP1 knockdown on TaClo toxicity (P<0.001), ***P<0.001, *P<0.05 when 
compared to CTL, Bonferroni post-test.  (B) RIP1 knockdown SH-SY5Y cells were pre-treated 
with Nec-1 (100μM) for 1 hour and then co-treated with TaClo (150μM) for 21 hours and 
viability measured by reduction of Alamar Blue (resazurin).  Data presented as mean % control 
+ SD from triplicate assays (n=3).  Significant effect of Nec-1 on TaClo treatment, P<0.01, Two-
way ANOVA. 
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As complete RIP1 knockdown was not achieved in SH-SY5Y by shRNA treatment, RIP1 knockout 
MEFs were generated from RIP1 -/- C57BL/6 mice in the lab of Liu, Z.G. (NIH National Cancer 
Institute, Bethesda, US) and obtained to further explore the involvement of RIP1 in TaClo 
toxicity.  RIP1 knockdown in RIP1 -/- MEFs was confirmed by Western blot (Hur, Lewis et al. 
2003) (Fig. 3.17 A).  Wild-type and RIP1 knockout MEF cells were treated with various 
concentrations of TaClo (100-500µM) and assessed for toxicity at 21 hours.  Viability was 
assessed by the Alamar Blue and confirmed by visual inspection.  RIP1 knockout conferred 
significant protection against TaClo toxicity when compared to wild-type MEFs (P<0.001, Two-
way ANOVA) with significant protection of MEFs seen at doses of 200 & 300µM TaClo 
(P<0.001, P<0.01, respectively, Bonfferoni post-test) supporting the evidence that TaClo 
treatment leads to SH-SY5Y cell death via necroptosis (Fig. 3.17 B).  These findings were 
supported by visual inspection of the cells under magnification showing a similar percentage of 
cells losing standard morphology as shown by the Alamar Blue test at the same 
concentrations. 
 
To investigate whether the protection mediated by Nec-1 in SH-SY5Y cells seen above was 
mediated by effects on RIP1, RIP1 -/- MEF cells were treated with toxic doses of TaClo and Nec-
1.  There was no significant effect of Nec-1 on TaClo toxicity in RIP1 -/- MEFs (Two-way ANOVA) 
nor any increase in metabolism in the vehicle treated group seen in SH-SY5Y cells (Fig. 3.17 C), 
suggesting that the protection conferred on TaClo treated SH-SY5Y cells was RIP1 dependent.  
Rip1 -/- MEF cells were also treated with toxic doses of TaClo and the pan-caspase inhibitor 
zVAD.fmk, to investigate if the cells were dying by apoptosis.  No significant effect of zVAD.fmk 
was observed in TaClo exposed RIP1 -/- MEFs (Fig. 3.17 C), suggesting that apoptosis was not 
involved in the toxic mechanism of TaClo.  Finally, Rip1 -/- MEF cells were treated with toxic 
doses of TaClo and the antioxidant NAC, to investigate the effect of oxidative stress on TaClo 
toxicity.  NAC significantly attenuated TaClo toxicity in RIP1 -/- MEFs (Fig. 3.17 C), suggesting 
that oxidative stress contributes to the toxic mechanism of TaClo. 
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Fig. 3.17 TaClo toxicity in wild-type & RIP1 -/- MEFs and the effect of RIP1 knockout on the 
effect of Necrostatin-1, zVAD.fmk & NAC on TaClo toxicity (A) RIP1 knockdown levels as 
assessed by Western blot in wild type (WT) and RIP -/- MEFS.  Adapted from (Hur, Lewis et al. 
2003).  (B) Wild-type & RIP1 -/- MEF cells were treated with various concentrations of TaClo for 
21 hours and viability measured by reduction of Alamar Blue (resazurin).  Data presented as 
mean % control + SD from triplicate assays (n=3).  Significant effect of RIP1 knockdown on 
TaClo toxicity (P<0.001), ***P<0.001, **P<0.01 when compared to CTL, Bonferroni post-test.  
(C) RIP1 -/- MEF cells were pre-treated with Nec-1 (100μM), zVAD.fmk (20μM) or NAC (5mM) 
for 1 hour and then co-treated with TaClo (300 & 250μM) for 21 hours and viability measured 
by reduction of Alamar Blue (resazurin).  Data presented as mean % control + SD from 
quadruplicate assays (n=3).  Significant effect of NAC on TaClo toxicity (P<0.01), no significant 
effect of Nec-1 or zVAD.fmk on TaClo treatment, Two-way ANOVA. **P<0.01, *P<0.05 when 
compared to CTL, Bonferroni post-test 
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3.3.3.1 Analysis of Cell Death Mechanism by Flow Cytometry 
Propidium Iodide (PI) is a red fluorescent dye that can be used to assess cell membrane 
integrity.  PI fluorescence increases exponentially when it is bound to nucleic acids compared 
to when it is not, and binds DNA by intercalating between bases (Tas and Westerneng 1981).  
The intact membrane of a healthy cell is impermeable to PI but it can enter cells when the 
membrane is damaged, such as during necrosis.  It is then able to come into contact with DNA 
resulting in an increase in fluorescent signal. 
 
Hoechst 33342(Hoechst)  is a blue fluorescent DNA binding dye that fluoresces more brightly 
when bound to the condensed form of chromatin found in apoptotic cells, but not when 
bound to chromatin in healthy cells (Ellwart and Dormer 1990). 
 
The properties of these two dyes allow the differentiation of cell death phenotype between 
necrotic and apoptotic when cells are double stained with PI and Hoechst and sorted by flow 
cytometry based on the knowledge that necrotic cells have damage cell membranes but no 
chromatin condensation and early apoptotic cells have chromatin condensation but intact cell 
membranes (Belloc, Dumain et al. 1994).  Staurosprine, a compound known to induce 
apoptosis in SH-SY5Y (Boix, Llecha et al. 1997), was used as a positive control for apoptosis in 
the assay. 
 
The population of whole single cells was selected using a plot of forward scatter (FSC-A), which 
measures cell size, against side scatter (SSC-A), which measures cell shape or granularity, (Fig. 
3.18 A) and fluorescence levels for Hoechst 33342 and PI measured in this population.  Fig. 
3.18 B shows the average number of total events that were included in the whole single cell 
population.  The number of events defined as whole single cells significantly decreases over 
time (P<0.001, Two-way ANOVA).  In the 100µM TaClo treated samples, there are significantly 
fewer whole single cells than in the 0.2% DMSO sample at 16 & 24 hours post treatment 
(P<0.05, P<0.001, respectively, Bonferroni post-test).  150µM TaClo treated samples showed 
significantly reduced levels of whole single cells at 12, 16 & 24 hours post treatment when 
compared to 0.2% DMSO (P<0.01, P<0.001, P<0.001, respectively, Bonferroni post-test).  
500nM Staurosporine treated samples had significantly fewer whole single cells than 0.2& 
DMSO at 8-24 hours post treatment (all P<0.001. Bonferroni post-test).  This corresponds with 
a decrease in viability observed by visual inspection of the samples before processing for flow 
cytometry. 
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Gates were defined based on Hoechst and PI fluorescence and defined as healthy (low 
Hoechst/low PI) apoptotic (high Hoechst/low PI), necrotic (low Hoechst/high PI) and late stage 
death (high Hoechst/high PI).  Healthy gate was set to contain approximately 90-95% of cells 
for 0.2% DMSO & 0h samples (limits 89.3-96.9%) and quadrants kept consistent within 
experiments. 
 
Treated cells showed a significant effect of treatment over time in cells defined as healthy, 
necrotic, late stage death (P<0.001, Two-way ANOVA) and apoptotic (P<0.05, Two-way 
ANOVA).  In individual populations, the healthy population showed no significant change when 
treated with 0.2% DMSO, but showed a significant reduction from 12 hours following 100µM 
TaClo treatment (P<0.05) and 8 hours following 150µM TaClo and following 500nM 
Staurosporine treatment (P<0.001, all Bonferroni post-test) (Fig 3.26 A-D & 3.27).  The late 
stage death population also showed no significant change when treated with 0.2% DMSO, but 
showed a significant increase at 24 hours following 100µM TaClo treatment and from 12 hours 
following 150µM TaClo (P<0.05) and from 8 hours post 500nM Staurosporine treatment 
(P<0.001, all Bonferroni post-test) (Fig 3.19 A-D & 3.20). 
 
When looking at specific death mechanisms, the apoptotic population showed no significant 
change when treated with 0.2% DMSO, 100 or 150µM TaClo but showed a significant increase 
at 4-12 hours following 500nM Staurosporine treatment (P<0.001, Bonferroni post-test) but no 
significant change 16 & 24 hours post 500nM Staurosprorine (Fig 3.19 A-D & 3.20).  This 
reduction in apoptotic death following longer Staurosporine treatment is probably due to the 
almost complete lack of viable cells seen at these times with this treatment. 
 
The necrotic population, however, showed no significant change when treated with 0.2% 
DMSO or 500nM Staurosporine but showed a significant increase from 12 hours following 
100µM TaClo treatment (P<0.05) and from 8 hours following 150µM TaClo (P<0.001, both 
Bonferroni post-test) (Fig 3.19 A-D & 3.20). 
 
This evidence suggests that TaClo causes SH-SY5Y cytotoxicity by a death mechanism involving 
membrane breakdown such as necrosis, unlike Staurosporine, a known apoptotic inducer, 
which leads to a form of cell death involving chromatin condensation such as apoptosis. 
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Fig. 3.18 Population definition for flow cytometric analysis of cell death phenotype ¶ SH-
SY5Y were treated with 0.2% DMSO, 100µM TaClo, 150µM TaClo or 500nM Staurosporine for 
0-24 hours and stained with Hoescht3342 and PI before fluorescence was assessed using flow 
cytometry (A) Representative density plot showing selection of whole single cells based on 
SSC-A and FSC-A  (B) Average no. total events defined as in single cell population (n=3).  
Significant effect of TaClo & Staurosporine on single cell population over time (P<0.001, Two-
way ANOVA), ***P<0.001, **P<0.01, *P<0.001, Bonferroni post-test. 
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Fig. 3.19 Flow cytometric analysis for cell death phenotype¶ SH-SY5Y cells were treated with 
0.2% DMSO, 100µM TaClo, 150µM TaClo or 500nM Staurosporine for 0,  4,  8, 12, 16 or 24 
hours and stained with Hoescht3342 and PI before fluorescence was assessed using flow 
cytometry.  Whole Cell populations were defined as healthy (blue), apoptotic (red), necrotic 
(green) or dead (black) dependent on relative Hoescht3342 or PI staining.  Example FACS dot 
plots shown. 
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Fig. 3.19 Flow cytometric analysis for cell death phenotype (cont.) 
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Fig. 3.19 Flow cytometric analysis for cell death phenotype (cont.) 
Chapter 3 The Toxicity of TCE & Metabolites 
150 
 
 
Fig. 3.19 Flow cytometric analysis for cell death phenotype (cont.) 
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Fig. 3.20 Effect of TaClo treatment on cell phenotype following TaClo & Staurosporine treatment as quantified by flow cytometry SH-SY5Y were treated with (A) 
0.2% DMSO, (B) 100µM TaClo, (C) 150µM TaClo or (D) 500nM Staurosporine for 0-24 hours and then loaded with 5µg/ml Hoescht 3342 and 1µg/ml PI before 
fluorescence was assessed using flow cytometry.  % Cells were defined as healthy, apoptotic, necrotic or late cell death dependent on relative Hoescht3342 or PI 
staining over time following treatment.  Data presented as mean + SD (n=3).  (A) No significant effect of 0.2 % DMSO on phenotype over time, (B-D) Significant 
effect of 100 & 150µM TaClo and 500nM Staurosporine treatment on phenotype over time, all P<0.001, Two-way ANOVA. ***P<0.001, **P<0.01, *P<0.05 when 
compared to 0 hour time point, Bonferroni post-test. 
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3.3.4 Involvement of Autophagy in TaClo Toxicity 
Autophagy is a regulated cellular process that serves to ensure degradation of damaged or un-
needed cellular components using the lysosomal machinery and allows for efficient synthesis 
and recycling of these molecules.  However, disruption of normal autophagic function, when 
un-regulated or overwhelmed, can lead to excessive degradation of cellular contents or 
insufficient clearance of toxic protein accumulations and eventually cell death. Further detail 
on autophagy can be found in section 1.3.3 above.  The effects of TaClo treatment on 
autophagy were examined, as dysfunction in this system and misfolded protein build-up have 
been previously linked with neurodegenerative conditions, in particular PD (Banerjee, Beal et 
al. 2010). 
 
Rapamycin is a bacterial product that can inhibit mTOR by forming a complex with the 
intracellular receptor of mTOR immunophilin 12-kDa FK506-binding protein (FKPB12) 
(Augustine, Bodziak et al. 2007).  This inhibition of mTOR induces autophagy in the cells as 
under normal cellular conditions, mTOR inhibits autophagy (Blommaart, Luiken et al. 1995).  
SH-SY5Y cells were co-treated with TaClo and Rapamycin to investigate whether this pathway 
was involved in TaClo mediated SH-SY5Y toxicity.  Rapamycin (P<0.05, Two-way ANOVA) 
significantly increased TaClo mediated toxicity in SH-SY5Y cells in a dose dependent manner 
(Fig. 3.21). 
 
 
Fig. 3.21 Effect of Rapamycin on TaClo toxicity in SH-SY5Y SH-SY5Y cells were pre-treated with 
Rapamycin (2.5 & 5μM) for 1 hour and then co-treated with TaClo (100 & 150μM) for 21 hours 
and viability measured by reduction of Alamar Blue (resazurin).  Data presented as mean % 
control + SD from quadruplicate assays (n=3).  Significant effect of rapamycin on TaClo toxicity 
(P<0.05), Two-way ANOVA. ***P<0.001, **P<0.01 when compared to 0.2% DMSO, Bonferroni 
post-test 
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3.3.4.1 Effect of TaClo Treatment on LC3-B 
Microtubule-associated protein1 light chain 3 (LC3) is a homologue of APG8P, which is 
essential for autophagy in yeast (Liang, Jackson et al. 1999) and present in two forms LC3-A 
and LC3-B.  A fraction of LC3-A is converted to LC3-B which forms an integral part of the 
autophagosome membranes and, therefore, levels of LC3-B in the cell directly correlate with 
the extent of autophagosome formation (Kabeya, Mizushima et al. 2000). 
 
Protein isolated from SH-SY5Ys treated with TaClo over various time points was probed for 
LC3-B levels by Western blot.  TaClo treatment significantly increased LC3-B expression in a 
time dependent manner (P<0.05, One-way ANOVA) with expression significantly higher at 8 
and 24 hours post treatment when compared to pre-treatment levels (P<0.05, Dunnett’s t-
test) (Fig. 3.22). 
 
 
Fig. 3.22 Expression of LC3-B in 100µM TaClo treated SY-SY5Y SH-SY5Y cells were treated with 
100µM TaClo for 0, 4, 8 or 24 hours and protein harvested.  Samples were probed for LC3-B.  
(A) Image is representative blot of LC3-B and GAPDH control (B) LC3-B intensity relative to 
GAPDH.  Data presented as fold-untreated + SD from quadruplicate assays (n=3).  * P<0.05, 
when compared to 0h, One-way ANOVA & Dunnett’s post-test 
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3.3.4.2 Involvement of Lysosomes in TaClo Toxicity 
Lysosomes are membrane bound organelles containing a range of enzymes capable of 
degrading cellular contents which are responsible for the degradation of material sequestered 
during autophagy by fusing with autophagosomes (Klionsky 2007). 
 
Bafilomycin A1 is antibiotic that had been shown to strongly inhibit the vacuolar H(+)-ATPase 
and so the acidification and protein degradation in lysosomes (Yoshimori, Yamamoto et al. 
1991).  SH-SY5Y cells were co-treated with Bafilomycin A1 and TaClo and viability assessed by 
Alamar Blue assay and confirmed by visual inspection.  Bafilomycin A1 treatment significantly 
increased TaClo toxicity (P<0.05, Two-way ANOVA) (Fig.3.23), suggesting that functioning 
lysosomes may provide protection against a TaClo induced toxic insult as part of the 
autophagic machinery. 
 
 
 
Fig. 3.23 Effect of Bafilomycin A1 on TaClo toxicity in SH-SY5Y SH-SY5Y cells were pre-treated 
with Bafilomycin A1 (500nM & 1μM) for 1 hour and then co-treated with TaClo (100 & 150μM) 
for 21 hours and viability measured by reduction of Alamar Blue (resazurin).  Data presented as 
mean % control + SD from quadruplicate assays (n=3).  Significant effect of Bafilomycin A1 on 
TaClo toxicity (P<0.05), Two-way ANOVA. ***P<0.001, *P<0.05 when compared to 0.2% 
DMSO, Bonferroni post-test 
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SH-SY5Y cells were assessed for levels of lysosome formation at various time points following 
TaClo treatment using LysotrackerTM Red and quantified by flow cytometry.  LysotrackerTM Red 
is an acidotropic probe for labelling and tracking acidic organelles such as lysosomes in live 
cells (Alberts, Johnson et al. 1994).  It consists of a fluorophore linked to a weak base that is 
only partially protonated at neutral pH; it is freely permeant to cell membranes and typically 
concentrates in spherical organelles. Its mechanism of retention has not been firmly 
established but is likely to involve protonation and retention in the membranes of the 
organelles. 
 
The population of whole single cells was selected using a plot of FSC-A, which measures cell 
size, against SSC-A, which measures cell shape or granularity, (Fig. 3.24 A) and fluorescence 
levels measured in this population.  Gates were set for high and low fluorescence based upon 
95% of control cells being in the low fluorescing population (Fig. 3.24 C).  A time and dose-
dependent increase in fluorescence was observed in both 100 & 150µM treated SH-SY5Y cells 
relative to control (Fig. 3.24 B) (P<0.001, Two-way ANOVA), with cells seeming to show more 
lysosome formation after 8 hours and a significant increase in the number of cells (61%) 
showing high fluorescence in 150µM treated cells at 8 (P<0.01) hours post treatment and 
almost all the cells present in the high fluorescing population by 16 hours (P<0.001) (Fig. 3.24 
B).  In the 100µM treated cells, lysosome formation was slower, with a significant increase also 
occurring by 16 hours (P<0.001) hours in 44% of cells and almost all cells showing high 
fluorescence by 24 hours (P<0.001) (Fig. 3.24 B).  These results suggest that lysosome 
formation is increased as a relatively early event in TaClo mediated SH-SY5Y toxicity. 
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Fig. 3.24 Effect of TaClo treatment on Lysotracker fluorescence in SH-SY5Y as quantified by flow cytometry SH-SY5Y were treated with 0.2% DMSO, 100 or 
150µM TaClo for 0-24 hours and then loaded with 50nM lysotracker before fluorescence was assessed using flow cytometry.  (A) Representative density plot 
showing selection of whole single cells based on SSC-A and FSC-A.  (B)  % Cells defined as having high fluorescence over time following treatment.  Data presented 
as mean + SD (n=3).  Significant effect of Taclo treatment on fluorescence over time (P<0.001), Two-way ANOVA.  ***P<0.001, **P<0.01 when compared to 0.2% 
DMOS at same time point, Bonferroni post-test.  (C)  Representative overlaid histograms of log selected single cell fluorescence at ex/em 488/585 at all timepoints.  
Bars show defined low and high fluorescing population boundaries.  
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3.3.4.3 Effect of TaClo Treatment on Aggresome Formation 
Aggresomes are inclusion bodies that form when the ubiquitin–proteasome machinery is 
overwhelmed with aggregation-prone proteins (Amijee, Madine et al. 2009), typically formed 
in response to cellular stress such as exposure to reactive oxygen species.  They appear to have 
a cytoprotective effect by sequestering toxic misfolded protein into aggregates during 
oxidative stress, for example LBs that are found in PD brains. 
 
SH-SY5Y were treated with 0.2% DMSO, 100 or 150µM TaClo or H2O2 as a positive control for 
0-24 hours and then fixed and stained for aggresomes with a red fluorescent molecular rotor 
dye to specifically detect denatured protein cargo within aggresomes and aggresome-like 
inclusion bodies in fixed and permeabilised cells. 
 
TaClo treated cells showed an increase in aggresome number and size (examples highlighted 
by the green arrows in Fig. 3.25) when compared to control in a time and dose dependent 
manner in 100 & 150µM TaClo, as well as H2O2 positive control treated cells (Fig. 3.25).  
Manual quantification of number of aggresomes per cell confirmed this with a significant 
increase in number of aggresomes per cell with treatment over time seen (P<0.001, Two-way 
ANOVA) and 100 & 150µM TaClo and H2O2 and showing a significant increase when compared 
to 0.2% DMSO from 24 (P<0.01), 12 (P<0.01) and 4 (P<0.01) hours post treatment respectively 
(Bonferroni Post test) (Fig. 3.26). 
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Fig. 3.25 Aggresome formation in TaClo treated SH-SY5Y SH-SY5Y cells were treated with for 0, 4, 8, 12 or 24 hours and then stained with DAPI and an aggresome 
dye.  Images show cells treated with 0.2% DMSO, 100µM TaClo, 150µM TaClo or 850µM H2O2 overlaid Hoechst 33342 and aggresome detector images (x 40 
magnification).  Aggresomes show as bright red foci (examples highlighted by green arrows). 
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Fig. 3.25 Aggresome formation in TaClo treated SH-SY5Y (cont.) 
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Fig. 3.25 Aggresome formation in TaClo treated SH-SY5Y (cont.) 
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Fig. 3.25 Aggresome formation in TaClo treated SH-SY5Y (cont.) 
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Fig. 3.26 Aggresome quantification in TaClo treated SH-SY5Y SH-SY5Y cells were treated for 0, 
4, 8, 12 or 24 hours and then stained with Hoechst 33342 and an aggresome dye.  Data shown 
as mean aggresomes per cell + SD (n=3).  Significant effect of TaClo & H2O2 treatment on 
number of aggresomes/cell over time (P<0.001, Two-Way ANOVA).  ***P<0.001, **P<0.01 
when compared to 0.2% DMSO at same time point, Bonferroni post-test. 
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3.3.5 Involvement of DNA Damage in TaClo Toxicity 
PARP-1 is a protein involved in DNA repair and cell death.  PARP-1 is an integral part of base 
excision repair of single or double strand breaks in DNA (Dantzer, Schreiber et al. 1999) when 
in its activated form.  Activated PARP, when involved in DNA excision repair, depletes cellular 
ATP levels, which, in cases of high DNA damage, can ultimately lead to necrosis (Bouchard, 
Rouleau et al. 2003). 
 
Protein was isolated from SH-SY5Y cells treated with 100µM TaClo and probed for relative full 
length and cleaved PARP levels by Western blot. Bands for full length PARP were present at all 
time points (Fig. 3.27 A) and no significant difference was observed in levels for up to 24 hours 
following 100µM TaClo treatment (One-way ANOVA) (Fig 3.27 B).  No bands were visible for 
cleaved PARP at any time point until 24h (Fig. 3.27 A), suggesting PARP inactivation only occurs 
late in TaClo mediated cell death. 
 
Fig. 3.27 Expression of full length (PARP) and cleaved (cPARP) PARP in 100µM TaClo treated 
SH-SY5YSH-SY5Y cells were treated with 100µM TaClo for 0, 4, 8 or 24 hours and protein 
harvested.  Samples were probed for PARP.  (A) Image is representative blot of PARP, cPARP 
and GAPDH control (B) PARP intensity relative to GAPDH.  Data presented as fold-untreated + 
SD from quadruplicate assays (n=3).  No significant difference when compared to 0h, One-way 
ANOVA.  (C) cPARP intensity relative to GAPDH.  Data presented as fold-untreated + SD from 
quadruplicate assays (n=3).  No significant difference, One-way ANOVA 
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SH-SY5Y cells were co-treated with toxic doses of TaClo and the PARP inhibitor PJ-34 
(Abdelkarim, Gertz et al. 2001) to investigate the involvement of PARP in TaClo mediated SH-
SY5Y toxicity.  At low levels of toxicity (<50% cell death) PJ-34 significantly amplified TaClo 
mediated toxicity in SH-SY5Y cells in a dose dependent manner, whereas at high levels of 
toxicity (>50% cell death) PJ-34 significantly attenuated TaClo toxicity in a dose dependent 
manner (Fig. 3.28).  This is consistent with results seen with known DNA damaging agents, as 
under low cellular stress levels, PARP repairs DNA damage, but at high levels of DNA damage, 
PARP depletes cellular ATP level  and leads to necrosis  (Bouchard, Rouleau et al. 2003). 
 
 
 
Fig. 3.28 Effect of PJ-34 on TaClo toxicity in SH-SY5Y SH-SY5Y cells were pre-treated with PJ-34 
(20μM) for 1 hour and then co-treated with TaClo (50-250μM) for 21 hours and viability 
measured by reduction of Alamar Blue (resazurin).  Data presented as mean % control + SD 
from quadruplicate assays (n=3).  Significant effect of PJ-34 on TaClo toxicity (P<0.001), Two-
way ANOVA. 
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Histone H2A.X is a histone involved in DNA double strand break repair (Yuan, Adamski et al. 
2010) that has been shown to be rapidly phosphorylated at Ser139 following exposure to DNA 
damaging agents (Rogakou, Pilch et al. 1998).  Protein was isolated from SH-SY5Y cells treated 
with 100µM TaClo and probed for phospho-histone H2A.X Ser139 (pH2AX) levels by Western 
blot. pH2AX levels were significantly increased following TaClo treatment (P<0.05, unpaired t-
test) (Fig. 3.29) suggesting TaClo exposure leads to double strand breaks in DNA. 
 
 
 
Fig. 3.29 Expression of Phospho-Histone H2A.X (pH2AX) in 100µM TaClo treated SY-SY5Y SH-
SY5Y cells were treated with 0.2% DMSO or 100µM TaClo for 24 hours and protein harvested.  
Samples were probed for pH2AX.  (A) Image is representative blot of pH2AX and GAPDH 
control (B) pH2AX intensity relative to GAPDH.  Data presented as fold-untreated + SD from 
quadruplicate assays (n=3).  *P<0.05 when compared to 0.2% DMSO, unpaired t-test 
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Calpain-1 belongs to a family of calcium-dependent, non-lysosomal cysteine proteases and is 
expressed in the central nervous system.  Calpian-1 is activated by micro-molar concentrations 
of Ca2+ (Glass, Culver et al. 2002) and can cleave a wide range of cellular components (Rami 
2003).  It has been shown that Calpain-1 is required for necrotic cell death induced by DNA 
damage and mediated by PARP activation (Moubarak, Yuste et al. 2007). 
 
Protein isolated from SH-SY5Ys treated with TaClo over various time points was probed for 
Calpain-1 levels by Western blot.  TaClo treatment significantly increased Calpain-1 expression 
in a time dependent manner (P<0.05, One-way ANOVA) with expression significantly higher at 
24 hours post treatment when compared to pre-treatment levels (P<0.05, Dunnett’s t-test) 
(Fig. 3.30). 
 
 
Fig. 3.30 Expression of Calpain-1 in 100µM TaClo treated SY-SY5Y SH-SY5Y cells were treated 
with 100µM TaClo for 0, 4, 8 or 24 hours and protein harvested.  Samples were probed for 
Calpain-1.  (A) Image is representative blot of Calpain-1 and GAPDH control (B) Calpain-1 
intensity relative to GAPDH.  Data presented as fold-untreated + SD from quadruplicate assays 
(n=3).  * P<0.05, when compared to 0h, One-way ANOVA & Dunnett’s post-test 
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3.3.6 Summary of Effects of Cell Death Pathway Inhibitors on TaClo Toxicity 
A summary of other cellular process modulators can be seen in Table 3.2.  Modulators have 
been separated into compounds with possible, but unknown involvement in TaClo toxicity, 
those that were toxic in the cells and those with no effect. 
 
Modulator Mechanism Concentration 
Effect on TaClo 
Toxicity 
Possible Involvement 
Resveratrol 
 Multiple non-
specific actions 
(↑SIRT1, ↑ERK, 
↓TNFα, antioxidant, 
↓PKC, ↑AMPK) 
25 & 50μM Increased toxicity 
Sirtinol Sirtuin inhibitor 2.5, 5, 25 & 50μM Increased toxicity 
SP600125 JNK Inhibitor 
500nM & 
1, 2.5, 5 & 20μM 
No sig effect up to 
20μM which was 
toxic 
Toxic 
Apocynin/Acetylvanillone 
NADPH Oxidase 
inhibitor :. ↓ROS.  
500μM & 1mM Increased toxicity 
LY29002 PI3K inhibitor 50 & 100μM Increased toxicity 
PP2 
Src tyrosine kinase 
inhibitor 
10 & 20μM Increased toxicity 
PP242 
Selective mTOR 
inhibitor 
100 & 500nM Increased toxicity 
Table 3.2 Summary of the effects of cell death pathway modulators on TaClo toxicity in SH-
SY5Y 
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Modulator Mechanism Concentration 
Effect on TaClo 
Toxicity 
No Effect 
3-Methyladenine PI3K inhibitor 
100μM & 1.5, 3 & 
4.5mM 
No effect 
Bongkrekic Acid 
Inhibits MTP 
formation 
10 & 20μM No effect 
Butylatedhydroxyanisole 
Mitochondrial-
targeting ROS 
scavenger 
25, 50, 100 & 
200μM 
No effect up to 
200μM which 
increased toxicity 
Deprenyl 
MAO-B & GAPDH 
inhibitor  
10, 100 & 200μM No effect 
Ebselen 
GSH peroxidase 
mimic 
5, 10, 35 & 50μM No effect 
Gö6976 PKC inhibitor 1 & 2.5μM No effect 
GW5074 Raf kinase inhibitor 
500nM & 
1μM 
No effect 
Idebenone 
analogue of 
coenzyme Q10 
(mitochondrial 
antioxidant) 
500nM & 
1, 5 & 10μM 
No effect up to 
10μM which 
increased toxicity 
K-252a PKC inhibitor 500nM & 1μM No effect 
MnTBAP SOD mimetic  25 & 50μM No effect 
MnTmPyP SOD mimetic 1 & 2.5μM No effect 
Procysteine Increases GSH levels 1, 5 & 10mM 
No effect up to 
10mM which 
increased 
Quinazoline 
NF-κB & LPS induced 
TNF inhibitor 
500nM & 1μM No effect 
SQ22536 Inhibits adylylcyclase 10, 20, 50 & 100μM No effect 
Table 3.2 Summary of the effects of cell death pathway modulators on TaClo toxicity in SH-
SY5Y (cont.) 
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3.4 Discussion 
3.4.1 General Neuronal Toxicity of TCE & Metabolites 
TCE did not show any significant toxicity in open system SH-SY5Y, differentiated midbrain 
neuron or DA neuron models used (Figs. 3.1, 3.2 & 3.3) which may be due to a number of 
factors: 
(i) TCE is not toxic at the doses used in the open system experiments and it requires 
higher exposure levels or a longer, more chronic, time period of treatment to exert 
any effect. 
(ii) The cell lines used may not express the enzyme (CYP2E1) needed to metabolise 
TCE into chloral and therefore its suspected toxic metabolites. 
(iii) Due to the volatile nature of TCE, the majority of the dose given could have 
evaporated out of the media and so dramatically reduced exposure. 
 
As SH-SY5Y have been shown to have CYP2E1 present (Posadas, Santos et al. 2012), factor (ii) 
was discounted and it was concluded that the lack of toxicity was due to (i) or (iii).  To try to 
determine what was happening SH-SY5Y cells were exposed to TCE in an airtight closed system 
and observed almost total cell death with exposure calculated to be ~6mM or 8500 ppm (Fig. 
3.4).  These results are in agreement with a previous thesis which exposed SH-SY5Y to TCE 
using a similar method in a smaller container and measured TCE levels in media and cells GC-
ECD.  They found that TCE was taken up quickly into the media (at µM levels) and cells (at mM 
levels) before levels rapidly decreased suggesting either substantial metabolism or ejection of 
the compound from the cells (Jiang 2008).  This suggests that in the open system models the 
volatility of TCE was likely to have been the main reason we were not seeing any toxicity and 
to examine TCE toxicity in vitro in more detail a more robust system of exposing cells to TCE 
needs to be developed.  The levels used to show toxicity in the closed system were ~100 x 
higher than those seen in workers in industrial areas of 1-100ppm (Williams-Johnson, 
Eisenmann et al. 1997), but our model is far more acute, with workers sometimes exposed  to 
low level TCE for decades.  A robust, long-term method of exposure in cells is needed to model 
typical human exposure. 
 
DCA was not found to be toxic at any doses examined in this study (Fig. 3.8), which was 
expected as we were modelling CNS neuronal populations and DCA mainly shows evidence of 
causing peripheral neuropathies (Moser, Phillips et al. 1999; Kaufmann, Engelstad et al. 2006; 
Felitsyn, Stacpoole et al. 2007). 
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Chloral was found to be toxic to both SH-SY5Y and midbrain neurons in our model in a dose-
dependent manner at doses > 200µM in SH-SY5Y and in a time and dose dependent manner at 
doses < 100 µM in midbrain neurons (Figs. 3.5 & 3.6).  The more potent toxicity observed in 
the midbrain neurons is likely to be due to the chronic dosing regimen (4 week) as opposed to 
acute (20 hours) used in the SH-SY5Y.  This supports the hypothesis that TCE leads to PD due to 
the formation of the neurotoxic compound TaClo via chloral (Bringmann, Bruckner et al. 2000; 
Jiang, Mutch et al. 2007).  However, chloral does not appear to show any specific toxicity 
towards DA neurons (Fig. 3.7) which does not support the theory that TCE exposure leads to 
DA neurotoxicity and so PD via chloral.  The toxic dose level of 100µM corresponds to 
~16µg/ml, a far lower exposure level than the dose of 100mg/ml which was shown by Cattano 
et al. to lead to neuroapoptosis in infant mouse brains (Cattano D., Straiko M.M.W. et al. 
2008).  The WHO Concise International Chemical Assessment Document 25 on Chloral Hydrate 
suggests chloral has a very short half-life of approximately 3 minutes and the majority of the 
dose is converted to trichloroethanol (Benson 2000).  It is unclear in our model whether chloral 
itself or conversion to trichlorethanol is the primary cause of toxicity; it is, therefore, difficult 
to see how well our toxic dose compares with the dose Cattano found to be neurotoxic in vivo 
and more research is needed into this. 
 
TaClo was acutely toxic in SH-SY5Y at ten times lower levels than chloral with an LD50 of 
~100µM and almost total cell death at 100µM (Fig. 3.6), supporting our hypothesis, that TCE is 
converted to the neuroactive TaClo via chloral, in agreement with the law of mass action.  This 
is higher than the toxicity seen by Akundi et al. in SK-N-SH neuroblastoma which showed an 
LD50 of ~200µM TaClo (Fig. 3.34) (Akundi, Macho et al. 2004). 
 
 
Fig. 3.31 Toxicity of TaClo in SK-N-SH cellsSK-N-SH cells were treated with TaClo for 24 hours 
and viability assessed by luminescent assay relating to metabolically active cells. Taken from 
(Akundi, Macho et al. 2004) 
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In midbrain neurons, TaClo showed a similar toxic profile to chloral, with 4 weeks treatment 
showing almost total cell death at 100µM and no significant death at 50µM (Figs. 3.6).  This 
may also support the fact that chloral toxicity is due to conversion to TaClo as the longer time 
period of treatment could allow time for the generation of TaClo from chloral as opposed to 
the shorter treatment time in SH-SY5Y.  In the chronic model, the increased length of exposure 
does not appear to affect toxicity, with viability following treatment of all doses, apart from 
100µM TaClo, consistent from 1 -4 weeks exposure.  This suggests there may be some 
threshold of TaClo concentration that needs to be crossed before toxicity occurs.  TaClo 
produces significant cell death in SH-SY5Y following 20 hour 50µM treatment, but not 
following 4 week 50µM treatment in midbrain neurons.  This could be explained as the 
hypothesis is that TCE exposure leads to DA cell death and therefore PD, so it would be 
expected that TaClo would show some specificity for DA neurons.  If this is the case, we could 
expect to see more toxicity in SH-SY5Y when compared to midbrain cultures as SH-SY5Y consist 
entirely of DA model cells, whereas the midbrain culture contains a mixture of cells, only a 
proportion of which are DA.  To further explore this we stained midbrain cultures treated for 4 
weeks for TH, an enzyme involved in DA metabolism widely used as a marker for DA neurons 
(Margolis, Coker et al. 2010).  TaClo showed a significant selectivity for DA neurons in the 
midbrain cultures, with >100µM TaClo causing almost total death of all cells but 25 & 50µM 
TaClo causing no reduction in total cell number but a significant reduction in TH positive 
neurons (Fig. 3.13 & 3.14).  This apparent specificity of TaClo toxicity for DA neurons is 
supported by the relative LD50 values of TaClo in DA model systems SH-SY5Y & midbrain 
neurons (100-150µM) being lower than those in the more general neural stem cells and MEFs 
(200-500µM) (Table 3.1).  This provides evidence for TCE, through TaClo, being involved in the 
DA neuron specific cell death and development of PD in exposed individuals.  However, as this 
DA specificity does not occur in chloral treated midbrain cultures (Fig. 3.7), this suggests a 
scenario where chloral is causing neuronal cell death in different manner to TaClo questioning 
whether a significant quantity of TaClo is formed from chloral in our models. 
 
When we investigated the time course of acute TaClo toxicity in SH-SY5Y, 150µM TaClo 
showed a steady decrease in cell number from 0-24 hours; however, 100µM TaClo did not 
appear lead to significant cell death until 4-8 hours following treatment (Fig. 3.12).  This 
possibly suggests that, at 100µM, a build-up of TaClo in cells is required before any toxic effect 
is triggered; again proposing some kind of thresholding event may be required for TaClo 
toxicity.  In all experiments discussed so far, the Alamar Blue fluorescence assay has been used 
to determine viability.  This assay uses metabolic activity as a marker for viability, but as 
metabolic activity may be affected by treatment, we used visual inspection to confirm our 
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results (Fig. 3.11).  To further confirm that the Alamar Blue assay correlates with viability, we 
compared the results seen with acute TaClo using Alamar Blue to cells treated in the same way 
but with viability assessed by crystal violet assay.  Crystal violet only enters viable cells so 
correlates directly with cell number.  In this experiment, crystal violet results correlated 
extremely well with Alamar Blue assay results, with both showing toxicity at >50µM TaClo and 
similar levels of viability seen at all doses examined (Fig. 3.10).  This supports the Alamar Blue 
assay as a reliable measure of cell viability in our TaClo toxicity assays.  In a study of a patient 
exposed to TCE for 20 years and diagnosed with PD, TaClo levels of 9ng/ml were recorded in 
his blood 2 months after last exposure (Kochen, Kohlmüller et al. 2003), an amount far lower 
than the doses of 7/14 mg/ml (25/50µM) that showed DA neuron toxicity in our models.  
Moreover, the exposure in this case was for a significantly longer time than our model.  Sontag 
et al. found locomotor deficits in  female rats dosed with 0.2 mg/kg/day for 7 weeks (Sontag, 
Heim et al. 1995), which equates to estimated plasma levels of 5ng/ml/day, based on 3-4 
month old female rats weighing ~250g and using the method of Bijsterbosch to estimate 
plasma volume (Bijsterbosch, Duursma et al. 1981).    Over the 7 weeks, this means a total 
dose of 245ng/ml, a dose more comparable with our shorter model of exposure, suggesting a 
possible relevance for our data in vivo.  It has been reported that tetrahydro-β-carbolines, such 
as TaClo, can undergo N-methylation in the brain (Matsubara, Collins et al. 1993), and N-
methyl TaClo was found to be a more potent neurotoxin than TaClo itself (Janetzky, Gille et al. 
1999), suggesting that N-methyl TaClo may be the more relevant toxin which needs 
investigating. 
 
Results in these toxicity assays were used to select doses for further investigation, with doses 
that showed approximately 50% reduction in viability chosen for future assays; 500µM for 
chloral and 100µM for TaClo (Table 3.1).  In assays where a decrease in toxicity was expected, 
this dose was combined with a slightly more toxic dose, 1mM for chloral and 150µM for TaClo, 
to allow observation of an increased viability.  In assays where an increase in toxicity was 
expected, this dose was combined with a slightly less toxic dose, 50µM for TaClo, to allow 
observation of decreased viability. 
 
3.4.2 What is the Main Mechanism of Neuronal Toxicity Mediated by TCE Metabolites? 
Apoptosis is the most studied form of programmed cell death and is characterised by 
morphological changes such as cellular shrinkage, nuclear condensation, DNA fragmentation 
and membrane blebbing.  It is mediated by the activation endogenous endonucleases, such as 
caspases, and cleavage of critical cellular substrates. As a number of studies have suggested 
Chapter 3 The Toxicity of TCE & Metabolites 
173 
 
that apoptosis is involved in the pathogenesis of some forms of PD (Anglade 1997; Nagatsu 
2002; Tatton, Chalmers-Redman et al. 2003)  we decided to investigate whether it was 
involved in the toxicity observed following chloral and TaClo exposure.  If chloral or TaClo were 
causing apoptosis in SH-SY5Y, then blockade of caspase activation by zVAD.fmk, a pan caspase 
inhibitor, should reduce the decrease in viability seen following treatment with these 
compounds.  Our results showed no significant protection against toxicity conferred by 
zVAD.fmk in SH-SY5Y treated with either chloral or TaClo (Fig. 3.15).  This finding was 
supported when TaClo treated cell extracts were probed for the presence of the active, 
cleaved form of caspase-3, one of the main executioner caspases which is essential for 
apoptosis (Nicholson, Ali et al. 1995).  No cleaved caspase-3 was found to be present until 24 
hours following TaClo treatment (Fig. 3.16), suggesting that caspase-3 is not a driving factor in 
TaClo mediated SH-SY5Y toxicity, and only occurs during the final processes of cell death.  This 
correlates well with a study in SK-N-SH cells by Akundi et al. which shows an increase in 
caspase-3 cleavage 24 hours after 150µM TaClo treatment (Akundi, Macho et al. 2004); 
however, they propose that this indicates TaClo mediates cell death by apoptosis in 
disagreement with our hypothesis. Finally, PARP has been shown to be cleaved by caspase-3 
and so inactivated as an early essential event in the apoptotic cascade to stop activated PARP 
depleting cellular NAD levels needed for the energy consuming process of apoptosis (Boulares, 
Yakovlev et al. 1999).  TaClo treated SH-SY5Y cell lysates were probed for PARP and PARP 
cleavage was also only found to occur as a late event, 24 hours following treatment (Fig. 3.35).  
Taken together these findings suggest that apoptosis is not the main form of cell death 
initiated by TaClo in SH-SY5Y. 
 
Some of the earliest reports of chemically induced PD cited necrosis as the method of cell 
death that occurred in these models (Thoenen and Tranzer 1968).  Necrosis has previously 
been thought of as an unregulated form of cell death characterised by a disruption of the 
cellular membrane and a swelling of the cytoplasm and mitochondria, culminating in the 
complete disintegration of organelles and total lysis of the cell.  However, Degterev detailed a 
form of programmed, caspase-independent, cell death with a necrotic morphology and termed 
it ‘necroptosis’ (Degterev, Huang et al. 2005).  As TaClo and chloral do not appear to cause SH-
SY5Y death by apoptosis, we investigated whether the toxic mechanism involved was 
necroptosis by co-treating chloral and TaClo with a small molecule, shown to specifically inhibit 
necroptosis by inhibiting the kinase activity of RIP1, called Nec-1 (Degterev, Huang et al. 2005).  
Nec-1 had no significant effect on chloral induced toxicity but significantly protected against 
TaClo in SH-SY5Y (Fig. 3.17), suggesting that TaClo may cause cell death by necroptosis but 
chloral may not.  This also provides more evidence against our hypothesis that chloral is toxic 
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via conversion to TaClo and suggests a separate mechanism for chloral induced neurotoxicity 
in SH-SY5Y.  RIP1, and in particular an active kinase domain, has been shown to be a key 
mediator of necroptosis (Holler, Zaru et al. 2000) and this active domain has been shown to be 
inactivated due to cleavage by caspase-8 (Lin, Devin et al. 1999) or caspase-6 (Van Raam, 
Ehrnhoefer et al. 2013) during apoptosis.  This is supported by a reported increase in 
necroptotic cell death in caspase-8 deficient mice (Bohgaki, Mozo et al. 2011)  We probed 
TaClo treated SH-SY5Y cell lysates for full length and cleaved RIP1 and found that while full 
length RIP1 expression is not affected by TaClo treatment, the amount of cleaved RIP1 present 
in the cell is significantly reduced to ~50% of control from 4 hours following treatment (Fig. 
3.19).  This suggests that the cell may be undergoing necroptosis relatively rapidly following 
TaClo treatment, as there is less of the cleaved, inactive, form present following treatment, 
due to the involvement of the full length form in necroptosis.  This also suggests this effect 
may be causative as it happens extremely early in the sequence of cell death events, prior to 
actual cell death being seen.  The levels of cleaved RIP are still significantly lower than control 
by 24 hours post treatment, but appear to be rising.  This may be linked with the activation of 
caspases seem by caspase 3 and PARP cleavage at 24 hours (Figs. 3.16 & 3.35). 
 
When RIP1 levels were knocked down in SH-SY5Y, a small but significant protection against 
TaClo insult was seen (Fig. 3.22), supporting the involvement of RIP1 in TaClo mediated SH-
SY5Y cell death and suggesting necroptosis as a possible mechanism.  Although the effect 
observed is relatively minor (10-20%), RIP1 was only knocked down to 50% of control (Fig. 
3.21) despite good viral take-up (Fig. 3.20), and it may be the case that there is still enough 
RIP1 present to achieve cell death in most cases.  To further investigate this, MEF cells with 
complete RIP1 knockout were sourced and a more significant - although not total - attenuation 
of TaClo toxicity was seen when compared to wild type MEFs (Fig. 3.24).  To support this, the 
ability of Nec-1 to attenuate TaClo toxicity was examined in RIP1 knockdown SH-SY5Y and RIP1 
knockout MEFs.  Nec-1 reduced TaClo toxicity in RIP1 knockdown SH-SY5Y (Fig. 3.23), but not 
to the extent seen in wild-type cells and no protection was seen in RIP1 knockout MEFs (Fig. 
3.24),  providing more evidence that RIP1 kinase inhibition - and so blockade of necroptosis - is 
the mechanism by which Nec-1 protects against TaClo mediated toxicity in our models.  This 
suggests that RIP1 is integrally involved in TaClo mediated cell death and that necroptosis is 
the mechanism of death activated. 
 
Some care needs to be taken, however, with this conclusion with a recent report that Nec-1 
has exactly the same structure as methyl-thiohydantoin-tryptophan, an inhibitor of 
indoleamine 2,3-dioxygenase (IDO), a rate limiting enzyme of the kynurenine pathway that 
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metabolises tryptophan to NAD+, proposing that Nec-1 is not a specific inhibitor of RIP1 and 
necroptosis, but also inhibits the kynurenine pathway (Vandenabeele, Grootjans et al. 2013).  
This is particularly interesting as abnormalities in the kynurenine pathway have been 
implicated in the pathology of neurological disorders, due to the presence of three neuroactive 
metabolites in the pathway.  One of the diseases kynurenine pathway disruption has been 
linked with is PD, with abnormalities in metabolites of the pathway found in brains and blood 
of PD patients (Ogawa, Matson et al. 1992; Hartai, Klivenyi et al. 2005) and altered expression 
of enzymes in the pathway seen in MPTP treated mice (Knyihár-Csillik, Csillik et al. 2004).  For a 
review of the complex involvement of kynurenine pathway metabolites in neuroprotection 
and neurotoxicity, and the involvement of the pathway in neurodegenerative disorders see 
(Sas, Robotka et al. 2007; Tan and Yu 2012).  This finding casts some doubt as to whether the 
protection against TaClo toxicity seen is entirely due to effects on RIP1 and necroptosis, or if 
inhibition of IDO and disruption of the kynurenine pathway contributes to, or is the major 
component of, Nec-1 mediated increases in viability following TaClo exposure.  To address 
these concerns, SH-SY5Y were treated with 1-methyl-L-tryptophan, an IDO inhibitor that does 
not have any effects on RIP1 (Cady and Sono 1991; Schmidt, Siepmann et al. 2012).  No 
significant effect on TaClo toxicity was onserved following 1-methyl-L-tryptophan, supporting 
the conclusion that the protective effect of Nec-1 on TaClo mediated cell death is due to RIP1 
kinase inhibition and blockade of a necroptotic pathway (Fig. 3.18). 
 
As there is still some cell death apparent even in RIP1 knockout cells, the effect of zVAD.fmk 
and NAC (antioxidant defence inducing agent; see Chapter 4) on TaClo toxicity were 
investigated in this cell line to see if apoptosis or oxidative stress were involved in this toxicity.  
No attenuation of TaClo toxicity by zVAD.fmk was seen, suggesting that the cells do not switch 
to an apoptotic death mechanism when necroptosis is blocked.  NAC was protective against 
TaClo toxicity; however this was to a far lower extent than that seen in wild type SH-SY5Y (Fig. 
3.25).  This can be explained by the fact that a far higher concentration of TaClo was used in 
the RIP 1 knockout MEFs than the SH-SY5Y (250 & 300µM compared to 100 & 150µM 
respectively) due to the relative resistance of these cells to TaClo toxicity so probably inducing 
higher levels of ROS.  This may suggest that TaClo induces cell death by activation of a 
necroptotic pathway, but if this pathway is blocked, general cellular damage, possibly due to 
oxidative stress, causes a level of damage to the cell that makes it unable to survive. 
 
Evidence provided so far suggests that the form of cell death mediated by TaClo in SH-SY5Y is 
likely a form of programmed necrosis and not apoptosis.  To further explore this we used a 
double staining flow cytometry method that discriminates between necrotic and apoptotic cell 
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death phenotypes based upon known morphological features.  Necrotic cell death is known to 
be characterised by disruption of the cell membrane, a feature not seen in apoptotic cells, and 
known to cause an increase in PI staining. However, in apoptosis chromatin condensation 
occurs, and this is not seen in necrotic cells and causes an increase in Hoechst 33342 staining.  
In SH-SY5Y treated with TaClo for varying time points, stained with both dyes mentioned and 
sorted by flow cytometry into apoptotic or necrotic categories based on Hoechst 33342/PI 
staining, we saw a time and dose-dependent increase in necrotic cells and no significant 
change in those classed as apoptotic (Fig 3.28).  We also treated SH-SY5Y with the known 
apoptosis inducing agent staurosporine as a control for apoptosis, and saw a significant 
increase in cells classified as apoptotic and no change in necrotic cells (Fig. 3.28), confirming 
the discriminatory capability of the assay. 
 
Taken together, this evidence suggests that TaClo treatment leads to a necrotic, and probably 
programmed, form of death in SH-SY5Y. 
 
3.4.3 Is Autophagy Affected During TCE Metabolite Neurotoxicity? 
Autophagy has been widely associated with PD, with evidence of both protective and cytotoxic 
role proposed (Reviewed in (Cheung and Ip 2009)).  Autophagy has also been implicated in the 
pathology of PD due to the importance of clearing toxic protein aggregates linked with the 
disease, such as mutated α-synuclein (Polymeropoulos, Lavedan et al. 1997; Kruger, Kuhn et al. 
1998; Zarranz, Alegre et al. 2004), in disease progression (Pan, Kondo et al. 2008).   Also, 
mutations in Parkin and PINK-1, two proteins liked with autophagy of damaged mitochondria 
(Narendra, Tanaka et al. 2008; Narendra, Jin et al. 2010), have been shown to lead to PD 
(Kitada, Asakawa et al. 1998; Valente, Abou-Sleiman et al. 2004). 
 
Rapamycin is a compound that is known to induce autophagy by inhibition of mTOR 
(Augustine, Bodziak et al. 2007).  We found that rapamycin treatment significantly increased 
TaClo mediated toxicity in SH-SY5Y (Fig. 3.29), suggesting that an increase in autophagy 
attenuates the mechanism of TaClo induced cell death.  This is surprising, as autophagy has 
been generally thought to have a protective effect in PD by clearing misfolded toxic protein 
aggregates and rapamycin has been shown to decrease the toxicity of other known PD-linked 
toxins such as rotenone (Pan, Rawal et al. 2009).  Conversely, there are also reports that 
inhibition of autophagy by melatonin can protect against rotenone induced toxicity in HeLa 
cells (Zhou, Chen et al. 2012), complicating analysis of this evidence.  However, it has been 
reported that rapamycin can block inhibition of mTOR by RTP801, a protein up regulated 
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following known PD toxin MPTP and 6-OHDA treatment which inhibits the phosphorylation of 
the pro-survival protein Akt and leads to cell death (Malagelada, Jin et al. 2010).  This suggests 
that the protective effect of rapamycin may not be due to suppression of autophagy but may 
be due to other effects it has in the cell.  A mechanism by which rapamycin has been shown to 
attenuate toxicity has also been described in renal tubule cells whereby rapamycin increases 
the toxicity of cyclosporine A  by blocking Akt activation and increasing cell death (Cheng, 
Chang et al. 2008).  These findings do not explain the attenuation of TaClo toxicity seen in SH-
SY5Y but suggest a more complex mechanism involving more than autophagy induction may 
be involved and showing more work is needed before conclusions can be fully drawn from this. 
 
In addition to the effect of autophagy on TaClo induced cell death, we looked at the effect of 
TaClo on autophagy.  We probed TaClo exposed cell lysates for LC3-B, an essential component 
of autophagic vesicles and a widely used marker for autophagy.  We found that LC3-B was 
significantly increased from 8 hours following TaClo treatment (Fig. 3.30), suggesting that 
autophagy is induced relatively early after insult and that TaClo may be causing damage to 
cellular contents.  
 
Lysosomes are acid hydrolase enzyme containing cellular organelles that fuse with autophagic 
vesicles to break down waste materials and cellular debris.  We looked at the expression of 
lysosomes following TaClo treatment and found increased lysosomes at 12 to 16 hours 
following TaClo treatment (Fig. 3.32), possibly suggesting an increase in lysosomal size or 
number needed to degrade debris engulfed in the autophagic vesicles seen with the increase 
in LC3-B at 8 hours post-treatment.  This supports a role for TCE mediated cell death through 
TaClo as a similar effect was seen in SH-SY5Y treated with the known PD toxin rotenone (Xiong 
2012).  We also looked at the effect of inhibition of lysosomal function using Bafilomycin A1, a 
compound which blocks the acidification of lysosomes and so their ability to function and 
degrade material brought to them by autophagic vesicles.  Decreased lysosomal function led to 
an increase in TaClo mediated toxicity, suggesting that a functioning lysosomal system protects 
against TaClo mediated cell death.  This agrees with evidence reported that the toxicity of PD-
linked neurotoxins rotenone and paraquat is attenuated by inhibition of autophagy (González-
Polo, Niso-Santano et al. 2007; Xiong 2012).  When taken with the increase in lysosomes seen, 
this evidence suggests TaClo may be damaging cellular contents that - if not cleared efficiently 
from the cytosol - may contribute to cell death. 
 
Aggresomes are inclusion bodies, such as Lewy Bodies in PD, made up of aggregation prone 
proteins that form when the autophagic machinery is overwhelmed (Amijee, Madine et al. 
Chapter 3 The Toxicity of TCE & Metabolites 
178 
 
2009).  They appear to have a cytoprotective effect by sequestering toxic misfolded protein 
into aggregates during oxidative stress or other forms a cellular damage.  SH-SY5Y showed a 
significant increase in aggresome number and size following TaClo treatment (Fig. 3.33 & 3.34), 
suggesting that there is a build-up of aggregating, damaged proteins that the autophagic 
machinery is incapable of clearing.  This suggests TaClo treatment may induce neurotoxicity 
similar to that seen in PD as mutations related to the disease, such as Parkin, have been shown 
to be involved in aggresome formation (Muqit, Davidson et al. 2004) and protein aggregation 
has been widely seen  in the pathology of the disease (Ross and Poirier 2004) and following 
exposure to known PD toxins rotenone and MPTP (Forno, Langston et al. 1986; Diaz-Corrales, 
Asanuma et al. 2005). 
 
Our evidence generally suggests that autophagy is activated following TaClo insult in SH-SY5Y, 
and that it is most probably functioning as a protective mechanism against damage to cellular 
contents and toxic protein aggregation.  However, our finding that rapamycin treatment 
increases TaClo toxicity in SH-SY5Y contradicts this hypothesis and suggests that increasing 
autophagy too much may actually contribute to toxicity.  Both findings could be relevant as 
autophagy is a tightly controlled process and there is evidence that increasing or decreasing 
autophagic activity can be harmful to cells, suggesting more research is necessary into the role 
autophagy plays in the toxic mechanism of TaClo. 
 
3.4.4 Does DNA Damage Occur During TCE Metabolite Neurotoxicity? 
DNA damage has been shown to be involved in PD with damage reported in the SNpc of PD 
patients (Zhang, Perry et al. 1999), and seen prior to cell death following exposure to known 
PD toxin rotenone (Sanders L.H., Mastroberardino P. G. et al. 2010).  DNA damage has also 
been shown to bring about a form of necrotic cell death by over activation of PARP, 
functioning as a DNA repair mechanism, leading to depletion of NAD and disruption of 
metabolism and eventually necrotic death (Zong, Ditsworth et al. 2004).  It has also been 
suggested that this mechanism requires the involvement of RIP1 (Xu, Huang et al. 2006), 
proposing the involvement of DNA damage and PARP over activation in TaClo mediated 
neurotoxicity. 
 
When PARP was inhibited pharmacologically in SH-SY5Y, an interesting effect was observed.  
With lower doses of TaClo, and so low toxicity, PARP inhibition increased cell death, but as 
TaClo doses, and so toxicity and cellular stress, increased, PARP inhibition protected against 
TaClo mediated toxicity in SH-SY5Y (Fig. 3.36).  This supports a hypothesis of TaClo somehow 
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leading to DNA damage, as at low levels of damage, PARP is repairing strand breaks in the DNA 
and so blockade of this process is harmful to the cells.  However, when DNA damage levels 
increase, the benefit of the PARP DNA repair mechanism is negated by the consumption of 
NAD and detrimental effect on cellular metabolism, and as such PARP inhibition protects 
against this effect.  Levels of PARP and cleaved PARP were examined in TaClo treated SH-SY5Y 
cell lysates following various exposure time points and PARP cleavage was shown to occur only 
at 24 hours post treatment (Fig. 3.35).  PARP cleavage, and so inactivation, occurs as a late 
event in the cell death process, which may be an attempt by the cell to arrest the depletion of 
NAD before a critical level is reached.  This involvement of PARP and NAD depletion in toxin 
mediated PD is supported by the findings that PARP inhibition blocks MPTP mediated NAD+ 
and ATP decreases in mouse brains (Cosi and Marien 1998; Iwashita, Yamazaki et al. 2004; 
Yokoyama, Kuroiwa et al. 2010), PARP null mice are protected against MPTP neurotoxicity and 
PARP is activated by MPTP in DA neurons (Mandir, Przedborski et al. 1999). 
 
A substantial increase in histone H2A.X phosphorylation at Ser139 was found in SH-SY5Y 
exposed to TaClo for 24 hours. H2AX has been shown to be involved in DNA double strand 
break repair (Yuan, Adamski et al. 2010) and to be rapidly phosphorylated at Ser139 following 
exposure to DNA damaging agents (Rogakou, Pilch et al. 1998).  The increased levels of pH2AX 
seen in this study provide direct evidence of DNA damage, probably double strand breaks, 
occurring with TaClo exposure. 
 
The cysteine protease Calpain-1 has been shown to be required for DNA damage driven, PARP 
mediated, necrotic cell death (Moubarak, Yuste et al. 2007).  We found levels of Calpain-1 
were significantly increased in SH-SY5Y following TaClo treatment (Fig. 3.37), giving further 
suggestion that this may be the mechanism of TaClo toxicity.  However, Calpains are activated 
and induced by Ca2+ influx into the cell, so as this increase is late in the cell death pathway, it 
may be incidental in the death mechanism and due to the entry of Ca2+ into the cell due to the 
breakdown in membrane integrity seen in necrosis. 
 
When taken together, this evidence suggests a possible mechanism by which TaClo either 
directly or indirectly, causes DNA damage, leading to over activation of PARP, depletion of NAD 
and necrotic cell death.  More exploration of this area, however, is needed to confirm this 
hypothesis. 
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3.4.5 What Other Pathways are Affected by TCE Metabolite Neurotoxicity? 
A variety of other cell death pathway mediators have also been used on the SH-SY5Y TaClo 
toxicity assay (Summarised Table 3.2).  They have been classified as those that have some 
effect on TaClo mediated SH-SY5Y death and could, therefore, possibly be involved, those that 
were toxic in the assay, and those that had no effect.   
 
Those that were toxic or had no effect may not necessarily be due to the fact that the targets 
of these compounds are not involved in the toxicity of TaClo but could be explained by in some 
cases by the lack of specificity of the compound (resveratrol, quinazoline) or the lack of 
specificity of the target (K252a, SP600125, SQ22536), with the complexity of cellular control 
meaning that many are involved in both cell survival and cell death pathways. 
 
Of those that may show involvement, the sirtuin inhibitor, Sirtinol, may be relevant as  
inhibition of  sirtuin 2 has been shown to be protective against neuronal toxicity in models of 
PD (Outeiro, Kontopoulos et al. 2007).  It has also been reported that sirtuin 1 consumes NAD, 
and when activated may endanger energetically compromised neurons (Liu, Gharavi et al. 
2009), an effect that would be expected to attenuate a TaClo toxic mechanism described 
earlier based on NAD depletion by DNA damage induced PARP overactivation.  In contrast to 
this, we found that sirtinol increased TaClo toxicity (data not shown).  However, sirtuin 2 has 
been shown to be involved in the cells defence against oxidative stress (Wang, Nguyen et al. 
2007), and so would have a protective effect.  Sirtun 1 has also been shown to have 
neuroprotective properties (Pfister, Ma et al. 2008), and inhibition of these properties could 
explain our findings.  More research is needed into the specific effects of sirtuins in neurons to 
allow more conclusive interpretation of these results. 
 
Resveratrol is an antioxidant that has been shown to protect against known PD toxins 6-OHDA 
and MPTP in animal models (Lu, Ko et al. 2008; Khan, Ahmad et al. 2010) and against DA 
toxicity in SH-SY5Y (Mi, Soon et al. 2007).  In contrast, we found that resveratrol treatment 
attenuated TaClo toxicity (Data not shown).  Although research generally cites the antioxidant 
properties of resveratrol, it has numerous other effects including up regulation of sirtuin 1, ERK 
and AMPK and down regulation of TNFα and Protein Kinase C.  With this lack of specificity it is 
difficult to dissect the specific system resveratrol is effecting in our model so we decided to 
use other cleaner antioxidants to explore the involvement of oxidative stress in the mechanism 
of TaClo mediated neurotoxicity (see Chapter 4). 
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The other compound which needs discussion, is the JNK inhibitor SPD600125, which had no 
effect of TaClo toxicity at normally used doses (Data not shown).  As JNK activation had been 
implicated in a hypothesised necrotic death mechanism driven by DNA damage and involving 
PARP, and RIP1 (Xu, Huang et al. 2006), this finding suggests that this is not the pathway by 
which TaClo mediates SH-SY5Y death; however this is an area which requires more research. 
 
3.4.6 Conclusions 
We have shown that the TCE metabolite TaClo leads to DA specific neuronal cell death in our 
model system.  This cell death appears to be necroptotic in nature, and not apoptotic, and may 
involve activation of autophagy and DNA damage.  We also found the intermediate compound 
in TCE metabolism to TaClo, chloral, to be toxic at a 10-fold lower potency than TaClo.  This 
toxicity does not appear to be DA neuron specific and may be mediated by a death mechanism 
neither apoptotic nor necroptotic in nature.  Finally, we did not see any direct toxicity in our 
open system models of TCE exposure, but did see potent toxicity following a high dose in an 
airtight closed system.  A more robust method of TCE exposure is needed to further investigate 
this. 
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4.1 Introduction 
The generation of ROS in cells has been shown to cause damage to organelles and cellular 
structures leading to cytotoxicity and, as such, has been implicated in a wide range of diseases.   
Studies have shown that this oxidative stress can be a key mediator in necroptosis (Kim, Dayani 
et al. ; Yu, Wang et al. 2002; Kim, Morgan et al. 2007; Ramana, Patel et al. 2010; Chen, Chiu et 
al. 2011) and has also been widely linked with PD (Alam, Jenner et al. 1997; Floor and Wetzel 
1998) suggesting it could be involved in the cell death mechanism of TaClo. 
 
Under conditions of oxidative stress, the cell has innate defence mechanisms to protect 
against damage caused by excess ROS.  These antioxidant defences are mediated by a series of 
enzymes that convert superoxide to H2O2 which is then further reduced to water.  There are 
two main classes of antioxidant enzyme: superoxide dismutases, that catalyse the breakdown 
of superoxide to H2O2 and oxygen (McCord, Keele Jr et al. 1971); and glutathione, which acts as 
a reducing agent by donating an electron from its thiol group to free radicals and ROS such as 
H2O2 (Dixon and Quastel 1923).  Measuring or altering cellular levels of these enzymes and 
examining the relationship between this and TaClo toxicity can help provide insight into the 
involvement of oxidative damage in this toxicity. 
 
Mitochondria are found in virtually all eukaryotic cells and function to generate cellular energy 
in the form of ATP by OXPHOS.  OXPHOS occurs by electron transfer through a chain of four 
membrane-bound enzyme complexes generating a proton concentration gradient used by 
ATP-synthase to produce ATP.  In healthy functioning mitochondria, a small amount of 
superoxide is generated by electrons leaking from the chain (Takeshige and Minakami 1979; 
Beyer 1992), and this is exponentially increased if the OXPHOS complexes are inhibited 
(Lambert and Brand 2004).  OXPHOS dysfunction has been linked with both PD (Mizuno, Ohta 
et al. 1989; Schapira, Cooper et al. 1990; Schapira, Mann et al. 1990; Rana, De Coo et al. 2000) 
and necroptosis (Ye, Wang et al. 2012) so is a candidate for involvement in TaClo mediated 
neurotoxicity. 
 
Loss of function mutations in DJ-1, a mitochondrially linked protein with involvement in 
antioxidant defence (Yokota, Sugawara et al. 2003), have been linked with PD (Bonifati, Rizzu 
et al. 2003); therefore the effect of TaClo on expression of this protein could link the toxin with 
PD and mitochondrial oxidative stress. 
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4.1.1 Aims 
This study aims to investigate the involvement of ROS and oxidative damage in the mechanism 
of TCE toxicity using the DA model cell line SH-SY5Y and to investigate mitochondria as a 
possible source of any ROS generated. 
 
To achieve these goals, the exposure paradigm employed in Chapter 3 was combined with 
investigations into oxidative stress markers and antioxidant defence to examine the 
involvement of ROS into TaClo toxicity.  Any possible effect on mitochondrial respiration was 
investigated using well-characterised OXPHOS Complex specific biochemical activity assays. 
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4.2 Methods 
For detailed descriptions of all methods see Material and Methods (Section 2), apart from 
those described below. 
4.2.1 Alamar Blue Assay in SH-SY5Y Grown in Galactose Media 
SH-SY5Y cells were switched from 10% GM to a growth media with Galactose replacing 
Glucose as the energy source (GAL).  GAL was Dulbecco’s Modified Eagle’s Media (glucose 
free)(D5030) made up in ddH2O, containing 10mM Galactose, 3.7mg/ml NaCO3, 0.11mg/ml 
Sodium Pyruvate (all Sigma Aldrich), 10% Heat-Inactivated Fetal Bovine Serum, 4mM L-
Glutamine, 40 units/ml Penicillin, 200μg/ml Streptomycin, 1% MEM Non-Essential Amino Acids 
and 5μg/ml Fungizone and grown for 2 weeks to acclimatise to the new media.  TaClo toxicity 
assay was then carried out and viability assessed by Alamar Blue assay as section 2.1.2.1. 
4.2.2 Effect of L-buthionine sulfoxamine on TaClo Toxicity in SH-SY5Y 
SH-SY5Y were grown in either 10% GM or 10% GM containing 2.5mM L-buthionine sufoxamine 
for 2 days before being seeded in 24 wells of a 48 well plate each.  TaClo toxicity assay was 
then carried out and viability assessed by Alamar Blue assay as section 2.1.2.1. 
4.2.3 Statistical Analysis 
For information on statistical methods see General Statistics (Sections 2.8, 2.8.1.1, 2.8.1.2, 
2.8.1.3 & 2.8.1.4) 
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4.3 Results 
4.3.1 Effect of TaClo on Cellular Superoxide Production 
To investigate whether superoxide was produced in SH-SY5Y following TaClo treatment, the 
well-characterised superoxide indicator dye 2’,7’–dichlorofluorescein diacetate (DCFDA) was 
used.  Following entry into the cell by diffusion, DCFDA is deacetylated by cellular esterases to 
a non-fluorescent compound, which is later oxidized by ROS into 2’, 7’ –dichlorofluorescin 
(DCF) (Bass, Parce et al. 1983). DCF is a highly fluorescent compound which can be detected by 
fluorescence microscopy. 
 
Superoxide levels in SH-SY5Y cells treated with TaClo were imaged by loading the cells with 
DCFDA.  While there was a small level of fluorescence in untreated cells, an apparent increase 
in fluorescence intensity in TaClo treated cells when compared to control was observed from 
approximately 8 hours in both 100 & 150µM, but not 0.2% DMSO, treated SH-SY5Y (Fig. 4.1 A-
C) suggesting elevated superoxide levels occurred in cells following TaClo treatment and that 
oxidative stress may play a role in TaClo mediated SH-SY5Y toxicity.  Increased fluorescence is 
seen in all H2O2 treated populations confirming the stain (Fig. 4.1 D).  At the later time points, 
the brightest stained cells appear to have a more spherical morphology than those fluorescing 
less, suggesting that the cells with the highest level of superoxide are losing structural 
integrity. 
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Fig. 4.1 ROS generation in SH-SY5Y cells treated with TaClo  SH-SY5Y cells were loaded with DCFDA and then treated with 0.2% DMSO, 100µM TaClo, 150µM 
TaClo or 850µM H2O2 for 0, 4, 8, 12 or 24 hours. Images show representative fields from 3 replicates (x 40 magnification). 
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Fig. 4.1 ROS generation in SH-SY5Y cells treated with TaClo (cont.) 
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Fig. 4.1 ROS generation in SH-SY5Y cells treated with TaClo (cont.) 
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Fig. 4.1 ROS generation in SH-SY5Y cells treated with TaClo (cont.) 
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4.3.2 GSH and TaClo Toxicity 
GSH is an endogenous antioxidant that is up-regulated during oxidative stress (Day, Suzuki et 
al. 2003).  GSH levels in protein isolated from SH-SY5Y cells were assayed at various time points 
following TaClo treatment by measuring the coloured product 2-nitro-5-thiobenzoic acid 
formed by the reaction of GSH and DTNB (Shaik and Mehvar 2006).  TaClo treatment 
significantly increased GSH levels in SH-SY5Y (P<0.001, One-way ANOVA) in a time-dependent 
manner with a slight but non-significant increase in GSH levels detected following 8 hours 
treatment, and an exponential significant increase 12 and 24 hours after treatment (P<0.05 
and P<0.001 respectively, Dunnett’s post-test) (Fig. 4.2).  This suggests activation of cellular 
antioxidant defence following TaClo treatment. 
 
L-buthionine sulfoximine (LBS) is known to deplete cellular GSH levels by inhibiting γ-
glutamylcysteine synthetase, a rate limiting enzyme in the glutathione biosynthesis pathway 
(Griffith 1982).  SH-SY5Y cells were co-treated with LBS and TaClo and a small but significant 
increase in TaClo induced toxicity was observed (P<0.001, Two-way ANOVA), with LBS 
significantly reducing viability following 50, 100 and 150µM Taclo treatment (P<0.05, P<0.001, 
P<0.01 respectively, Bonferroni post-test) (Fig. 4.3).  This supports the previous indications that 
oxidative stress is intrinsically involved in TaClo toxicity as an inhibition of intracellular 
antioxidant defences leads to an increase in the potency of the toxin. 
 
N-Acetyl Cysteine (NAC) is a precursor molecule for the glutathione, and therefore can 
promote glutathione production and protect cells from oxidative stress (de Flora, Bennicelli et 
al. 1985; Issels, Nagele et al. 1988).  SH-SY5Y cells were co-treated with toxic doses of chloral 
or TaClo and NAC (5 & 2.5mM).  NAC had no significant effect on chloral toxicity (Fig. 4.4 A), 
but significantly protected against TaClo induced toxicity in a dose-dependent manner 
(P<0.001, Two-way ANOVA), with 5mM NAC almost totally abrogating toxicity in both 100 & 
150µM TaClo treated cells (both P<0.001, Bonferroni post-test) bringing viability back up to 85 
& 91% of control respectively (Fig. 4.4 B).  This suggests a critical involvement of ROS and 
oxidative stress in the toxic mechanism of TaClo, but not chloral, in SH-SY5Y. 
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Fig. 4.2 Effect of TaClo on Glutathione levels in SH-SY5Y Protein was isolated from SH-SY5Y 
neuroblastoma cells treated with 100 μM TaClo for various time points and then assayed for 
GSH concentration by reduction of DTNB.  Data presented as mean % control + SD from 
quadruplicate assays (n=3).  *** P<0.001, * P<0.05 when compared to 0h, One-way ANOVA & 
Dunnett’s post-test 
 
 
 
 
 
Fig. 4.3 Effect of L-buthionine sulfoxamine on TaClo toxicity in SH-SY5Y SH-SY5Y cells were 
pre-treated with LBS (2.5mM) for 3 days and then co-treated with TaClo (200, 150, 100 & 
50μM) for 21 hours and viability measured by reduction of Alamar Blue (resazurin). Data 
presented as mean % control + SD from triplicate assays (n=3).  Significant effect of LBS on 
TaClo toxicity (P<0.001), Two-way ANOVA.  ***P<0.001, **P<0.01, *P<0.05 when compared to 
0.2% DMSO, Bonferroni post-test 
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Fig. 4.4 Effect of N-acetylcysteine on chloral & TaClo toxicity in SH-SY5Y SH-SY5Y cells were 
pre-treated with NAC (2.5 & 5mM) for 1 hour and then co-treated with chloral (2.5 & 5mM) or 
TaClo (100 & 150μM) for 21 hour and viability measured by reduction of Alamar Blue 
(resazurin).  Data presented as mean % control + SD from quadruplicate assays (n=3).  (A) No 
significant effect of NAC on chloral treatment (B) Significant effect of NAC on TaClo treatment 
(P<0.001), Two-way ANOVA.  ***P<0.001 when compared to 0.2% DMSO, Bonferroni post-test 
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4.3.4 Mitochondrial OXPHOS Activity Assays 
Inhibition of Complex I has been widely reported in PD patients and models (Nicklas, Youngster 
et al. 1987; Mizuno, Ohta et al. 1989; Schapira, Mann et al. 1990; Betarbet, Sherer et al. 2002; 
Lambert and Brand 2004) as well as disruption of Complexes II & III in PD (Shults, Haas et al. 
1997; Rana, De Coo et al. 2000).  Therefore, the involvement of TaClo in mitochondrial 
dysfunction was investigated as a possible site of production of the ROS shown to be involved 
in toxicity above. 
 
The methods used were based on those of the NHS Mitochondrial Diagnostic Service, 
Newcastle University, used to diagnose mitochondrial disease in muscle biopsies.  In this study 
Mitochondria were isolated from SH-SY5Y cells and then biochemically assayed for OXPHOS 
Complex activity in Complex specific assays in the presence of various TaClo concentrations.  
Pig heart mitochondria were used to confirm assay function on every study day and normal 
ranges for them and SH-SY5Y mitochondria are listed in Table 4.1. 
 
Complex PHM* (1:20 dilution) SH-SY5Y (1:5 dilution) 
I 6.93 + 1.67 0.79 + 0.27 
II 10.2 + 1.32 0.83 + 0.26 
I/II 0.68 + 0.16 0.94 
III 64.00 + 14.7 6.72 + 3.43 
IV 56.78 + 9.91 9.92 + 1.76 
* Taken from standard operating procedures of Mitochondrial Diagnostic Service, Newcastle 
University which were generated from a library of results. 
 
Table 4.1 Normal ranges of OXPHOS Complex I, II, III & IV Normal ranges of OXPHOS Complex 
I (nmols NADH oxidised. min-1 unit citrate synthase-1), II (nmols DCPIP reduce. min-1 unit 
citrate synthase-1), III (K.sec-1) & IV (x 10-3 K.sec-1/unit citrate synthase-1) in untreated pig heart 
(PHM) and SH-SY5Y mitochondria. 
 
 
 
 
 
 
 
 
 
Chapter 4 Mitochondria & Oxidative Stress 
195 
 
4.3.4.1 TaClo 
Complex I activity in SH-SY5Y generated mitochondria was significantly reduced by >10μM 
TaClo in a dose-dependent manner with an IC50 of approximately 50μM (Fig. 4.5).  This can also 
be seen in the example traces (Fig. 4.6) with the slope of the red line (representing the rate of 
NADH oxidation, corresponding to Complex I activity) prior to rotenone addition at 5 minutes 
(arrow) decreasing as TaClo concentrations increase.  As inhibition of Complex I has been 
shown to cause generation of superoxide (Lambert and Brand 2004), this suggests 
mitochondrial dysfunction may be a source of the oxidative damage in the neurotoxic 
mechanism of TCE mediated by TaClo. 
 
 
Fig. 4.5 Acute Effect of TaClo on OXPHOS Complex I activity in SH-SY5Y mitochondria OXPHOS 
Complex I activity in mitochondria isolated from SH-SY5Y cells treated with TaClo (500, 200, 
100, 50, 10 & 1µM) or control (0.2% DMSO) as measured as rotenone-sensitive NADH: 
ubiquinone oxidoreductase activity.  Data presented as mean & control + SD from triplicate 
assays (n=3).  *** P<0.001, ** P<0.01 when compared to 0.2% DMSO, One-way ANOVA & 
Dunnett’s post-test. 
 
 
Treatment Mean Complex I activity  
(µM/min) 
Mean Complex II activity  
(µM/min) 
CI/CII 
0.2% DMSO 0.79 + 0.27 0.83 + 0.26 0.94 
100uM TaClo 0.26*** + 0.10 0.87 + 0.23 0.30*** 
500uM TaClo 0.07*** + 0.02 0.74 + 0.18 0.09*** 
 
Table 4.2 Summary of the effects of TaClo on mitochondrial Complex I & II OXPHOS Complex I 
& II activity in mitochondria isolated from SH-SY5Y cells treated with TaClo (500 & 100µM) or 
control (0.2% DMSO) as measured as rotenone-sensitive NADH: ubiquinone oxidoreductase 
(CI) or succinate: ubiquinone oxioreductase (CII) activity.  Data presented as mean + SD from 
triplicate assays (n=3).  *** P<0.001, when compared to 0.2% DMSO, One-way ANOVA & 
Dunnett’s post-test. 
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Fig. 4.6 Sample traces for the acute effect of TaClo on OXPHOS Complex I activity in SH-SY5Y 
mitochondria OXPHOS Complex I activity in mitochondria isolated from SH-SY5Y cells treated 
with TaClo (500, 200, 100, 50, 10 & 1µM) or control (0.2% DMSO) as µmols NADH oxidised/min 
(red line).  Sample traces from (A) 0.2% DMSO, (B) 1µM TaClo, (C) 10µM TaClo, (D) 50µM 
TaClo, (E) 100µM TaClo, (F) 200µM TaClo& (G) 500µM TaClo.  Blue lines are programme 
generated gradients pre & post rotenone (5µM) addition (arrow) at ~5 min to account for non-
Complex I driven NADH oxidation. 
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Exposure of Complexes III, and IV to TaClo resulted in a significant decrease in activity in 
Complexes III & IV at a TaClo dose of 500µM, but no effect was observed following 100 µM 
exposure (Fig. 4.7).  No inhibition of Complex II was seen following exposure to either 100 or 
500µM TaClo (Fig. 4.7).  This can be seen in the sample traces, with no change in the slope of 
the line of Complex II, III or IV function apparent following addition of mitochondria in 100µM 
treated assay but a decrease in the slope following 500µM TaClo treatment in Complex III & IV 
but not II traces (Fig. 4.8).  Complex I:II ratio is a widely used measure of mitochondrial 
function, and this was significantly reduced in a dose dependent manner following TaClo 
treatment (Table 4.2). 
 
 
 
 
 
 
Fig. 4.7 Acute Effect of TaClo on OXPHOS Complex II, III & IV activity in SH-SY5Y mitochondria 
OXPHOS Complex II, III & IV activity in mitochondria isolated from SH-SY5Y cells treated with 
TaClo (500 & 100µM) or control (0.2% DMSO) as measured by succinate: ubiquinone 
oxioreductase (CII), reduction of oxidised cytochrome c due to the oxidation of ubiquinol-2 
(CIII) or oxidation of cytochrome c (II) (CIV) activity respectively.   Data presented as mean % 
control + SD from triplicate assays (n=3).  *** P<0.001 when compared to 0.2% DMSO, One-
way ANOVA & Dunnett’s post-test. 
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Fig. 4.8 Sample traces for the acute effect of TaClo on OXPHOS Complex II, III & IV activity in 
SH-SY5Y mitochondria OXPHOS Complex II, III & IV activity in mitochondria isolated from SH-
SY5Y cells treated with TaClo (500 & 100µM) or control (0.2% DMSO) as measured as 
succinate: ubiquinone oxioreductase (CII), reduction of oxidised cytochrome c due to the 
oxidation of ubiquinol-2 (CIII) or oxidation of cytochrome c (II) (CIV) respectively (red line).  
Sample traces from Complex II (A) 0.2% DMSO, (B) 100µM TaClo, (C) 500µM TaClo, Complex III 
(D) 0.2% DMSO, (E) 100µM TaClo, (F) 500µM TaClo, Complex IV (G) 0.2% DMSO, (H) 100µM 
TaClo, (I) 500µM TaClo.  Blue lines are programme generated gradients (non-enzymatic 
cytochrome c reduction in Complex III graph).  Arrows represent mitochondrial addition. 
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4.3.4.2 Chloral 
As chloral has also been shown to be toxic to DA neurons in models above, the activity of 
OXPHOS Complexes I-IV was also investigated in relation to chloral toxicity.  Interestingly, 
chloral showed a different inhibitory profile of OXPHOS Complexes in comparison to TaClo.  
500µM chloral significantly and almost completely inhibited Complexes I and II but only 
showed a slight, although statistically significant inhibition of Complex IV (Fig. 4.9), 
concentrations of 100µM and below showed no significant inhibition (data not shown).  This is 
in contrast to TaClo which showed Complex I inhibition at relatively low concentrations and 
inhibition of Complex III and IV at higher concentrations, but no inhibition of Complex II at all.  
Although the high chloral concentrations needed for OXPHOS Complex inhibition may not be 
physiologically relevant, the fact that it shows a different toxicity profile to TaClo questions the 
hypothesis that chloral toxicity is mediated through conversion to TaClo. 
 
 
 
 
 
Fig. 4.9 Acute effect of Chloral on OXPHOS Complex I, II &IV activity in SH-SY5Y mitochondria 
OXPHOS Complex I, II & IV activity in mitochondria isolated from SH-SY5Y cells treated with 
Chloral (1mM) or control (0.2% DMSO) as measured by NADH: ubiquinone oxidoreductase 
activity (CI), succinate: ubiquinone oxioreductase (CII), or oxidation of cytochrome c (II) (CIV) 
activity respectively.   Data presented as mean % control + SD from triplicate assays (n=3).  
***P<0.001, *<P<0.05 when compared to 0.2% DMSO, unpaired t-test. 
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Fig. 4.10 Sample traces for the acute effect of Chloral on OXPHOS Complex I, II &  IV activity 
in SH-SY5Y mitochondria OXPHOS Complex I, II & IV activity in mitochondria isolated from SH-
SY5Y cells treated with chloral (1mM) or control (0.2% DMSO) as measured as rotenone-
sensitive NADH: ubiquinone oxidoreductase (CI), succinate: ubiquinone oxioreductase (CII) or 
oxidation of cytochrome c (II) (CIV) respectively (red line).  Sample traces from Complex I (A) 
0.2% DMSO, (B) 1mM chloral, Complex II (C) 0.2% DMSO, (D) 1mM chloral, Complex IV (E) 0.2% 
DMSO, (F) 1mM chloral.  Blue lines are programme generated gradients (pre & post rotenone 
(5µM) addition at ~5 min in CI).  Arrows represent (A & B) rotenone or (C-D) mitochondrial 
addition. 
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When assessing Complex III activity, the oxidation of ubiquinol-2 with cytochrome c as the 
electron acceptor is used as an indicator of function, with the colour change due to 
cytochrome c reduction measured.  In this assay there is a background level of cytochrome c 
reduction that occurs sporadically without ubiquinol-2 or mitochondria present which is 
measured prior to the assay to enable an accurate calculation of the reduction dependent on 
Complex III.  However, when chloral is present in the assay, the sporadic, non-enzymatic, 
reduction of cytochrome c is inhibited in a dose-dependent manner with doses as low as 
100µM chloral causing significant inhibition (Fig. 4.11).  This can be seen in the sample traces 
that show a decrease in the slope representing cytochrome c activity in a dose dependent 
manner (Fig. 4.12).  This invalidates the assay and does not allow the accurate measurement of 
the effect of chloral on Complex III activity but suggests chloral may inhibit the electron 
accepting properties of cytochrome c. 
 
 
 
 
Fig. 4.11 Effect of Chloral on the non-enzymatic reduction of cytochrome c (oxidised) Non-
enzymatic reduction of cytochrome c by various concentrations of Chloral or control (0.2% 
DMSO).   Data presented as mean % control + SD from triplicate assays (n=3).  *** P<0.001 
when compared to 0.2% DMSO, One-way ANOVA & Dunnett’s post-test. 
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Fig. 4.12 Sample traces for the effect of Chloral on the non-enzymatic reduction of 
cytochrome c (oxidised) Non-enzymatic reduction of cytochrome c by various concentrations 
of Chloral or control (0.2% DMSO) (red line).  Sample traces from (A) 0.2% DMSO, (B) 100µM 
chloral, (C) 500µM chloral, (D) 1mM chloral.  Blue lines are programme generated gradients. 
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4.3.5 Mitochondrial Oxidative Stress and TaClo Toxicity 
To determine the production of superoxide in the mitochondria following TaClo treatment we 
used the mitochondrially specific fluorescent superoxide indicator MitoSOX™ Red.  MitoSOX™ 
Red reagent is live-cell permeant and is rapidly and selectively targeted to the mitochondria. 
Once in the mitochondria, MitoSOX™ Red reagent is oxidized by superoxide, but not other ROS 
or reactive nitrogen species (RNS), and exhibits red fluorescence.  SH-SY5Y were treated with 
toxic concentrations of TaClo for various amounts of time before loading with MitoSOXTM Red 
and then imaged or fluorescence measured by flow cytometry. 
 
Representative images of MitoSOX™ Red fluorescence in TaClo treated cells are shown in Fig. 
4.13, with an increase in fluorescence apparent from 4 hours in 100 & 150µM TaClo and H2O2 
treated populations.  Flow cytometrically assessed whole single cell populations were selected 
using a plot of FSC-A, which measures cell size, against SSC-A, the latter measuring cell shape 
or granularity, (Fig. 4.14 A) and fluorescence levels were measured within this population.  
There appeared to be 3 distinct populations seen on the fluorescence histograms so gates 
were set for high, mid and low fluorescence based upon these populations (Fig. 4.14 B). 
 
To examine the basic increase in MitoSOX™ Red fluorescence, mid and high populations were 
combined and a time and dose-dependent increase in fluorescence was observed in both 100 
& 150µM treated SH-SY5Y cells relative to control (Fig. 4.14 C) (P<0.001, Two-way ANOVA).  
150µM TaClo treated cells seemed to show more mitochondrial superoxide production after 4 
hours (Fig. 4. 14 C) with a significant increase in the number of cells (30%) showing high 
fluorescence at 8 (P<0.05) hours post treatment and almost all the cells (98%) present in the 
high fluorescing population by 16 hours (P<0.001) (Fig. 4.14 C).  In the 100µM treated cells, 
mitochondrial superoxide production was slower, with a slight increase in MitoSOX™ Red 
fluorescence appearing to occur at 4 & 8 hours post dose (Fig. 4.14 B), but a significant 
increase in cell number not occurring until 16 hours (P<0.001) hours in 54% of cells and almost 
all cells (97%) showing high fluorescence by 24 hours (P<0.001) (Fig. 4.14 C).  These results 
suggest that mitochondrial superoxide formation is increased as a relatively early event in 
TaClo mediated SH-SY5Y toxicity. 
 
When looking at the distribution of cells between the high, mid and low populations, the 
majority of the 0.2% DMSO treated cells stay in the low fluorescing population (Fig. 4.14 Di), 
which correlates with imaged cells (Fig. 4.13 A).  100µM treated SH-SY5Y showed a time-
dependent increase in mid fluorescing cells from 0 -24 hours post TaClo, but only showed an 
increase in the high fluorescing population at 16 and 24 hours (Fig. 4.14 Dii).  In the 150µM 
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treated cells, there was also a time-dependent increase in the mid fluorescing population up to 
12 hours, where it stabilised and then started to decrease at 24 hours post dose, as well as a 
time-dependent increase in high fluorescing cells from 12 hours, with the majority of the cells 
in this population by 24 hours (Fig 4.14 Diii).  This is consistent with the imaged cells, with a 
population of cells that are more fluorescent than those seen in the control groups present for 
all treated cells, and then a population that is brighter again and seems to be morphologically 
more spherical that the other populations (Fig. 4.13 A-C).  The positive control stained H2O2 
treated SH-SY5Y showed bright fluorescence in all treated cell populations from 4-24 hours 
after treatment, confirming the activity of the dye (Fig. 4.13 D).  The spread of the populations 
over time is reasonably similar to the results seen with the flow cytometry, however, in the 
imaged 100µM treated group, there appears to be an increase in the high fluorescing cells not 
seen in those analysed by flow cytometry. 
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Fig. 4.13 Mitochondrial ROS generation in SH-SY5Y cells treated with TaClo SH-SY5Y cells were loaded with MitoSOXTM Red and then treated with 0.2% DMSO, 
100µM TaClo, 150µM TaClo or 850µM H2O2 for 0, 4, 8, 12 or 24 hours. Images show representative fields from 3 replicates (x 40 magnification). 
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Fig. 4.13 Mitochondrial ROS generation in SH-SY5Y cells treated with TaClo (cont.) 
  
 
C
h
ap
te
r 4
                                                                                           M
ito
ch
o
n
d
ria &
 O
xid
ative Stress 
 
2
07
 
 
Fig. 4.13 Mitochondrial ROS generation in SH-SY5Y cells treated with TaClo (cont.) 
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Fig. 4.13 Mitochondrial ROS generation in SH-SY5Y cells treated with TaClo (cont.) 
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Fig. 4.14 Effect of TaClo treatment on MitoSOXTM Red fluorescence TaClo treatment as quantified by flow cytometry SH-SY5Y were treated with 0.2% DMSO, 100 
or 150µM TaClo for 0-24 hours and then loaded with 5µM MitoSOXTM Red before fluorescence was assessed using flow cytometry.  (A) Representative density plot 
showing selection of whole single cells based on SSC-A and FSC-A.  (B)  Representative overlaid histograms of selected single cell fluorescence at ex/em 488/585 at 
all time points.  Bars show defined low, medium and high fluorescing population boundaries.  (C)  % Cells defined as having increased (medium or high) 
fluorescence over time following treatment.  Data presented as mean + SD (n=3).  Significant increase in fluorescence over time (P<0.001), Two-way ANOVA.  
***P<0.001, *P<0.05  when compared to 0.2% DMOS at same time point, Bonferroni post-test.  (D) % cells defined as low, medium or high fluorescence following 
(i) 0.2% DMSO, (ii) 100 or (iii) 150µM TaClo.  Data presented as mean + SD (n=3). 
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MnSOD is an enzyme found in the mitochondria (Weisiger and Fridovich 1973) that protects 
against superoxide induced oxidative damage by catalysing the dismutation of superoxide into 
oxygen and hydrogen peroxide (McCord, Keele Jr et al. 1971). 
 
SH-SY5Y cells were treated with a shRNA containing lentiviral vector to overexpress MnSOD 
levels in order to investigate the involvement of mitochondrially generated superoxide in TaClo 
toxicity.  Viral take-up was good, as seen by the viral conferred GFP expression relative to 
inherent DAPI staining (Fig. 4.15 A i-iii), and probing for MnSOD levels by Western blot showed 
expression increased to ~5-fold that seen in control (Fig. 4.15 B).  MnSOD overexpressing 
control SH-SY5Y cells were then treated with TaClo (20-250µM) and viability assayed by Alamar 
Blue fluorescence confirmed by visual inspection.  MnSOD overexpression showed a small, but 
significant, protection against TaClo toxicity when compared to control cells (P<0.05, Two-way 
ANOVA) with an increase in viability seen when compared to control in 20, 50 & 100µM TaClo 
treated cells (Fig. 4.15 C).  At doses of >150 µM TaClo, almost total cell death was seen and no 
protection was seen with MnSOD overexpression at these levels. 
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Fig. 4.15 Effect of MnSOD over expression on TaClo toxicity in SH-SY5Y  
(A) Transfection efficiency: SH-SY5Y cells were treated with MnSOD overexpressing lentivirus 
expressing GFP and co-stained with DAPI.  Images show (i) DAPI stained cell nuclei, (ii) GFP 
expression (iii) overlaid (x 40 magnification).  (B) MnSOD expression levels: SH-SY5Y cells were 
treated with MnSOD (duplicate) over expressing lentivirus or untreated.  Protein samples 
isolated from cells were probed for MnSOD.  (i)Image is representative blot from (1) untreated, 
(2 & 3) MnSOD over expressed cells.  (ii)  Relative MnSOD intensity in untreated and MnSOD 
over expressed cells a & b relative to GAPDH.  Data presented as fold-untreated + SD from 
triplicate assays (n=3).  *** P<0.001, when compared to untreated, unpaired t-test.  (C) Wild 
type and MnSOD over expressed SH-SY5Y cells were treated with TaClo (20-250μM) for 21 
hours and viability measured by reduction of resazurin. Data presented as mean % control + SD 
from triplicate assays (n=3).  Significant effect of MnSOD overexpression on TaClo toxicity 
(P<0.05), Two-way ANOVA. 
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DJ-1 is a protein found in neurons and axons that appears to have multifaceted functions 
(Cookson 2003), mutations of which have been shown to have links with PD (Bonifati, Rizzu et 
al. 2003).  As one of the functions of DJ-1 appears to relate to ROS, with the protein 
functioning as a sensor for ROS (Mitsumoto and Nakagawa 2001) or being protective against 
oxidative stress (Yokota, Sugawara et al. 2003; Taira, Saito et al. 2004), we decided to look at 
the effect of TaClo on DJ-1 expression. 
 
Protein isolated from SH-SY5Ys treated with TaClo over various time points was probed for DJ-
1 levels by Western blot.  TaClo treatment showed a significant increase in DJ-1 expression in a 
time-dependent manner (P<0.001, One-Way ANOVA) with significantly higher levels occurring 
by 8 hours post treatment (P<0.001) which are maintained until 24 hours (P<0.001) (Fig. 4.16). 
 
 
Fig. 4.16 Expression of DJ-1 in 100µM TaClo treated SY-SY5Y SH-SY5Y cells were treated with 
100µM TaClo for 0, 4, 8 or 24 hours and protein harvested.  Samples were probed for DJ-1.  (A) 
Image is representative blot of DJ-1 and GAPDH control (B) DJ-1 intensity relative to GAPDH.  
Data presented as fold-untreated + SD from quadruplicate assays (n=3).  Significant difference 
over time (P<0.001) One-way ANOVA.  ***P<0.001  when compared to 0h, Dunnett’s post-test 
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4.3.6 TaClo Toxicity in SH-SY5Y Under Increased Mitochondrial Respiration 
It has been reported that cancer cells, such as SH-SY5Y neuroblastoma, when grown in media 
using glucose as an energy source, generate most of their energy by glycolysis, but when 
grown in media using galactose as an energy source, they switch to mainly mitochondrial 
respiration (Rossignol, Gilkerson et al. 2004).  It has also been shown that this switch to 
mitochondrial metabolism can increase the toxicity of toxins that inhibit mitochondrial 
OXPHOS Complexes, such as rotenone (Garside, Burnham et al. 2012). 
 
We grew SH-SY5Y in 10mM galactose media for 2 weeks and then exposed them to TaClo and 
assessed viability using the Alamar Blue assay.  We found that TaClo significantly decreased 
cell viability (P<0.001, One-way ANOVA) and that doses >1µM were significantly toxic when 
compared to control (P<0.001, Dunnett’s post-test).  SH-SY5Y grown in glucose media did not 
show significant death until doses >50µM (Fig. 3.6).  However, when the effect of TaClo on 
galactose versus glucose grown SH-SY5Y was compared, no significant difference in viability 
was seen (Two-way ANOVA, data not shown). 
 
 
 
Fig. 4.17 Effect of TaClo on Galactose grown SH-SY5Y viability SH-SY5Y cells were grown in 
growth media with 10mM galactose replacing glucose as the energy source and treated with 
various concentrations of TaClo overnight for 21h and viability measured by reduction of 
Alamar Blue (resazurin).  Data presented as mean % control + SD from quadruplicate assays 
(n=3).  *** P<0.001, when compared to 0.2% DMSO, One-way ANOVA & Dunnett’s post-test. 
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4.4 Discussion 
4.4.1 Is Oxidative Stress Increased Following TaClo Treatment? 
Oxidative stress has been widely reported to be a factor in the development of PD with 
markers of oxidative stress, such as lipid peroxidation and oxidative DNA damage in the SNpc 
of PD patients brains (Dexter, Carter et al. 1989; Alam, Jenner et al. 1997).  Exposure to PD-
linked neurotoxins rotenone and MPTP has also been shown to lead to oxidative damage in DA 
model systems (Desole, Miele et al. 1995; Testa, Sherer et al. 2005).  In addition to this, ROS 
have been shown to be integrally involved in programmed necrotic cell death (Morgan, Kim et 
al. 2008; Chen, Chi et al. 2009), suggesting oxidative stress may be a key mediator in TaClo 
neurotoxicity.  While there appears to be a baseline level of superoxide present in untreated 
SH-SY5Y, this appears to have increased from ~8 hours following TaClo treatment when 
assessed by DCFDA fluorescence (fig 4.1 A-C), suggesting TaClo induces superoxide production.   
At later time points, those cells with the highest levels of fluorescence look as if they have lost 
structural integrity and become more spherical, suggesting that a high level of superoxide may 
induce cell death. 
 
4.4.2 How does TaClo Interact with Cellular Antioxidant Defences? 
GSH is an endogenous antioxidant that can donate an electron to ROS and so stabilise them 
and which has been shown to be up regulated during conditions of oxidative stress (Day, 
Suzuki et al. 2003).  Dysfunction in this system has been linked to PD, with GSH levels shown to 
be reduced in the SNpc of patients with PD (Sofic, Lange et al. 1992; Sian, Dexter et al. 1994) 
leaving this region susceptible to oxidative damage.  We measured expression of GSH and 
found an exponential increase in levels from 8 -24 hours following TaClo treatment (Fig. 4.2), 
suggesting activation of antioxidant defences and an increased production of ROS.  This 
appears to support the earlier evidence - and time course - of increased ROS production from 8 
hours post TaClo exposure. 
 
LBS, a chemical known to deplete cellular GSH levels (Griffith 1982), was then used in order to 
investigate whether the removal of GSH would affect TaClo toxicity.  We saw a significant 
decrease in viability following TaClo exposure in those cells co-treated with LBS (Fig. 4.3), 
suggesting a protective effect of GSH and the involvement of ROS in TaClo neurotoxicity.  This 
finding is consistent with reports that rotenone toxicity in a neuroblastoma cell line is 
potentiated following GSH depletion with LBS (Sherer, Betarbet et al. 2003), as is MPTP 
mediated death in DA neurons in an animal model (Wüllner, Löschmann et al. 1996). 
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NAC has been shown to have antioxidant properties by acting as a precursor for GSH and so 
increasing GSH levels in the cell (de Flora, Bennicelli et al. 1985; Issels, Nagele et al. 1988)  and 
has been reported to protect against IFN-γ-induced necroptosis in a cell model (Thapa, 
Basagoudanavar et al. 2011).  It has been widely hypothesised that NAC may constitute a valid 
protective therapy against PD (Martínez, Martínez et al. 1999; Prasad, Cole et al. 1999); it is 
currently in clinical trials to test this, and it has been shown to protect against DA neuron 
degeneration in an α-synuclein overexpressing mouse model of the disease (Clark, Clore et al. 
2010).  NAC has also been reported to show protection against known PD toxins MPTP, 
rotenone and paraquat (Hoffer, Baum et al. 1996; Li, Ragheb et al. 2003; Molina-Jiménez, 
Sánchez-Reus et al. 2005; Sharma, Kaur et al. 2007).  We found that NAC significantly - and 
almost totally - abrogated TaClo toxicity in SH-SY5Y (Fig. 4.4 B).  This suggests a major role of 
oxidative damage in the DA neurotoxicity of TCE mediated by TaClo.  Interestingly, NAC co-
treatment did not have any significant effect of chloral mediated toxicity in our model (Fig. 4.4 
A), suggesting ROS may not be involved in chloral toxicity and giving support to previously 
discussed evidence suggesting separate mechanisms may be responsible for TaClo and chloral 
mediated cell death.  It has been reported that NAC can repair impaired Complex I deficiency 
in aged mice (Mart  nez Banaclocha 2000), which may offer an alternative, or summative, 
protective mechanism to the commonly thought increased oxidative protection mediated 
through GSH. 
 
4.4.3 Do TCE Metabolites Affect Mitochondrial OXPHOS function? 
Mitochondrial dysfunction and generation of ROS have been widely associated with 
necroptotic cell death (Schulze-Osthoff, Bakker et al. 1992; Goossens, Stangé et al. 1999; Davis, 
Hawkins et al. 2010).  Inhibition of Complex I of the mitochondrial OXPHOS chain has been 
proposed as the major causative factor in the neurotoxicity of known PD toxins MPTP and 
rotenone (Nicklas, Vyas et al. 1985; Nicklas, Youngster et al. 1987; Li, Ragheb et al. 2003) and 
Complex I activity has been shown to be lowered in PD patients (Mizuno, Ohta et al. 1989; 
Schapira, Cooper et al. 1990).  As mitochondrial dysfunction has also been shown to lead to 
increased ROS production (Lambert and Brand 2004), this evidence suggests OXPHOS 
inhibition as a possible source of TaClo mediated oxidative stress.  In adjusting the parameters 
of the mitochondrial OXPHOS activity assays from those developed for human muscle biopsies, 
we found that the normal ranges of activity of all Complexes, I-IV, were significantly lower in 
our SH-SY5Y generated samples than those generated from pig heart muscle (Table 4.1).  This 
is as a result of the number of mitochondria present in the pig heart muscle being far higher 
than those from SH-SY5Y due to a far higher number of cells in the original pig heart sample 
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than the SH-SY5Y, as opposed to any difference in mitochondrial number or activity in the 
different tissues. 
 
We found that TaClo inhibited Complex I activity in our assay with an IC50 of ~50µM and almost 
total inhibition at 200µM (Fig 4.5 & 4.6).  This shows a far more potent inhibition that that 
found by Janetzky et al. who reported an IC50 of 250µM and almost total inhibition at 700µM 
(Janetzky, God et al. 1995).  However, Janetzky et al. used rat brain homogenates in their assay 
rather than isolated mitochondria and showed that an increase in incubation time from 5 to 30 
minutes increased potency, possibly suggesting that in the homogenate more time is required 
for exposure of the toxin to the mitochondria than in our isolated mitochondria model.  The 
concentrations of TaClo that brought about Complex I inhibition in SH-SY5Y generated 
mitochondria correlated well with those that led to SH-SY5Y cell death (Fig 3.9), suggesting 
Complex I inhibition as a major contributory factor to TaClo neurotoxicity in the system.  A 
recent report stated that although they have been shown to inhibit Complex I, rotenone, MPTP 
and paraquat are still toxic to DA neurons in a mouse without functioning Complex I, and, in 
the case of rotenone, toxicity was increased (Choi, Kruse et al. 2008).  However, these results 
have not been confirmed and do not seem to be compatible with the literature, and in 
particular, a study carried out by Marella et al..  They found that expression of NDI1 - a yeast 
NADH-quinone oxidoreductase that can act as an alternative to Complex I - in a rat model 
significantly protected against rotenone toxicity (Marella, Seo et al. 2008) suggesting the 
results seen by Choi et al. are unlikely to be relevant, possibly due to incomplete knockdown of 
Complex I. 
 
We also saw inhibition of Complexes III & IV, but only following exposure to a relatively higher 
concentration of TaClo (500 µM), and no inhibition of Complex II whatsoever at doses <500 µM 
TaClo (Figs. 4.7 & 4.8).  Inhibition of Complex III has shown to be present in the brains of PD 
patients (Haas, Nasirian et al. 1995; Shinde and Pasupathy 2006) and can lead to superoxide 
formation (Beyer 1992), suggesting possible relevance of this finding in TCE mediated PD.  
There has also been a link between Complex IV inhibition proposed with the finding that PINK-
1 knockdown leads to inhibition of Complex IV (Gegg, Cooper et al. 2009) suggesting possible 
Complex IV inhibition in the disease.  The lack of significant Complex II inhibition concurs with 
the findings of Krueger et al. that inhibition of Complex II by MPP+ and N-methyl β-carbolines 
in PD, if present, is small enough to be insignificant in relevance when compared to Complex I 
inhibition (Krueger, Tan et al. 1993).  The physiological significance of the inhibition of 
Complexes III & IV seen in this model is questionable, as prior to the concentrations needed to 
achieve this building up in the cell, there will have been almost total inhibition of Complex I.  
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The resultant increase in ROS to which this leads, means the chances of the cell surviving to 
build up sufficient TaClo to inhibit Complexes III and IV is not likely to physiologically 
significant. 
As yet, there have been no reported studies of the effect of chloral on mitochondrial OXPHOS.  
We found that 1mM chloral considerably inhibited Complex I & II activity by ~75%, and showed 
as small, 15% decrease in Complex IV activity (Figs. 4.9 & 4.10).  As seen with TaClo, the 
concentration of chloral needed to inhibit Complexes I & II are similar to those that lead to cell 
death (Fig 3.5).  In this case the inhibition of both Complexes I & II means that the OXPHOS 
chain will not be able to generate ATP, unlike in the case seen with TaClo exposure where 
electrons can still travel along the chain and generate the proton gradient needed to produce 
ATP when Complex I is inhibited as Complex II is fully functioning.  In combination with the 
finding that the antioxidant promoter NAC has no effect of chloral toxicity in SH-SY5Y (Fig. 4.4 
A) - suggesting that ROS generation is not a key factor in chloral mediated cell death - this 
proposes a possible mechanism whereby a lack of ATP may contribute to cytotoxicity. 
 
In the assay we used to measure the activity of Complex III, cytochrome c is reduced and this is 
measured to indicate Complex III activity.  However, when attempting to measure baseline 
cytochrome c reduction with chloral present, the rate of cytochrome c reduction was reduced, 
meaning that this assay could not be used to accurately measure Complex III activity.  
Following further investigation into this property of chloral, we found that it inhibited the 
reduction of cytochrome c in a dose dependent manner, with doses as low as 100µM showing 
a significant reduction and 1mM almost completely ablating cytochrome c reduction (Figs. 4.11 
& 4.12).  Whilst speculative, this could be explained as chloral has been shown to react with 
tryptamine by Pictet-Spengler condensation reaction to form TaClo (Bringmann, Feineis et al. 
2000); it could do the same with cytochrome c.  This would propose a hypothesis of chloral 
reacting with cytochrome c and stopping its ability to transfer electrons during OXPHOS, 
therefore depleting cellular ATP levels causing cell death.  More evidence for  chloral causing 
OXHPOS dysfunction can be found in the report that chloral has been shown to dissociate 
cytochrome c oxidase (Complex IV) (Griffin and Landon 1981); however this does not agree 
with our finding that chloral only has a slight inhibitory effect on Complex IV (Fig. 4.9). 
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4.4.4 Does TaClo Induce Superoxide in Mitochondria? 
MitoSOXTM Red is a mitochondrially targeted superoxide indicator.  It has previously been used 
to show an increase in mitochondrial superoxide production in Pink-1 deficient DA neurons 
(Wang, Chou et al. 2011) - a mutation that has previously been linked with PD (Valente, Abou-
Sleiman et al. 2004) - as well as to show an increase in superoxide not consumed by the 
cellular antioxidant MnSOD, in HEPG2 cells exposed to known PD toxin rotenone (Dlasková, 
Hlavatá et al. 2008).  We saw an apparent increase in mitochondrial superoxide in a dose 
dependent manner with150µM TaClo treated cells appearing to show an increase from 4 hours 
post treatment onwards, which was significantly quantified by flow cytometry at 8 hours (Figs. 
4.13 & 4.14).  When looking at the images, the increased superoxide appears to begin slightly 
earlier in the mitochondria than the cell in general, starting at 4 hours in mitochondria 
compared to 8 hours in the cell as a whole, suggesting that the source of any superoxide may 
be the mitochondria.  However when quantified, the mitochondrial superoxide is only 
significantly increased by 8 hours, and this cannot be compared with general cellular 
superoxide as we have been unable to quantify DCFDA fluorescence. 
 
When looking at the increase in fluorescence caused by superoxide production using flow 
cytometry, two distinct populations of cells can be seen (Fid 4.14 B) and these populations are 
also visible in the images taken (Fig 4.13).  We can find no reports of this in the literature but 
believe that the separate populations may represent two distinct groups of cells: those that 
are trying to combat the increased superoxide - the mid fluorescing population; and those that 
have reached a threshold where the damage incurred by the increased superoxide is excessive 
enough to cause the cell to become unviable and begin to die - the high fluorescing 
population.  This hypothesis is supported by the observation that in the imaged samples, there 
are two populations visible and those that have the highest fluorescence appear to have lost 
regular morphology and have become more spherical.  The possibility of a threshold can also 
be seen when looking at cells with general increased fluorescence when assessed by flow 
cytometry, and there appears to be a dramatic rise in the number of cells classified as 
increased in fluorescence between 8 and 12 hours following 150 µM and between 12 and 16 
hours following 100µM TaClo (Fig. 4.14 C).  This observation of a threshold of superoxide 
generation, combined with our evidence of a caspase-independent necrotic death phenotype 
(see Chapter 3), is similar to that seen by Wabnitz et al. who reported a threshold effect of 
H2O2 exposure between 12.5 & 50µM led to a caspase-independent mitochondrially linked 
necrotic death in primary human T-cells (Fig. 4.18) (Wabnitz, Goursot et al. 2010). 
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Fig. 4.18 Long-term oxidative stress induces caspase-independent T-cell death in primary 
human T cells Primary human T cells were treated with the indicated concentrations of H2O2 
for 26 h in the presence (black columns) or absence (white columns) of the pan-caspase 
inhibitor Z-VAD-fmk (20 mM). Cell death was analyzed using Annexin V/7-AAD staining.  Taken 
from (Wabnitz, Goursot et al. 2010) 
 
Polymorphisms in the mitochondrially targeted superoxide dismutase, MnSOD, have been 
linked with PD (Shimoda-Matsubayashi, Matsumine et al. 1996; Wang, Chen et al. 2010) and 
these polymorphisms have been shown to increase the risk of developing PD when exposed to 
pesticides (Fong, Wu et al. 2007).  MnSOD overexpression in mice also protected against the 
PD-linked neurotoxin, and mitochondrial Complex I inhibitor, MPTP (Klivenyi, St. Clair et al. 
1998) and MnSOD levels in cerebrospinal fluid have been shown to be increased in PD patients 
(Yoshida, Mokuno et al. 1994).  We found that MnSOD overexpressing SH-SY5Y showed a small 
but significant protection against TaClo cytotoxicity when compared to wild type cells (Fig. 
4.15).  This evidence implicates mitochondrially generated superoxide is involved in TaClo 
mediated SH-SY5Y toxicity and provides a link between TaClo, mitochondrial dysfunction and 
PD. 
 
Mutations in the PARK7 gene, DJ-1, have been linked with PD (Bonifati, Rizzu et al. 2003), and 
have also been shown to have cytoprotective effects with regard to oxidative stress (Yokota, 
Sugawara et al. 2003; Taira, Saito et al. 2004).  The protective effects of DJ-1in neurons are 
mediated by translocation to the mitochondria (Junn, Jang et al. 2009), suggesting the 
mechanism of DJ-1 neuroprotection against ROS involves mitochondria.  DJ-1 expression has 
also been shown to be up-regulated following sub lethal exposure to the PD-linked and ROS 
generating toxin paraquat (Mitsumoto, Nakagawa et al. 2001), and to protect against rotenone 
exposure by enhancing clearance of damaged mitochondria via mitophagy (Gao, Yang et al. 
2012).  We saw a significant increase in DJ-1 expression in SH-SY5Y form 8 hours following 
treatment (Fig. 4.16).  This suggests that TaClo exposure may lead to oxidative damage in the 
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mitochondria that the cell may be trying to protect against it by increasing production of the 
antioxidant sensor and defence protein DJ-1 and provides a link between TaClo exposure and 
PD. 
 
4.4.5 Does the Energy Generation Mechanism Affect TaClo Toxicity in SH-SY5Y? 
It has been reported that a switch of energy source from glucose to galactose can make cancer 
cells switch from mainly glycolytic to a mainly mitochondrial respiration driven method of 
energy production (Rossignol, Gilkerson et al. 2004) and that this switch can increase the 
toxicity of compounds that inhibit mitochondrial OXPHOS Complexes, such as the PD-linked 
toxin rotenone (Garside, Burnham et al. 2012).  We found that cells grown in galactose-rich 
media showed significant cell death when treated with TaClo even at extremely low levels of 
up to 1µM (Fig. 4.17) whereas glucose grown cells only showed significant death at levels 
>50µM (Fig. 3.9) suggesting a possible lower threshold for toxicity in cells grown in galactose 
media and the involvement of mitochondrial OXPHOS chain dysfunction in TaClo mediated cell 
death.  However, when TaClo toxicity to SH-SY5Y was compared between cells grown in 
glucose and galactose media, there was no significant difference observed, suggesting that this 
previous finding may not be significant and may require more investigation to confirm these 
preliminary observations.  It would also be useful to compare metabolism between the cells 
grown in the different energy sources to see if a significant shift in energy generation has 
occurred.  A recent report that D-galactose has been shown to cause oxidative stress and 
necroptosis in SH-SY5Y, although at higher doses than used in this study (>30g/L as opposed to 
1.8g/l in this study) question the validity of the work in this cell line (Li, He et al. 2011). 
 
4.4.6 Conclusions 
We have shown that oxidative stress is integrally involved in TaClo mediated neurotoxicity with 
increased levels of ROS and activated antioxidant defences found following TaClo treatment.  
The observed ROS may be generated by inhibition of the mitochondrial OXPHOS chain with 
TaClo mainly affecting Complex I and increased superoxide found in mitochondria and PD 
linked mitochondrial antioxidant defences increased.  Finally, we have not seen a similar set of 
results with chloral, possibly suggesting that chloral may be toxic itself, rather than its toxicity 
being due to its conversion to TaClo. 
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5.1 Introduction 
TCE was classified as a moderately toxic compound by the International Programme on 
Chemical Safety’s Environmental Health Criteria 50 on Trichloroethylene, with oral LD50s of 
2400-4920 mg/kg seen, and reported CNS depressant, irritant, and cancer causing effects and 
toxicity to liver and kidney seen following long term, relatively high dose, exposure in rodents 
(World Health Organization, United Nations Environment Programme et al. 1985; Williams-
Johnson, Eisenmann et al. 1997).  Chloral hydrate has been widely used as a sedative and 
hypnotic in human and veterinary medicine and therefore has similar acute toxic properties to 
most general anaesthetic, in that overdose can lead to CNS depression, coma and death.  The 
W.H.O. Concise International Chemical Assessment Document on chloral also reports mild 
hepatotoxicity and possible tumorigenic effects (Benson 2000). There is not a great deal of 
published data on TaClo toxicity, besides the suspected neurotoxic effect investigated in this 
study.  General tolerance of chronic exposure of the compounds in the strains and species to 
be studied therefore needs investigation. 
 
Measurement of altered neurotransmitter levels by HPLC or mass spectrometry in PD patients 
and models has been used as a marker of disease progression (Yang and Beal 2011).  Reduced 
levels of DA and its major metabolites are the main effect studied, due to the degeneration of 
DA neurons associated with the disease (Bernheimer, Birkmayer et al. 1973).  However, there 
have also been reports of altered levels of serotonin (5-HT), noradrenaline, glutamate and 
gamma-aminobutyric acid (GABA) in PD (Scatton, Javoy-Agid et al. 1983; de Jong, Lakke et al. 
1984; Mayeaux, Stern et al. 1984; Griffith, Okonkwo et al. 2008; Kish, Tong et al. 2008).  
Exploration of these neurotransmitters would be a useful tool in analysis of PD progression in 
animal models. 
 
There are a wide range of behavioural tests that have been developed to try and assess motor 
function in rodents, including the accelerating rotarod (Jones and Roberts 1968), grip strength 
(Cabe, Tilson et al. 1978), the pole test (Matsuura, Kabuto et al. 1997) and the label test 
(Fleming, Salcedo et al. 2004).  The effectiveness and variability of these tests can lead to 
problems with reproducibility and a lack of sensitivity so it is preferable to use combinations 
when assessing motor function in rodent models of PD. 
 
MPTP has been reported to cause SNpc DA neuron degeneration and development of PD by 
inhibition of mitochondrial OXPHOX Complex I (Langston, Ballard et al. 1983; Seniuk, Tatton et 
al. 1990; Hantraye, Varastet et al. 1993).  Acute MPTP treatment in C57BL/6 mice has been 
shown to lead to a decrease in SNpc DA neuron numbers and a decrease in motor function 
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that can be reliably measured using the accelerating rotarod test (Hutter-Saunders, 
Gendelman et al. 2012).  However there are various differing results in behavioural 
phenotypes seen following different administration and testing regimens (Sedelis, Schwarting 
et al. 2001).  The effect of chronic MPTP treatment on mouse motor function, SNpc neuron 
number and neurotransmitter level and its possible use as a positive control in PD toxin 
investigations in vivo needs further assessment. 
 
5.1.1 Aims 
This study aims to assess to general tolerability of i.p. TCE, chloral, TaClo and MPTP in male 
C57BL/6 mice and Wistar rats as well as looking at any changes in motor function, 
neurotransmitter levels or SNpc neuron number in treated animals. 
 
To achieve this, a dosing paradigm will be designed based on previously known toxicological 
data and longitudinal behavioural testing will be performed.  Post mortem, brains will be taken 
and neurotransmitter levels measured using LC-MS/MS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2 Methods 
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For detailed methods see Material and Methods (Section 2). 
 
All animals were to be dosed i.p. twice weekly for 8 weeks to model chronic exposure of the 
chemicals.  This route was chosen following discussion with the NACWO and NVS as a reliable 
and relatively uninvasive method of dosing that would not be expected to lead to high attrition 
levels over the course of the study.  The regimen and length of dosing was selected as the 
maximum frequency and extent of i.p. dosing in rodents laid out in the licence for this project 
granted according to the UK Animals (Scientific procedures) Act of 1986. 
 
A dose of 500mg/kg was chosen for TCE exposure based on data from the U.S. Department of 
Health and Human Services Toxicological Profile for TCE which reported a NOEAL effect on 
general toxicological events of 1000mg/kg/day in chronic oral dosed studies of over 365 days 
in rats and mice (Williams-Johnson, Eisenmann et al. 1997) and a lack of overt toxicity reported 
by Guehl et al. in mice dosed 400mg/kg/day TCE for 5 days a week over 4 weeks (Guehl, 
Bezard et al. 1999). 
 
Chloral was dosed at 100mg/kg based on review of the W.H.O. Concise International Chemical 
Assessment Document 25 - Chloral Hydrate which reports LOAEL of 144 & 160mg/kg in 14 and 
90 day oral exposure studies in mice (Benson 2000).   
 
TaClo has been less widely studied.  Sontag et al. dosed rats with 0.2mg/kg/day TaClo i.p.and 
0.4mg/kg twice daily p.o. for 7 weeks and observed no overt toxicity (Sontag, Heim et al. 1995; 
Sontag, Lange et al. 2009).  As we dosed twice weekly, 1mg/kg TaClo was selected as a dose 
that was believed not to be toxic. 
 
MPTP is a well-studied PD-linked toxin.  Antzoulatos et al. reported that a dose of 10mg/kg i.p. 
was well tolerated in C57BL/6 mice when given daily for 5 days, but higher doses led to 
mortality (Antzoulatos, Jakowec et al. 2010); therefore a dose of 10mg/kg twice weekly for 8 
weeks was used here. 
 
C57BL/6 mice and Wistar rats were used in this study as they are both widely used model 
species in toxicological and neurotoxicological studies and have a wide range of data published 
on expected tolerability of neurotoxic compounds and performance in behavioural paradigms.  
In addition C57BL/6 mice have a range of transgenic PD mutant models which may be useful in 
further studies. 
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5.2.1 Statistical Analysis 
For information on statistical methods see General Statistics (Sections 2.8 & 2.8.2) 
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5.3 Results 
5.3.1 C57BL/6 Mice 
5.3.1.1 General Tolerance 
0.9% NaCl, 500mg/kg TCE, 100mg/kg Chloral, 1mg/kg TaClo & 10mg/kg MPTP i.p. at 10ml/kg 
were well tolerated by all animals dosed throughout the study.  No obvious signs of discomfort 
were displayed following dosing and all animals survived until study termination. 
5.3.1.1.1 Clinical Signs 
No overt clinical or behavioural abnormalities were observed in any of the treatment groups 
over the course of the study. 
5.3.1.1.2 Weight 
Animals in all treatment groups showed similar significant normal increase in weight over time 
(P<0.001, Two-way Repeated Measures ANOVA) with minor fluctuations over the study (Fig 
5.1).  There was a significant difference in weight between treatment groups (P<0.05, Two-way 
Repeated Measures ANOVA), with chloral and TaClo treated mice showing generally lower 
weights than vehicle, TCE and MPTP treated groups (Fig 5.1).  There was also a significant 
effect of treatment on weight over time (P<0.001, Two-way Repeated Measures ANOVA); 
however only chloral treated animals showed a periodically significantly lower weight at 
specific time points when compared to the vehicle group (P<0.01 and P<0.05, Bonferroni post-
test) (Fig. 5.1).  This intermittently lower weight was not considered clinically relevant. 
 
Fig. 5.1 Effect of TCE, Chloral, TaClo & MPTP on C57BL/6 mouse weight Weight (g) of TCE 
(500mg/kg), Chloral (100mg/kg), TaClo (1mg/kg), MPTP (10mg/kg) or control (10ml/kg Olive 
Oil) treated C57BL/6 mice.   Data presented as mean (n=6).  Significant difference over time 
(P<0.001), between treatment groups (P<0.05) and of treatment over time (P<0.001), Two-way 
Repeated Measures ANOVA.  **P<0.01, *P<0.05  when compared to vehicle at relevant 
timepoint, Bonferroni post-test 
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5.3.1.2 Behavioural Testing 
5.3.1.2.1 Rotarod 
To assess motor function in this study, the accelerating rotarod, a well characterised 
behavioural paradigm used in rodent models (Jones and Roberts 1968), was used prior to, and 
then at 2, 4, 6 & 8 weeks following, the first dose.  Animals were placed on a steadily 
accelerating rotating rod and the time taken to fall off was recorded.  No significant 
differences between treatment groups and no significant effect of treatment over time were 
found, but there was a significant difference in performance over time across all groups 
(P<0.01, Two-way, Repeated Measures ANOVA) (Fig 5.2).  No significant difference was seen at 
any time point for any treatment when compared to vehicle, apart from a small but significant 
increase in average fall latency observed in 100mg/kg chloral (131%) and 1mg/kg TaClo (133%) 
treated animals at 8 weeks (P<0.001, Bonferroni post-test) (Fig 5.2).  This may suggest slightly 
improved motor function in animals treated with chloral & TaClo twice weekly for 8 weeks, but 
no effect following treatment with TCE or MPTP. 
 
 
Fig. 5.2 Effect of TCE, Chloral, TaClo & MPTP on C57BL/6 mouse motor function as assessed 
by the Rotarod test Average fall latency of TCE (500mg/kg), Chloral (100mg/kg), TaClo 
(1mg/kg), MPTP (10mg/kg) or control (0.9% NaCl) treated C57BL/6 mice over time, triplicate 
trials.   Data presented as mean % control + SEM (n=6).  Significant difference over time 
(P<0.01), No significant difference between treatment groups or of treatment over time, Two-
way Repeated Measures ANOVA.  ***P<0.001 when compared to vehicle at relevant 
timepoint, Bonferroni post-test 
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5.3.1.2.2 Pole Test 
The pole test; which has been developed to test more fine motor control than the accelerating 
rotarod in mice (Matsuura, Kabuto et al. 1997), was used  in this study to further assess any 
effects of the treatments on the motor skills of the animals at the same time points as the 
rotarod test.  Animals were placed face up on a pole and total time to complete the trial, time 
to turn on the pole, time to descend the pole and number of falls per three trials were 
recorded for all animals. 
 
There were no significant differences observed in total trial time between treatment groups, 
between the different trials and no significant effect of treatment over time (Two-way, 
Repeated Measures ANOVA) (Fig 5.3A).  Neither were there any significant differences 
between vehicle and compound treated animals at any time point (Bonferroni post-test), but 
there did seem to be a possible trend towards an increased time taken to complete the trial in 
500mg/kg TCE, 100mg/kg chloral & 10mg/kg MPTP treated mice following 6 weeks dosing.  
However this increase returns to vehicle levels by 8 weeks treatment (Fig 5.3A). 
 
Similar results were seen when looking at time to turn and time to descend the pole, with no 
significant differences detected in turn or descent time between treatment groups and no 
significant effect of treatment over time, but a significant difference in performance was seen 
over time in both turning and descent latency (P<0.01, Two-way, Repeated Measures ANOVA) 
(Fig 5.3 B & C).  Again, there were no significant differences between vehicle and compound 
treated animals at any time point (Bonferroni post-test), but there did seem to be a possible 
trend towards an increased time taken to turn on the pole in 100mg/kg chloral treated mice 
following 6 weeks dosing and in time to descend the pole in 500mg/kg TCE, 100mg/kg chloral 
& 10mg/kg MPTP dosed animals, again following 6 weeks treatment.  However, as with 
possible differences seen in total trial time, this increase returns to vehicle levels by 8 weeks 
treatment (Fig 5.3 B & C). 
 
No significant differences in number of falls were seen between treatment groups and no 
significant effect of treatment over time, but a significant increase in number was observed 
over time (P<0.05, Two-way, Repeated Measures ANOVA) (Fig 5.3 D).  A significant increase in 
the number of falls was detected following 6 weeks 100mg/kg chloral treatment (P<00.1, 
Bonferroni post-test), but this difference was not carried forward following 8 weeks dosing (Fig 
5.3 D).  Interestingly, no vehicle-treated animal fell throughout the whole study, whereas 
animals in all other treatment groups did - predominantly from 4 weeks onwards - suggesting a 
possible loss of fine motor control in TCE, chloral, TaClo & MPTP treated animals (Fig. 5.3 D).
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Fig. 5.3 Effect of TCE, Chloral, TaClo & MPTP on C57BL/6 mouse fine motor control as assessed by the Pole test Average (A) Total Time (B) Turn Latency, (C) 
Descent Latency & (D) Number of Falls of TCE (500mg/kg), Chloral (100mg/kg), TaClo (1mg/kg), MPTP (10mg/kg) or control (0.9% NaCl) treated C57BL/6 mice over 
time.   Data presented as triplicate trial means + SEM (n=6).  Significant difference over time ((B & C, P<0.01, D P<0.05), No significant difference over time (A), 
between treatment groups or of treatment over time (A, B, C & D), Two-way Repeated Measures ANOVA.  **P<0.01 when compared to vehicle at relevant 
timepoint, Bonferroni post-test 
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5.3.1.2.3 Label Test 
The label test, another test designed to assess motor function - specifically motor response to 
aversive stimuli (Fleming, Salcedo et al. 2004) - was used in this study.  A small sticky label is 
placed on the snout of the mouse and the time until removal is recorded.  No significant 
differences in label-removal latency were seen between treatment groups and no significant 
effect of treatment over time, but a significant increase was observed over time (P<0.001, 
Two-way, Repeated Measures ANOVA) (Fig 5.4).  No significant differences between vehicle 
and compound treated animals at any time point were seen (Bonferroni post-test), but there 
did seem to be a possible trend towards a decreased time taken to remove the label in all 
compound treated mice when compared to the vehicle group following 4 weeks dosing.  It is 
worth noting that this decrease is not apparent by 6 weeks treatment (Fig 5.4).   
 
 
 
 
Fig. 5.4 Effect of TCE, Chloral, TaClo & MPTP on C57BL/6 mouse fine motor control as 
assessed by the Label test Average sticker removal latency of TCE (500mg/kg), Chloral 
(100mg/kg), TaClo (1mg/kg), MPTP (10mg/kg) or control (0.9% NaCl) treated C57BL/6 mice 
over time, triplicate trials.   Data presented as mean % control + SEM (n=6).  Significant 
difference over time (P<0.001), No significant difference between treatment groups or of 
treatment over time, Two-way Repeated Measures ANOVA 
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5.3.1.2.4 Grip Strength 
As abnormalities in grip strength have been reported in mouse models of PD (Colotla, Flores et 
al. 1990), a test of grip strength using a strain gage was used in this study (Cabe, Tilson et al. 
1978).  There were no significant differences observed in grip strength between treatment 
groups, between the different trials and no significant effect of treatment over time (Two-way, 
Repeated Measures ANOVA) (Fig 5.5).  Neither were there any significant differences between 
vehicle and compound treated animals at any time point (Bonferroni post-test), with all 
treatment groups appearing to stay relatively stable throughout the study (Fig. 5.5).  This data 
suggests that TCE, chloral, TaClo & MPTP have no effect on mouse grip strength at the doses 
given in this study. 
 
 
 
 
Fig. 5.5 Effect of TCE, Chloral, TaClo & MPTP on C57BL/6 mouse grip strength Average grip 
strength of TCE (500mg/kg), Chloral (100mg/kg), TaClo (1mg/kg), MPTP (10mg/kg) or control 
(0.9% NaCl) treated C57BL/6 mice over time, triplicate trials.   Data presented as mean % 
control + SEM (n=6).  Significant difference over time (P<0.01), No significant difference 
between treatment groups or of treatment over time, Two-way Repeated Measures ANOVA 
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5.3.1.3 Neurotransmitter Levels 
Alterations in neurotransmitter levels has been reported in the brains of PD patients with 
reduced levels of DA - a hallmark of the condition - and decreases in serotonin, noradrenaline, 
and GABA (Bernheimer, Birkmayer et al. 1973; Rinne and Sonninen 1973; Riederer, Birkmayer 
et al. 1977; Scatton, Javoy-Agid et al. 1983; Gerlach, Gsell et al. 1996) and glutamate has also 
been linked with the pathogenesis of the disease (Blandini, Porter et al. 1996).  
Neurotransmitter levels were therefore measured in the caudate putamen and forebrain of 
study animals by LC-MS/MS post mortem. 
 
DA or HVA levels were not quantified due to limitations in the assay; however the DA 
metabolite DOPAC was measured.  No significant decrease in DOPAC levels were observed in 
the forebrain following all treatments and in the caudate putamen following TCE, chloral or 
MPTP exposure; however a significant decrease in TaClo treated animals was detected 
(P<0.05, Dunnett’s post-test) (Fig. 5.6 A). 
 
 
 
 
Fig. 5.6 Effect of TCE, Chloral, TaClo & MPTP on caudate putamen & forebrain DOPAC 
metabolite levels in C57BL/6 mice Levels of DOPAC in Caudate Putamen & Forebrain of TCE 
(500mg/kg), Chloral (100mg/kg), TaClo (1mg/kg), MPTP (10mg/kg) & vehicle (0.9% NaCl) 
treated C57BL/6 mice when assessed by LC-MS/MS.   Data presented as mean ng/mg wet 
tissue from duplicate samples + SD (n=3-6).  (A-Caudate & Forebrain) No significant difference 
between groups, One-way ANOVA.  *P<0.05 when compared to vehicle, Dunnett’s post-test. 
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As with DA, 5-HT levels could not be measured in the brain samples due to assay limitations 
but 5-HT metabolite 5-Hydroxyindoleacetic acid (5-HIAA) was quantified.  TCE and chloral did 
not have any significant effect on 5-HIAA levels in either the caudate putamen or forebrain, 
but TaClo and MPTP treated groups showed a large and significant increase in 5-HIAA in both 
brain regions (caudate TaClo & MPTP and forebrain MPTP, P<0.01; forebrain TaClo, P<0.001, 
all Dunnett’s post-test) (Fig. 5.7). 
 
 
 
 
 
Fig. 5.7 Effect of TCE, Chloral, TaClo & MPTP on caudate putamen & forebrain 5-HIAA levels 
in C57BL/6 mice Levels of 5-HIAA in Caudate Putamen & Forebrain of TCE (500mg/kg), Chloral 
(100mg/kg), TaClo (1mg/kg), MPTP (10mg/kg) & vehicle (0.9% NaCl) treated C57BL/6 mice 
when assessed by LC-MS/MS.   Data presented as mean ng/mg wet tissue from duplicate 
samples + SD (n=5-6).  (Caudate & Forebrain) Significant difference between groups (both 
P<0.001), One-way ANOVA.  ***P<0.001, **P<0.01 when compared to vehicle, Dunnett’s post-
test. 
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Levels of GABA, the major inhibitory neurotransmitter in the CNS, were unchanged in the 
forebrain in all treatment groups, and in the caudate putamen following TCE and MPTP 
treatment, but were significantly reduced by ~40% in chloral and TaClo exposed animals in the 
caudate (both P<0.01, Dunnett’s post-test) (Fig. 5.8 A).  Glutamate, the most common 
excitatory neurotransmitter in the CNS, was not significantly altered in TCE treated animals in 
either the caudate putamen or the forebrain, but reduced by about a third in TaClo & MPTP 
exposed groups and almost completely in chloral dosed animals in both brain regions (caudate 
TaClo and forebrain TaClo & MPTP, P<0.05; caudate MPTP, P<0.01: cauduate & forebrain 
chloral, P<0.001, all Dunnett’s post-test) (Fig. 5.8 B). 
 
 
 
Fig. 5.8 Effect of TCE, Chloral, TaClo & MPTP on caudate putamen & forebrain GABA & 
Glutamate levels in C57BL/6 mice Levels of (A) GABA & (B) Glutamate in Caudate Putamen & 
Forebrain of TCE (500mg/kg), Chloral (100mg/kg), TaClo (1mg/kg), MPTP (10mg/kg) & vehicle 
(0.9% NaCl) treated C57BL/6 mice when assessed by LC-MS/MS.   Data presented as mean 
ng/mg wet tissue from duplicate samples + SD (n=5-6).  (A-Forebrain) No significant difference 
between groups, (A-Caudate & B-Caudate & Forebrain) significant difference between groups 
(A-Caudate, P<0.01, B-both, P<0.001), One-way ANOVA.  ***P<0.001, **P<0.01, *P<0.05 when 
compared to vehicle, Dunnett’s post-test. 
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5.3.2 Wistar Rats 
5.3.2.1 General Tolerance 
1mg/kg TaClo and 100mg/kg Chloral i.p. at 1ml/kg were well tolerated by all animals dosed 
throughout the study.  No obvious signs of discomfort were displayed following dosing and all 
animals survived until study termination. 
 
500mg/kg TCE i.p. at 1ml/kg was not well tolerated by any rats in this group.  All rats showed 
agitation, vocalisation and signs of pain at injection of the compound.  During the study, one 
rat in this group had to be terminated due to compound related effects (see section 5.3.2.1.1 
below for details). 
5.3.2.1.1 Clinical Signs 
No overt clinical or behavioural abnormalities were observed in the 1mg/ml TaClo or 
untreated groups over the course of the study. 
 
100mg/kg Chloral treated animals were observed to be drowsy, disorientated and have 
increased appetite immediately and for 1 hour following dosing but these abnormalities had 
abated by 4 hours post dose. 
 
500mg/kg TCE treated animals were observed to be agitated, disorientated, 
guarding/scratching the injected region of the abdomen, have hunched posture and have 
increased aggression to cage mates immediately and for 1 hour following dosing.  These 
abnormalities were only occasionally observed at 4 hours and were always abated by 24 hours 
post-dose. 
 
Rat number 20 (500mg/kg TCE) was found to have increased vocalisation when handled 
throughout the duration of the study. 
 
Rat number 19 (500mg/kg TCE) was found to have diarrhoea on day 45, during a period of 
decreased weight (see section 5.3.2.1.1 above) and was terminated due to this deterioration in 
condition.  Post mortem revealed distended intestines and a solid blockage in the colon as a 
possible cause of illness. 
 
All 100mg/kg Chloral and 500mg/kg TCE treated animals were found to have various levels of 
gut stasis on post mortem, which was likely to have been compound related. 
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Rat 13 (100mg/kg Chloral) was found to have left lateral and left median liver lobes adhered at 
post mortem.  This was not thought to be compound related due to lack of occurrence in co-
treated animals. 
5.3.2.1.2 Weight 
1mg/kg TaClo and 100mg/kg Chloral treated animals showed similar significant normal 
increase in weight over the study (P<0.001, Two-way, Repeated Measures ANOVA), but 
500mg/kg TCE treated rats did not show any significant weight gain over the study (Fig. 5.13). 
There was a significant effect of treatment over time (P<0.001, Two-way Repeated Measures 
ANOVA), with TCE treated rats not showing the increase seen in chloral and TaClo treated 
animals (Fig. 5.13).  No significant difference between treatment group weights (Two-way, 
Repeated Measures, ANOVA) or between groups at specific time points (Bonferroni post-test) 
were seen (Fig. 5.13).  The lack of weight gain in the TCE treated rats was considered clinically 
relevant and related to TCE exposure. 
 
Rat 19 was observed to have significant weight loss (-10-15%) from day 42 to day 45 and as 
such was terminated on day 45 due to deteriorating condition and as such was excluded from 
statistical analysis.  No other animals had any significant (>10%) weight loss over the course of 
the study. 
 
Fig. 5.9 Effect of TCE, Chloral & TaClo on Wistar rat weight Weight (g) of TCE (500mg/kg), 
Chloral (100mg/kg), TaClo (1mg/kg) treated Wistar rats.   Data presented as mean (n=3/4).  
Significant difference over time (P<0.001), and of treatment over time (P<0.001) but no 
significant difference between treatment groups, Two-way Repeated Measures ANOVA. 
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5.3.2.2 Behavioural Testing 
The accelerating rotarod test has also been used in rats so it was used in this study to assess 
motor function.  Rats 1 (Control), 10 (1mg/kg TaClo), 13, 14 (both 100mg/kg chloral) 19 and 20 
(both 500mg/kg TCE) were excluded from the analysis due to aversion to performing the task 
(jumping off apparatus, climbing over lanes, not attempting to walk on rod) from week 2 (Rats 
19 & 20), week 6 (Rats 1 & 10) and week 8 (Rats 13 & 14).  The reluctance of Rats 19 & 20 may 
have been treatment-related due to the clinical signs associated with TCE dosing (see section 
5.2.3.1.1).  A significant decrease in fall latency was observed over the study (P<0.001, Two-
way, Repeated Measures, ANOVA), which was not treatment-related and there was no 
significant difference between treatment groups overall (Two-way, Repeated Measures 
ANOVA) or when compared to the control group at individual time points (Bonferroni post-
test) (Fig 5.14 A).  This suggests that TCE, chloral & TaClo treatment had no effect on motor 
function at the doses used in this study. 
 
The grip strength test was also used in this study to complement the data gained from the 
rotarod.  Rat 19 (500mg/kg TCE) was excluded from the analysis due to aversion to performing 
the task (jumping off apparatus) in week 8; this averseness may have been treatment-related 
due to the clinical signs associated with TCE dosing (see section 5.2.3.1.1).  There were no 
significant differences observed in grip strength between treatment groups, between the 
different trials and no significant effect of treatment over time (Two-way, Repeated Measures 
ANOVA) (Fig 5.14 B).  There were also no significant differences between control and 
compound-treated animals at any time point (Bonferroni post-test), with all treatment groups 
appearing to stay relatively stable throughout the study apart from a possible trend towards a 
decrease in grip strength in the 1mg/ml TaClo treated rats (Fig. 5.14 B).  This data suggests that 
TaClo may lead to a decrease in grip strength when dosed twice weekly at 1mg/kg, but TCE 
and chloral appear to have no effect on rat grip strength at the doses given in this study. 
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Fig. 5.10 Effect of TCE, Chloral, TaClo & MPTP on Wistar rat motor function and grip strength 
Average % control (A) rotarod fall latency & (B) grip strength of TCE (500mg/kg), Chloral 
(100mg/kg), TaClo (1mg/kg) treated or untreated Wistar rats over time. Data presented as 
mean % control of triplicate trials +SEM (n=2-4).  Significant difference over time (A, P<0.001), 
No significant difference over time (B), between treatment groups or of treatment over time 
(A & B), Two-way Repeated Measures ANOVA. 
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5.3.2.3 Neurotransmitter Levels 
Neurotransmitter levels were measured in the caudate putamen and forebrain of study 
animals by LC-MS/MS post mortem to assess the effect of TCE and metabolite exposure in rats. 
 
In the rats, DA and DOPAC levels were not measured due to limitations in the assay; however 
in rat brains, 5-HT levels were quantifiable.  TCE, chloral & TaClo treatment had no significant 
effect on HVA (Fig. 5.11 A), 5-HT & 5-HIAA (Fig. 5.12) or GABA & glutamate levels in either the 
caudate putamen or forebrain of the animals studied (all One-way ANOVA).  This suggests the 
possibility of a species difference in the effect of the chemicals on the neurotransmitter levels 
when compared with the results seen in the mice. 
 
 
 
 
Fig. 5.11 Effect of TCE, Chloral & TaClo on caudate putamen & forebrain HVA levels in Wistar 
rats Levels of HVA in Caudate Putamen & Forebrain of TCE (500mg/kg), Chloral (100mg/kg) & 
TaClo (1mg/kg) treated and untreated control Wistar rats when assessed by LC-MS/MS.   Data 
presented as mean ng/mg wet tissue from duplicate samples + SD (n=2-4).  No significant 
difference between groups, One-way ANOVA. 
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Fig. 5.12 Effect of TCE, Chloral & TaClo on caudate putamen & forebrain 5-HT & 5-HIAA levels 
in Wistar rats Levels of 5-HT & 5-HIAA in (A) Caudate Putamen & (B) Forebrain of TCE 
(500mg/kg), Chloral (100mg/kg) & TaClo (1mg/kg) treated and untreated control Wistar rats 
when assessed by LC-MS/MS.   Data presented as mean ng/mg wet tissue from duplicate 
samples + SD (n=2-4).  No significant difference between groups, One-way ANOVA 
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Fig. 5.13 Effect of TCE, Chloral & TaClo on caudate putamen & forebrain GABA & Glutamate 
levels in Wistar rats Levels of GABA & Glutamate in (A) Caudate Putamen & (B) Forebrain of 
TCE (500mg/kg), Chloral (100mg/kg) & TaClo (1mg/kg) treated and untreated control Wistar 
rats when assessed by LC-MS/MS.   Data presented as mean ng/mg wet tissue from duplicate 
samples + SD (n=4).  No significant difference between groups. 
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5.4 Discussion 
5.4.1 Are Chronic TCE, Chloral and TaClo Well Tolerated in C57BL/6 Mice and Wistar Rats? 
This study showed TCE, chloral, TaClo and MPTP to be well tolerated by C57BL/6 mice at the 
doses and regimen used, with no overt toxicity, clinical signs or lack of weight gain apparent 
(Fig. 5.1).  Chloral treated mice were significantly lower in weight than vehicle periodically 
throughout the study (Fig 5.1) but this group was smaller at study start and gained weight at 
the same rate as all other groups suggesting that this is not clinically relevant nor related to 
the treatment. 
 
As in the mice, TaClo was well-tolerated by Wistar rats as dosed in this study, with normal 
weight gain and no clinical signs or overt toxicity observed throughout the study period (Fig 
5.13).  However, TCE and chloral were less well-tolerated in this study.  Despite being given the 
same total doses as the mice, chloral induced drowsiness, disorientation and increased 
appetite and TCE caused abdominal pain on administration, agitation, disorientation, hunched 
posture and increased aggression as well as a lack of characteristic weight gain in rats.  Post 
mortem investigations found varying levels of gut stasis in all chloral and TCE treated rats.  The 
occurrence of these symptoms in the rats, despite the tolerance of the mice to the same 
doses, may be due to the fact that the rats were administered the compounds at a ten-fold 
higher concentration, albeit in a ten-fold lower volume. 
 
The sedative effect seen with chloral is not surprising as the compound is a well-known and 
widely used anaesthetic agent (Silverman and Muir Iii 1993) and the gut stasis observed in the 
chloral treated rats correlates with reports of adynamic ileus in anaesthetised rats caused by 
the irritant property of the compound in the visceral peritoneum (Fleischman, McCracken et 
al. 1977).  Although the reported cases were following higher doses of chloral, our repeated 
lower administration could be expected to yield the same effects.   Chloral treated rats also 
showed an acute effect on feeding behaviour as seen by constant eating of food pellets placed 
in the cage directly following dosing; however, as there was no significant weight gain, a 
persistent increase in appetite does not seem to be the cause of this behaviour.  The observed 
feeding could be possibly due to chloral exposure causing a feeling of emesis in the animals, as 
it is similar to a phenomenon known as pica, which is illness response behaviour in rats 
whereby they eat non-nutritive substances due to a lack of ability to vomit (Takeda, Hasegawa 
et al. 1993), although this does not agree with reports of general reduced food intake in rats 
administered emetic agents (Takeda, Hasegawa et al. 1993; De Jonghe, Lawler et al. 2009).  
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While these observations are easily explained, they present problems in the use this of 
regimen and species as a chronic model to study any possible involvement of chloral in PD. 
 
I.p. administration of TCE induced obvious signs of pain in all rats on administration and 
continuing for up to 4 hours post dosing.  The vocalisation, guarding of injection site and 
aggression seen in the rats immediately following dosing suggests that TCE was causing acute 
pain.  This may have been due to a number of known solvent effects, such as decreasing local 
temperature in the injection site, affecting membrane permeability, or an, as yet, 
uncharacterised effect on local pain receptors or neurons.  Further investigation is needed to 
confirm the cause of this apparent acute pain.  The more chronic pain indicated by guarding 
behaviour and hunched posture may be due to the observation reported that TCE can enhance 
production of histamine and inflammatory mediators in rat peritoneal mast cells (Seo, Ikeda et 
al. 2008).  TCE treated animals also showed signs of disorientation consistent with reports of 
dizziness in a large scale investigation in to 188 workers exposed to TCE (Barret, Faure et al. 
1984), with symptoms reported in a patient who suffered seizures and slurred speech, 
disorientation, dissociative amnesia, and bizarre behaviour following inhalation abuse of TCE 
(Miller, Mycyk et al. 2002) and in a case of industrial TCE exposure where weakness and 
dizziness were reported (Bond 1996).  Post mortem examinations revealed gut stasis in all TCE 
treated animals and animal 19 had diarrhoea, which is consistent with effects reported in a 
human population exposed to TCE in drinking water in which 52% of exposed individuals 
suffered gastrointestinal dysfunction (Byers, Levin et al. 1988).  Another possible explanation 
for the problems observed in the gut could possibly be due to TCE, or chloral formed from TCE, 
causing irritation in the peritoneum leading to the effects described above.  The lack of normal 
weight gain seen in TCE treated rats (Fig 5.13) may have been due to the stress and pain of the 
injections, or possibly due to the gastrointestinal problems seen in this group, although the 
same effects were seen in chloral treated animals which did not show any problems in gaining 
weight.  The lack of weight gain is likely due to the effects of the compound in the peritoneum 
as reports show normal weight gain in animals administered with TCE at doses up to 
1000mg/kg/day in acute and chronic studies when given by oral gavage (Maltoni C, Lefemine G 
et al. 1986; Goldsworthy and Popp 1987) suggesting there is no direct effect of TCE on 
appetite. 
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5.4.2 Do Chronic TCE, Chloral, TaClo and MPTP Treatment Affect Motor Function? 
No consistent significant decrease in motor function was observed in TCE, chloral, TaClo or 
MPTP C57BL/6 mice when assessed by rotarod (Fig. 5.2), Pole (Fig. 5.3), Sticker (Fig. 5.4) or 
Grip Strength (Fig. 5.5) tests.  Generally, all groups’ performance in the tests decreased over 
time; this was believed to be due to habituation to the tests, with animals possibly learning 
that reduced participation resulted in early cessation of the test and return to the home cage, 
rather than an actual decrease in motor function, but there were no differences between 
treatment groups. 
 
The rotarod test has been previously used to show a decrease in motor function following 
acute exposure to PD toxins MPTP and rotenone (Pan-Montojo, Anichtchik et al. 2010; 
Chagniel, Robitaille et al. 2012), and Colotla et al. showed that rotarod performance was 
affected by relatively high (9 x 30mg/kg), but not lower (9 x 10 or 20mg/kg) doses of MPTP 
(Colotla, Flores et al. 1990).  All mice in this study showed a change in performance over time; 
however this was not found to be significantly related to treatment over the course of the 
study (Fig. 5.2).  This is not consistent with results seen in rats exposed to 1000mg/kg TCE five 
times per week for 6 weeks p.o. which developed a small but significant reduction in rotarod 
performance (Liu, Choi et al. 2010), although this could be explained by the higher and more 
acute dosing regimen and species difference.  An apparent increase in motor function to 
~150% when compared to vehicle treated animals was seen in chloral and TaClo treated mice 8 
weeks following first dosing (Fig 5.2).  This effect has previously been reported in MPTP treated 
mice which showed increased activity despite reduced SNpc DA levels (Rousselet, Joubert et al. 
2003).  There have also been reports of temperature affecting DA levels in mice treated with 
PD-linked toxins, with increased DA seen following administration of a single dose of rotenone 
at 21oC, but decreased levels seen at 28oC (Crutchfield and Dluzen 2006).  However, as this 
effect is not seen in any of the other behavioural paradigms, these results are thought to be 
artefact. 
 
Fine motor control has been shown to be inhibited in MPTP treated mice in the pole test 
following a relatively high and acute dosing regimen, with mice administered 30mg/kg twice a 
day for 4 or 5 days (Ogawa, Hirose et al. 1985; Abe, Taguchi et al. 2001).  Behavioural analysis 
of mice in this study by the pole test showed a general increase in the time taken to turn and 
descend the pole over the duration of the study; however there were no overall differences 
between the treated and vehicle groups (Fig 5.3).  A possible increase in time to descend was 
seen in TCE, chloral & MPTP at 6 weeks; however this was not significant and had returned to a 
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similar level to vehicle treated mice by 8 weeks (Fig 5.3 C), suggesting the result is an artefact.  
When looking at number of falls per three trial session, it is interesting to note that no mouse 
from the vehicle treated group fell throughout the duration of the study but all other groups 
had an increase in number of falls, generally from 4 weeks treatment onwards, with chloral 
treated animals showing significantly more falls at 6 weeks than vehicle (Fig 5.3 D).  There was 
no statistical significance in the effect of treatment on the increase in falls, but at these doses 
for this exposure there does seem to be a trend towards a decrease in motor function.  While 
previous studies mentioned have reported decreased performance in the pole test following 
MPTP treatment, this effect was with higher, more acute doses and there are reports of acute 
lower total doses of 30mg/kg MPTP twice in one day, or 10mg/kg/day for 5 days showing no 
decrease in motor function as assessed by the test (Rommelfanger, Edwards et al. 2007; 
Antzoulatos, Jakowec et al. 2010).  These reports suggest that our dosing regimen may not be 
exposing the mice to high enough levels of the toxins.  It has also been reported that this 
decreased performance in the pole test recovers to control levels by 3 days post dosing in 
C57BL/6 mice administered 4 x 15mg/kg doses of MPTP in one day (Sedelis, Hofele et al. 2000).  
As our behavioural testing was carried out 3 days post previous dose, this report suggests 
another possible reason no significant effects were observed.  A final observation of caution 
when analysing the results seen in the pole test lie in the fact that this test is generally widely 
used to assess endpoint motor function, whereas here it has been used to assess fine motor 
control throughout the study on a number of occasions.  This may mean that habituation and 
learning or memory may also have an effect on performance and mean more variables are 
included in the test that may affect its reliability seen in reported use. 
 
The label test has been previously used to show a decrease in motor function in a 6-OHDA PD 
rat model (Schallert, Fleming et al. 2000) and an α-synuclein overexpressing mutant mouse 
model of the disease (Fleming, Salcedo et al. 2004).  When assessing motor response to 
aversive stimuli using the label test, all animals showed an increased latency to remove the 
label over time, with a distinct increase from 4 week trial onward (Fig. 5.4), but this effect was 
not dependent on treatment.  As in the pole test, the label test is generally used as an 
endpoint motor function assessment, and, as we used repeated tests to determine fine motor 
control throughout the study, this could be the reason for the decreased performance in the 
test.  As this test relies on the aversive nature of the label on the forehead of the animal, 
repeated occurrences could lead to habituation and a decrease in the aversive stimuli so 
reducing the drive to remove the label.   
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There was a slight decrease in grip strength in all groups when tested in week 8 but no 
difference between toxin and vehicle-treated animals (Fig 5.5).  Grip strength is not thought to 
be a sensitive marker for motor dysfunction in PD as it has been reported that mice that show 
a decreased motor function - as assessed by rotarod - have no significant change in grip 
strength (Sedelis, Hofele et al. 2000). 
 
In TCE, chloral & TaClo treated rats, no reduction in motor function when compared to control 
animals, or generally over time, was seen when assessed by grip strength (Fig. 5.14 B), while 
there was a decrease in the performance of all groups on the rotarod from baseline which was 
not treatment-related and levelled out to a similar level for all post dose tests (Fig. 5.14 A).  In 
both tests a number of animals had to be excluded due to a lack of compliance in the test 
protocol.  This could possibly be explained by the size of the rats which were relatively large 
(500-600g) and so easily able to escape from the apparatus, or possibly due to habituation to 
the equipment allowing rats to learn ways to avoid task performance and, in the case of the 
TCE treated animals, this may have been related to the discomfort and anxiety related with 
dosing of the compound.  Due to the low number of animals included in the analysis of these 
tests, the clinical effects seen in some groups and the lack of compliance in the tests, the 
behavioural results reported are not thought to be robust enough from which to draw reliable 
conclusions. 
 
While there is a report of reduced rotarod performance in TCE exposed rats (Liu, Choi et al. 
2010), this study used a far higher and more acute dosing regimen that that used here, 
possibly explaining the lack of consistency with the results following TCE exposure here.  No 
studies into the effect of chloral on motor function have been found in the literature, and 
while there have been reports of late-onset reduced spontaneous nocturnal activity and 
altered responses in apomorphine challenge in rats exposed to TaClo (Sontag, Heim et al. 
1995; Heim and Sontag 1997; Sontag, Lange et al. 2009), no comparable tests to those used 
here have been reported to confirm or challenge the findings of this study with regards to the 
effects of peripheral TaClo on motor function. 
 
This lack of a significant behavioural effect in our model does not necessarily mean that TCE 
and its metabolites do not show any PD linked toxicity as although the motor behaviour is a 
widely used marker of PD progression, motor deficits only manifest later in disease 
progression, with >70-80% neuronal death in the SNpc is needed before symptoms are 
detected (Hirsch, Graybiel et al. 1988; Fearnley and Lees 1991; Tillerson, Caudle et al. 2002; 
Chaudhuri, Healy et al. 2006).  Investigation of neurotransmitter levels and DA neuron 
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numbers in the SNpc need assessment to fully elucidate disease progression, and there are 
many reports of a decrease in DA levels and DA neuron numbers in the SNpc of toxin treated 
or genetically modified rodent models of PD without any apparent behavioural effect 
(Petroske, Meredith et al. 2001; Przedborski, Jackson-Lewis et al. 2001; Jackson-Lewis and 
Przedborski 2007; Hutter-Saunders, Gendelman et al. 2012). 
 
Taken together, our behavioural battery shows some possible trends towards motor 
dysfunction in the treated mice but no conclusive evidence.  This may be due to a lack of 
toxicity of the compounds to SNpc DA neurons, insufficient exposure of the toxins achieved in 
the target brain regions, variability in the tests or inadequate SNpc DA cell death reached to 
give a phenotypic deficit.  Due to lack of compliance in the rats, the behavioural studies were 
not considered relevant.  
 
5.4.3 Do Chronic TCE, Chloral, TaClo and MPTP Treatment Affect Neurotransmitter Levels? 
A LC-MS/MS method was developed to measure neurotransmitter levels in rodent brain 
homogenates as part of this study.  However, the method has not been fully characterised and 
it is not as sensitive or repeatable as needed.  One of the major flaws with the assay is a lack of 
ability to detect any DA, HVA, 5-HT or noradrenaline (NA) in the mouse, or DA, DOPAC or NA in 
the rat samples.  This could possibly be due to a problem with the solid phase extraction (SPE) 
not capturing these particular neurotransmitters efficiently or a problem with the stability of 
the compounds with them potentially degrading through the process.  In a study into its 
stability in aqueous solutions, DA was found to be rapidly oxidised in neutral or basic solutions 
(Shen and Ye 1994).  As we would expect DA to be present in the basic elute of SPE, this 
oxidation could explain the lack of ability of the assay to detect the DA, with similar effects 
possibly being seen for 5-HT and NA.  As oxidation of these compounds seems a possible cause 
of the lack of detection of the catecholamines in this assay, future studies could use an 
antioxidant mixture in the homogenates to increase stability, such as the method described in 
a study which showed the use of an antioxidant mixture of acetic acid, disodium edetate, l-
cysteine and ascorbic acid significantly improved the stability of DA, 5-HT and NA in rat brain 
homogenates (Thorré, Pravda et al. 1997).  In addition, further optimisation of the SPE method 
should be carried out to confirm or improve its efficacy. 
 
Although DA levels have not been quantified, DA metabolites DOPAC and HVA are relevant 
indicators of DA level and turnover in the brain.  In the mouse study, DOPAC levels were 
significantly reduced in TaClo treated animals and there were also trends towards reduced 
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levels in chloral and MPTP treated groups; however these were not significant possibly due to 
the variability in the assay.  The significant reduction in DOPAC following TaClo administration 
is concurrent with a report of decreased DA and DOPAC metabolism, measured by in vivo 
voltammetry with carbon fibre electrodes, in the striatum of rats intranigrally administered 
with TaClo (Grote, Clement et al. 1995).  A study reports decreased DOPAC and HVA, although 
interestingly not DA, levels in rats treated with oral TCE at doses of 1000mg/kg/day for 6 
weeks (Liu, Choi et al. 2010), which does not correlate with our finding that TCE has no 
significant effect on DOPAC levels.  However, with our chronic i.p. dosing regimen, animals are 
not exposed to the same level of TCE as in this study.  If the hypothesis that the DA 
neurotoxicity of TCE is mediated by TaClo, the reduction in DOPAC following TaClo exposure 
we report here may correlate with the work of Liu et al., with the dose of TCE they 
administered converting to TaClo and reducing DOPAC levels.  A study that also administered 
10mg/kg MPTP i.p., although in a more acute regimen, found a similar decrease in HPLC 
measured DOPAC levels in the striatum of exposed mice (Araki, Mikami et al. 2000), and a 
recent investigation to the effects of MPTP in retinal neurons found that DOPAC and HVA 
levels were reduced at even relatively low doses of acute MPTP (10mg/kg total) (Hamilton, 
Trickler et al. 2012).  These findings support the possible reduction in DOPAC seen in MPTP 
exposed animals in this study, and suggest that TaClo, and possibly MPTP, reduce levels of DA 
metabolites DOPAC in the brains of C57BL/6 mice and may lead to the development of PD. 
 
We found that 5-HT metabolite 5-HIAA was significantly increased in TaClo and MPTP exposed 
animals, and the chloral groups showed a possible, but not significant trend towards an 
increased level of 5-HIAA.  This increase in 5-HIAA could signify an increase in 5-HT turnover in 
agreement with a report of increased 5-HT levels following TaClo administration in a mouse 
model (Gerlach, Xiao et al. 1998).  The increase in 5-HIAA seen in the MPTP group correlates, 
to an extent, with a reports of increased 5-HIAA levels in the striatum, but not cortex, of MPTP 
dosed mice (Fukuda, Hara et al. 1988) and the striatum and hypothalamus of monkeys 
exposed to MPTP (Di Paolo, Bedard et al. 1986) and a study in C57BL/6 mice which found dose 
related increases in 5-HIAA, which correlated with increased motor activity (Chia, Ni et al. 
1996).  However, this is complicated by studies that found 5-HIAA is decreased in serotonergic 
neurons (Song and Ehrich 1998) and in in vivo brain microdialysate in a rat MPTP model (Ozaki, 
Nakahara et al. 1987).  As depression is a common symptom of PD, the increase in 5-HIAA and 
decrease in DOPAC seen in this study may be a relevant finding when compared with reports 
that 5-HIAA is increased and DOPAC and HVA decreased in the cerebro-spinal fluid (CSF) of  
depressed patients (Mitani, Shirayama et al. 2006), raising the possibility that the animals in 
this study may develop depression as a sign of PD caused by TaClo or MPTP exposure. 
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However, more investigations need to be carried out with regards to this, as previous studies 
have found a decrease in 5-HIAA levels in the CSF of PD patients suffering from depression 
(Kostić, Djuričić et al. 1987; Mayeux, Stern et al. 1988), and other studies reporting no change 
in CSF 5-HIAA levels in PD patients at all (Chia, Cheng et al. 1993).  A study in rats also found 
increased 5-HIAA levels in the brains of animals subjected to acute stress (De La Garza II and 
Mahoney III 2004), the increased 5-HIAA seen in our study could also possibly be due to an 
increase in stress levels due to any neurotoxic effects resulting from TaClo or MPTP exposure.  
Changes in serotonin release and turnover, and the clinical effects of these changes, in PD and 
following exposure to neurotoxins, are complicated as evidenced by the contradictory reports 
found in the literature on the subject.  More investigation is therefore needed into the changes 
reported in this study to elucidate their significance. 
 
GABA was significantly reduced in the caudate of animals exposed to chloral and TaClo but not 
those given TCE or MPTP or any group in the forebrain.  This is contrary to a report that GABA 
levels are increased following TaClo administration in rats, however, GABA levels were 
measured immediately following one acute administration by microdialysis (Gerlach, Xiao et al. 
1998), rather than  in brain tissue following 8 weeks chronic administration used in this study, 
which may explain the difference seen.  Investigations into the effects of anaesthetics on GABA 
neurotransmission found that in chloral hydrate anaesthetised rats, GABA firing rates were 
significantly decreased in the ventral tegmental area (Lee, Steffensen et al. 2001) and SNpc 
(Windels and Kiyatkin 2006), perhaps offering an explanation into the reduction in GABA seen 
with chloral exposure here; however, these studies were carried out while the animals were 
anaesthetised rather than chronically treated with chloral.  Studies into chronic low level TCE 
exposure in gerbils and rats on GABA levels found no significant effect in the hippocampus or 
cerebellum (gerbils)(Briving, Jacobson et al. 1986), or midbrain (rats) (Honma, Hasegawa et al. 
1980), consistent with the results seen here.  As GABA levels have been shown to be reduced 
in the post mortem brains of PD patients (Gerlach, Gsell et al. 1996), and GABA spiny neurons 
are thought to be part of the mechanism by which striatal DA depletion in PD leads to motor 
dysfunction, this reduction of GABA in chloral and TaClo exposed mice supports the hypothesis 
that TCE metabolites lead to development of PD.  However, in this study and other reports, 
TCE did not significantly reduce GABA levels, questioning the hypothesis. 
 
Glutamate was found to be moderately decreased in TaClo and MPTP treated mice and 
severely depleted in chloral exposed animals in both the caudate putamen and forebrain, but 
TCE treatment did not affect glutamate levels in either brain region.  As mentioned above with 
regards to GABA, a study found an immediate increase in glutamate levels in rats following 
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TaClo exposure (Gerlach, Xiao et al. 1998), in contrast to our results; however this may be 
explained by the difference in experimental protocol.  C57BL/6 mice treated with MPTP 
subchronically, although in a slightly more acute model than used in this study, showed a 
significant reduction in striatal glutamate, but acutely dosed animals showed increased levels 
(Robinson, Freeman et al. 2003; Holmer, Keyghobadi et al. 2005).  This is in agreement with 
our findings following MPTP exposure here and also offers a possible explanation for the 
previously mentioned discrepancy between the decreased glutamate seen in this chronic TaClo 
exposure model and reports of increased glutamate immediately following acute TaClo 
treatment, as both TaClo and MPTP are thought to enact their toxic mechanism by inhibition 
of mitochondrial OXPHOS Complex I.  Following chronic TCE exposure, glutamate levels were 
found to be unchanged in hippocampus, and slightly increased in cerebellum (Briving, 
Jacobson et al. 1986), but significantly decreased in the midbrain (Honma, Hasegawa et al. 
1980), suggesting regionally specific effects of the compound.  No direct reports on the effect 
of chloral on glutamate levels were found; however the effect of chloral on glutamate levels 
may be due to its general anaesthetic properties, as  volatile general anaesthetics have been 
reported to inhibit glutamate release (Bianchi, Battistin et al. 1991; Schlame and Hemmings Jr 
1995; Westphalen and Hemmings Jr 2003). 
 
In the rat study, no treatment groups showed any significant effect on any neurotransmitter 
levels in either brain region examined. A possible reason behind the lack of effect seen in the 
rat model may be due to the lack of specificity and accuracy of the LC-MS/MS model and the 
small number of animals with reportable results (as low as two individuals in some groups) 
leading to increased error in the assay.  Future development of a more acceptable 
neurotransmitter detection method may allow further investigation of this and propose a 
reason, if any, behind the lack of effect of TCE, chloral & TaClo on neurotransmitter levels in 
this study. 
 
5.4.4 Conclusions 
TCE, chloral, TaClo and MPTP were extremely well tolerated in C57BL/6 mice in this study at 
the doses and route of administration used with no overt signs of toxicity reported.  TaClo was 
also well tolerated in Wistar rats, but chloral, and, to a greater extent TCE, were less well 
tolerated and if any future studies are to be carried out in these compounds in rats a different 
route of exposure must be developed. 
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TCE and metabolites induced no significant effect on motor function as assessed by any of the 
behavioural paradigms used in this study in rats or mice, suggesting substantial degeneration 
of nigral DA neurons (>70% degeneration) has not occurred. 
 
TCE had no significant effect on neurotransmitter levels in either the caudate putamen or 
forebrain of exposed animals.  However, TaClo and TCE showed some effect on DA and 5-HT 
metabolite levels in mice, consistent with some reports of PD.  TaClo and chloral also showed 
decreases in GABA, and TaClo, MPTP, and particularly chloral, showed decreases in glutamate 
levels in mice.  The rat model showed no significant changes in any neurotransmitter in either 
brain region in any treatment group.  However, these results need to be regarded with 
caution, as the LC-MS/MS method developed to measure these levels did not show a 
consistent level of performance across the study, and could not detect certain 
neurotransmitters at all. 
 
In conclusion, this pilot study suggests C57BL/6 as a more appropriate model for investigation 
of TCE neurotoxicity, but behavioural assessment of motor function requires higher dosing or a 
longer assessment period and neurotransmitter LC-MS/MS needs more development to 
confirm results seen. 
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6.1 Introduction 
α-synuclein is a small protein found in nerve terminals that is a major constituent of Lewy 
bodies in PD (Spillantini, Schmidt et al. 1997; Spillantini, Crowther et al. 1998) and has been 
shown to be integrally important in the development of PD in MPTP treated animals (Dauer, 
Kholodilov et al. 2002).  Mutations in the gene encoding α-synuclein have also been linked 
with development of PD (Polymeropoulos, Lavedan et al. 1997; Zarranz, Alegre et al. 2004).  
One such mutation is the replacement of an alanine with a proline at position 30 in the protein 
(A30P), which was discovered in a German family (Kruger, Kuhn et al. 1998).  This mutation has 
been shown to protect α-synuclein against degradation by the autophagy and the proteasome 
(Cuervo, Stafanis et al. 2004; Song, Patel et al. 2009), which could increase levels in the cell, 
and has been shown to increase oligomerisation and fibrillation into toxic aggregates (Conway, 
Harper et al. 1998; Conway, Lee et al. 2000) which in combination would promote SNpc 
neuron degradation and aid PD progression.  A transgenic strain of C57BL/6 mice expressing 
human A30P α-synuclein has been developed in the laboratory of Prof. Philipp Kahle at the 
University of Tubingen using a pan-neuronal Thy1 promoter (Kahle, Neumann et al. 2000).  
This mouse develops a condition that mimics the development of PD with abnormal age-
dependent α-synuclein accumulation in the brainstem and an overexpression of tau 
phosphorylation seen (Kahle, Neumann et al. 2000; Frasier, Walzer et al. 2005).  Spontaneous 
locomotor activity - as assessed by distance travelled, no of rears and stereotypy counts - 
significantly increased by 12 months and motor co-ordination - as assessed by accelerating 
rotarod - significantly decreased by 17.5 months (Freichel, Neumann et al. 2007).  Although 
there are no reports of decreased DA levels or DA neuron number in this model, a related 
model from the same laboratory which expressed A30P specifically in the olfactory neurons 
under a different promoter showed a significant decrease in DA in this region and a decrease 
in DA neuron number, that was not quite significant (P=0.08) (Nuber, Petrasch-Parwez et al. 
2011). 
 
In addition to the motor deficits seen in PD, disruption to many other systems may occur, 
sometimes well before motor symptom development. Some of the major non-motor 
symptoms of PD include dementia, depression, sleep disturbance, gastrointestinal and 
autonomic dysfunction and fatigue (for review see (Chaudhuri, Healy et al. 2006)).  Dementia 
and other cognitive deficits are a major area of non-motor PD research, with many studies 
showing associations between the diseases (Cooper, Sagar et al. 1991; Dubois and Pillon 1997; 
Emre 2003; Riedel, Klotsche et al. 2008) and Dementia with Lewy Bodies (DLB) providing a 
condition that shows hallmarks of both diseases (McKeith, Mintzer et al. 2004).  The human 
A30P overexpressing mouse model previously discussed has been shown to induce cognitive 
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decline when assessed by Morris water maze, and to have α-synuclein pathology in the 
nucleus of the amygdala (Freichel, Neumann et al. 2007). 
 
While there is evidence for both genetic and environmental risk factors in development of PD, 
it has been suggested that it is likely that for most cases that there is a complex interplay 
between these influences in the causation of the disease (Warner, Schapira et al. 2003).   This 
has been supported by studies showing that drosophila expressing mutant DJ-1 are more 
susceptible to developing PD when exposed to environmental toxins such as paraquat and 
rotenone (Meulener, Whitworth et al. 2005) and that Parkin null mice are more susceptible to 
rotenone (Casarejos, Menéndez et al. 2006).  However, no increase in sensitivity to MPTP was 
seen in the human A30P overexpressing mice mentioned above (Rathke-Hartlieb, Kahle et al. 
2001), suggesting limitations to this theory. 
 
A reduction in DA neuron number in the SNpc of PD patients is characteristic in disease 
pathology (Bernheimer, Birkmayer et al. 1973).  Methods of counting DA neurons in the SNpc 
are therefore widely used as a marker of disease progression in toxin driven animal models of 
the disease (Javoy, Sotelo et al. 1976; Betarbet, Sherer et al. 2000; Khaindrava, Ershov et al. 
2010). 
 
In a previous study by Sontag et al., rats treated with 0.2mg/kg TaClo daily for 7 weeks showed 
no change in apomorphine induced locomotor activity 4 to 9 days following end of treatment, 
but showed a significant increase 12 weeks later (Sontag, Heim et al. 1995), suggesting that 
behavioural effects may take time to develop following TaClo treatment and suggesting that 
testing should extend beyond the dosing period when looking for motor deficits in TCE & TaClo 
treated animals. 
 
6.1.1 Aims 
This study aims to continue to assess the general tolerability of TCE and TaClo in both male and 
female and wild type and A30P mutant α-synuclein over expressing C57BL/6 mice and to 
explore any changes in motor or cognitive function, neurotransmitter level or SNpc neuron 
number in treated animals and to compare susceptibility between mutant and wild type.  To 
achieve this, the dosing paradigm developed in Chapter 5 will be used. More extensive 
longitudinal motor behaviour will be performed in conjunction with a measure of spatial 
learning and memory, assessment of neuron numbers by stereology post mortem and 
previously developed methods to measure neurotransmitter levels by LC-MS/MS. 
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6.2 Methods 
For detailed methods see Material and Methods (Section 2). 
 
A 2-sided power calculation was used to estimate the sample size needed for this study based 
on the Rotarod data generated in the pilot study in the TCE treated animals, the per cent 
decrease in latency (25%) needed to achieve statistical significance  in TCE exposed rats in the 
study published by Liu et al. (Liu, Choi et al. 2010), a significance level of 0.05 and a power of 
0.8.  This analysis gave a recommended sample size of 8 animals per group, so we decided to 
use a group size of 10, 5 male and 5 female, to give significant power to this study across all 
the various measurements to be used. 
 
Due to the lack of any toxicity or behavioural effects seen in C57BL/6 in the pilot study 
(Chapter 5), the doses of TCE and TaClo to be used in this study were increased 2-fold with 
animals administered 1000mg/kg TCE and 2mg/kg TaClo. 
 
Animals were dosed twice weekly for 8 weeks.  Motor behaviour assessed every 4 weeks for 
40 weeks (32 weeks after dosing completed) cognitive behaviour assessed in week 41 (32 
weeks after dosing completed)  and brains taken for stereological analysis and 
neurotransmitter assay on week 42 (34 weeks after dosing completed). 
 
6.2.1 Statistical Analysis 
For information on statistical methods see General Statistics (Sections 2.8 & 2.8.2) 
 
No significant difference between male and female groups were found in any test in any 
treatment at any time point so male and female results were combined to give n=10 in further 
analysis of results for simplification. 
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6.3 Results 
6.3.1 Genotyping 
Human A30P α-synuclein overexpressing mice were bred in house from a trio sourced from the 
laboratory of Kahle at the University of Tubingen, Germany (Kahle, Neumann et al. 2000).  To 
confirm offspring used in the study had the mutation present, DNA extracted from ear 
punches from all mice, as well as one of the trio as a positive control and a wild type C57BL/6 
negative control, was probed for the presence of the mutation by PCR using primers specific 
for the A30P mutant gene.  All A30P mice on study and the positive control had clearly defined 
bands present at 247 kbp, whereas the negative control had no band (Fig. 6.1) confirming the 
presence of the A30P mutation in the bred mice.
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Fig. 6.1 Confirmation of A30P mutant α-synuclein mutation presence DNA was isolated from ear punches taken form all mice to be used on study and the 
mutation amplified by PCR using primers specific for the insert.  Inverted images show PCR product run on a 1% agarose gel alongside molecular size marker with 
all study animals (A1M-A20M & A1F-A20F), spare animals (S1-3) and a positive control original breeder (+ve) showing a distinct band at 247 kbp that is not present 
for the negative control wild type (-ve).
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6.3.2 General Tolerance 
Olive oil, 1000mg/kg TCE and 2mg/kg TaClo i.p. at 10ml/kg were well tolerated-following 
dosing by all animals throughout the study.  No obvious signs of discomfort were displayed 
following dosing.  A proportion of animals had to be terminated due to various clinical 
abnormalities, none of which were thought to be test-compound related (see section 6.3.2.1 
below for details). 
 
6.3.2.1 Clinical Signs 
A number of clinical and behavioural abnormalities were observed in all of the treatment 
groups over the course of the study, some of which led to early termination or required 
antibiotic treatment, and are described below: 
 
Clinical signs that resulted in early termination of animals are described in Table 6.1.  Terminal 
abnormalities occurred in both A30P and wild type C57BL/6 animals and in olive oil and TCE 
treated groups but there were no clinical signs resulting in early terminations in any TaClo 
treated animals. 
 
Post mortem observations resulting from animals with no obvious clinical signs are described 
in Table 6.2.  Lesion found post mortem at study termination in one olive oil treated A30P 
animal, all other animals no observations post mortem. 
 
Clinical signs that did not result in early termination of animals are described in Table 6.3.  
Abnormalities occurred in both A30P and wild type C57BL/6 animals and in olive oil and TaClo 
treated groups but there were no clinical signs in TCE treated animals that did not result in 
early study termination. 
 
The fighting and wounds on animals A6M, A10M, W2M, & W12-15F (all treatment groups) 
occurred during a period of building work taking place directly above the animal holding room 
and are thought to be caused by the stress induced by excess noise caused by this work rather 
than related to treatment as were spread over all three treatment groups and both A30P 
mutant and wild type animals. 
 
 
 
 
Chapter 6 TCE & TaClo in wt & A30P mice 
259 
 
 
 
 
Animal Strain Treatment Study 
Day 
Clinical Sign Weight 
loss 
Post 
Mortem 
A13M A30P 10ml/kg 
olive oil 
178 Weight loss observed, weight 
maintained until day 192 when 
found dead 
10% No 
obvious 
lesions 
W1F Wild 
Type 
10ml/kg 
olive oil 
17 2cm
2
 abscess found on 
abdomen, terminated by 
anaesthesia and decapitation 
No 
significant 
White puss 
filled 
growth in 
abdomen 
W5F Wild 
type 
10ml/kg 
olive oil 
7 Severe weight loss, terminated 
by cervical dislocation 
>20% No 
obvious 
lesions 
A6M & 
A10M 
A30P 1000mg/kg 
TCE 
140 Wound to groin area, penis not 
visible and bladder appeared 
distended 
No 
significant 
Distended 
bladder 
W6M Wild 
type 
1000mg/kg 
TCE 
140 Subdued, pale extremities, 
terminated by cervical 
dislocation 
>15% No 
obvious 
lesions 
Table 6.1 Terminal clinical signs 
 
 
 
Animal Strain Treatment Study Day Clinical Sign Weight loss Post Mortem 
A9M A30P 10ml/kg 
olive oil 
Study 
termination 
No obvious 
sign 
No 
significant 
2cm diameter, white 
fluid filled cyst found 
on right kidney 
Table 6.2 Post mortem clinical signs 
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Animal Strain Treatment Study Day Clinical Sign Weight loss 
W2M Wild 
type 
1ml/kg olive oil 129 Wounds on back.  Treated with Dermasol
TM
*  t.d. for 8 days.  Wounds closed by end of treatment 
and completely healed by study day 171. 
No significant 
A15M A30P 2mg/kg TaClo 199 Scabs on back and open wound in groin/anal area.  Treated with Baytril®** 16 UI, diluted 1 in 10 in 
saline, s.c. for 9 days.  All wounds appeared healed and animal in good condition at end of 
treatment. 
No significant 
W13M Wild 
type 
2mg/kg TaClo 241 1cm
2
 abscess found on groin (possibly preputial gland).  Treated with Baytril®**, 15 UI, diluted 1 in 
10 in saline, s.c. for 5 days.  Abscess appeared reduced in size over treatment period and healed 
with animal in good condition at end of treatment. 
No significant 
W15M Wild 
type 
2mg/kg TaClo 205 Scab on both flanks.  Wounds not considered severe, animal recovered without treatment. No significant 
W11F Wild 
type 
2mg/kg TaClo 220 Tip of tail severed.  Cause unknown, possibly caught in cage lid during bedding change, no clinical 
relevance. 
No significant 
W12F 
W13F 
W14F W 
15F 
Wild 
type 
2mg/kg TaClo 73 Various levels of hair loss/barbering on head, back & forearms, continued until the end of the study.  
Skin was not broken in any cases so not considered detrimental to animals.  Thought to be due to 
stress or dominance behaviour. 
No significant 
* DermasolTM -0.05% Clobetasol Propionate BP (International Veterinary, Huntigton Beach, California, USA) 
**Baytril® -active ingredient: enrofloxacin (Bayer Animal Health, Newbury, UK) 
Table 6.3 Non-terminal clinical signs 
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6.3.2.2 Weight 
Animals in all treatment groups for both A30P mutant and wild type mice showed similar 
significant normal increase in weight over time (P<0.001, Two-way Repeated Measures 
ANOVA) with minor fluctuations over the study (Fig 6.2).  There was no significant difference in 
weight between treatment groups or significant effect of treatment over time (Two-way 
Repeated Measures ANOVA) and no treated animals showed any significantly lower weight at 
specific time points when compared to the vehicle group (Bonferroni post-test) (Fig. 6.2).  This 
data shows that TCE and TaClo at the exposure levels used in this study have no significant 
effect on either wild type or A30P mutant mouse body weight. 
 
 
 
Fig. 6.2 Effect of TCE &TaClo & MPTP on A30P α-synuclein overexpressing & wt C57BL/6 
mouse weight Weight (g) of TCE (1000mg/kg), TaClo (2mg/kg) or control (10ml/kg Olive Oil) 
treated (A) wild-type or (B) A30P C57BL/6 mice over time.  Data presented as mean (n=8-10).  
(A & B) Significant difference over time (P<0.001), No significant difference between treatment 
groups or of treatment over time, Two-Way Repeated Measures ANOVA 
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6.3.3 Behavioural Testing 
6.3.3.1 Rotarod 
To assess motor function in this study, the accelerating rotarod, a well characterised 
behavioural paradigm used in rodent models (Jones and Roberts 1968), was used prior to and 
every 4 weeks until 40 weeks after the first dose.  Animals were placed on a steadily 
accelerating rotating rod and time to fall off was recorded.  No significant differences between 
treatment groups and no significant effect of treatment over time were found in either A30P 
mutant or wild type mice, but there was a significant difference in performance over time 
across all groups in both A30P and wild type (P<0.001, P<0.05, respectively, Two-way, 
Repeated Measures ANOVA) (Fig 6.3).  No significant difference was seen at any time point for 
any treatment when compared to vehicle (Bonferroni post-test).  This data suggests that TCE & 
TaClo have no effect on longitudinal motor function in animals treated at the doses used in this 
study for 8 weeks and assessed for 40 weeks, but overexpression of A30P mutant α-synuclein 
may decrease motor function as assessed by the accelerating rotarod test. 
 
 
 
Fig. 6.3 Effect of TCE & TaClo on A30P α-synuclein overexpressing & wt C57BL/6 mouse 
motor function as assessed by the Rotarod test Average fall latency (sec) of vehicle (10ml/kg 
olive oil), TCE (100mg/kg) or TaClo (2mg/kg), treated (A) wild-type or (B) A30P C57BL/6 mice 
over time, triplicate trials.   Data presented as mean + SEM (n=8-10).  (A & B) Significant 
difference over time (P<0.05, P<0.001 respectively), No significant difference between 
treatment groups or of treatment over time, Two-Way Repeated Measures ANOVA 
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6.3.3.2 Pole Test 
The pole test, which has been developed to test more fine motor control than the accelerating 
rotarod in mice (Matsuura, Kabuto et al. 1997), was used  in this study to further assess any 
effects of the treatments on the motor skills of the animals at the same time points as the 
rotarod test.  Animals were placed face up on a pole and total time to complete trial, time to 
turn on pole, time to descend pole and number of falls per three trials recorded for all animals. 
 
There were no significant differences observed in total trial time between treatment groups or 
effect of treatment over time, but there was a significant increase in total time over the test 
period in both A30P overexpressing and wild type mice (P<0.001, P<0.01 respectively, Two-
way, Repeated Measures ANOVA) (Fig 6.4 & 5 A).  There were also no significant differences 
between vehicle and compound-treated animals at any time point (Bonferroni post-test), but 
there did seem to be a possible trend towards a consistently increased, but not statistically 
significant, time taken to complete the trial in TCE and TaClo treated mice in the A30P group 
from ~16 weeks post first dosing maintained until the end of the testing period (Fig 6.5 A). 
 
Similar results were seen when looking at time to turn and time to descend the pole, with no 
significant differences detected in turn or descent time between treatment groups and no 
significant effect of treatment over time, but a significant difference in performance was seen 
over time in A30P and wild type animals in both turning (P<0.001, Two-way, Repeated 
Measures ANOVA) (Fig 6.4 & 5 B) and descent latency (P<0.001, P<0.05 respectively, Two-way, 
Repeated Measures ANOVA) (Fig 6.4 & 5 C).  Again, no significant differences between vehicle 
and compound treated animals at any time point were seen, apart from a probably anomalous 
significant decrease in time to turn on the pole seen at week 28 in wild type TCE treated 
animals (P<0.05, Bonferroni post-test).   As in total time, there did seem to be a possible trend 
towards a consistently increased, but not statistically significant, time taken to descend in TCE 
and TaClo treated mice when looked at separately in the A30P group from ~16 weeks post first 
dosing maintained until the end of the testing period (Fig 6.5 C).  When looking at turn time, 
this possible decrease in time between treated and control groups is far less marked (Fig 6.5 
C), suggesting that the major effect seen in the difference in the time taken to complete the 
trial comes from time to descend the pole, rather than turn. 
 
No significant differences in number of falls were seen between treatment groups and no 
significant effect of treatment over time, but a significant increase was observed in both A30P 
and wild type mice over time (P<0.001, Two-way, Repeated Measures ANOVA) (Fig 6.4 & 5 D).  
No significant difference in the number of falls was detected between control and TCE & TaClo 
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treated groups at any time point tested throughout the study (Bonferroni post-test).  As seen 
with total time and descent time, there did seem to be a possible trend towards a consistently 
increased, but not statistically significant, time taken to descend in TCE and TaClo treated mice 
when looked at separately in the A30P group from ~16 weeks post first dosing maintained 
until the end of the testing period with TCE treated animals falling almost twice as often as 
controls and TaClo treated falling over 1.5 times more often (Fig 6.5 D). 
 
This data suggests that TCE & TaClo may lead to a slight but not significant decrease in 
longitudinal fine motor control in animals that overexpressed human A30P mutant α-synuclein 
treated at the doses used in this study for 8 weeks. 
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Fig. 6.4 Effect of TCE & TaClo on wild-type C57BL/6 mouse motor function as assessed by the Pole test Average (A) total time, (B) turn time (C) descent time (all 
sec) & (D) Number of falls per trial of vehicle (10ml/kg olive oil), TCE (100mg/kg) or TaClo (2mg/kg), treated wild-type C57BL/6 mice over time, triplicate trials.  
Data presented as mean + SEM (n=8-10).  (A-D) Significant difference over time (P<0.01, P<0.001, P<0.05, P<0.001, respectively), No significant difference between 
treatment groups or of treatment over time, Two-Way Repeated Measures ANOVA.  *P<0.05 when compared to vehicle at relevant time point, Bonferroni post-
test 
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Fig. 6.5 Effect of TCE & TaClo on A30P α-synuclein overexpressing C57BL/6 mouse motor function as assessed by the Pole test Average (A) total time, (B) turn 
time (C) descent time (all sec) & (D) Number of falls per trial of vehicle (10ml/kg olive oil), TCE (100mg/kg) or TaClo (2mg/kg), treated A30P α-synuclein 
overexpressing C57BL/6 mice over time, triplicate trials.  Data presented as mean + SEM (n=8-10).  (A-D) Significant difference over time (P<0.001), No significant 
difference between treatment groups or of treatment over time, Two-Way Repeated Measures ANOVA 
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6.3.3.3 Gait Analysis 
Differences in gait and stride length have been reported in animal models of PD (Tillerson, 
Caudle et al. 2002; Amende, Kale et al. 2005) and have been shown to be a relevant marker of 
decreased motor function in transgenic mice (Crawley 1999), so animal gait was analysed from 
post dose weeks 28 to 40 by painting animals’ hind paws and running them down a corridor to 
the home cage allowing measurement of stride length.  There were no significant differences 
observed in average stride length between treatment groups or effect of treatment over time 
in either A30P or wild type mice, and no significant change between trials in the A30P animals 
but there was a significant increase in total time over the test period in the wild type groups 
(P<0.001, Two-way, Repeated Measures ANOVA) (Fig 6.6 A).  There were also no significant 
differences between vehicle and compound treated animals at any timepoint apart from in the 
TCE treated animals at week 32 where a significant increase in TCE treated animals was seen 
when compared to control (P<0.01, Bonferroni post-test); however this change was not 
maintained with stride length returning to control levels by the next test in week 36, 
suggesting this potential effect is not relevant.  These results suggest that neither TCE nor 
TaClo treatment mice has any significant effect on stride length in wild type or A30P 
overexpressing mice. 
 
 
 
 
 
Fig. 6.6 Effect of TCE & TaClo on A30P α-synuclein overexpressing & wt C57BL/6 mouse 
motor function as assessed by gait analysis Average stride length (mm) of vehicle (10ml/kg 
olive oil), TCE (100mg/kg) or TaClo (2mg/kg), treated (A) wild-type or (B) A30P C57BL/6 mice 
over time, triplicate trials.   Data presented as mean + SEM (n=8-10).  (A) Significant difference 
over time (P<0.001), (B) No significant difference over time, (A & B) No significant difference 
between treatment groups or of treatment over time, Two-Way Repeated Measures ANOVA.  
**P<0.01 when compared to vehicle at relevant timepoint, Bonferroni post-test 
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6.3.3.4 Grip Strength 
As abnormalities in grip strength have been reported in mouse models of PD (Colotla, Flores et 
al. 1990) and spinal pathology has been reported in A30P overexpressing mice (Neumann, 
Kahle et al. 2002), a test of grip strength using a strain gage was used in this study (Cabe, Tilson 
et al. 1978).  There were no significant differences observed in grip strength between 
treatment groups and no significant effect of treatment over time in either A30P or wild type 
mice; however there was a significant difference over time in both groups (P<0.05, P<0.001 
respectively, Two-way, Repeated Measures ANOVA) (Fig 6.7).  There were also no significant 
differences between vehicle and compound treated animals at any timepoint in either A30P or 
wild type mice (Bonferroni post-test), with all treatment groups appearing to stay relatively 
stable throughout the study.  This data suggests that TCE and TaClo have no effect on mouse 
grip strength at the doses given in this study. 
 
 
 
 
 
Fig. 6.7 Effect of TCE & TaClo onA30P α-synuclein overexpressing & wt C57BL/6 mouse grip 
strength Average grip strength (g) of vehicle (10ml/kg olive oil), TCE (100mg/kg) or TaClo 
(2mg/kg), treated (A) wild-type or (B) A30P C57BL/6 mice over time, triplicate trials.   Data 
presented as mean + SEM (n=8-10).  (A & B) Significant difference over time (P<0.001, P<0.05 
respectively), No significant difference between treatment groups or of treatment over time, 
Two-Way Repeated Measures ANOVA 
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6.3.3.5 Barnes Maze 
As the A30P overexpressing mouse model used in this study have been shown to have 
cognitive deficits (Freichel, Neumann et al. 2007), learning and memory were assessed in this 
study.  The Barnes maze is a test used to assess spatial and learning and both short and long 
term memory using the mouse’s ability to find and remember the location of an escape box 
located under one of 20 equally spaced holes around the edge of a circular maze using visual 
cues as landmarks (Barnes 1979; Patil, Sunyer et al. 2009). 
 
Learning is assessed using the time to find the escape hole (primary latency), time to enter 
escape box (total latency), number of errors before finding escape hole (primary errors) and 
total number of errors before entering escape box (total errors) over four trials for each of 4 
consecutive days. 
 
For all four measurements of learning, for all treatment groups and in both A30P and wild type 
mice, there were no significant differences between treatment groups or of treatment over 
time but all animals significantly improved at finding and entering the escape box over the 
days of the study (P<0.001, Two-way Repeated Measures ANOVA) (Figs. 6.8 & 9).  There is a 
possible trend towards a decrease in primary latency & errors in the TaClo treated wild type 
mice on Day 1 (Fig. 6.8 A & C) and an increase in total errors in the TCE treated wild type mice 
on day 3 (Fig. 6.8 D), although these are not significant (Bonferroni post-test) and on the 
following Day are back to being the same as control levels, suggesting an anomaly.  There also 
appears to be a slight but non-significant (P=0.099, Bonferroni post-test) increase in primary 
errors in TaClo treated A30P mice when compared to vehicle treated animals on Day 4 (Fig. 6.9 
C).  This suggests TaClo may lead to a slight decrease in learning ability when combined with 
overexpression of A30P mutant human α-synuclein in C57BL/6 mice. 
 
Taken together this data suggests that TCE & TaClo, at the exposure levels used in this study, 
do not lead to significant spatial learning deficits in wild type or A30P mice; however there 
may be a suggestion that TaClo in combination with overexpressed A30P mutant human α-
synuclein may have a small effect on learning as seen by the slight increase in number of errors 
seen before the escape box was found in A30P mice exposed to TaClo on Day 4 of the learning 
phase of the Barnes maze.
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Fig. 6.8 Effect of TCE & TaClo on wt C57BL/6 mouse spatial learning as assessed by the Barnes maze  Average (A) primary latency, (B) total latency ( both sec), (C) 
primary errors & (D) total errors to find target of vehicle (10ml/kg olive oil), TCE (100mg/kg) or TaClo (2mg/kg), treated wild-type or C57BL/6 mice over time, 
quadruplicate trials.   Data presented as mean + SEM (n=8-10).  (A-D) Significant difference over time (P<0.001), No significant difference between treatment 
groups or of treatment over time, Two-Way Repeated Measures ANOVA 
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Fig. 6.9 Effect of TCE & TaClo on A30P α-synuclein overexpressing C57BL/6 mouse spatial learning as assessed by the Barnes maze  Average (A) primary latency, 
(B) total latency ( both sec), (C) primary errors & (D) total errors to find target of vehicle (10ml/kg olive oil), TCE (100mg/kg) or TaClo (2mg/kg), treated wild-type or 
C57BL/6 mice over time, quadruplicate trials.   Data presented as mean + SEM (n=8-10).  (A-D) Significant difference over time (P<0.001), No significant difference 
between treatment groups or of treatment over time, Two-Way Repeated Measures ANOVA 
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Memory is assessed in the probe phase of the Barnes maze, where on Day 5 (short term 
memory) and Day 12 (long term memory) a single trial is carried out with no escape box and 
primary latency (time to find hole where box should be), number of holes visited, first hole 
visited and number of nose pokes in each hole of the maze are recorded.  A score is also 
generated by assigning each hole a numerical value based on how far it is from the target hole 
and calculating the sum of nose pokes in each hole based on these values (e.g 3 pokes in a hole 
4 away from target gives a score of 12, 2 pokes in a hole 9 away from target a score of 18 etc.) 
to give a numerical value to performance in the test. 
 
No significant differences between treatment groups were observed in primary latency in 
either A30P or wild type animals in either short or long term tests (One-way ANOVA) (Fig 6.10).  
However in the long term memory test in theA30P animals, there was a trend towards an 
increase in primary latency with TCE and TaClo treated animals taking 24.38 & 24.20 seconds 
respectively to find the target hole as compared to 13.50 seconds taken by vehicle treated 
mice (Fig. 6.10 B(ii)) and in the short term test, vehicle treated wild type animals showed a 
trend towards an increase in primary latency in vehicle treated animals (Fig. 6.10 A(i)).  All 
other values were similar across treatment groups and between A30P and wild type animals. 
 
There were also no significant differences between treatment groups observed in number of 
holes visited in either A30P or wild type animals in either short or long term tests (One-way 
ANOVA) (Fig 6.11).  In the long term memory test in theA30P animals, there was a trend 
towards an increase in primary latency with TCE and TaClo treated animals visiting over 5 holes 
as compared to below 3 in the vehicle treated group, although this was not significant (Fig. 
6.11 B(ii)).  All other values were similar across treatment groups and between A30P and wild 
type animals. 
 
When looking at the primary hole animals visited in the trials, no significant difference in the 
median hole visited between any of the groups was observed in either short or long term 
memory probes in either the A30P mutant or wild type mice (Kruskal Wallis test) (Fig. 6.12).  In 
the A30P mutant short term memory test, the TaClo animals showed a trend towards primarily 
visiting a hole further from the target with an upper quartile of 4.5 as compared to 3 & 2 for 
vehicle and TCE respectively (Fig. 6.12 B(i)), a finding which was more pronounced in the long 
term memory test with more TCE and particularly TaClo (upper quartiles of 4 & 6.5 
respectively) treated animals showing a preference towards a first move further from the 
target hole than vehicle (2.5) (Fig. 6.12 B(ii)).  In the wild type mice short term memory probe, 
similar results were seen but with more TCE treated mice (upper quartile of 7) seeming to 
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show a slight increase in distance from target of first hole visited than vehicle or TaClo (4.5 & 5 
respectively) (Fig. 6.12 A(i)), and this trend increased in the long term memory test with less 
vehicle animals (upper quartile 3) primarily exploring farther from the target than TCE and 
TaClo (8 & 5.5 respectively) (Fig. 6.12 A(ii)).
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Fig. 6.10 Effect of TCE & TaClo on A30P α-synuclein overexpressing & wt C57BL/6 mouse spatial memory as assessed by the Barnes maze primary latency 
Average primary latency (sec) to find target hole during (i) short term (Day 5) or (ii) long term (Day 12) probe test of vehicle (10ml/kg olive oil),TCE (100mg/kg) or 
TaClo (2mg/kg), treated (A) wild-type  or (B) A30P C57BL/6 mice.   Data presented as mean + SEM (n=8-10).  No significant difference between treatment groups, 
One-Way ANOVA. 
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Fig. 6.11 Effect of TCE & TaClo on A30P α-synuclein overexpressing & wt C57BL/6 mouse spatial memory as assessed by the Barnes maze number of holes 
explored Average no. of holes explored hole during (i) short term (Day 5) or (ii) long term (Day 12) probe test of vehicle (10ml/kg olive oil),TCE (100mg/kg) or TaClo 
(2mg/kg), treated (A) wild-type  or (B) A30P C57BL/6 mice.   Data presented as mean + SEM (n=8-10).  No significant difference between treatment groups, One-
Way ANOVA. 
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Fig. 6.12 Effect of TCE & TaClo on A30P α-synuclein overexpressing & wt C57BL/6 mouse spatial memory as assessed by the Barnes maze primary hole visited 
Primary hole visited during (i) short term (Day 5) or (ii) long term (Day 12) probe test of vehicle (10ml/kg olive oil),TCE (100mg/kg) or TaClo (2mg/kg), treated (A) 
wild-type  or (B) A30P C57BL/6 mice.   Data presented as median + quartiles (n=8-10).  No significant difference between treatment groups, Kruskal Wallis test. 
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In general there were no consistent significant differences between the times TCE or TaClo 
treated animals poked any holes throughout the maze when compared to vehicle in either 
strain in short or long term probe tests (unpaired t-test) (Fig 6.13).  There were a few holes 
where a significant difference is seen; wild-type short term probe, hole +5 significantly 
increased pokes in  TCE group; A30P short term probe, hole -3 significantly decreased pokes in 
TCE group; A30P long term probe, hole +1 significantly increased pokes in TaClo group (all 
P<0.05, unpaired t-test) (Fig. 6.13).  However, these results were not consistent across groups 
and probes and were not considered relevant.  When comparing the spread of holes poked 
away from the target hole, in the A30P mice short term memory probe, the spread is relatively 
even with the vehicle mice exploring as far as seven holes from target, TCE as far as eight and 
TaClo exploring as far as the opposite hole to the target (Fig. 6.13 B(i)).  In the long term 
memory probe, there is a more significant difference in exploratory behaviour, with the vehicle 
treated group exploring no further than three holes away from the target and both the TCE 
and TaClo treated groups visiting as far as the hole opposite the target (Fig. 6.13 B(ii)).  In 
comparison, the wild type mice of all treatment groups show significantly more nose pokes 
suggesting more exploratory behaviour and all explore the entire maze in both the long and 
short term probes, with animals exploring as far as the opposite hole to the target (Fig. 6.13 A). 
 
When using the quantifiable score for each animal, similar results can be seen.  In the A30P 
short term probe there are no significant difference in the median scores between the groups 
(Kruskal Wallis test); however, the TaClo group shows a far greater upper quartile (62 
compared to 18 & 11 in vehicle and TCE respectively), suggesting some animals are exploring 
more and gaining a higher score following TaClo treatment (Fig 6.14 B (i)), correlating with the 
greater spread in holes explored seen previously.  In the A30P long term memory probe, TCE 
and TaClo treated groups show a slight, but not significant increase in median score when 
compared to vehicle (Kruskal Wallis test); however there are quite substantial increases in the 
upper quartile from 7.5 in the vehicle to 47 in the TCE treated, and 98 in TaClo treated groups 
(Fig. 6.14 B (ii)) supporting the increase in spread of nose pokes to holes a greater distance 
from the target in compound treated animals.  In wild type animals, no significant differences 
in median scores or quartile values were seen in either short or long term memory tests 
(Kruskal Wallis test) but both median and quartile values were higher in wild type groups when 
compared to A30P animals supporting the increased general exploratory behaviours in the test 
(Fig 6.14 A). 
 
In summary, there were no statistically differences between treatment groups in either strain 
in any measure of the probe test.  There is a suggestion that TCE & TaClo treated A30P animals 
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may have some deficit in long term memory with the increased exploration away from the 
target hole but this cannot be confirmed with this study.  There is also a difference between 
wild-type and A30P animals with wild-type showing far more exploratory behaviour in both 
short and long term memory probes. 
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Fig. 6.13 Effect of TCE & TaClo on A30P α-synuclein overexpressing & wt C57BL/6 mouse spatial memory as assessed by the Barnes maze nose pokes Average 
nose pokes in each hole during (i) short term (Day 5) or (ii) long term (Day 12) probe test of vehicle (10ml/kg olive oil),TCE (100mg/kg) or TaClo (2mg/kg), treated 
(A) wild-type  or (B) A30P C57BL/6 mice.   Data presented as mean + SEM (n=8-10).  *P<0.05 when compared to vehicle (unpaired t-test) 
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Fig. 6.14 Effect of TCE & TaClo on A30P α-synuclein overexpressing & wt C57BL/6 mouse spatial memory as assessed by the Barnes maze poke score Poke score 
during (i) short term (Day 5) or (ii) long term (Day 12) probe test of vehicle (10ml/kg olive oil),TCE (100mg/kg) or TaClo (2mg/kg), treated (A) wild-type  or (B) A30P 
C57BL/6 mice.   Data presented as median + quartiles (n=8-10).  No significant difference between treatment groups, Kruskal Wallis test 
Chapter 6 TCE & TaClo in wt & A30P mice 
281 
 
6.3.4 Neurotransmitter Levels 
An alteration in neurotransmitter levels has been reported in the brains of PD patients with 
reduced levels of DA a hallmark of the condition and decreases in serotonin, noradrenaline, 
and GABA (Bernheimer, Birkmayer et al. 1973; Rinne and Sonninen 1973; Riederer, Birkmayer 
et al. 1977; Scatton, Javoy-Agid et al. 1983; Gerlach, Gsell et al. 1996) with glutamate also 
linked with the pathogenesis of the disease (Blandini, Porter et al. 1996).  Neurotransmitter 
levels were therefore measured in the caudate putamen and forebrain of study animals by LC-
MS/MS post mortem. 
 
DA levels were not quantified due to limitations in the assay and neither was DOPAC in A30P 
animals; however DOPAC and HVA were measurable in wild-type animals and HVA in A30P.  
No significant changes in DOPAC or HVA levels were observed in the either brain region 
following TCE or TaClo treatment in either strain of mice (One-way ANOVA) (Fig. 6.15).  There 
were also no significant differences seen in HVA levels between wild-type and A30P animals 
(see Appendix A). 
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Fig. 6.15 Effect of TCE & TaClo on caudate putamen & forebrain DA metabolite levels in A30P 
α-synuclein overexpressing & wt C57BL/6 mice Levels of (A) DOPAC & (B) HVA in Caudate 
Putamen & Forebrain of TCE (1000mg/kg), TaClo (2mg/kg) treated and vehicle (10ml/kg olive 
oil) in wt & A30P α-synuclein overexpressing C57BL/6 mouse when assessed by LC-MS/MS.   
Data presented as mean ng/mg wet tissue from duplicate samples + SD (n=4-10).  (A & B, 
Caudate & Putamen, wt & A30P) No significant difference between groups, One-way ANOVA. 
NB. All data obtained for A30P mice for DOPAC was below limits of quantification. 
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5-HT levels could not be measured in the A30P brain samples due to assay limitations but 5-HT 
in the caudate of wild-type animals and both regions in A30P mice as well as metabolite 5-
HIAA in both brain regions of both strains were quantified.  TCE or TaClo exposure had no 
significant effect on 5-HT levels in either the caudate putamen or forebrain of wild type 
animals, or 5-HIAA levels in brain region of wild-type or A30P overexpressing mice (One-way 
ANOVA) (Fig. 6.16).  However, the levels 5-HT detected in the wild-type mice were extremely 
low (0.02-0.05ng/mg wet tissue) so may not be reliable due to assay performance.  There was 
a significant reduction in 5-HIAA seen in the A30P overexpressing mice when compared to 
wild-type (see Appendix A). 
 
 
 
 
 
Fig. 6.16 Effect of TCE & TaClo on caudate putamen & forebrain 5-HT levels in A30P α-
synuclein overexpressing & wt C57BL/6 mice Levels of (A) 5-HT & (B) 5-HIAA in Caudate 
Putamen & Forebrain of TCE (1000mg/kg), TaClo (2mg/kg) treated and vehicle (10ml/kg olive 
oil) in wt & A30P α-synuclein overexpressing C57BL/6 mouse when assessed by LC-MS/MS.   
Data presented as ng/mg wet tissue from duplicate samples + SD (n=4-8).  (A & B, Caudate & 
Putamen, wt & A30P) No significant difference between groups, One-way ANOVA. 
NB. All data obtained for A30P mice for 5-HT was below limits of quantification. 
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Levels of GABA were unchanged in the forebrain and caudate putamen following TCE and 
TaClo treatment in either mouse strain (One-way ANOVA) (Fig. 6.17 A), but were significantly 
reduced in A30P mice in comparison to wild type animals in both brain regions (see Appendix 
A).  Due to problems with the assay, glutamate could not be measured in A30P animal 
forebrain and was not significantly altered in TCE or TaClo exposed animals in either the 
caudate putamen of both strains or the forebrain of wild-type animals (One-way ANOVA) (Fig. 
6.17 B).  Glutamate levels were also unchanged between both strains in the caudate putamen 
(see Appendix A). 
 
 
 
 
 
Fig. 6.17 Effect of TCE & TaClo on caudate putamen & forebrain GABA & Glutamate levels in 
A30P α-synuclein overexpressing & wt C57BL/6 mice Levels of GABA and Glutamate in (A) 
Caudate Putamen & (B) Forebrain of TCE (1000mg/kg), TaClo (2mg/kg) treated and vehicle 
(10ml/kg olive oil) in wt & A30P α-synuclein overexpressing C57BL/6 mouse when assessed by 
LC-MS/MS.   Data presented as ng/mg wet tissue from duplicate samples + SD (n=6-10).  (A & 
B, Caudate & Putamen, wt & A30P) No significant difference between groups, One-way 
ANOVA. 
NB. All data obtained for A30P mice forebrain for glutamate bas below limits of quantification. 
 
Chapter 6 TCE & TaClo in wt & A30P mice 
285 
 
6.3.5 SNpc DA Neuron Number 
As deterioration of the DA neurons of the SNpc has been shown to be characteristic in PD 
(Bernheimer, Birkmayer et al. 1973), DA neuron number and size were assessed in this study 
using stereology.  Stereology is a method of estimating geometrical quantities that can be used 
to estimate the number and size of cells in a defined 3D region from a series of sections.  
Design based stereological analysis, such as that used in this study, has been shown to 
accurately estimate DA neuron number in the SNpc of C57BL/6 mice when compared to counts 
obtained through serial reconstruction (Baquet, Williams et al. 2009).  Stereological analysis 
has previously shown a decrease in DA neuron number in the SNpc of 6-OHDA and MPP+ 
induced animal models of PD (Sonsalla, Zeevalk et al. 2008; Healy-Stoffel, Ahmad et al. 2012).  
In this study stereology was used  to estimate the number and volume of TH-positively stained 
DA neurons in the SNpc of fixed and processed brains taken from a proportion of the animals 
used to assess behaviour. 
 
In both wild-type and A30P overexpressing animals, a significant decrease in TH-positive cells 
in the SNpc was seen in both TCE (wt: P<0.001, A30P: P<0.05, unpaired t-test) and TaClo (wt: 
P<0.001, A30P P<0.01, unpaired t-test) exposed groups, with number of cells reduced to ~50% 
vehicle in wild-type and ~70% vehicle in A30P animals (Fig. 6.18 A & 6.20).  When comparing 
TH-positive cell number between mutant and wild-type mice, A30P overexpressing animals 
showed a significant decrease in cell number to ~70% wild-type in the vehicle and ~80% in the 
TaClo treated group (both P<0.05, unpaired t-test), but there was no significant decrease in the 
TCE treated animals (P=0.30, unpaired t-test) (Fig. 6.18 A & 6.20). 
 
When looking at DA cell density in the SNpc, wild-type animals showed similar results to cell 
number, with a 50% decrease in density seen in both TCE and TaClo treated animals when 
compared to vehicle (both P<0.001, unpaired t-test) (Fig. 6.17 B & 6.19).  A30P overexpressing 
mice showed a significant difference in density between vehicle TaClo (P<0.05, unpaired t-
test), but not TCE treated groups (P=0.18, unpaired t-test) (Fig. 6.18 B & 6.20).  Looking at the 
effect of A30P overexpression, a significant decrease in TH-positive cell density to 50% of wild 
type values was seen in the vehicle treated animals (P<0.001, unpaired t-test), but no 
significant effect of the mutation was seen in either TCE or TaClo treated animals (P=0.30, 0.06 
respectively, unpaired t-test) (Fig. 6.18 B & 6.20). 
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Fig. 6.18 Effect of TCE & TaClo on SNpc DA neuron number and density in A30P α-synuclein 
overexpressing & wt C57BL/6 mice Total (A) number and (B) density of TH-positive cells in the 
SNpc of TCE (1000mg/kg), TaClo (2mg/kg) & vehicle (olive oil) treated wt & A30P 
overexpressing C57BL/6 mice assessed by stereological analysis.   Data presented as mean + SD 
(n=5/6).  ***P<0.001, **P<0.01, *P<0.05 when compared to strain vehicle, +++P<0.001, 
+P<0.05 when compared to same treatment wt group, both unpaired t-test 
 
TCE or TaClo treatment did not cause any significant change in the volume of TH-positive cells 
in the SNpc of exposed wild-type or A30P overexpressing mice when compared to vehicle 
groups (wt: P=0.38, 0.49, A30P: P=0.59, 0.57 respectively, unpaired t-test) (Fig 6.19).  A30P 
overexpressing animals appear to show an increase in DA cell volume when compared to wild-
type; however this effect is not significant in vehicle or TCE treated groups (P=0.11, 0.19, 
respectively, unpaired t-test) but is in the TaClo treated mice with A30P mutant DA cells 
reduced to 70% of wild-type (P<0.05, unpaired t-test) (Fig. 6.19). 
 
 
Fig. 6.19 Effect of TCE & TaClo on SNpc DA neuron volume in A30P α-synuclein 
overexpressing & wt C57BL/6 mice Cell body volume of TH-positive cells in the SNpc of TCE 
(1000mg/kg), TaClo (2mg/kg) & vehicle (olive oil) treated wt & A30P overexpressing C57BL/6 
mice assessed by stereological analysis.   Data presented as mean + SD (n=5/6).  +P<0.05 when 
compared to same treatment wt group, unpaired t-test. 
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Fig. 6.20 TH positive staining in TCE & TaClo treated A30P α-synuclein overexpressing & wt 
C57BL/6 mice Representative images of TH positive staining in the SNpc in Control, 500mg/kg 
TCE & 2mg/kg TaClo in or wt or A30P α-synuclein overexpressing C57BL/6  (x40 magnification, 
scale bars represent 200µm).
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6.4 Discussion 
6.4.1 Is Chronic TCE and TaClo Exposure Well Tolerated in Wild Type and A30P Mutant Human 
α-synuclein Overexpressing C57BL/6 Mice? 
During this study, wild-type and A30P mutant overexpressing C57BL/6 mice from all groups 
generally showed normal weight gain throughout the duration of the study with no significant 
differences apparent between treatment groups (Fig. 6.2), and no problems were associated 
with any i.p. dosing injections, suggesting that TCE and TaClo were relatively well tolerated at 
the doses and regimens used. 
 
However, despite this relatively good tolerance at dosing, a number of clinical and behavioural 
abnormalities were observed in all of the treatment groups over the course of the study, some 
of which led to early termination.  The most severe abnormalities that resulted in early 
termination of affected individuals - three animals with severe weight loss, one with an 
abscess in the abdomen and two with severe fighting injuries - occurred in the vehicle and TCE 
treated animals in both wild-type and A30P mutant animals, but not in any TaClo dosed mice 
(Table 6.1).  As vehicle and TCE both involved injection of olive oil, whereas TaClo was dosed in 
0.9% NaCl due to solubility properties, this suggests that these severe clinical abnormalities 
observed were likely due to the olive oil rather than test-compound related.  It has been 
reported that olive oil injection to the peritoneum of Sprague Dawley rats can lead to the 
formation of lipogranulomas, nodules of necrotic, fatty tissue associated with granulomatous 
inflammation around a deposit of an oily substance (Ramot, Ben-Eliahu et al. 2009), and, 
separately, that lipogranulomas induced in the abdomen of inbred mice can lead to systemic 
lupus erythematosus, a systemic autoimmune syndrome resulting in inflammation and tissue 
damage (Shaheen, Satoh et al. 1999).  Ingestion of olive oil has also been shown to lead to 
diarrhoea (Carper 1989), which could also have occurred if olive oil was injected into the 
intestines rather than intra-peritoneal cavity during dosing.  These suggest possible olive oil 
related explanations behind the weight loss and abscesses that led to early termination of 
animals in this study. 
 
A number of clinical signs that were not considered severe enough to need early termination 
of affected animals (Table 6.3).  One wild-type male animal in the TaClo treated group showed 
a swelling in the abdominal region, which reduced in size and healed with antibiotic treatment.  
The animal did not show any significant weight loss and appeared in good health following 
treatment and was therefore considered acceptable to continue on the study.  One animal was 
found with a lost tail tip, which was thought to be due to the tail getting caught in the cage lid 
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when bedding was changed.  One cage of TaClo treated female wild-type animals showed 
severe barbering behaviour/hair loss to back, forearms and head in four out of five animals.  
Due to the position of the hair loss and the fact that one animal was not affected; this was 
thought to be dominance behaviour by the unaffected individual rather than self-inflicted 
stress behaviour.  As no skin was broken and affected animals did not appear subdued, all 
animals were retained on study; however as this only occurred in one treatment group, this 
behaviour may have been a sign of increased stress or aggression due to TaClo administration.  
All other non-terminal signs observed were skin wounds thought to be due to fighting and 
some needed antibiotic treatment; however no wounds were considered severe enough to 
warrant study discontinuation.  These signs may could indicate increased aggressive or stress 
behaviour, but no aggression or stress behaviours were tested in this study and as they 
occurred across all groups and strains were not thought to be treatment related.  During the 
period when the majority of the fighting leading to wounds occurred, construction work was 
occurring on the floor directly above the animal holding room, with heavy machinery used 
throughout the light cycle.  The noise generated by this work may have caused increased stress 
in the animals and led to the increase in aggression observed. 
 
6.4.2 Does Chronic TCE and TaClo Exposure Affect Longitudinal Motor Function in Wild Type 
and A30P Mutant Human α-synuclein Overexpressing C57BL/6 Mice? 
As described in Section 5.4.2, the accelerating rotarod test has been used to show a decrease 
in motor function following exposure to PD-linked neurotoxins, including TCE.  No significant 
decrease in motor function was observed in TCE or TaClo or when compared to vehicle treated 
groups in wild-type or A30P mutant α-synuclein overexpressing C57BL/6 mice when assessed 
by rotarod (Fig. 6.3).  However, all groups show a slight but significant decrease in rotarod 
performance over time in both strains of mice, with A30P overexpressing animals appearing to 
markedly decrease from 20 to 24 weeks in all treatment groups (Fig. 6.3).  However, this 
apparent decrease in motor function as assessed by rotarod in the later stages of the study 
may be due to habituation to repeated testing incidences, or a weight-related decrease in 
performance that occurs at animal weights of over 40g (see Appendix B for details) rather than 
loss of DA neurons.  There were no significant differences seen between wild-type and A30P 
mutant animals in the study (see appendix A), which is consistent with reported lack of 
discrimination of motor dysfunction assessed by the rotarod in the same strain of A30P mice 
used in our study until 17months (Freichel, Neumann et al. 2007), with our study terminating 
at 13 months, and a lack of any effect in a separately generated A30P mutant α-synuclein 
mouse (Plaas, Karis et al. 2008).  Any possible effects on motor function that could have been 
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seen using this test may have been masked due to problems in consistent performance of the 
test with individual animals showing an apparent lack of drive in the test, turning around and 
walking backwards on the treadmill, or attempting to climb dividers between lanes all 
occurring during testing periods and leading to a decrease in fall latency and leading to 
increased variability of results. 
 
The pole test has previously been used to show a decline in fine motor performance following 
exposure to neurotoxins linked to development of PD (see Section 5.4.2).  In this study no 
overall difference was seen in fine motor control as assessed by any examined parameter in 
the pole test between vehicle and TCE or TaClo treated groups in either wild-type or A30P 
overexpressing animals; however in all measures of ability to complete the pole task in the 
A30P mice, the vehicle treated group show consistently slightly higher performance levels 
from week 20 onwards than both TCE and TaClo treated animals suggesting a possible trend 
towards an effect (Figs. 6.4 & 6.5).  In the wild-type animals at week 28 of the study, the TCE 
treated group showed a significantly lower time to turn on the test when compared to the 
vehicle group (Fig. 6.4 B); however, this was the only time in the study any treatment groups 
showed a significant difference from control and when taken in the context of previous and 
following measurements is thought to be anomalous.  All treatment groups of both strains 
showed a general increase in the time taken to turn and descend the pole and to complete the 
task, as well as in the number of falls recorded over the duration of the study (Figs. 6.4 & 5).  
This decrease in fine motor control seen over time may be due to habituation of the animals to 
the task as it occurred across all treatment groups and the vast majority of previous published 
uses of the pole test have not used it repeatedly, with the only published report of repeated 
use of the pole test found only repeatedly used for 3 weeks (Balkaya, Kröber et al. 2013) as 
opposed to over 40 weeks in this study. Another possible explanation could be due to a similar 
weight-related decrease in performance to that seen in the rotarod test occurring at weights 
of over 40g (see Appendix B).  The decrease in performance of all measurements observed 
appeared far more pronounced in the A30P overexpressing animals when compared to the 
wild-type; however this was not statistically significant when vehicle treated animals from the 
two strains were compared (see Appendix A), but suggests a possible trend towards 
overexpression of A30P mutant α-synuclein leading to a decrease in fine motor control in 
C57BL/6 mice.  Performance in this test showed large inter- and intra-subject variability, due in 
part to the fact that any mouse falling from the pole was assigned the maximum time of 30 
seconds, whereas instances where the task was completed reported average values of 2 to 4 
seconds to turn, 3 to 5 seconds to descent and 5 to 8 seconds in total.  This led to large 
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variability in the final data and may have masked any possible effects that TCE or TaClo 
exposure or A30P overexpression may have caused. 
 
Stride length has been reportedly decreased in MPTP treated C57BL/6 mice (Tillerson, Caudle 
et al. 2002; Amende, Kale et al. 2005) suggesting it as a relevant marker of motor dysfunction 
in PD and the strain of A30P mice used have been shown to develop an unsteady gait over 
time (Neumann, Kahle et al. 2002).  No significant differences between vehicle and TCE or 
TaClo treated groups of either wild-type or A30P overexpressing mice were observed (Fig. 6.6).  
However, in wild type animals, TCE exposed mice showed significantly longer stride length 
than vehicle in week 32 only; however, this was thought to be anomalous, as preceding and 
subsequent data points are closely matched with vehicle data.  Interestingly, wild-type mouse 
stride-length increased significantly over the course of the study, whereas A30P animals did 
not (Fig. 6.6).  A possible explanation for this could be that the wild-type animals got used to 
the test more rapidly than the mutant due to either differences in learning or anxiety and the 
later stride length was more representative, although if this was the case it would suggest not 
enough habituation and training was carried out prior to test start.  More exploration into this 
effect would be needed to ascertain any significance.  While the wild-type animals stride 
length increased and the A30P mutant did not, there were no significant differences between 
the strains (see Appendix A).  This is in contrast to findings by Plaas et al., who found 
decreased stride length in mouse with an A30P point mutation introduced into the α-synuclein 
gene at 13 months of age when compared to wild-type (Plaas, Karis et al. 2008).  However, 
they introduced the mutation into the mouse α-synuclein gene rather than introducing 
mutated human α-synuclein and effects were only seen in forepaw stride length whereas this 
study measured hind paw stride length. 
 
The data observed in this study suggests that TCE & TaClo, at the dosage used in this study, do 
not result in sufficient SNpc DA neuron degeneration to cause a significant decrease in motor 
function as assessed by the accelerating rotarod, pole test or gait analysis in either wild-type or 
A30P overexpressing C57BL/6 mice.  However, some levels of DA cell death may have occurred 
in the SNpc of treated animals without significant motor dysfunction occurring, as it has been 
shown that >70-80% cell death is required before behavioural deficits are seen (Hirsch, 
Graybiel et al. 1988; Fearnley and Lees 1991; Tillerson, Caudle et al. 2002; Chaudhuri, Healy et 
al. 2006). 
 
There was a significant decrease in grip strength over time in all treatment groups of both 
strains observed, which manifested as a sharp decrease from pre-dose to 4 weeks which then 
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levels off across the rest of the study period (Fig. 6.7).  No significant difference between TCE 
or TaClo exposed animals and vehicle was seen in either wild-type or A30P mutant animals 
(Fig. 6.7) and no significant difference was seen between wild-type or mutant animals (see 
Appendix A).  As previously mentioned in Section 5.4.2, grip strength is not thought to be a 
sensitive marker for motor dysfunction in PD, however the strain of A30P mutant α-synuclein 
overexpressing mice used have been reported to show spinal pathology, as the Thy1 promoter 
expresses the insert in the brainstem and spinal cord and a weakening of extremities 
(Neumann, Kahle et al. 2002). 
 
As spinal cord pathology has been reported to manifest as a reduction in grip strength and gait 
abnormalities (Guo, Qiu et al. 2013), and has been implicated in the development of motor 
dysfunction in the A30P mice used in this study (Neumann, Kahle et al. 2002), these symptoms 
would have been expected to be have been picked up by our grip strength and gait analysis 
tests.  However, no differences in grip strength or gait were seen between wild-type and A30P 
mutant animals in this study (Appendix A).  Although Neumann et al. describe these motor 
behavioural deficits, they do not specify the age of the mice when the symptoms manifest, 
suggesting this may only occur at ages above those reached in our study.  
 
6.4.3 Does Chronic TCE and TaClo Exposure Affect Cognitive Function in Wild Type and A30P 
Mutant Human α-synuclein Overexpressing C57BL/6 Mice? 
PD has been widely associated with cognitive decline (Taylor, Saint-Cyr et al. 1986; Cooper, 
Sagar et al. 1991; Owen, James et al. 1992) and MPTP has been shown to lead to disruption of 
cognitive behaviour in both exposed human patients (Stern, Tetrud et al. 1990) and animal 
models (Tanila, Björklund et al. 1998; Yang, He et al. 2004) .  In addition, Freichel et al. 
reported a slight decrease in cognition in A30P mutant α-synuclein overexpressing mice, as 
well as α-synucleinopathy in the central nucleus of the amygdala, an area involved in cognitive 
behaviour in mice  (Freichel, Neumann et al. 2007).  Therefore, cognitive function was assessed 
in this study as spatial learning and memory by means of the Barnes maze. 
 
Spatial learning was assessed by measuring the time and amount of errors prior to the mice 
finding and entering the target hole (Figs. 6.8 & 9).  No significant differences were found 
between TCE or TaClo treated groups when compared to control in either wild-type or A30P 
mutant animals in any parameter analysed suggesting that they have no effect on spatial 
learning.  However, when comparing wild-type and A30P mutant animals, A30P mutant 
animals took significantly longer to find the target hole on the first day of the trial.  This 
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suggests that the A30P mice took longer to realise where the hole was, or remember from the 
previous trial, suggesting a possible learning deficit when compared to wild type C57BL/6 (see 
Appendix A for details).  No differences were seen in time to enter target or errors before 
finding target, but, in contrast to the finding that A30P took longer to find the target than wild-
type animals, wild-type animals made significantly more errors prior to entering the target box 
(see Appendix A for details).  As this difference is not seen in primary errors, it suggests either 
a lack of recognition of the box when found, or a lack of drive to escape the maze in wild type 
animals when compared to A30P mutants, as more searching - and therefore errors - occurs 
between animals finding and entering the escape box. 
 
Spatial memory was assessed by measuring the time to find the target hole and the 
distribution of errors away from the target hole, on the day immediately following the end of 
training (short-term memory) and a week later (long-term memory) (Figs. 6.10-12).  No 
significant differences were seen between TCE or TaClo treated and vehicle groups in short 
term memory as in either strain.  However, a possible trend towards a decrease in time to find 
target hole in wild-type TCE and TaClo exposed animals compared to vehicle was observed 
suggesting improved short term memory.  However, this finding is not supported by other 
measures in the test and is thought to be an artefact.  
 
When looking at long term memory, there were no significant differences between treatment 
groups in either strain (Figs. 6.10-12) suggesting that TCE or TaClo exposure do not lead to long 
term special memory deficits.  There was however a trend towards an increase in time taken 
to find the first hole and number of holes visited in A30P mutant animals exposed to both TCE 
and TaClo (Fig. 6.10 & 11 B(ii)).  This is supported by the finding that TCE and TaClo exposed 
A30P mutant animals investigated a far wider range of holes from the target in the long term 
probe test, with both TCE and TaClo groups containing individuals that explored ten holes 
away from the target whereas vehicle animals explored no more than three holes from the 
target (Fig. 6.12).  The poke score calculated should reflect this, however the spread of score 
results suggests that it is a minority animals in each of the TaClo and TCE groups that 
contributed to the majority of the exploratory behaviour away from the target hole with three 
individuals in each group scoring over 50 as compared to none in the vehicle group (Fig. 6.13).  
This could be explained by differences in inter-individual susceptibility, and could still signify an 
effect of TCE and TaClo in the A30P mutant animals with a higher proportion of individuals 
showing a decrease in long term spatial memory performance in the test. 
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This lack of effect of TCE and TaClo on spatial learning and memory in the C57BL/6 mice 
correlates with a study carried out by Sontag et al., who reported no effect on learning and 
memory in rats dosed 0.2mg/kg TaClo daily for 7 week, when assessed on the COGITAT hole 
board (Sontag, Lange et al. 2007).  When combined with our results this suggests that 
TCE/TaClo do not contribute to the cognitive deficits sometimes seen in PD in rodent models.  
However, other known PD-linked neurotoxins MPTP, 6-OHDA and rotenone have been shown 
to lead to working and spatial memory impairment in a variety of behavioural tests (Da Cunha, 
Gevaerd et al. 2001; Miyoshi, Wietzikoski et al. 2002; Ferro, Bellissimo et al. 2005; Moreira, 
Barbiero et al. 2012), however, no reports of deficits in Barnes maze performance have been 
found.  The effect of A30P mutant α-synuclein expression on cognition has previously been 
looked at in a drosophila model, which found that overexpression did lead to learning and 
memory impairment; however, not to the extent than was seen following rotenone exposure 
(Yy, Jiang et al. 2011).  This could support the possible trend towards long term memory 
problems in A30P overexpressing mice exposed to the potential PD-neurotoxin TaClo 
observed. 
 
There seems to be a marked difference in performance in both the short and long term probe 
test between the wild-type and A30P mutant α-synuclein overexpressing mice, with the wild-
type animals seeming to have far more exploratory behaviour and therefore more errors than 
the A30P mutants (see Appendix A for details).  This could possibly be due to a reduction in 
activity levels between the strains, as although this was not seen in the tests of locomotor 
activity, the tests measured forced locomotor and no measures of spontaneous activity were 
examined in this study.  Another possible explanation could be due to a decreased drive to 
enter the target box in wild-type animals when compared to A30P overexpressing mice, 
possibly due to reduced anxiety,  is supported by the finding that they made significantly more 
errors before entering the box during the training phase. 
 
6.4.4 Does Chronic TCE and TaClo Exposure Affect Neurotransmitter Levels in Wild Type and 
A30P Mutant Human α-synuclein Overexpressing C57BL/6 Mice? 
As mentioned previously in section 5.4.3, the LC-MS/MS method developed to measure 
neurotransmitter levels was not found to give accurate or repeatable results during this study.  
The results in this investigation in wild-type and A30P overexpressing mice were less reliable 
than those seen in the pilot study.  This was possibly due to the use of perchloric rather than 
formic acid in the extraction process which was an attempt at a better extraction method but 
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may have resulted in oxidation of the neurotransmitters before detection, with no or 
extremely low levels of DA, 5-HT & NA detected and a 10-fold drop in levels of 5-HIAA and HVA 
in A30P mice when compared to wild-type levels.  Levels of DOPAC, glutamate and GABA were 
relatively similar to those seen in pilot mice, with all three slightly higher than pilot C57BL/6 
animals. 
 
No significant changes were found in any neurotransmitter levels in any brain region in either 
wild-type or A30P overexpressing animals, but this is thought to be related to the poor 
performance of the LC-MS/MS or SPE as previously mentioned.  If the assay is accurate, the 
fact that there were no significant differences in DA metabolite level in either strain of mice in 
this study following TaClo exposure, when treatment with half the concentration of TaClo 
significantly reduced DOPAC levels in C57BL/6 mice in the pilot study may be due to the 
differing lengths of time between dosing and brain sampling.  There have been reports that 
surviving DA neurons in neurotoxin induced rodent models of SNpc degeneration enter a state 
of hyperactivity and increase production and release of DA from terminals (Agid, Javoy et al. 
1973; Zigmond, Acheson et al. 1984) and decreased DA uptake from the synapse (Garris, 
Walker et al. 1997) compensate for the loss of  DA release from damaged neurons and 
maintain pathway integrity.  As this compensatory process takes time to develop, it may not 
have yet increased DA levels in the pilot animals as they were culled almost immediately post 
final dose, whereas the brains of the mice in this study were not sampled until 34 weeks 
following the final dose giving the animals time to compensate for the loss of DA neurons in 
the SNpc by increasing DA production. 
 
The significant increase in 5-HIAA levels seen in the TaClo treated pilot study mice is not 
repeated in this study, with no change seen in the caudate of either strain, with a possible 
decrease in 5-HIAA in the wild-type, and possible increase in A30P animals not significant.  
However, these results are not thought to be reliable with levels of 5-HIAA detected of a 
magnitude smaller than those seen in the pilot animals and the range of the results of 
individual animals suggesting that the assay was not accurate enough to draw any conclusions 
from the data generated. 
 
A moderate but significant decrease in GABA and glutamate levels were seen in pilot mice 
exposed to TaClo.  This is not replicated in this study; however, a small reduction in the levels 
of both neurotransmitters are seen in all wild type animals in both brain regions, and these 
changes are not significant, possible due to variability of the assay.  The A30P overexpressing 
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results are more fluctuating and seem less reliable making it difficult to draw conclusions from 
the data. 
Almost all neurotransmitters appeared to be present in higher amounts in the wild-type 
animals in comparison to the A30P overexpressing animals, although only significantly so in 
GABA and, particularly 5-HIAA (see Appendix A).  In the case of 5-HIAA this is almost certainly 
an assay related decrease as the levels seen in the A30P are >10 times lower than those in the 
wild-type animals and >100 times lower than those seen in the pilot study mice, an effect that 
would almost certainly have a major physiological effect. 
 
6.4.5 Does Chronic TCE and TaClo Exposure Affect SNpc DA Neurons in Wild Type and A30P 
Mutant Human α-synuclein Overexpressing C57BL/6 Mice? 
Loss of SNpc DA neurons is a hallmark of the pathology of PD (Bernheimer, Birkmayer et al. 
1973; Dickson, Braak et al. 2009; Lees, Hardy et al. 2009).  DA neuron numbers were estimated 
in the SNpc of a proportion of the animals dosed in this study by stereology and a significant 
decrease was observed in both wild-type and A30P mutant α-synuclein overexpressing mice 
exposed to TCE and TaClo when compared to those treated with olive oil vehicle (Fig. 6.18 A). 
This finding is supported by studies that found a similar decrease in DA neuron number of the 
SNpc of rats more acutely exposed to TCE (Liu, Choi et al. 2010) and animals treated with 
known PD neurotoxins MPTP and 6-OHDA (Javoy, Sotelo et al. 1976; Seniuk, Tatton et al. 
1990). 
 
A30P overexpression led to a significant drop in the SNpc DA neuron numbers in the vehicle 
and TaClo treated groups, with the effect more pronounced in the vehicle group (Fig. 6.18 A).  
Although a slight decrease in DA neuron number in the SNpc of TCE and TaClo treated A30P 
animals was seen when compared to wild-type, no major additive effect was present.  This is 
consistent with reports that sensitivity to MPTP is not increased in the same PD-associated 
Thy1 promoted A30P mutant α-synuclein transgenic mice used in this study (Rathke-Hartlieb, 
Kahle et al. 2001) nor in wild-type human α-synuclein overexpressing mice exposed to 
paraquat (Fernagut, Hutson et al. 2007).  Density of DA neurons in the SNpc is relatively 
consistent with number of neurons in all groups (Fig. 6.18 B), which is to be expected as there 
is no significant difference in SNpc volume between treatment groups or strain, as calculated 
during stereology (Fig. 2.9). 
 
Individual DA neuronal volume was measured and although there no effect of treatment was 
seen in cell volume in either strain, A30P mutant α-synuclein overexpressing animals showed a 
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trend towards larger cell volumes than wild-type in vehicle and TCE groups and were 
significantly larger in TaClo treated mice (Fig. 6.19).  This correlates with a report of enlarged 
brainstem and spinal cord neurons in similar mice, overexpressing human A53T mutant α-
synuclein (Martin, Pan et al. 2006) and possibly suggests that the cells are under stress as cell 
swelling is a morphological hallmark of necrosis (Van Cruchten and Van den Broeck 2002), 
conversely,  a post mortem study on the brains of PD patients showed no increase in SNpc cell 
volume in cells containing Lewy bodies (Gertz, Siegers et al. 1994).  The fact that no increase in 
neuron volume is observed in TCE or TaClo exposed animals of either strain, despite the fact 
that a reduction in cell number is seen seems to disagree with the hypothesis that increased 
volume is apparent in cells under stress.  This could possibly be explained as there was a long 
delay (32 weeks) between final chemical exposure and post mortem SNpc DA neuron number 
assessment and the apparent DA neuron death seen in TCE and TaClo treated mice could have 
occurred in affected cells in the weeks following dosing with remaining cells unaffected by 
chemicals that had been cleared from the system by the time the brains were sampled.  
Another possible explanation for the increase in cell volume in the A30P mice could be that 
while the mutant animals were generated from the same base strain as the wild-type animals 
used in the study, C57BL/6, the animals would have been developing down separate lines for a 
number of generations and spontaneous changes in physiology may have occurred leading to 
the development of slightly different sized neurons.  More investigation is needed into this 
possible increase in DA neuron size in A30P mice to determine the cause and relevance of the 
finding. 
 
6.4.6 Conclusions 
During this study the olive oil vehicle may have led to some early study terminations due to 
abdominal problems, and noise from construction work in close proximity to the animal 
holding rooms may have led to increased stress behaviours.  However, these signs were not 
thought to be TCE or TaClo related, suggesting both to be well tolerated in both wild-type and 
A30P overexpressing mutant strains, with no severe clinical signs thought to be related to 
exposure to either chemical. 
 
No effect of TCE or TaClo on motor or cognitive function was seen in either wild-type or A30P 
mutant α-synuclein overexpressing C57BL/6 mice in this study.  However, differences in 
performance in the Barnes maze between wild-type and mutant animals suggest possible 
effects of the mutation on spontaneous activity or anxiety levels. 
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The LC-MS/MS method used to measure neurotransmitter levels in this study gave fluctuating 
and varied results and did not appear repeatable or accurate, making it difficult to draw any 
conclusions from the data generated.  No significant changes in any neurotransmitter 
examined were found, and although differences in the levels of 5-HIAA and glutamate were 
significantly reduced in A30P overexpressing mice in comparison to wild-type, the results were 
not thought to be physiologically feasible. 
 
TCE and TaClo exposure led to significant DA neuronal loss on the SNpc of animals in both wild-
type and A30P mutant α-synuclein overexpressing C57BL/6 mice.  Cell numbers were slightly 
lower in A30P animals than wild-type; however, no additive effect of chemical exposure and 
A30P overexpression was found.  In addition, DA neurons in A30P mutant mice appeared to 
have a trend towards slightly increased cell volume when compared to wild-type, possibly 
suggesting A30P mutant α-synuclein mediates some kind of stress response in the cells. 
 
In conclusion, while TCE and TaClo did not appear to lead to any major motor or cognitive 
deficits in either wild-type or A30P mutant α-synuclein overexpressing C57BL/6 mice, exposure 
to both chemicals did lead to decreased DA neuronal number in the SNpc suggesting TCE 
exposure as a possible causative factor in development of PD.
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7.1 Introduction 
The principal aim of this thesis was to investigate whether TCE exposure could lead to SNpc DA 
neurodegeneration and the development of PD and, if so, to investigate possible mechanisms 
that led to this.  Although difficulties were encountered developing an exposure paradigm for 
TCE in in vitro studies, investigations into the administration of known metabolites of TCE 
report DA neuronal cell death, and a hypothesis of a possible mechanism behind this toxicity 
has been proposed based on the results observed.  This was supported by observations of DA 
cell death in the SNpc in in vivo models of TCE and metabolite exposure. 
 
7.2 TCE Mediated Cell Death in vitro 
Although TCE did not show any toxicity in either SH-SY5Y or midbrain neurons in the open 
system models used, high levels of toxicity were observed when SH-SY5Y were exposed to a 
high TCE atmosphere in a closed system, in agreement with similar work carried out in a 
previous thesis (Jiang 2008).  An accurate closed delivery system needs to be developed to 
investigate the toxicity of TCE more fully. 
 
TCE mediated neurotoxicity has been hypothesised to be due to the actions of its metabolite 
TaClo, formed via the intermediate compound chloral (Bringmann, Bruckner et al. 2000; 
Riederer, Foley et al. 2002; Jiang, Mutch et al. 2007).  Chloral and TaClo were both found to be 
neurotoxic to SH-SY5Y, with TaClo being ten times more potent, supporting this theory.  Both 
compounds were also found to be toxic to stem cell derived midbrain neuron cultures and 
TaClo was found to be preferentially toxic to DA neurons, implicating it in the DA specific 
pathology seen in PD.  However, chloral did not show this specificity, suggesting it may be 
cytotoxic by a separate, TaClo independent, mechanism, possibly due to the induction of 
membrane permeability through its general anaesthetic property. 
 
7.3 Proposed Mechanism of TCE Mediated Cell Death in vitro 
Investigations into the involvement of programmed cell death mechanisms in TaClo 
neurotoxicity suggest that necroptosis, and not apoptosis is the major cell death pathway 
activated by TaClo as the necroptosis inhibitor Nec-1 blocks TaClo cytotoxicity but the pan 
caspase inhibitor zVAD.fmk does not.  This is contrary to reports that apoptosis is the major 
form of cell death in DA neurons in PD (Anglade 1997; Tatton, Chalmers-Redman et al. 2003; 
Nagatsu and Sawada 2006).  As necroptosis is a relatively recently characterised process, many 
previously published studies would not have investigated its involvement in PD.  It could be 
suggested that the programmed necrotic death seen in this study could be a cell-specific 
mechanism; that SH-SY5Y preferentially die by necroptosis, possibly due to the fact they are a 
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neuroblastoma cell line which will inherently have altered cell death control.  However, flow 
cytometric investigation into cell death showed a distinct difference in phenotype between 
TaClo and a known apoptosis-inducing agent, staurosporine, with TaClo treated SH-SY5Y 
showing membrane permeability typical of necrosis and staurosporine dosed cells showing 
chromatin condensation characteristic of apoptosis. 
 
There is a possible link between necroptosis, PD toxin mediated cell death and the TaClo 
induced death in this study in the involvement of PARP activation.  It has been reported that 
PARP activation, downstream of RIP1 and upstream of AIF, was essential for necroptosis (Xu, 
Chua et al. 2010), and also that PARP activation and subsequent NAD+ and ATP depletion is 
integrally involved in MPTP toxicity in mouse brain and isolated DA neurons (Cosi and Marien 
1998; Mandir, Przedborski et al. 1999).  With the hypothesis that MPTP is thought to exert its 
effects via Complex I inhibition and ROS generation, this is interesting with regards to the 
TaClo mediated cell death reported here, as TaClo also inhibits Complex I and generates ROS 
(Chapter 4), and, in addition, is thought to depend on the over-activation of PARP, as seen in 
the effects of a PARP inhibitor on TaClo toxicity in SH-SY5Y (Fig. 3.28).  This suggests a possibly 
integral role for PARP activation due to ROS mediated DNA damage in necroptosis activation 
and cell death following TaClo exposure. 
 
A recent paper has revealed that nec-1 has the same structure as the kynurenine pathway 
enzyme IDO inhibitor methyl-thiohydantoin-tryptophan (Vandenabeele, Grootjans et al. 2013).  
This introduces doubt into the conclusions formed that TaClo leads to cell death through 
inhibition of RIP1 kinase activity and necroptosis, as the IDO inhibiting effect of nec-1 may 
contribute to the protection against TaClo seen in this study.  However, the supporting 
evidence demonstrated in this thesis - that an IDO inhibitor does not rescue cells from TaClo 
toxicity, Nec-1 does not have any effect on TaClo toxicity in RIP1 knockout MEF cells, RIP1 
knockout protects against TaClo exposure, levels of cleaved RIP1 are altered in TaClo treated 
cells, and FACS analysis shows TaClo treated cells present a necrotic phenotype - suggest that 
RIP1 kinase activity and programmed necrosis is involved in TaClo cytotoxicity. 
 
Although the evidence proposed so far suggests RIP1 mediated necrosis as the death 
mechanism involved in TaClo neurotoxicity, the fact that RIP1 knockout cells still show 
significant death suggests that other factors may contribute.  Significant death only happens at 
relatively high exposure levels, at TaClo concentrations that induce almost total inhibition of 
mitochondrial Complex I, which may induce cell death due to damage caused by excessive ROS 
production and reduced ATP synthesis. 
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This study found that oxidative stress is integrally involved in the toxic mechanism of TaClo, as 
evidenced by the almost complete reversal of TaClo neurotoxicity by the antioxidant NAC and 
increased levels of superoxide in the mitochondria following TaClo exposure.  A possible 
source for the ROS implicated was suggested by the finding that TaClo was found to be an 
inhibitor of mitochondrial OXPHOS chain Complex I, an effect that is known to generate 
superoxide (Lambert and Brand 2004), and that has been widely implicated in PD (Mizuno, 
Ohta et al. 1989; Schapira, Cooper et al. 1990).  This inhibition of Complex I is consistent with 
the effects of known PD-linked toxins rotenone and MPP+, with studies suggesting a Complex I 
IC50 for rotenone of 0.1-100nM and of 4mM for MPP+, depending on the method and system 
used (McNaught, Thull et al. 1995; Choi, Kruse et al. 2008).  The results of this thesis suggest 
that TaClo is not as potent as rotenone but more potent than MPP+, with an IC50 of 
approximately 50μM, but the dose and level of TaClo inhibition of Complex I and those that 
induce SH-SY5Y cell death strongly correlate in the study, suggesting it is a major contributory 
factor to the demonstrated TaClo neurotoxicity.  If TCE does mediate toxicity via metabolism 
to TaClo and subsequent inhibition of Complex I and oxidative damage, this may explain the 
SNpc DA neuron specific cell death and development of PD as it has been reported that MPTP 
derived oxidative stress shows higher toxicity in SN rather than mesolimbic DA neurons, 
suggesting CI inhibition is preferentially damaging to SN DA neurons (Hung and Lee 1998). 
 
This study also looked at the effect of TaClo exposure on other markers of cell damage.  An 
increase in lysosome number suggest that the activity of autophagic machinery is increased in 
cells following TaClo treatment, which may be due to an increase in protein damage by the 
ROS generated in the mitochondria via inhibition of Complex I by TaClo.  A subsequent 
increase in aggresomes (protein aggregates such as LBs) indicates that the autophagic system 
may have been overwhelmed and unable to deal with the increase in damaged cellular 
contents.  Interestingly, induction of autophagy by rapamycin increased TaClo mediated cell 
death in this model, suggesting autophagic induction may have a harmful rather than 
protective effect.  This is supported by a report that activation of mTOR, by the 
neuroprotective protein Oxi-α, and subsequent repression of autophagy in DA neurons 
protects against ROS mediated death (Choi, Kim et al. 2010).  This proposes a possible 
mechanism by which TaClo inhibits Complex I and increases ROS production, resulting in a 
harmful activation of autophagy and cell death. 
 
DNA damage would be expected to occur following an increase in cellular ROS levels, and a 
suggestion of this was seen in the response pattern exhibited following PARP inhibition and 
TaClo exposure.  At low levels of cellular stress, PARP promotes cell survival by mediating DNA 
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repair, but at higher stress levels, over activation of this pathway depletes NAD levels and 
negatively affects metabolism leading to a toxic effect of PARP.  An increased level of histone 
H2AX phosphorylation, a direct marker of DNA damage, particularly double strand breaks, was 
observed following 24 hour TaClo treatment.  DNA damage and histone H2AX phosphorylation 
have been reported in both cellular and drosophila models following oxidative stress(Zhao, 
Traganos et al. 2008; Park, Lee et al. 2012) , suggesting a link between ROS generated by TaClo 
via mitochondrial Complex I inhibition and DNA damage in the cell possibly contributing to the 
activation of cell death. 
 
Looking at the relative times that the various events linked with TaClo mediated cell death 
occurred in this study may give insight into the possible toxic mechanism; a relative timeline of 
events is summarised in fig. 7.1.  Inhibition of mitochondrial Complex I occurs almost 
immediately as TaClo comes into contact with the enzyme, indicating it as a primary event in 
the neurotoxic activity of TaClo.  However, exactly when this occurs following exposure of the 
cells to TaClo containing growth media is not immediately obvious as the time for TaClo to 
enter the cell has not been studied in this project.  A previous thesis found that 3 hours 
following TaClo administration, >90% of the compound was present in the cells as opposed to 
the media (Jiang 2008), suggesting that TaClo enters the cell rapidly and preferentially and that 
Complex I would likely be exposed to the compound relatively early following dosing.  The next 
events to occur at 4 hours post dose, with approximately 25% cell death,  are an increase in 
the autophagic marker LC-3, suggesting up regulation of autophagy, and a decrease in the 
proportion of cleaved RIP1 present, suggesting possible blockade of caspases which may 
correlate with the activation of necroptosis.  8 hours following first exposure approximately a 
third of cells are dead and a significant increase in mitochondrially located superoxide and 
expression of the mitochondrially located oxidative stress sensor molecule DJ-1 are seen, 
indicating that the mitochondria are under increased oxidative stress.  Also at 8 hours post 
dose, an increase in lysosome number is seen, suggesting that induction of autophagy has 
occurred, and a significant proportion of the cells are showing a necrotic phenotype 
characterised by increased membrane permeability.  By 12 hours almost half the original cells 
have died and the antioxidant defence molecule GSH has increased 3-fold and significant 
numbers of LB-like protein aggregates have developed, suggesting a high level of ROS induced 
cellular damage.  Finally, 24 hours after first being exposed to TaClo, over 80% of cells are dead 
and caspase-3 has been activated leading to PARP cleavage and calpain-1 has been activated 
suggesting Ca2+ handling has been disrupted.  These features suggest the cell is under extreme 
stress and is suffering terminal breakdown. 
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Fig. 7.1. Proposed time course of SH-SY5Y cell death mediated by TaClo Possible time course 
of events leading to SH-SY5Y death following TaClo exposure and corresponding levels of cell 
death.  CI inhibition happens almost immediately following exposure of TaClo to the Complex, 
followed at 4 hours by an increase in autophagic induction markers and reduced cleavage of 
RIP1, which may be an early sign of necroptosis initiation.  By 8 hours, significant numbers of 
cells are showing membrane damage, mitochondrial ROS levels are increased and expression 
of the mitochondrial ROS defence molecule DJ-1 are up-regulated and an increase in lysosome 
numbers are seen.  At 12 hours exposure, levels of the cytosolic anti-oxidant defence molecule 
GSH have increased and a substantial number of LB-like aggresomes have been formed.  By 24 
hours, almost all cells are dead and general cell disintegration as seen by the presence of 
caspase-3 and calpain activation and PARP cleavage 
 
A hypothesis generated from this evidence can suggest that TaClo enters the cell and 
mitochondria where it inhibits Complex I leading to increased ROS production which damages 
cellular contents leading to protein aggregation, increased autophagy, DNA damage and, 
ultimately, necroptotic cell death. 
 
The original hypothesis of this thesis was that TCE toxicity is mediated by metabolism to TaClo 
through chloral, a theory that was supported by the finding that both TaClo and chloral are 
toxic to SH-SY5Y, with TaClo being 10 times more potent.  However, further investigations 
found distinct differences in the effects of chloral and TaClo on cells, suggesting that while 
chloral is converted to TaClo, it may also contribute to TCE toxicity in its own right.  The first 
difference noted was that while TaClo showed specificity towards DA neurons in inducing 
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death in midbrain cultures, chloral did not have this effect.  Also, Nec-1 and NAC protected 
against TaClo neurotoxicity but had no significant effect on chloral induced cell death, 
signifying that necroptosis and oxidative stress are not integrally involved in chloral toxicity.  
Finally, when looking at inhibition of mitochondrial OXPHOS complexes, chloral was found to 
have a noticeably different profile to TaClo.  TaClo significantly inhibited Complex I at relatively 
low levels and inhibited Complexes III and IV at higher levels but had no effect on Complex II at 
all.  Chloral, in contrast, severely inhibited Complexes I and II at similar levels, and only had a 
mild effect on Complex IV. Possibly the most interesting effect was noted when trying to 
measure Complex III (coenzyme Q;cytochrome c-oxidoreductase).  The assay was not able to 
be carried out as it was found that chloral inhibited the reduction of cytochrome c, at relatively 
low doses.  This could propose a mechanism of chloral toxicity whereby it blocks the reduction 
of cytochrome c on OXPHOS, increasing ROS and decreasing ATP levels in the cell; however 
more investigation would be needed to substantiate this theory.  Any possible toxic effect of 
chloral may not be significant in TCE mediated DA cell death, as the concentrations that were 
needed to elicit any toxicity were relatively high, and in vivo, chloral is readily converted to 
TaClo which has toxic effects at doses far lower than those needed by chloral. 
 
7.4 Effects of TCE Exposure in Animal Models 
TCE, its metabolites chloral and TaClo and a positive control, MPTP, did not have any 
significant effect on motor function as assessed by a behavioural battery in either mouse or rat 
model following 8 weeks treatment.  A possible trend towards decreased fine motor control in 
the pole test was seen in mice, with all treatment groups having animals that fell from the pole 
from 4 weeks, whereas no control animals fell at any point in the study; however, this effect 
was not significant.  Although DA or HVA could not be measured directly, a reduction in DA 
metabolite DOPAC was seen in TaClo exposed mice when measured by LC-MS/MS, but no 
changes in rat brains.  All compounds were well tolerated in mice but TCE and chloral treated 
rats experienced a range of side effects, so the mouse model was considered preferential for 
further study. 
 
Wild-type and A30P mutant α-synuclein overexpressing mice were treated with TCE and TaClo 
to further assess toxic effects of the compounds and to investigate whether they have any 
synergistic effects with the effects of mutated α-synuclein.  As in the pilot study, no significant 
effects on motor function were seen in exposed animals assessed throughout 8 week dosing 
period and for the next 32 weeks.  There were possible trends towards a motor deficit in A30P 
overexpressing animals exposed to both TCE and TaClo but this potential effect was not 
significant, possibly due to inherent variability in the tests.  Cognitive function was also 
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assessed and TCE and TaClo were found to have no significant effect on spatial learning or 
memory, although a possible small effect on long term memory may have been seen in the 
extent of exploration away from the target hole seen in TCE and TaClo treated A30P 
overexpressing mice.  However, this result could not be statistically confirmed and would need 
more exploration to provide more conclusive answers. 
 
Despite the lack of any motor dysfunction, TCE and TaClo were both found to induce 
approximately 50% DA cell death in the SNpc in wild-type and A30P overexpressing mice to a 
similar degree.  These findings concur with reports that motor dysfunction does not manifest 
in PD until 70-80% of DA neurodegeneration is seen in the SNpc (Hirsch, Graybiel et al. 1988; 
Fearnley and Lees 1991; Tillerson, Caudle et al. 2002; Chaudhuri, Healy et al. 2006) and the 
lack of any conformed motor dysfunction in the test battery used in this study. 
 
The LC-MS/MS method developed to measure neurotransmitter levels in rodent brain 
homogenates did not prove to have been fully characterised and was not as sensitive or 
repeatable as needed.  The assay showed a lack of ability to detect DA or NA in any of the 
samples or 5-HT in any of the mouse samples leading to a lack of characterisation of the major 
neurotransmitters linked with PD development.  Possible reasons for the lack of consistency in 
results from the assay have been discussed in detail in Chapters 5 & 6, and this lack of 
relaibility has made it difficult to draw any conclusions from the data generated.  The most 
robust data generated appeared to be that for the pilot mice, with relative consistency in 
presence and levels of DOPAC, HVA, 5-HIAA, glutamate and GABA seen.  The results in these 
neurotransmitters were in general agreement with those reported in toxin generated PD 
models in the literature with reductions in DOPAC, as well as glutamate and GABA and an a 
increase in 5-HIAA found in TaClo treated animals.  The lack of consistently similar results in 
TCE and chloral treated animals may be due to a lack of high enough exposure reaching the 
brain, with TCE in particular known to be an extremely volatile chemical, a large proportion of 
doses of which are exhaled by exposed animals (Williams-Johnson, Eisenmann et al. 1997).  
The later study using wild-type and A30P overexpressing mice of the same strain, found similar 
levels of DA neurodegeneration in the SNpc of both TCE and TaClo dosed animals, although 
both at double the dose of the pilot, suggesting that this lack of any effect on neurotransmitter 
levels may be down to assay error and throwing doubt on the significant results seen with 
TaClo. 
When comparing neurotransmitter levels between pilot animals - which were culled almost 
immediately following the final dosing - and A30P study animals - which were kept for 34 
weeks following dosing before brains were taken for analysis - the lack of apparent accuracy of 
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the assay, especially in the wild-type animals from the A30P study, needs to be taken into 
account.  This is especially manifest in the seeming 100 fold decrease in 5-HIAA levels between 
pilot A30P animals, which, even taking differences in age into consideration, appears to be 
physiologically impossible.  Any conclusions drawn from attempting to assess this data for 
possible recovery effects therefore need to be viewed with extreme caution. 
 
Taken together, these results suggest that TCE and TaClo induce cell death in SNpc DA 
neurons, with TaClo an order of magnitude more potent, but dose regimen and time course 
examined so far have not led to an extent of cell death to reveal any motor dysfunction.  This 
agrees with the hypothesis that TCE exposure induces PD through metabolism to the DA 
neurotoxin TaClo. 
 
7.5 Study Limitations 
The major limitation of this study is a lack of a successful method of delivery of TCE into the 
cellular models used, so the majority of studies were carried out using TCE metabolites chloral 
and TaClo.  Due to the volatile nature of TCE, when cells were dosed with TCE directly in 
growth media, the TCE evaporated from the flask/plate and if the system was closed to keep 
the levels of TCE constant, cells died due to lack of oxygen.  A closed system was developed 
that allowed a consistent atmosphere of TCE to occur in a container that contained enough 
oxygen to maintain the cells; however, this model did not allow delivery of specific accurate 
doses and was impractical.  As chloral has been shown to be formed in vivo following TCE 
exposure and TaClo can be formed from chloral in man, suggesting that TaClo may be formed 
from TCE in theory, the study still has significance and value but a valid TCE delivery system 
needs to be developed to allow assessment of the effects of the solvent itself in in vitro 
models. 
 
Another limitation of the study is that it was a relatively broad investigation into the 
neurotoxicity of TCE and its metabolites and the involvement of several pathological 
mechanisms in this.  The study went into relative detail to explore the involvement of oxidative 
stress and mitochondrial OXPHOS inhibition, however further investigation into mitochondrial 
membrane potential, mitophagy, ATP turnover and cellular metabolic rate and oxidative 
defence may have been useful.  In addition, although some evidence was found for increased 
autophagy and DNA damage in TaClo mediated cell death, more in-depth investigation of 
these areas to confirm their involvement and assess the extent of the contribution they make 
to the toxicity observed would be useful; however, due to time constraints this was not 
possible. 
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The in vivo work carried out for this thesis suffered due to the limited time and extent of 
dosing that was allowed under the UK Animals (Scientific procedures) Act of 1986.  Animals 
could only be dosed twice weekly for 8 weeks, and in the main study in wild-type and A30P 
mutant α-synuclein overexpressing C57BL/6 mice, animals were not sacrificed for ex vivo 
assessment until 36 weeks later to allow time for possible development of motor dysfunction.  
This dosing paradigm is semi-chronic and temporary and therefore does not allow the constant 
low level exposure over time which best models human exposure.  It also does not allow 
examination of the development of pathology, i.e. whether cell death occurs rapidly following 
dosing or gradually over time, whether any level of recovery occurs or assessment of the 
persistence of TCE and metabolites.  This could have been assessed to some level by 
examination of the pilot study animal brains, which were sacrificed immediately following 
dosing; however time constraints did not allow this. 
  
Other limitations of this thesis include the investigations into RIP1 involvement in TaClo 
mediated cell death using MEFs rather than SH-SY5Y when looking at toxicity in RIP1 knockout 
cells.  A RIP1 knockdown SH-SY5Y cell line was generated using siRNA; however this only 
reduced RIP1 by ~50% and a stable RIP1 knockout SH-SY5Y line was not available, so MEFs 
were sourced instead.  In addition to this, in many studies investigating necroptosis, RIP3 
knockout cells are used to confirm the presence of the death pathway; however, only 
relatively low levels of RIP3 knockdown were achieved in this study and a knockout line was 
not sourced.  GSH levels were assessed in the study as a sign of increased oxidative stress.  The 
assay researched measured both total GSH and oxidised GSH, with the oxidised form of the 
protein proportional to the level of oxidative stress.  The part of the assay measuring oxidised 
GSH was not successful in this study so levels of total GSH were used to measure changes in 
expression and represent an anti-oxidative response.  Oxidised GSH can be measured by LC-
MS/MS; however, time constraints meant this was not possible in this study.  Finally, the 
behavioural tests used to assess motor function in this project were used repeatedly every 4 
weeks for 40 weeks.  These tests were designed, and are generally used, for pre and post 
treatment assessment of function immediately following training in relatively young animals, 
rather than the repeated use with relatively long gaps in aging individuals used here.  This may 
have contributed to the large variability in results seen with some animals learning how to get 
around carrying out the tasks, differences in recollection of how to carry out the task between 
animals, and size, weight and condition of animals affecting performance in the tests as the 
study progressed.  Development of motor function tests that assess the animal in more natural 
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behaviours that require less/no training would be better used in long term studies requiring 
repeated assessment. 
 
7.6 Future Directions 
The findings of this thesis have opened up various pathways of future research, both in vitro 
and in vivo: 
7.6.1 Further in vitro Investigations 
 
o A method of accurate delivery of TCE that takes into account the volatility of the 
compound, such as the one described by McDermott et al. (McDermott, Allshire et al. 
2007), is required to better explore the effects of the solvent itself rather than its 
metabolites on cellular models. 
 
o Although the toxicity studies carried out in DA model SH-SY5Y in this thesis have been 
reproduced in stem cell derived midbrain neurons, it would be useful to repeat the 
mechanistic studies carried out in SH-SY5Y in midbrain cultures as a more 
representative model for the human SNpc. 
 
o Basic studies were carried out in to the mechanism of chloral mediated cell death in 
this study; however, it would be interesting to repeat the more in-depth investigations 
carried out with regards to TaClo toxicity for this compound to see if the hypothesis 
that TCE neurotoxicity is mediated by TaClo via metabolism through chloral.  Further 
to this, it would be interesting to measure TaClo levels by LC-MS/MS in cells exposed 
to chloral to examine whether this metabolism takes place in the models used and at 
what levels TaClo is formed.  This would give insight into the involvement, directly or 
through TaClo formation, that chloral may have in TCE induced neurotoxicity. 
 
o The involvement of autophagy and DNA damage has been suggested in the toxic 
mechanism of TaClo in SH-SY5Y.  More in-depth investigation of these mechanisms 
would be useful to elucidate the importance and extent of these processes in TaClo 
neurotoxicity and whether they are causal or secondary mediators of the death seen. 
 
o The involvement of PD-linked mutated proteins such as α-synuclein, PINK1, Parkin and 
LRRK2 could be analysed to try and develop a more direct link with the disease 
through measurement of the levels of these proteins in toxin-treated cells or the 
development of transgenic cell lines with the proteins knocked-out or over-expressing 
mutant forms. 
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7.6.2 Further in/ex vivo Investigations 
o Due to animal licensing limitations, the in vivo studies carried out in this thesis were 
only able to expose animals twice weekly for 8 weeks.  A more chronic and long term 
low level exposure paradigm would be more representative of human TCE exposure 
and give a more accurate model.  A possible alternative would be oral dosing; 
however, long term oral dosing has a relatively high rate of attrition, especially in mice, 
due to the comparative ease of accidental lung dosing.  Another possible route of 
exposure would be that used by Blossom et al., where animals are exposed  to TCE at 
levels up to 0.1mg/ml in drinking water and housed in enclosed, ventilated caging 
racks to limit TCE air contamination (Blossom, Doss et al. 2008). 
 
o No significant differences were found in motor function in this thesis, despite up to 
50% loss of DA neurons in the SNpc.  In future studies it may be useful to examine non-
motor symptoms that manifest prior to motor dysfunction in PD, such as GI transit, as 
markers for the development of the condition.  In addition, future studies should use a 
more robust and consistent positive control, as reports detailing the effects of MPTP 
exposure are varied.  A model that combines chronic MPTP exposure and co-treatment 
of probenecid could be a more viable and reliable control (Petroske, Meredith et al. 
2001). 
 
o Animals from the pilot study carried out in this thesis could have pathology assessed 
by stereology to examine possible differences between animals sacrificed immediately 
on cessation and those allowed to develop for more time in the main study, as well as 
to explore effects in rats and determine whether they are consistent with those seen 
in mice.  In addition, main study and pilot brains could be assessed for the presence of 
PD markers, such as phosphorylated α-synuclein, by histopathology and regions 
involved in learning and memory assessed for any possible toxicity in these areas. 
 
o Investigations into the mechanism of TCE mediated neurotoxicity in vivo could be used 
to try and translate the in vitro findings of this thesis.  Co-treatment of Nec-1 or NAC 
with TCE and TaClo could be used to examine the involvement of necroptotic cell 
death and oxidative stress in animal models and ex vivo measurement of 
mitochondrial OXPHOS Complexes in mitochondria isolated from the SNpc of exposed 
and control animals could explore the extent, if any, of Complex inhibition. 
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o Pharmacokinetics of TCE could be explored in the animal models developed alongside 
behavioural and pathological investigations, including the formation, distribution and 
persistence of TCE and its various metabolites. 
 
7.7 Final Conclusions 
In conclusion, the main results of this thesis suggest that TCE does lead to DA 
neurodegeneration in the SNpc of exposed individuals, probably through metabolism to the 
neurotoxic compound TaClo.  The neurotoxic properties of TaClo are DA specific and relatively 
potent with death seen at µM concentrations in acute models.  The mechanism of 
neurotoxicity is hypothesised to be through inhibition of mitochondrial Complex I, inducing 
increased ROS production and damage of intracellular organelles, DNA and proteins, which in 
turn leads to the activation of autophagy and PARP activation.  This intracellular stress 
instigates RIP1 mediated necroptosis and death of the cells.  The hypothesis proposed is 
summarised in Fig 7.2.
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Fig. 7.2. Proposed 
mechanism of DA cell death 
and development of PD due 
to TCE exposure TCE enters 
the bloodstream of exposed 
individuals and is 
metabolised in the liver by 
CYP2E1 to chloral, which in 
turn combines with 
endogenous tryptamine to 
form TaClo.  TaClo can cross 
the membrane of DA 
neurons where it inhibits 
Complex I of the 
mitochondrial OXPHOS chain 
generating ROS.  The ROS 
produced then causes 
further impairment to 
mitochondria as well as 
damaging protein, and 
activating autophagy, and 
DNA, leading to PARP over 
activation and ATP depletion.  
These insults cause the cell 
to activate RIP1 mediated 
programmed necrosis 
(necroptosis) leading to loss 
of the DA neurons of the 
SNpc and development of PD
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A.1 Introduction 
Mutations in the gene encoding α-synuclein have been linked with development of PD 
(Polymeropoulos, Lavedan et al. 1997; Zarranz, Alegre et al. 2004).  One such mutation is the 
replacement of an alanine with a proline at position 30 in the protein (A30P), which was 
discovered in a German family (Kruger, Kuhn et al. 1998).  This mutation has been shown to 
protect α-synuclein against degradation by autophagy and the proteasome (Cuervo, Stafanis et 
al. 2004; Song, Patel et al. 2009), which could increase levels in the cell, and has been shown to 
increase oligomerisation and fibrillation into toxic aggregates (Conway, Harper et al. 1998; 
Conway, Lee et al. 2000) which in combination would promote SNpc neuron degradation and 
aid PD progression. 
 
A transgenic strain of C57BL/6 mice expressing human A30P mutant α-synuclein has been 
developed in the laboratory of Prof. Philipp Kahle at the University of Tubingen using a pan-
neuronal Thy1 promoter (Kahle, Neumann et al. 2000).  This mouse develops a condition that 
mimics the development of PD with abnormal age-dependent α-synuclein accumulation in the 
brainstem and an overexpression of tau phosphorylation seen (Kahle, Neumann et al. 2000; 
Frasier, Walzer et al. 2005).  Spontaneous locomotor activity, as assessed by distance travelled, 
number of rears and stereotypy counts, significantly increased by 12 months and motor co-
ordination, as assessed by accelerating rotarod, significantly decreased by 17.5 months 
(Freichel, Neumann et al. 2007).  Although there are no reports of decreased DA levels or DA 
neuron number in this model, a related model from the same laboratory which expressed 
A30P specifically in the olfactory neurons under a different promoter showed a significant 
decrease in DA in this region and a decrease in DA neuron number, that was not quite 
significant (P=0.08) (Nuber, Petrasch-Parwez et al. 2011).  This mouse model has also been 
shown to induce cognitive decline when assessed by Morris water maze, and to have α-
synuclein pathology in the nucleus of the amygdala (Freichel, Neumann et al. 2007) suggesting 
possible cognitive decline in addition to motor symptoms. 
 
A.1.1 Aims 
This study aims to assess the effect of A30P mutant α-synuclein over-expression in C57BL/6 
mice and to explore any changes in motor or cognitive function, neurotransmitter level or 
SNpc neuron number in mutant animals.  Extensive longitudinal motor behaviour will be 
performed in conjunction with a measure of spatial learning and memory and previously 
developed methods to measure neurotransmitter levels by LC-MS/MS and neuron numbers by 
stereology post mortem. 
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A.2 Methods 
For detailed methods see Material and Methods (Section 2). 
 
The analysis carried out in this study uses the vehicle (10ml/kg olive oil) treated groups of wild 
type and A30P overexpressing animals from the study described in Chapter 6 (n=8, 5 male & 3 
female wild type and 3 male & 5 female A30P due to early terminations in the study). 
 
A.2.1 Statistical Analysis 
For information on statistical methods see General Statistics (Sections 2.8 & 2.8.2). 
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A.3 Results 
A.3.1 Behavioural Testing 
A.3.1.1 Rotarod 
To assess motor function in this study, the accelerating rotarod, a well characterised 
behavioural paradigm used in rodent models (Jones and Roberts 1968), was used prior to and 
every 4 weeks until 40 weeks after the first dose.  Animals were placed on a steadily 
accelerating rotating rod and time to fall off was recorded.  There was no significant difference 
between mutant and wild type animals, but were significant differences in performance over 
time and effect of the mutation over time (P<0.01, P<0.05, respectively, Two-way Repeated 
Measures ANOVA).  However, the relevance of this difference between groups over time is 
unclear with both groups of animals fluctuating over the course of the study but the decrease 
in performance of wild-type animals from week 24, suggesting a possible motor deficit (Fig 
A.1).  No significant difference was seen at any time point for any treatment when compared 
to vehicle (Bonferroni post-test). 
 
 
Fig. A.1 Effect of A30P α-synuclein overexpression on C57BL/6 mouse motor function as 
assessed by the Rotarod testAverage fall latency (sec) of wild type and A30P α-synuclein 
overexpressing C57BL/6 mice over time, triplicate trials.   Data presented as mean + SEM (n=8).  
Significant difference over time (P<0.01) and effect of mutation over time (P<0.05), No 
significant difference between groups, Two-Way Repeated Measures ANOVA 
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A.3.1.2 Pole Test 
The pole test, which has been developed to test more fine motor control than the accelerating 
rotarod in mice (Matsuura, Kabuto et al. 1997), was used  in this study to further assess any 
effects of the treatments on the motor skills of the animals at the same time points as the 
rotarod test.  Animals were placed face up on a pole and the total time to complete trial, the 
time to turn on pole, the time to descend pole and number of falls per three trials recorded for 
all animals. 
 
There was no significant difference between mutant and wild type animals or effect of 
mutation over time in total time, time to turn, time to descend or number of falls in the pole 
test, but were significant differences over time for all parameters (P<0.001 for time to turn, 
P<0.01 for total time, descent time and number of falls, Two-way Repeated Measures ANOVA).  
Despite the lack of significant effects, A30P overexpressing mice appeared to take consistently 
longer to perform the task and to fall more often from approximately 16 weeks until the end 
of the study period (Fig. A.2).  An exception to this trend was observed at week 28 where wild 
type animal performance level dropped for one trial before returning to normal (Fig. A.2), this 
result is considered an anomaly. 
 
Taken together this data does not provide any significant evidence of a decrease in fine motor 
control in A30P overexpressing C57BL/6 animals but does suggest a possible trend towards 
decreased motor function with the consistently decreased performance of mutant animals 
compared to wild-type in the later stages of the study.
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Fig. A.2 Effect of A30P α-synuclein overexpression on C57BL/6 mouse motor function as assessed by the Pole test Average (A) total, (B) turn, (C) descent time 
(sec) & (D) number of falls of wild type and A30P α-synuclein overexpressing C57BL/6 mice over time, triplicate trials.   Data presented as mean + SEM (n=8).  (A-D) 
Significant difference over time (B, P<0.001, A, C, D, P<0.01).  (A-D) No significant difference between groups or effect of mutation over time, Two-Way Repeated 
Measures ANOVA.
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A.3.1.3 Gait Analysis 
Differences in gait and stride length have been reported in animal models of PD (Tillerson, 
Caudle et al. 2002; Amende, Kale et al. 2005), so animal gait was analysed from post dose 
weeks 28 to 40 by painting animals’ hind paws and running them down a corridor to the home 
cage allowing measurement of stride length.  There were no significant differences observed in 
average stride length between groups or effect of overexpression of A30P mutant α-synuclein 
over time, and no significant change between trials in the A30P animals but there was a 
significant change in stride length over the test period (P<0.01, Two-way, Repeated Measures 
ANOVA) (Fig A.3).  There were, in addition, also no significant differences between vehicle and 
compound-treated animals at any time point (Bonferroni post-test).  While the performance of 
the A30P overexpressing mice remained relatively constant throughout the testing period, the 
performance of the wild type mice appears to increase from 32 weeks post first dose (Fig A.3).  
These results suggest that A30P overexpression in C57BL/6 mice has no significant effect on 
stride length. 
 
 
Fig. A.3 Effect of A30P α-synuclein overexpression on C57BL/6 mouse motor function as 
assessed by gait analysisAverage stride length (mm) of wild type and A30P α-synuclein 
overexpressing C57BL/6 mice over time, triplicate trials.   Data presented as mean + SEM (n=8).  
Significant difference over time (P<0.01), no significant difference between groups, or of 
mutation over time, Two-Way Repeated Measures ANOVA 
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A.3.1.4 Grip Strength 
As abnormalities in grip strength have been reported in mouse models of PD (Colotla, Flores et 
al. 1990) and spinal pathology has been reported in A30P overexpressing mice (Neumann, 
Kahle et al. 2002), a test of grip strength using a strain gage was used in this study (Cabe, Tilson 
et al. 1978).  There were no significant differences observed in grip strength between wild type 
mice and A30P overexpressing animals and no significant effect of the mutation over time; 
however there was a significant difference over time in both groups (P<0.001, Two-way, 
Repeated Measures ANOVA) (Fig A.4).  There were also no significant differences between 
groups at any time point (Bonferroni post-test).  This data suggests that overexpression of 
A30P mutant human α-synuclein in C57BL/6 mice does not affect grip strength. 
 
 
Fig. A.4 Effect of A30P α-synuclein overexpression on C57BL/6 mouse grip strengthAverage 
grip strength (g) of wild type and A30P α-synuclein overexpressing C57BL/6 mice over time, 
triplicate trials.   Data presented as mean + SEM (n=8).  Significant difference over time 
(P<0.001), no significant difference between treatment groups, or effect of treatment and 
mutation over time, Two-Way Repeated Measures ANOVA 
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A.3.1.5 Barnes Maze 
As the A30P overexpressing mouse model used in this study have been shown to have 
cognitive deficits (Freichel, Neumann et al. 2007), learning and memory were assessed in this 
study.  The Barnes maze is a test used to assess spatial and learning and both short and long 
term memory using the mouse’s ability to find and remember the location of an escape box 
located under one of 20 equally spaced holes around the edge of a circular maze using visual 
cues as landmarks (Barnes 1979; Patil, Sunyer et al. 2009). 
Learning is assessed using the time to find the escape hole (primary latency), time to enter 
escape box (total latency), number of errors before finding escape hole (primary errors) and 
total number of errors before entering escape box (total errors) over four trials for each of four 
consecutive days. 
When comparing A30P and wild type mice, primary latency was significantly higher in A30P 
mice on Day 1 before reaching a similar level by Day 3 (Fig. 6.10 A & B).  This finding is not 
replicated when looking at total latency (Fig. 6.11 A & B) or primary errors (Fig. 6.12 A & B).  
However, when looking at the total errors, this finding is reversed, with more errors being 
made by the wild type than A30P mice before box entry.
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Fig. A.5 Effect of A30P α-synuclein overexpression on wt C57BL/6 mouse spatial learning as assessed by the Barnes maze primary & total latency & errors 
Average (A) primary & (B) total latency (sec)  and (C) primary & (D) errors to find target of wild type and A30P α-synuclein overexpressing C57BL/6 mice over time, 
quadruplicate trials.   Data presented as mean + SEM (n=8).  (A-D) Significant difference over time (P<0.001), (A) Significant difference between groups (P<0.05) 
and effect of mutation over time (P<0.001), (B) no significant difference between groups or effect of mutation over time, (C) significant difference between groups 
(P<0.05), no significant effect of mutation over time. (D) Significant effect of mutation over time (P<0.05), no significant difference between groups, Two-Way 
Repeated Measures ANOVA.  ***P<0.001, *P<0.05 when compared to wild type relevant time point, Bonferroni post-test
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Memory is assessed in the probe phase of the Barnes maze, where on Day 5 (short term 
memory) and Day 12 (long term memory) a single trial is carried out with no escape box and 
primary latency (time to find hole where box should be), first hole visited and number of nose 
pokes in each hole of the maze are recorded.  A score is also generated by assigning each hole 
a numerical value based on how far it is from the target hole and calculating the sum of nose 
pokes in each hole based on these values (e.g 3 pokes in a hole 4 away from target gives a 
score of 12, 2 pokes in a hole 9 away from target gives a score of 18 etc.) to give a numerical 
value to performance in the test. 
Investigations showed no significant difference between wild-type or A230p overexpressing 
mice in latency to find the target in either short or long term probes (unpaired t-test); 
however, wild-type mice did show a trend towards a longer time to find the target in the short 
(P=0.20) but not long term tests (Fig. A.6) 
 
 
Fig. A.6 Effect of A30P α-synuclein overexpression on C57BL/6 mouse spatial memory as 
assessed by the Barnes maze primary latency Average primary latency (sec) to find target hole 
during (A) short term (Day 5) or (B) long term (Day 12) probe test of wild type and A30P α-
synuclein overexpressing C57BL/6 mice.   Data presented as mean + SEM (n=8).  (A & B) No 
significant difference between groups, unpaired t-test. 
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When comparing the first hole visited in both probe tests between A30P mutant and wild-type 
animals, the results reflected the time taken to find the first hole with no significant difference 
between groups in either long or short term tests (un-paired t-test) with all mice in both 
groups first visiting a hole in the correct half of the maze apart from one individual in the wild-
type group short term probe which first visiting the opposite hole to the target (Fig. A.7).  This 
may offer a possible explanation for the trend towards higher primary latency observed in the 
wild-type short term test. 
 
 
 
Fig. A.7 Effect of A30P α-synuclein overexpression on C57BL/6 mouse spatial memory as 
assessed by the Barnes maze primary hole visited Primary hole visited during (A) short term 
(Day 5) or (B) long term (Day 12) probe test of wild type and A30P α-synuclein overexpressing 
C57BL/6 mice.   Data presented as median + scatter (n=8).  (A & B) No significant difference 
between groups, unpaired t-test. 
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There were significant differences between the number of times A30P animals poked their 
nose in a variety of the holes in the probe test when compared to wild-type mice in both short 
and long term probes (short, P<0.001, -1, P<0.01, T, P<0.05, +1, +8, +9, -4, -5, -9, O; long, 
P<0.01, +5, +9, -1, -5, P<0.05, T, +4, +6, -2, -4; all unpaired t-test) (Fig A.8).  When comparing 
the spread of holes poked away from the target hole, the A30P overexpressing animals appear 
to show a less exploratory behaviour than the wild-type animals with A30P animals only rarely 
exploring further than four holes from the target and never more than seven and the wild type 
mice showing  significantly more nose pokes throughout the maze suggesting more 
exploratory behaviour and exploring the entire maze in both the long and short term probes, 
with animals visiting the opposite hole to the target (Fig. A.8). 
 
 
 
 
Fig. A.8 Effect of A30P α-synuclein overexpression on C57BL/6 mouse spatial memory as 
assessed by the Barnes maze nose pokes Average nose pokes in each hole during (A) short 
term (Day 5) or (B) long term (Day 12) probe test of wild type and A30P α-synuclein 
overexpressing C57BL/6 mice.   Data presented as mean + SEM (n=8).  (A & B) ***P<0.001, 
**P<0.01, *P<0.05 when compared to wild-type, unpaired t-test. 
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When using the quantifiable score for each animal, similar results can be seen.  Wild type 
animals have significantly higher scores in both short and long term probes (P<0.01 & P<0.001 
respectively, unpaired t-test).  This finding is more pronounced in the long term probe with the 
lowest scoring wild type animal scoring over double the highest scoring A30P mouse.  This 
would seem to suggest a decrease in spatial memory in the wild-type mice when compared to 
A30P overexpressing animals but care is needed in analysing the results as the effect may be 
due to the decreased exploratory behaviour seen in the A30P animals. 
 
 
 
 
Fig. A.9 Effect of A30P α-synuclein overexpression on C57BL/6 mouse spatial memory as 
assessed by the Barnes maze poke score Poke Score during (A) short term (Day 5) or (B) long 
term (Day 12) probe test of wild type and A30P α-synuclein overexpressing C57BL/6 mice.   
Data presented as median + scatter (n=8).  ***P<0.001, **P<0.01, when compared with wild 
type, unpaired t-test. 
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A.3.2 Neurotransmitter Levels 
Although there are no reports of decreased DA levels in this model, a related model from the 
same laboratory which expressed A30P specifically in the olfactory neurons under a different 
promoter showed a significant decrease in DA in this region (Nuber, Petrasch-Parwez et al. 
2011).  Neurotransmitter levels were therefore measured in the caudate putamen and 
forebrain of study animals by LC-MS/MS post mortem. 
 
DA levels were not quantified due to limitations in the assay and neither was DOPAC in A30P 
animals; however DOPAC and HVA were measurable in wild-type animals and HVA in wild-
type.  No significant changes in DOPAC or HVA levels were observed in the either brain region 
between mouse strains in HVA (unpaired t-test) (Fig. A.10). 
 
Fig. A.10 Effect of A30P α-synuclein overexpression on caudate putamen & forebrain DA 
metabolite levels in C57BL/6 mice Levels of (A) DOPAC & (B) HVA in Caudate Putamen & 
Forebrain wt & A30P overexpressing C57BL/6 mice when assessed by LC-MS/MS.   Data 
presented as mean ng/mg wet tissue from duplicate samples + SD (n=4-10).  (A & B) No 
significant difference between groups, unpaired t-test. 
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5-HT levels could not be measured in the A30P brain samples due to assay limitations but 5-HT 
in the caudate of wild-type animals and both regions in A30P mice as well as metabolite 5-
HIAA in both brain regions of both strains were quantified.  A30P overexpression significantly 
reduced 5-HIAA levels in both the caudate putamen and forebrain of mice in this study 
(caudate, P<0.05; forebrain, P<0.01; both unpaired t-test) (Fig. A.11) 
 
 
 
Fig. A.11 Effect of A30P α-synuclein overexpression on caudate putamen & forebrain 5-HT 
levels in C57BL/6 mice Levels of (A) 5-HT & (B) 5-HIAA in Caudate Putamen & Forebrain wt & 
A30P overexpressing C57BL/6 mice when assessed by LC-MS/MS.   Data presented as mean 
ng/mg wet tissue from duplicate samples + SD (n=4-10).  (A ) No significant difference between 
groups, (B) significantly different from wt, *P<0.05, **P<0.01, all unpaired t-test. 
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Levels of GABA were significantly reduced in A30P mice in comparison to wild type animals in 
both brain regions (both P<0.01, unpaired t-test) (Fig. A.12 A).  Due to problems with the assay, 
glutamate could not be measured in A30P animal forebrain and was not significantly altered 
between strains in the caudate putamen (unpaired t-test) (Fig. A.11 B). 
 
 
 
 
Fig. A.12 Effect of A30P α-synuclein overexpression on caudate putamen & forebrain GABA 
& Glutamate levels in C57BL/6 mice Levels of (A) GABA & (B) Glutamate in Caudate Putamen 
& Forebrain wt & A30P overexpressing C57BL/6 mice when assessed by LC-MS/MS.   Data 
presented as mean ng/mg wet tissue from duplicate samples + SD (n=6-8).  (A) Significantly 
different from wt, (B)  no significant difference between groups, **P<0.01, all unpaired t-test. 
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A.3.3 SNpc DA Neuron Number 
As deterioration of the DA neurons of the SNpc has been shown to be characteristic in PD 
(Bernheimer, Birkmayer et al. 1973), DA neuron number and size were assessed in this study 
using stereology.  Stereology is a method of estimating geometrical quantities that can be used 
to estimate the number and size of cells in a defined 3D region from a series of sections.  
Design based stereological analysis, such as that used in this study, has been shown to 
accurately estimate DA neuron number in the SNpc of C57BL/6 mice when compared to counts 
obtained through serial reconstruction (Baquet, Williams et al. 2009).In this study, stereology 
was used  to estimate the number and volume of TH-positively stained DA neurons in the SNpc 
of fixed and processed brains taken from a proportion of the animals used to assess behaviour. 
 
A30P overexpressing animals appear to show an increase in DA cell volume when compared to 
wild-type; however this effect is not quite significant (P=0.11, unpaired t-test) (Fig. A.13). 
However, A30P overexpressing animals did show a significant decrease in cell number to 71% 
wild-type number (P<0.05, unpaired t-test) (Fig. A.13 A), and a significant decrease in TH-
positive cell density to 56% of wild type values (P<0.001, unpaired t-test) (Fig. A.13 B). 
 
 
Fig. A.13 Effect A30P α-synuclein overexpression on SNpc DA Neuron number, density & 
volume in C57BL/6 mice Total (A) number, (B) density & (C) cell body volume of TH-positive 
cells in the SNpc of wt & A30P overexpressing C57BL/6 mice assessed by stereology.   Data 
presented as mean + SD (n=6).  ***P<0.001, *P<0.05 when compared to wt, unpaired t-test 
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A.4 Discussion 
As described in Section 5.4.2, the accelerating rotarod test has been used to show a decrease 
in motor function following exposure to PD-linked neurotoxins.  Both wild-type and A30P 
overexpressing mice show a slight but significant decrease in rotarod performance, with A30P 
overexpressing animals appearing to markedly decrease from 24 weeks until week 40 where it 
slightly rises again (Fig. A.1).  However, this apparent decrease in motor function as assessed 
by rotarod in the later stages of the study may be due to habituation to repeated testing 
incidences, or a weight-related decrease in performance that occurs at animal weights of over 
40g (see Appendix B for details) rather than loss of DA neurons.  There were no significant 
differences seen between wild-type and A30P mutant animals in the study but, a significant 
effect of the mutation over time was seen with A30P animals showing a greater decrease in 
performance over time, suggesting an overexpression of A30P mutant α-synuclein in mice may 
lead to decreased motor performance.  This is not consistent with reported lack of 
discrimination of motor dysfunction assessed by the rotarod in the same strain of A30P mice 
used in our study until 17months (Freichel, Neumann et al. 2007), with our study terminating 
at 13 months, and a lack of any effect in a separately generated A30P mutant α-synuclein 
mouse (Plaas, Karis et al. 2008), and may be a statistical artefact as the difference in 
performance over time is not consistent or marked at any point.  The ability to discriminate 
effects on motor function using this test may have been masked due to problems in consistent 
performance of the test with individual animals showing an apparent lack of drive in the test, 
turning around and walking backwards on the treadmill, or attempting to climb dividers 
between lanes, all occurring during testing periods and leading to a decrease in fall latency and 
leading to increased variability of results. 
 
The pole test has previously been used to show a decline in fine motor performance following 
exposure to neurotoxins linked to development of PD (see Section 5.4.2).  In this study, all 
parameters of the pole test showed a significant decrease in performance over time, but no 
overall difference was seen in fine motor control for wild-type and A30P overexpressing 
groups of  animals nor any significant effect of the mutation over time (Fig. A.2).   All treatment 
groups of both strains showed a general increase in the time taken to turn and descend the 
pole and to complete the task, as well as in the number of falls recorded over the duration of 
the study (Fig. A.2).  This decrease in fine motor control seen over time may be due to 
habituation of the animals to the task as it occurred across all treatment groups and the vast 
majority of previous published uses of the pole test have not used it repeatedly, with the only 
published report of repeated use of the pole test found only repeatedly used for 3 weeks 
(Balkaya, Kröber et al. 2013) as opposed to over 40 weeks in this study. Another possible 
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explanation could be due to a similar weight-related decrease in performance to that seen in 
the rotarod test occurring at weights of over 40g (see Appendix B).  Although there were no 
significant differences in performance of the test between wild-type and mutant animals, A30P 
overexpressing mice showed consistently lower performance across all measured parameters, 
suggesting a possible trend towards overexpression of A30P mutant α-synuclein leading to a 
decrease in fine motor control in C57BL/6 mice.  Performance in this test showed large inter- 
and intra-subject variability, due in part to the fact that any mouse falling from the pole was 
assigned the maximum time of 30 seconds, whereas instances where the task was completed 
reported average values of 2 to 4 seconds to turn, 3 to 5 seconds to descent and 5 to 8 
seconds in total.  This led to large variability in the final data and may have masked any 
possible effects that A30P overexpression may have caused. 
 
The strain of A30P mice used in this study have been shown to develop an unsteady gait over 
time (Neumann, Kahle et al. 2002), suggesting a possible effect of the mutation on gait and 
stride length.  We observed no significant differences between wild-type and A30P 
overexpressing mice or effect of the mutation on stride length, but did see a significant 
difference in performance over time (Fig. A.3).  Interestingly, wild-type mouse stride length 
appeared to increase substantially over the course of the study, whereas A30P animals did not 
to the same extent (Fig. A.3).  A possible explanation for this could be that the wild-type 
animals got used to the test more rapidly than the mutant due to either differences in learning 
or anxiety and the later stride length was more representative, or due to the fact that A30P 
animal stride length was decreased relative to the normal increase in repeated tests seen with 
wild-type animals.  If this was the case it would suggest not enough habituation and training 
was carried out prior to test start and definitive conclusions cannot be drawn from the results 
seen, with and more exploration into this effect needed to ascertain any significance.  Findings 
by Plaas et al. showed significantly decreased stride length in mouse with an A30P point 
mutation introduced into the α-synuclein gene at 13 months of age when compared to wild-
type (Plaas, Karis et al. 2008).  However, they introduced the mutation into the mouse α-
synuclein gene rather than introducing mutated human α-synuclein and effects were only seen 
in forepaw stride length whereas this study measured hind paw stride length. 
 
The data observed in this study suggests that overexpression of A30P mutant α-synuclein in 
C57BL/6 does not result in sufficient SNpc DA neuron degeneration to cause a significant 
decrease in motor function as assessed by the accelerating rotarod, pole test or gait analysis.  
However, some levels of DA cell death may have occurred in the SNpc of mutant animals 
without significant motor dysfunction occurring, as it has been shown that >70-80% cell death 
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is required before behavioural deficits are seen (Hirsch, Graybiel et al. 1988; Fearnley and Lees 
1991; Tillerson, Caudle et al. 2002; Chaudhuri, Healy et al. 2006). 
 
There was a significant variation in grip strength over time in both strains observed, which 
manifested as a sharp decrease from pre-dose to 4 weeks which then generally levels off 
across the rest of the study period with periodic fluctuations occurring.  However, no 
significant difference was seen between wild-type or mutant animals nor an effect of mutation 
over time observed (Fig. A.4).  As previously mentioned in Section 5.4.2, grip strength is not 
thought to be a sensitive marker for motor dysfunction in PD; however the strain of A30P 
mutant α-synuclein overexpressing mice used have been reported to show spinal pathology, as 
the Thy1 promoter expresses the insert in the brainstem and spinal cord and causes a 
weakening of extremities (Neumann, Kahle et al. 2002).  As spinal cord pathology has been 
reported to manifest as a reduction in grip strength and gait abnormalities (Guo, Qiu et al. 
2013), and has been implicated in the development of motor dysfunction in the A30P mice 
used in this study (Neumann, Kahle et al. 2002), these symptoms would have been expected to 
be have been picked up by our grip strength and gait analysis tests.  However, no differences in 
grip strength or gait were seen between wild-type and A30P mutant animals in this study 
Although Neumann et al. describe these motor behavioural deficits, they do not specify the 
age of the mice when the symptoms manifest, suggesting this may only occur at ages above 
those reached in our study.  
 
PD has been widely associated with cognitive decline (Taylor, Saint-Cyr et al. 1986; Cooper, 
Sagar et al. 1991; Owen, James et al. 1992) and there have been reports of a slight decrease in 
cognition in A30P mutant α-synuclein overexpressing mice, as well as α-synucleinopathy in the 
central nucleus of the amygdala, an area involved in cognitive behaviour in mice  (Freichel, 
Neumann et al. 2007).  Therefore, cognitive function was assessed in this study as special 
learning and memory by means of the Barnes maze. 
 
Spatial learning was assessed by measuring the time and number of errors prior to the mice 
finding and entering the target hole (Fig. A.5).  When comparing wild-type and A30P mutant 
animals, A30P mutant animals took significantly longer to find the target hole on the first day 
of the test, and there was a significant effect of the mutation over time.  This suggests that the 
A30P mice took longer to realise where the hole was, or remember from the previous trial, 
suggesting a possible learning deficit when compared to wild type C57BL/6.  No differences 
were seen in time to enter target or errors before finding target, but, in contrast to the finding 
that A30P took longer to find the target than wild-type animals, wild-type animals made 
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significantly more errors prior to entering the target box, and the mutation had a significant 
effect over time.  As this difference is not seen in primary errors, it suggests either a lack of 
recognition of the box when found, or a lack of drive to escape the maze in wild type animals 
when compared to A30P mutants, as more searching, and therefore errors,  occurs between 
animals finding and entering the escape box. 
 
Spatial memory was assessed by measuring the time to find the target hole and the 
distribution of errors away from the target hole, on the day immediately following the end of 
training (short-term memory) and a week later (long-term memory) (Figs. A.6-9).  The effect of 
A30P mutant α-synuclein expression on cognition has previously been looked at in a 
drosophila model, which found that overexpression did lead to learning and memory 
impairment, but, not to the extent that was seen following exposure to the PD linked 
neurotoxin rotenone (Yy, Jiang et al. 2011).  When looking at primary latency and primary hole 
visited, there are no apparent differences in the long term probe, and while there may appear 
to be a trend towards increased primary latency in wild-type animals short-term probe, this 
effect is not significant and, excluding one outlier, there are no apparent differences in first 
hole visited (Fig. A.6 & 7).  There seems to be a marked difference in performance in both the 
short and long term probe test between the wild-type and A30P mutant α-synuclein 
overexpressing mice, with the wild-type animals seeming to have far more exploratory 
behaviour and therefore significantly  more errors at a number of holes than the A30P 
mutants.  As the significant increase in errors is spread across the whole maze with wild-type 
animals showing similarly significantly more pokes at holes near the target as well as opposite 
the target, this is not thought to be due to an effect on memory, but more an effect on general 
activity.  This is also manifested by a far greater spread of average pokes from the target hole 
in wild-type animals and corresponding significantly increased poke score (Fig. A.8 & 9).  This 
could possibly be due to a difference in activity levels between the strains.  Although this was 
not seen in the tests of locomotor activity, the tests measured forced locomotor and no 
measures of spontaneous activity were examined in this study.  Another possible explanation 
could be due to a decreased drive to enter the target box in wild-type animals when compared 
to A30P overexpressing mice, possibly due to reduced anxiety, which  is supported by the 
finding that they made significantly more errors before entering the box during the training 
phase.  One possible explanation for this could be that there have been reports of 
hyperactivity in DA leisioned animals (Pycock, Kerwin et al. 1980), possibly due to 
compensatory increased DA production in remaining DA neurons (Agid, Javoy et al. 1973; 
Zigmond, Acheson et al. 1984). 
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The LC-MS/MS method developed to measure neurotransmitter levels was not found to give 
accurate or repeatable results during this study.  The results in this investigation in wild-type 
and A30P overexpressing mice were less reliable than those seen in the pilot study (Chapter 5).  
This was possibly due to the use of perchloric rather than formic acid in the extraction process 
which was an attempt at a better extraction method but may have resulted in oxidation of the 
neurotransmitters before detection, with no or extremely low levels of DA, 5-HT & NA 
detected and a 10-fold drop in levels of 5-HIAA and HVA when compared to wild-type levels.  
Levels of DOPAC, glutamate and GABA were relatively similar to those seen in pilot mice study, 
with all three slightly higher than pilot C57BL/6 animals.  Almost all neurotransmitters 
appeared to be present in higher amounts in the wild-type animals in comparison to the A30P 
overexpressing animals, although only significantly so in GABA and, particularly 5-HIAA (see 
Appendix A).  In the case of 5-HIAA this is almost certainly an assay related decrease as the 
levels seen in the A30P are >10 times lower than those in the wild-type animals and >100 
times lower than those seen in the pilot study mice, an effect that would almost certainly have 
a major physiological effect. 
 
Loss of SNpc DA neurons is a hallmark of the pathology of PD (Bernheimer, Birkmayer et al. 
1973; Dickson, Braak et al. 2009; Lees, Hardy et al. 2009).  DA neuron numbers were estimated 
in the SNpc of a proportion of the animals in this study by stereology and A30P overexpression 
led a significant drop in the SNpc DA neuron numbers and density when compared to vehicle 
(Fig. A.14 A&B), suggesting that overexpression of A30P mutant α-synuclein in mouse brain 
leads to toxicity in DA neurons and possibly contributes to PD.  The fact that no motor function 
was observed despite loss of approximately 30% SNpc DA neurons is consistent with the 
widespread report that behavioural deficits are only seen when 70-80% DA neuronal loss 
occurs in the SNpc (Hirsch, Graybiel et al. 1988; Fearnley and Lees 1991; Tillerson, Caudle et al. 
2002; Chaudhuri, Healy et al. 2006). 
 
Individual DA neuronal volume was measured and A30P mutant α-synuclein overexpressing 
animals showed a trend towards larger cell volumes than wild-type, although this effect is not 
quite significant (Fig. A.13 C).  This correlates with a report of enlarged brainstem and spinal 
cord neurons in similar mice, overexpressing human A53T mutant α-synuclein (Martin, Pan et 
al. 2006) and possibly suggests that the cells are under stress as cell swelling is a morphological 
hallmark of necrosis (Van Cruchten and Van den Broeck 2002); conversely,  a post mortem 
study on the brains of PD patients showed no increase in SNpc cell volume in cells containing 
Lewy bodies (Gertz, Siegers et al. 1994).   Another possible explanation for the increase in cell 
volume in the A30P mice could be that while the mutant animals were generated from the 
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same base strain as the wild-type animals used in the study, C57BL/6, the animals would have 
been developing down separate lines for a number of generations and spontaneous changes in 
physiology may have occurred leading to the development of slightly different sized neurons.  
More investigation is needed into this possible increase in DA neuron size in A30P mice to 
determine the cause and relevance of the finding. 
 
In conclusion, although there were no significant differences in motor behaviour in the motor 
function tests, or consistent changes in neurotransmitter levels, mutant human A30P α-
synuclein did lead to a 30% decrease in SNpc DA neuronal number.  This suggests that if the 
animals survived for longer, functional and biochemical changes may occur at ages greater 
than the 14 months in this study.  In addition to this, while there were not thought to be 
significant changes in learning or memory in the Barnes maze, A30P overexpressing animals 
did appear to show a significant decrease in exploratory behaviour in the test, a finding which 
may merit more investigation. 
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B.1 Introduction 
Motor function is an important behavioural marker used to assess development of PD.  The 
rotarod test and pole test are two widely used paradigms designed to measure motor function 
in rodent models of the disease (Jones and Roberts 1968; Matsuura, Kabuto et al. 1997).  
While performing these tests over a long period in the study described in Chapter 6, it was 
noticed that as some animals grew larger, their ability to perform in the rotarod and pole tests 
decreased.  If this effect is found to be significant, it could impair the ability of the tests to 
detect motor dysfunction in the study. 
A.1.1 Aims 
This study aims to assess the effect of weight on performance in motor function tests in A30P 
mutant α-synuclein over-expressing C57BL/6 mice.  Motor behaviour will be assessed by the 
rotarod and pole tests. 
 
B.2 Methods 
For detailed methods see Material and Methods (Section 2). 
 
The analysis carried out in this study uses the A30P overexpressing animals from the study 
described in Chapter 6 (n=27, 12 male & 15 female due to early terminations in the study) and 
the data from the final behavioural assessment carried out on week 40 of the study with the 
animals in the age range 53-56 weeks and with weights ranging from 29-54g at this point. 
 
B.2.1 Statistical Analysis 
Statistical significance was analysed using SPSS Statistics 17.0 (2008) and bivariate correlation 
assessed by Pearson’s r test for correlations.  Statistical significance was considered when 
*P<0.05, **P<0.01 or ***P<0.001. 
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B.3 Results 
B.3.1 Rotarod 
The accelerating rotarod is a well characterised behavioural paradigm used to detect motor 
dysfunction in rodent models (Jones and Roberts 1968).  Animals are placed on a steadily 
accelerating rotating rod and time to fall off recorded.  The test had been carried out every 4 
weeks for 40 weeks in this study.  The results from the final testing period (Week 40) and the 
weights of the animals recorded in the same week were used to assess whether the weight of 
the animals has any effect on performance in the test. 
 
A Pearson product-moment correlation coefficient was computed to assess the relationship 
between animal bodyweight and fall latency on the accelerating rotarod. There was a 
significant negative correlation between the two variables (r = -0.616, P<0.001), which can be 
seen in the scatter plot in Fig. B.1. These results suggest that there is a relatively strong 
correlation between increased body weight and decreased performance on the rotarod. 
 
Looking at the data, it appears that the major decrease in performance occurs when the mice 
reach 40g in body weight; therefore it was decided to split the mice into two groups, those 
weighing more than 40g and those weighing less than 40g.  The Pearson product-moment 
correlation coefficient was again used to assess the relationship between animal bodyweight 
and fall latency on the rotarod in the two separate groups and found no significant correlation 
in the animals which weighed 40g or below (r=0.098, P=0.700), but there was a significant 
negative correlation between weight and rotarod performance in the animals weighing 40g 
and above (r= -0.821, P<0.01) (Fig. B.2 A).  This correlation is stronger than that seen in the 
whole group of animals and suggests that animals weighing over 40g struggle to stay on the 
accelerating rotarod. 
 
To see how this correlation relates to performance, average fall latency of animals weighing 
40g or below was compared with those weighing more than 40g.  Animals weighing over 40g 
had a significantly lower fall latency than those weighing 40g or below (P<0.01, unpaired t-
test) (Fig. B.2 B), supporting the proposal that when animals reach 40g body weight, 
performance in the accelerating rotarod test decreases as weight increases. 
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Fig. B.1 Effect of weight on performance in the Rotarod test in A30P α-synuclein 
overexpressing C57BL/6 miceAverage fall latency (sec) in rotarod test and weight (g) of A30P 
α-synuclein overexpressing C57BL/6 mice in week 40 of testing.   Data presented as mean fall 
latency from triplicate trials and weight measured in the same week (n=27) with linear fit line 
(R2 = 0.379).  Significant negative correlation between weight and average fall latency (r= -
0.616, P<0.001) Pearson’s r test for correlations. 
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Fig. B.2 Difference in performance between A30P α-synuclein overexpressing C57BL/6 mice weighing above and below 40g in the Rotarod test (A) Average fall 
latency (sec) in rotarod test and weight (g) of (i) <40g or (ii) >40g A30P α-synuclein overexpressing C57BL/6 mice in week 40 of testing.   Data presented as mean 
fall latency from triplicate trials and weight measured in the same week (n=27) with linear fit line (i, R2 = 0.01, ii, R2 = 0.674).  (i) No significant correlation between 
weight and average fall latency (r= -0.098, P=0.700).  (ii) Significant negative correlation between weight and average fall latency (r= -0.821, P<0.01) Pearson’s r 
test for correlations.  (B) Average fall latency in rotarod test of A30P α-synuclein overexpressing C57BL/6 mice weighing <40g (n=18) or >40g (n=9) in week 40 of 
testing.  Data presented as mean + SD of triplicate trials.  **P<0.01 when compared to <40g, unpaired t-test 
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B.3.2 Pole Test 
The pole test has been developed to test more fine motor control than the accelerating 
rotarod in mice (Matsuura, Kabuto et al. 1997).  Animals are placed face up on a pole and the 
total time to complete trial, time to turn on the pole, the time to descend the pole and the 
number of falls per three trials recorded.  As with the rotarod, the test had been carried out 
every 4 weeks for 40 weeks in this study and the results from the final testing period (Week 
40) and the weights of the animals recorded in the same week were used to assess whether 
the weight of the animals has any effect on performance in the test. 
 
A Pearson product-moment correlation coefficient was again used to assess the relationship 
between animal bodyweight and performance on the pole test. There was a significant positive 
correlation between the two variables when looking at total time to perform the test (r=0.704, 
P<0.001) (Fig. B.3), time to turn on the pole (r=0.718, P<0.001) (Fig. B.4), time to descend the 
pole (r=0.684, P<0.001) (Fig. B.5) and number of times an animal fell from the pole per three 
trials (r=0.685, P<0.001) (Fig. B.6).  These results suggest that there is a relatively strong 
correlation between increased body weight and increased time taken to complete the pole 
test or number of falls while taking part in the test. 
 
When the animals were separated into those weighing at most 40g and those weighing above 
40g, there was no significant correlation between weight and performance in any of the 
measures looked at in the pole test (data not shown).  However, when individual performance 
was assessed, animals weighing over 40g showed a reduction in ability to perform the test, 
with significantly increased total, turn and descent latency and number of falls seen (all 
P<0.01, unpaired t-test) (Fig. B.7).  These results suggest that increased body weight does have 
an effect on performance in the pole test; however, this seems to occur across the range of 
weights observed in this study as opposed to only above a certain weight as seen in the 
rotarod test. 
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Fig. B.3 Effect of weight on total latency in the Pole test in A30P α-synuclein overexpressing 
C57BL/6 miceAverage total latency (sec) on the pole test and weight (g) of A30P α-synuclein 
overexpressing C57BL/6 mice in week 40 of testing.  Data presented as mean fall latency from 
triplicate trials and weight measured in the same week (n=27) with linear fit line (R2 = 0.495).   
Significant positive correlation between weight and average total latency (r=0.704, P<0.001), 
Pearson’s r test for correlations. 
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Fig. B.4 Effect of weight on turn latency in the Pole test in A30P α-synuclein overexpressing 
C57BL/6 miceAverage turn latency (sec) on the pole test and weight (g) of A30P α-synuclein 
overexpressing C57BL/6 mice in week 40 of testing.  Data presented as mean turn latency from 
triplicate trials and weight measured in the same week (n=27) with linear fit line (R2 = 0.516).   
Significant positive correlation between weight and average turn latency (r=0.718, P<0.001), 
Pearson’s r test for correlations. 
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Fig. B.5 Effect of weight on descent latency in the Pole test in A30P α-synuclein 
overexpressing C57BL/6 miceAverage descent latency (sec) on the pole test and weight (g) of 
A30P α-synuclein overexpressing C57BL/6 mice in week 40 of testing.  Data presented as mean 
total latency from triplicate trials and weight measured in the same week (n=27) with linear fit 
line (R2 = 0.468).   Significant positive correlation between weight and average descent latency 
(r=0.684, P<0.001), Pearson’s r test for correlations. 
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 Fig. B.6 Effect of weight on number of falls in the Pole test in A30P α-synuclein 
overexpressing C57BL/6 miceAverage number of falls on the pole test and weight (g) of A30P 
α-synuclein overexpressing C57BL/6 mice in week 40 of testing.  Data presented as mean 
number of falls from triplicate trials and weight measured in the same week (n=27) with linear 
fit line (R2 = 0.469).   Significant positive correlation between weight and average number of 
falls (r=0.685, P<0.001), Pearson’s r test for correlations 
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Fig. B.7 Difference in Performance between A30P α-synuclein overexpressing C57BL/6 mice weighing above and below 40g in the Pole test Average (A) total, (B) 
turn & (C) descent latency and (D) number of falls in pole test of A30P α-synuclein overexpressing C57BL/6 mice weighing <40g (n=18) or >40g (n=9) in week 40 of 
testing.  Data presented as mean + SD of triplicate trials.  **P<0.01 when compared to <40g, unpaired t-test 
Appendix B Effect of Weight on Motor Performance in mice 
348 
 
B.4 Discussion 
This study shows a relatively strong correlation between increased weight and decreased 
performance in motor function assessed by the accelerating rotarod.  This effect seems to 
occur only when the mice weigh 40g and performance decreases relative to weight gain from 
this point as weight gets higher.  Possible reasons for this could be due to an increase in 
abdomen size occurring due to the extra body weight obstructing the ability of the animal to 
stay on the rotating drum, more effort required to keep a heavier body stable and moving 
throughout the test, or the weight gain could be a sign of a general reduction in athletic 
condition of the animal reducing ability in the test rather than the extra weight itself reducing 
performance. 
 
In the pole test, there is also a general correlation between increased weight and decreased 
performance in the test across all measures (turn time, descent time, total time and number of 
falls), suggesting that weight negatively affects pole test performance.  This result was seen 
across the entire weight range of animals in the study (29-54g), unlike the results seen in the 
rotarod where the effect on performance only occurred at 40g and above.  This may mean that 
the pole test is more susceptible to be effected by weight gain, possibly due to the fact that it 
is a more difficult task requiring more fine motor control that the rotarod, or may just be due 
to the fact that errors on the pole test are given a maximum score, punishing errors more 
strictly than in the rotarod and greatly increasing the variability in the test.  These effects in 
the pole test may be due to the increased strength needed to support the weight of larger 
animals as they manoeuvre on the pole or, as in the rotarod, awkwardness in performing the 
test due to greater body/abdomen size. 
 
A major limitation with these findings is that they were only examined in human A30P mutant 
α-synuclein overexpressing animals as these animals were the ones that experienced the large 
increases in weight that were shown to affect performance.  Whether this weight gain 
correlates with decreased motor function due to the α-synuclein overexpression or some 
other effect of the mutation may be the cause of the results seen and the study would need 
repeating in a more controlled manner using wild-type mice to confirm. 
 
Despite these limitations, these findings are useful to know with regards future studies 
investigating motor function, especially longitudinal studies or those where treatments or 
Appendix B Effect of Weight on Motor Performance in mice 
349 
 
mutations may increase body mass, as this study has shown that animals weight may affect 
results and would need to be controlled for. 
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C.1 One-way ANOVA  (TaClo Toxicity Curve, Fig. 3.9) 
Analysed using SPSS, output: 
Treatment 
 
Case Processing Summary 
 
Treatment 
Cases 
 Valid Missing Total 
 N Percent N Percent N Percent 
Viability 0.2% DMSO 3 100.0% 0 .0% 3 100.0% 
1000uM TaClo 3 100.0% 0 .0% 3 100.0% 
500uM TaClo 3 100.0% 0 .0% 3 100.0% 
200uM TaClo 3 100.0% 0 .0% 3 100.0% 
100uM TaClo 3 100.0% 0 .0% 3 100.0% 
50uM TaClo 3 100.0% 0 .0% 3 100.0% 
20uM TaClo 3 100.0% 0 .0% 3 100.0% 
10uM TaClo 3 100.0% 0 .0% 3 100.0% 
5uM TaClo 3 100.0% 0 .0% 3 100.0% 
1uM TaClo 3 100.0% 0 .0% 3 100.0% 
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Tests of Normality
b
 
 
Treatment 
Kolmogorov-Smirnov
a
 Shapiro-Wilk 
 Statistic df Sig. Statistic df Sig. 
Viability 1000uM TaClo .297 3 . .917 3 .443 
500uM TaClo .269 3 . .950 3 .567 
200uM TaClo .218 3 . .988 3 .787 
100uM TaClo .359 3 . .811 3 .140 
50uM TaClo .362 3 . .804 3 .125 
20uM TaClo .278 3 . .940 3 .528 
10uM TaClo .324 3 . .877 3 .317 
5uM TaClo .190 3 . .998 3 .904 
1uM TaClo .287 3 . .929 3 .486 
a. Lilliefors Significance Correction 
b. Viability is constant when Treatment = 0.2% DMSO. It has been omitted. 
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Oneway 
 
 
[DataSet0] H:\PCK\SY5Y Toxicity Assays\TaClo\Final TaClo Data.sav 
 
 
Test of Homogeneity of Variances 
Viability 
Levene Statistic df1 df2 Sig. 
2.368 9 20 .052 
 
 
ANOVA 
Viability 
 Sum of Squares df Mean Square F Sig. 
Between Groups 33366.024 9 3707.336 27.287 .000 
Within Groups 2717.253 20 135.863   
Total 36083.278 29    
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Post Hoc Tests 
 
 
Multiple Comparisons 
Viability 
Dunnett t (2-sided)
a
 
(I) Treatment (J) Treatment 
Mean Difference (I-
J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1000uM TaClo 0.2% DMSO -90.74912
*
 9.51710 .000 -118.7893 -62.7090 
500uM TaClo 0.2% DMSO -92.81401
*
 9.51710 .000 -120.8542 -64.7738 
200uM TaClo 0.2% DMSO -83.22956
*
 9.51710 .000 -111.2697 -55.1894 
100uM TaClo 0.2% DMSO -53.19971
*
 9.51710 .000 -81.2399 -25.1595 
50uM TaClo 0.2% DMSO -28.22190
*
 9.51710 .048 -56.2621 -.1817 
20uM TaClo 0.2% DMSO -22.56426 9.51710 .154 -50.6044 5.4759 
10uM TaClo 0.2% DMSO -20.02346 9.51710 .246 -48.0636 8.0167 
5uM TaClo 0.2% DMSO -18.25837 9.51710 .331 -46.2985 9.7818 
1uM TaClo 0.2% DMSO -11.01708 9.51710 .816 -39.0572 17.0231 
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
*. The mean difference is significant at the 0.05 level. 
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C.2 Two-way ANOVA  (TaClo & N-acetylcysteine, Fig 4.4B) 
Analysed using SPSS, output: 
Combined 
 
Case Processing Summary 
 
Combined 
Cases 
 Valid Missing Total 
 N Percent N Percent N Percent 
Viability 0.2% DMSO 3 100.0% 0 .0% 3 100.0% 
5mM NAC 3 100.0% 0 .0% 3 100.0% 
2.5mM NAC 3 100.0% 0 .0% 3 100.0% 
150uM TaClo 3 100.0% 0 .0% 3 100.0% 
150uM TaClo & 5mM NAC 3 100.0% 0 .0% 3 100.0% 
150uM TaClo & 2.5mM NAC 3 100.0% 0 .0% 3 100.0% 
100uM TaClo 3 100.0% 0 .0% 3 100.0% 
100uM TaClo & 5mM NAC 3 100.0% 0 .0% 3 100.0% 
100uM TaClo & 2.5mM NAC 3 100.0% 0 .0% 3 100.0% 
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Tests of Normality
b
 
 
Combined 
Kolmogorov-Smirnov
a
 Shapiro-Wilk 
 Statistic df Sig. Statistic df Sig. 
Viability 5mM NAC .345 3 . .838 3 .210 
2.5mM NAC .272 3 . .946 3 .552 
150uM TaClo .313 3 . .894 3 .368 
150uM TaClo & 5mM NAC .319 3 . .885 3 .340 
150uM TaClo & 2.5mM NAC .283 3 . .935 3 .507 
100uM TaClo .214 3 . .990 3 .804 
100uM TaClo & 5mM NAC .253 3 . .965 3 .639 
100uM TaClo & 2.5mM NAC .177 3 . 1.000 3 .967 
a. Lilliefors Significance Correction 
b. Viability is constant when Combined = 0.2% DMSO. It has been omitted. 
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Univariate Analysis of Variance 
 
 
Between-Subjects Factors 
  Value Label N 
Toxin .00 0.2% DMSO 9 
1.00 150uuM TaClo 9 
2.00 100uM TaClo 9 
Inhibitor .00 0.2% DMSO 9 
1.00 5mM NAC 9 
2.00 2.5mM NAC 9 
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Tests of Between-Subjects Effects 
Dependent Variable:Viability 
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Corrected Model 15074.636
a
 8 1884.330 216.262 .000 
Intercept 169806.995 1 169806.995 19488.483 .000 
Toxin 7993.360 2 3996.680 458.693 .000 
Inhibitor 4807.239 2 2403.619 275.860 .000 
Toxin * Inhibitor 2274.038 4 568.509 65.247 .000 
Error 156.838 18 8.713   
Total 185038.468 27    
Corrected Total 15231.474 26    
a. R Squared = .990 (Adjusted R Squared = .985) 
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Post Hoc Tests 
 
Toxin 
Multiple Comparisons 
Viability 
Dunnett t (2-sided)
a
 
(I) Toxin (J) Toxin 
Mean Difference (I-
J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
150uuM TaClo 0.2% DMSO -41.9791
*
 1.39150 .000 -45.3167 -38.6415 
100uM TaClo 0.2% DMSO -24.2367
*
 1.39150 .000 -27.5743 -20.8991 
Based on observed means. 
 The error term is Mean Square(Error) = 8.713. 
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
*. The mean difference is significant at the 0.05 level. 
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Homogeneous Subsets 
 
Inhibitor 
 
 
Multiple Comparisons 
Viability 
Dunnett t (2-sided)
a
 
(I) Inhibitor (J) Inhibitor 
Mean Difference (I-
J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
5mM NAC 0.2% DMSO 31.2259
*
 1.39150 .000 27.8883 34.5635 
2.5mM NAC 0.2% DMSO 23.9745
*
 1.39150 .000 20.6369 27.3121 
Based on observed means. 
 The error term is Mean Square(Error) = 8.713. 
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
*. The mean difference is significant at the 0.05 level. 
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Univariate Analysis of Variance 
 
 
Between-Subjects Factors 
  Value Label N 
Combined .00 0.2% DMSO 3 
1.00 5mM NAC 3 
2.00 2.5mM NAC 3 
3.00 150uM TaClo 3 
4.00 150uM TaClo & 
5mM NAC 
3 
5.00 150uM TaClo & 
2.5mM NAC 
3 
6.00 100uM TaClo 3 
7.00 100uM TaClo & 
5mM NAC 
3 
8.00 100uM TaClo & 
2.5mM NAC 
3 
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Tests of Between-Subjects Effects 
Dependent Variable:Viability 
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Corrected Model 15074.636
a
 8 1884.330 216.262 .000 
Intercept 169806.995 1 169806.995 19488.483 .000 
Combined 15074.636 8 1884.330 216.262 .000 
Error 156.838 18 8.713   
Total 185038.468 27    
Corrected Total 15231.474 26    
a. R Squared = .990 (Adjusted R Squared = .985) 
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Post Hoc Tests  
 
Combined 
Multiple Comparisons 
Viability 
 Bonferroni 
 
(I) Combined (J) Combined 
Mean Difference (I-
J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
0.2% DMSO 5mM NAC -4.3034 2.41014 1.000 -13.3999 4.7930 
2.5mM NAC .1752 2.41014 1.000 -8.9212 9.2717 
150uM TaClo 73.0382
*
 2.41014 .000 63.9418 82.1347 
150uM TaClo & 5mM NAC 18.5966
*
 2.41014 .000 9.5002 27.6931 
150uM TaClo & 2.5mM NAC 30.1742
*
 2.41014 .000 21.0778 39.2707 
100uM TaClo 44.2497
*
 2.41014 .000 35.1532 53.3461 
100uM TaClo & 5mM NAC 9.3171
*
 2.41014 .041 .2207 18.4136 
100uM TaClo & 2.5mM NAC 15.0150
*
 2.41014 .000 5.9186 24.1115 
5mM NAC 0.2% DMSO 4.3034 2.41014 1.000 -4.7930 13.3999 
2.5mM NAC 4.4787 2.41014 1.000 -4.6178 13.5751 
150uM TaClo 77.3417
*
 2.41014 .000 68.2452 86.4381 
150uM TaClo & 5mM NAC 22.9001
*
 2.41014 .000 13.8036 31.9965 
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150uM TaClo & 2.5mM NAC 34.4776
*
 2.41014 .000 25.3812 43.5741 
100uM TaClo 48.5531
*
 2.41014 .000 39.4567 57.6496 
100uM TaClo & 5mM NAC 13.6205
*
 2.41014 .001 4.5241 22.7170 
100uM TaClo & 2.5mM NAC 19.3185
*
 2.41014 .000 10.2220 28.4149 
2.5mM NAC 0.2% DMSO -.1752 2.41014 1.000 -9.2717 8.9212 
5mM NAC -4.4787 2.41014 1.000 -13.5751 4.6178 
150uM TaClo 72.8630
*
 2.41014 .000 63.7665 81.9594 
150uM TaClo & 5mM NAC 18.4214
*
 2.41014 .000 9.3249 27.5178 
150uM TaClo & 2.5mM NAC 29.9990
*
 2.41014 .000 20.9025 39.0954 
100uM TaClo 44.0744
*
 2.41014 .000 34.9780 53.1709 
100uM TaClo & 5mM NAC 9.1419
*
 2.41014 .048 .0454 18.2383 
100uM TaClo & 2.5mM NAC 14.8398
*
 2.41014 .000 5.7433 23.9362 
150uM TaClo 0.2% DMSO -73.0382
*
 2.41014 .000 -82.1347 -63.9418 
5mM NAC -77.3417
*
 2.41014 .000 -86.4381 -68.2452 
2.5mM NAC -72.8630
*
 2.41014 .000 -81.9594 -63.7665 
150uM TaClo & 5mM NAC -54.4416
*
 2.41014 .000 -63.5381 -45.3452 
150uM TaClo & 2.5mM NAC -42.8640
*
 2.41014 .000 -51.9605 -33.7676 
100uM TaClo -28.7886
*
 2.41014 .000 -37.8850 -19.6921 
100uM TaClo & 5mM NAC -63.7211
*
 2.41014 .000 -72.8176 -54.6247 
100uM TaClo & 2.5mM NAC -58.0232
*
 2.41014 .000 -67.1197 -48.9268 
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150uM TaClo & 5mM NAC 0.2% DMSO -18.5966
*
 2.41014 .000 -27.6931 -9.5002 
5mM NAC -22.9001
*
 2.41014 .000 -31.9965 -13.8036 
2.5mM NAC -18.4214
*
 2.41014 .000 -27.5178 -9.3249 
150uM TaClo 54.4416
*
 2.41014 .000 45.3452 63.5381 
150uM TaClo & 2.5mM NAC 11.5776
*
 2.41014 .005 2.4811 20.6740 
100uM TaClo 25.6530
*
 2.41014 .000 16.5566 34.7495 
100uM TaClo & 5mM NAC -9.2795
*
 2.41014 .042 -18.3760 -.1831 
100uM TaClo & 2.5mM NAC -3.5816 2.41014 1.000 -12.6780 5.5149 
150uM TaClo & 2.5mM NAC 0.2% DMSO -30.1742
*
 2.41014 .000 -39.2707 -21.0778 
5mM NAC -34.4776
*
 2.41014 .000 -43.5741 -25.3812 
2.5mM NAC -29.9990
*
 2.41014 .000 -39.0954 -20.9025 
150uM TaClo 42.8640
*
 2.41014 .000 33.7676 51.9605 
150uM TaClo & 5mM NAC -11.5776
*
 2.41014 .005 -20.6740 -2.4811 
100uM TaClo 14.0755
*
 2.41014 .001 4.9790 23.1719 
100uM TaClo & 5mM NAC -20.8571
*
 2.41014 .000 -29.9535 -11.7606 
100uM TaClo & 2.5mM NAC -15.1592
*
 2.41014 .000 -24.2556 -6.0627 
100uM TaClo 0.2% DMSO -44.2497
*
 2.41014 .000 -53.3461 -35.1532 
5mM NAC -48.5531
*
 2.41014 .000 -57.6496 -39.4567 
2.5mM NAC -44.0744
*
 2.41014 .000 -53.1709 -34.9780 
150uM TaClo 28.7886
*
 2.41014 .000 19.6921 37.8850 
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150uM TaClo & 5mM NAC -25.6530
*
 2.41014 .000 -34.7495 -16.5566 
150uM TaClo & 2.5mM NAC -14.0755
*
 2.41014 .001 -23.1719 -4.9790 
100uM TaClo & 5mM NAC -34.9326
*
 2.41014 .000 -44.0290 -25.8361 
100uM TaClo & 2.5mM NAC -29.2346
*
 2.41014 .000 -38.3311 -20.1382 
100uM TaClo & 5mM NAC 0.2% DMSO -9.3171
*
 2.41014 .041 -18.4136 -.2207 
5mM NAC -13.6205
*
 2.41014 .001 -22.7170 -4.5241 
2.5mM NAC -9.1419
*
 2.41014 .048 -18.2383 -.0454 
150uM TaClo 63.7211
*
 2.41014 .000 54.6247 72.8176 
150uM TaClo & 5mM NAC 9.2795
*
 2.41014 .042 .1831 18.3760 
150uM TaClo & 2.5mM NAC 20.8571
*
 2.41014 .000 11.7606 29.9535 
100uM TaClo 34.9326
*
 2.41014 .000 25.8361 44.0290 
100uM TaClo & 2.5mM NAC 5.6979 2.41014 1.000 -3.3985 14.7944 
100uM TaClo & 2.5mM NAC 0.2% DMSO -15.0150
*
 2.41014 .000 -24.1115 -5.9186 
5mM NAC -19.3185
*
 2.41014 .000 -28.4149 -10.2220 
2.5mM NAC -14.8398
*
 2.41014 .000 -23.9362 -5.7433 
150uM TaClo 58.0232
*
 2.41014 .000 48.9268 67.1197 
150uM TaClo & 5mM NAC 3.5816 2.41014 1.000 -5.5149 12.6780 
150uM TaClo & 2.5mM NAC 15.1592
*
 2.41014 .000 6.0627 24.2556 
100uM TaClo 29.2346
*
 2.41014 .000 20.1382 38.3311 
100uM TaClo & 5mM NAC -5.6979 2.41014 1.000 -14.7944 3.3985 
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Based on observed means. 
 The error term is Mean Square(Error) = 8.713. 
*. The mean difference is significant at the 0.05 level. 
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C.3 Two-way Repeated Measures ANOVA  (A30P Pole Test total time, Fig 6.4 A) 
Analysed using GraphPad Prism, output: 
 
Table Analyzed Data 1       
          
Two-way RM ANOVA Matching by cols       
          
Source of Variation % of total variation P value     
  Interaction 2.09 0.9629     
  Time 17.32 P<0.0001     
  Treatment 3.26 0.2601     
  Subjects (matching) 27.4714 P<0.0001     
          
Source of Variation P value summary Significant?     
  Interaction ns No     
  Time *** Yes     
  Treatment ns No     
  Subjects (matching) *** Yes     
          
Source of Variation Df Sum-of-squares Mean square F 
  Interaction 20 397.3 19.87 0.5058 
  Time 10 3296 329.6 8.393 
  Treatment 2 620.8 310.4 1.425 
  Subjects (matching) 24 5228 217.8 5.546 
  Residual 240 9425 39.27   
          
Number of missing values 0       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bonferroni posttests         
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Vehicle (10 ml/kg Olive Oil) vs. 
TCE (1000 mg/kg)         
Treatment 
Vehicle (10 ml/kg 
Olive Oil) 
TCE (1000 
mg/kg) 
Differe
nce 
95% CI of 
diff. 
0 7.889 8.792 0.9028 
-10.25 to 
12.06 
4 8.593 14.13 5.532 
-5.625 to 
16.69 
8 11.78 11.33 
-
0.4444 
-11.60 to 
10.71 
12 9.148 12.17 3.019 
-8.139 to 
14.18 
16 10.37 12.5 2.13 
-9.028 to 
13.29 
20 9.259 11 1.741 
-9.417 to 
12.90 
24 9.704 13.29 3.588 
-7.570 to 
14.75 
28 13.26 15.67 2.407 
-8.750 to 
13.56 
32 15.85 19.46 3.606 
-7.551 to 
14.76 
36 17.19 19.83 2.648 
-8.509 to 
13.81 
40 13.7 18.75 5.046 
-6.111 to 
16.20 
Treatment Difference t P value Summary 
0 0.9028 0.2494 
P > 
0.05 ns 
4 5.532 1.528 
P > 
0.05 ns 
8 -0.4444 0.1228 
P > 
0.05 ns 
12 3.019 0.8338 
P > 
0.05 ns 
16 2.13 0.5883 
P > 
0.05 ns 
20 1.741 0.4809 
P > 
0.05 ns 
24 3.588 0.9911 
P > 
0.05 ns 
28 2.407 0.665 
P > 
0.05 ns 
32 3.606 0.9962 
P > 
0.05 ns 
36 2.648 0.7315 
P > 
0.05 ns 
40 5.046 1.394 
P > 
0.05 ns 
 
Vehicle (10 ml/kg Olive Oil) vs.         
Appendix C Statistical Analysis 
370 
 
TaClo (2 mg/kg) 
Treatment 
Vehicle (10 ml/kg 
Olive Oil) 
TaClo (2 
mg/kg) 
Differe
nce 
95% CI of 
diff. 
0 7.889 9.2 1.311 
-9.239 to 
11.86 
4 8.593 10.33 1.741 
-8.810 to 
12.29 
8 11.78 10.73 -1.044 
-11.59 to 
9.506 
12 9.148 10.73 1.585 
-8.965 to 
12.14 
16 10.37 14.2 3.83 
-6.721 to 
14.38 
20 9.259 14.2 4.941 
-5.610 to 
15.49 
24 9.704 17 7.296 
-3.254 to 
17.85 
28 13.26 16.17 2.907 
-7.643 to 
13.46 
32 15.85 18.9 3.048 
-7.502 to 
13.60 
36 17.19 21.87 4.681 
-5.869 to 
15.23 
40 13.7 19.33 5.63 
-4.921 to 
16.18 
          
Treatment Difference t P value Summary 
0 1.311 0.383 
P > 
0.05 ns 
4 1.741 0.5085 
P > 
0.05 ns 
8 -1.044 0.3051 
P > 
0.05 ns 
12 1.585 0.4631 
P > 
0.05 ns 
16 3.83 1.119 
P > 
0.05 ns 
20 4.941 1.443 
P > 
0.05 ns 
24 7.296 2.131 
P > 
0.05 ns 
28 2.907 0.8494 
P > 
0.05 ns 
32 3.048 0.8905 
P > 
0.05 ns 
36 4.681 1.368 
P > 
0.05 ns 
40 5.63 1.645 
P > 
0.05 ns 
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